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Abstract 
Malignant pleural mesothelioma (MPM) is an aggressive cancer that is strongly associated 
with asbestos exposure. Majority of patients with MPM present with advanced disease and 
the treatment paradigm mainly involves palliative chemotherapy and best supportive care. 
The current chemotherapy options are limited and ineffective hence there is an urgent need to 
improve patient outcomes. This requires better understanding of the genetic alterations 
driving MPM to improve diagnostic, prognostic and therapeutic strategies.  
This research aims to gain further insights in the pathogenesis of MPM by exploring the 
tumour transcriptional and mutational profiles. We compared gene expression profiles of 25 
MPM tumours and 5 non-malignant pleura. This revealed differentially expressed genes 
involved in cell migration, invasion, cell cycle and the immune system that contribute to the 
malignant phenotype of MPM. We then constructed MPM-associated co-expression networks 
using weighted gene correlation network analysis to identify clusters of highly correlated 
genes. These identified three distinct molecular subtypes of MPM associated with genes 
involved in WNT and TGF-ß signalling pathways. Our results also revealed genes involved in 
cell cycle control especially the mitotic phase correlated significantly with poor prognosis. 
Through exome analysis of seven paired tumour/blood and 29 tumour samples, we identified 
frequent mutations in BAP1 and NF2. Additionally, the mutational profile of MPM is enriched 
with genes encoding FAK, MAPK and WNT signalling pathways. We also found mutations in 
several novel genes involved in chromatin remodelling other than BAP1 and SETD2 that may 
contribute to dysregulation of gene expression in MPM. 
In conclusion, MPM is a complex disease with heterogeneous molecular aberrations. By 
combining findings from both transcriptome and exome analyses, we identified alterations in 
genes involved in common signalling pathways such as FAK, WNT and MAPK. These may 
have important roles in driving MPM carcinogenesis with therapeutic implications and 
require further explorations. 
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Chapter 1 - Introduction 
1.1 Background 
Malignant mesothelioma is a neoplasm that originates from mesothelial cells lining the body 
cavities including the pleura, pericardium, peritoneum and tunica vaginalis. The pleura is the 
most commonly affected area and is known as malignant pleural mesothelioma (MPM) which 
is the focus of this thesis work. Asbestos is the main causative agent but other risk factors and 
genetic susceptibilities have been implicated. MPM is still considered a relatively rare type of 
cancer accounting for only 0.8% of cancer cases and 1.5% cancer deaths in the United 
Kingdom (UK)1. The long latency period between exposure and development of MPM has 
given rise to the increased incidence seen in many developed countries over the past two 
decades and the incidence continues to rise in many developing countries worldwide.   
MPM is an aggressive cancer and is often diagnose at an advanced stage. Patients with MPM 
commonly present with dyspnoea, chest pain or pleural effusion. Initial assessments generally 
include a computed tomography (CT) scan, thoracentesis, pleural fluid cytology assessment, 
and pleural biopsy. The diagnosis of MPM remains challenging as it relies on an adequate 
tissue biopsy sample for histopathological analysis taking into considerations appropriate 
clinical, radiological and surgical findings.  
MPM is categorised into three main histologic subtypes: epithelioid, sarcomatoid and 
biphasic MPM. Histologic subtype is a well-established prognostic factor in MPM. 
Epithelioid MPM confers significantly better prognosis compared to biphasic and 
sarcomatoid MPM. According to the International Association for the Study of Lung Cancer 
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(IASLC) and International Mesothelioma Interest Group (IMIG) studies the median survival 
for epithelioid, biphasic and sarcomatoid MPM are 19, 13 and 8 months respectively; and the 
median survival by stage of disease and after maximal cytoreductive surgery is also reported 
(Table 1.1)2. Two validated prognostic scoring systems developed by the Cancer and 
Leukaemia Group B (CALGB) and European Organisation for Research and Treatment of 
Cancer (EORTC) have been proposed for patients with MPM3,4. These groups examined the 
effects of various pre-treatment variables on survival in patients with MPM. Several variables 
were identified as important prognostic factors including age, performance status, histologic 
subtype, weight loss, haematologic and biochemistry parameters. Amongst these, poor 
performance status and non-epithelioid subtypes werereported by both groups to be associated 
with worse prognosis. 
Chemotherapy is the standard of care for patients with MPM. A combination of pemetrexed 
(anti-folate) and cisplatin (platinum-compound) is an established frontline treatment with 
statistically significant improvement in overall survival by three months and quality of life 
over cisplatin alone as shown in a randomized phase III trial5. The response to chemotherapy 
remains short-lived and no other second-line treatments are licensed. However, a small subset 
of long–term responders can be identified. Surgery is not performed frequently as the majority 
of patients present with inoperable disease. For resectable disease, the optimal type of surgery 
is still unclear. A seminal feasibility clinical trial showed extra-pleural pneumonectomy (EPP) 
offers no benefit compared to no surgical intervention6. A prospective randomized trial 
(NCT02040272) has recently started recruiting in the UK and aims to answer the benefits of a 
less extensive surgery, extended pleurectomy decortication, versus no surgery. Adjuvant 
hemithoracic RT to improve loco regional control is no longer given as patient will require 
pneumonectomy while the benefit of prophylactic tract RT given to prevent tumour seeding at 
surgical instrumented site remains controversial as studies have shown conflicting result but is 
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still routinely given in some centres7. 
Table 1.1. Median survival of patients with MPM according to disease stage (American 
Joint Committee on Cancer Cancer Staging Manual, 7th edition) and after surgery. 
Stage T N M 
Median survival (months) 
(IMIG+IASLC) 
 With radical 
surgery 
I T1 N0 M0 20 30 
IA T1a N0 M0   
IB T1b N0 M0   
II T2 N0 M0 19 22 
III T1, T2 N1 M0 16 16 
 T1, T2 N2 M0   
 T3 N0, 1, 2 M0   
IV T4 Any N M0 11 12 
 Any T N3 M0   
 Any T Any N M1   
 
1.2 Mesothelial cells and the pleura 
Mesothelial cells are derive from the mesoderm but are capable of expressing both epithelial 
and mesenchymal properties. They display mainly epithelial phenotypes and markers such as 
polygonal cell shape, cytokeratin intermediate filaments and basement membrane; and 
occasionally the presence of mesenchymal markers such as vimentin, desmin and alpha 
smooth muscle actin8,9. Simsir et al. have demonstrated mesothelial cells possess well-
developed tight junctions, adherens junctions, gap junctions and desmosomes; and also 
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express predominantly N-cadherin in addition to E- and P- cadherins10. In response to insult, 
mesothelial cells begin to proliferate and regenerate. Several theories exist and suggest new 
mesothelial cells regenerate after injury from centripetal migration of cells at the wound edge 
and the origins of these regenerating mesothelial cells remain uncertain but free-floating cells 
from serosal fluid have been implicated11. Mesothelial cells are also capable of forming cells 
of different mesenchymal lineages through transdifferentiation from an epithelial to 
mesenchymal phenotype such as fibroblasts, endothelial and smooth muscle cells depending 
on the presence of different types of growth factors and cytokines12. These observations led to 
the speculation of the existence of cancer stem cells (CSC) in MPM. CSC share many 
characteristics of normal stem cells including self-renewal and multilineage differentiation. 
Aside from these, a CSC population has been hypothesised to play an essential role in tumour 
initiation, growth, recurrence, and treatment resistance13–15. Several studies aimed to identify 
CSC in MPM but results were not conclusive. Side population cells are considered to be 
potential CSC in various tumours  and those with low or negative CD105 were isolated from 
MPM and found to be tumorigenic16. Other studies claimed to have isolated floating stem 
cells from cultured peritoneal mesothelioma cells but lacked the usual stem cell markers such 
as CD133, CD31 and CD14417. Yamazaki et al found MPM cell lines expressing CD24 and 
CD26 correlated with CSC properties18. Resistance to cancer therapy is another hallmark of 
CSC and Cortes-Derrick proposed chemoresistance to pemetrexed and cisplatin is associated 
with the expression of stem cell markers CD133, Bmi-1, uPAR and ABCG219. Further 
characterization of CSC in MPM is warranted as it can lead to better understanding of the 
cells of origin, tumour progression and as potential therapeutic targets in MPM  
Around 70% percent of malignant mesothelioma cases are pleural in origin and occur mainly 
on the parietal pleura instead of the visceral pleura20,21. The pleura is covered by a single layer 
of flattened mesothelial cells made up of squamous-like cells and cuboidal mesothelial cells. 
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The functions of mesothelium are to provide a protective barrier and to facilitate movement of 
the pleural surfaces during respiration through secretion of glycoproteins. Furthermore, they 
are involved in membrane transport, participate in inflammation and tissue repair process by 
secreting various immunomodulatory mediators such as cytokines, growth factors, nitric 
oxide, reactive nitrogen and oxygen species and also capable of changing cell adhesion 
molecule expression22. An in vitro study showed mesothelial cells produce a variety of 
extracellular matrix (ECM) molecules and regulate ECM turnover through the synthesis of 
matrix metalloproteinases and tissue inhibitors of metalloproteinases23. 
1.3 Epidemiology 
Asbestos is a well-established causal factor for MPM. The World War II period saw the 
largest use of asbestos because of demand that accompanied industrialization. However, the 
rise in MPM cases did not occur immediately because of the long latency period between 
exposure and disease development.  The long latency period explains the rising incidence of 
MPM worldwide despite asbestos being banned in many countries and the incidence is 
predicted to decline only sometime between year 2015 and 203024. There is also a significant 
heterogeneity in incidence by country with industrialised countries having the highest 
incidence rate reflecting past use and production of asbestos25. Australia has the highest 
incidence in 2010 at 35 cases per million while incidence in the United States of America 
(USA) might have peaked and has been steadily declining since year 2000 due to the decline 
in asbestos use since 196026,27. In the UK, the incidence rates have increased since late 1970s 
that correlated with the peak use of asbestos around early 1960s1. 
Data from the World Health Organisation (WHO) analysis of MPM from 1994-2008 reported 
an age-adjusted mortality rate of 4.9 per million with a mean age of death at 70 years and 
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observed large differences by sex with a male to female ratio of 3.6:128. In 2011, there were 
2,570 new cases recorded with a male to female ratio of 5.5:1; and 2,429 deaths from MPM 
recorded in 2012 in the UK. This is in keeping with the prediction that MPM mortality in 
Great Britain will peak at around 1,950-2,450 deaths per year between 2011-2015 and 
expected to decline rapidly thereafter29.  
In non-Western or developing countries the incidence is expected to peak at a later period due 
to later use of asbestos compared to Western countries. Many cases particularly in developing 
countries have been unreported leading to an underestimation of global incidence rate. Park et 
al. estimated 38,900 cases to have occurred between 1994-2008 in countries without reported 
mesothelioma based on cumulative data on incidence rate and asbestos use30. Similarly, 
inaccurate reporting of MPM deaths prior to the introduction of a uniform disease 
classification system may have contributed to the underestimated incidence rates globally31. 
Geographical areas and occupations associated with high exposure of asbestos correlated with 
higher incidence and deaths due to MPM. In the UK, areas of West Dunbartonshire and 
Barrow-in –Furness have the highest standardized mortality ratio and the occupations with the 
highest proportional mortality ratios are metal plate workers, vehicle body builders, plumbers, 
gas fitters and carpenters32. In addition, indirect non-occupational exposure to asbestos such 
as living in the vicinity of an industrial or natural source of asbestos areas or living with a 
person exposed to asbestos has accounted for 8.3% of all mesothelioma cases in Italy but has 
been estimated to account for approximately 30% of all cases in the USA33. Small clusters of 
mesothelioma have also occurred such as in the villages of Turkey possibly due to other 
environmental exposure such as erionite (an asbestos-like mineral) or transmission in an 
autosomal dominant manner as suggested by a six-generation extended pedigree analysis34,35.  
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With the exception of the USA and possibly the UK, the observed incidence of this disease is 
just the tip of the iceberg especially in many developing countries. The increasing cases of 
this fatal disease worldwide and its limited treatment options highlighted the importance of 
research in understanding the disease biology in order to improve diagnosis, therapies and 
outcomes. 
1.4 Risk factors 
1.4.1 Asbestos 
Asbestos is the most extensively investigated cause of MPM and it was not until 1947 when 
the first case of MPM with current diagnostic criteria was documented and published in the 
New England Journal of Medicine36. However, the first causal relationship between MPM and 
asbestos was reported by Wagner in 1956 whereby he documented 32 out of 33 MPM cases 
with asbestos exposure in the Kimberley area, South Africa37. 
There are two major groups of asbestos: serpentine and amphiboles. Chrysotile also known as 
white asbestos is the only serpentine and accounts for more than 90% of the asbestos used 
worldwide. Among the amphiboles, crocidolite, also known as blue asbestos, is considered to 
be the most oncogenic and found to confer increased risk by 500 fold compared to 
chrysotile38. The carcinogenicity of chrysotile remains controversial and its contribution to 
malignant mesothelioma was thought to be attributed to contamination with amphiboles while 
other studies found chrysotile do not accumulate in the lungs as they could be partially 
digested compared to amphibole asbestos which are resistant to cellular enzymes39. However, 
studies on lung fibre contents in patients with MPM have found increased odd ratios not only 
for amphiboles fibres but also chrysotile fibres alone40. Aside from solubility, the 
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carcinogenicity of asbestos fibres also depends on its diameter and length. The biologically 
active or inhalable asbestos fibres are those with a diameter of less than 3 micrometres and a 
length between 5 and 100 micrometres41. Only 20% of all asbestos fibres fall into this 
category including crocidolite that have the capacity to penetrate and irritate the pleura to 
induce disease including pleural plaques, asbestosis or malignant mesothelioma42. In general, 
the majority of patients are exposed to both types of asbestos and the WHO has concluded 
that all types of asbestos are in fact oncogenic43. 
Around 80% of MPM are related to asbestos but the remaining 20% of cases have no 
documented asbestos exposure suggesting other etiologic factors including genetic 
susceptibility in certain individuals44. Even in cases where asbestos exposure was not known 
lung content examination from a study revealed significant asbestos fibres count were present 
in these cases suggesting potential unrecognized exposure45. The lifetime risk of developing 
MPM after asbestos exposure ranges from 4 to 10% and majority of exposed individuals 
develop other asbestos-related lung disease such as pulmonary fibrosis, pleural plaques, 
recurrent effusions and lung cancer46. The risk of lung cancer in asbestos-exposed individuals 
is further increased by cigarette smoking that is prevalent in this group of individuals and the 
risk persists for up to 40 years even after smoking cessation compared to asbestos workers 
who never smoke47. In contrast, smoking alone does not increase the risk of MPM in a case-
control study48. Either way, smoking cessation may be the only way to reduce the risk of lung 
cancer in previously asbestos-exposed workers.  
The mean latency period between asbestos exposure to the time of MPM diagnosis is around 
32 years after initial exposure and only 1% of the cases had a latent period of less than 15 
years while no cases was identified in those with less than 10 years of exposure49. More 
recent studies have revised and reported the mean latency period to be between 42.8 to 48.5 
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years50,51. There is no definite explanation for this long latent period but one could postulate 
that cells exposed to asbestos acquire multiple molecular aberrations over the years and 
eventually transform. The findings by Hilliard et al. showed the latency period is inversely 
correlated with intensity of exposure and found the latency period for intermittent and 
continuous exposure to be 42 years versus 49.5 years respectively51. A pooled analysis of 8 
cohort studies found the median latency period to be 38.4 years and women tended to have a 
longer latency period compared to men52. The number of female cases not known to be 
directly exposed to asbestos tends to be lower compared to those with known occupational 
exposure. Indirect exposure to asbestos could be a result from proximity to asbestos factories, 
close contact with asbestos workers with fibres found in their clothing, asbestos in old 
buildings or electrical apparatus. In addition, the study observed the median duration of 
exposure was 3.75 years and the risk of developing pleural MPM increased up to 45 years 
after first exposure. A population-based case control study on asbestos-exposed males 
estimated a dose-response relationship with logistic regression method and found the effect of 
total duration of asbestos exposure decreased when age at first exposure and time since last 
exposure increased53. 
Studies based on history of asbestos exposure invariably suffer from inaccurate estimation of 
exposure while studies based on lung content analyses might offer more precise risk 
estimation. The risk of asbestos-induced MPM was found to be dose-dependent in animal 
models54. However, the effect appears to be different in humans as shown in a lung content 
analysis study which found higher levels of exposure to asbestos is more likely to cause 
asbestosis instead of MPM and the latter is more likely to occur with smaller amount of 
exposure to crocidolite compared to chrysotile55.  
The mechanisms of asbestos-induced malignant changes in mesothelial cells are multifaceted. 
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Firstly, long and thin asbestos fibres including crocidolite can directly penetrate and deposit in 
the pleura to initiate asbestos-related disease including MPM42. Secondly, asbestos fibres are 
capable of disrupting mitotic spindles during mitosis resulting in aneuploidy and other 
chromosomal abnormalities leading to cell transformation56. Thirdly, asbestos fibres generate 
a chronic inflammatory process by generating extracellular high molecular group binding 
protein 1 (HMGB1) following phagocytosis of asbestos fibres by macrophages and human 
mesothelial cells. HMGB1 leads to secretion of tumour necrosis factor (TNF)-alpha that 
promotes cell survival and resistance to asbestos-induced cytotoxicity through activation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)57. Furthermore, 
HMGB1 releases reactive oxygen and nitrogen species thereby inducing DNA damage, strand 
breaks and G to T transversions58. Asbestos fibres are capable of inducing 
autophosphorylation of mitogen-activated protein kinases (MAPK) and extracellular-signal-
regulated kinases (ERK) 1 and 259. The MAPK/ERK cascade is also activated by asbestos-
induced autophosphorylation of epidermal growth factor receptor (EGFR). 
1.4.2 Other risk factors including genetic susceptibility 
Around 20% of MPM cases are not associated with asbestos exposure suggesting other 
etiologic factors or genetic susceptibility. A number of other non-asbestos related agents are 
implicated in the development of MPM. Erionite, a naturally occurring fibrous zeolite 
compound is strongly associated with MPM after high incidence of MPM was reported in 
villages of Cappadocia, Turkey and found extensive use of erionite in the houses of MPM 
cases. Intrapleural injections of erionite in animal models resulted in MPM in >90% of 
cases60. However, some households were spared despite the presence of erionite in the home 
buildings and analysis of a six generation extended pedigree in Turkey suggested a possibility 
of genetic susceptibility through autosomal dominant transmission35. This was challenged by 
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another study that found the risk of MPM was due to indoor exposure to erionite and familial 
clustering might be coincidental or erionite might be contributing to MPM in genetically 
susceptible individuals61.  
Multiwalled carbon nanotubes, products of nanotechnology, have also been implicated in 
MPM development due to their morphological resemblance to asbestos fibres including 
needle-like shape, high durability and propensity to migrate to the pleural when inhaled. Thin 
and high crystallinity carbon nanotubes have been shown to pierce the mesothelial cell 
membrane and induce cytotoxicity in vitro and initiate inflammation with subsequent 
transformation in vivo in mesothelial cells62. The same study observed frequent homozygous 
deletion of CDKN2A/2B that is often inactivated in MPM. There is no evidence reported to 
date regarding human exposure to carbon nanotubes and development of MPM. 
Simian virus 40 (SV40) is a polyomavirus with double-stranded DNA of monkey origin and 
the most likely route of transmission to human was through SV40 contaminated polio 
vaccines between 1955-196363. SV40 has been identified in several tumours including MPM. 
SV40 exerts its oncogenic effects via an antisense mechanism that suppresses late viral gene 
expression allowing cells to survive the infection and the high levels of wild type p53 in 
human mesothelial cells allow SV40 to persist in an episomal state with expression of large T 
antigen (Tag)64. SV40 Tag binds to and inactivates tumour suppressors p53, pRb and other 
proteins leading to activation of insulin-like growth factor 1 (IGF 1) pathway including AKT 
activation leading to cell survival and proliferation65. In addition, Tag is able to transactivate 
MET and ERK pathways through production of hepatocyte growth factor (HGF) and 
upregulation of Notch-1 respectively 66,67. 
Intrapleural inoculation of SV40 in hamsters resulted in the development of MPM68. This led 
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to the identification of SV40 sequences by polymerase chain reaction (PCR) in 60% of human 
mesotheliomas specimens and was later confirmed in a multi-centre study in the USA69,70. 
However other groups outside of the USA did not detect SV40 in MPM suggesting possible 
geographical variations in the use of previously SV40-contaminated polio vaccine or 
differences in detection methods71,72. Lopez-Rios et al also showed that most of their initial 
positive results of SV40 in 60% of MPM were due to plasmid PCR amplification rather than 
that of SV4073. To date, it is still not entirely clear the causal role of SV40 in MPM due to the 
conflicting laboratories results and the overall incidence of MPM is not consistent with the 
millions of previously SV40-contaminated polio vaccines. 
In vitro studies have demonstrated that SV40 can transform human mesothelial cells but 
asbestos acts synergistically as strong co-carcinogen in increasing the rate of malignant 
transformation64,74. These suggest SV40 contribution to MPM development as a co-factor and 
potentially could be a marker to identify asbestos exposed individuals who may be at high 
risk of developing MPM.  
Ionising radiation is a well-recognized carcinogen and a potential risk factor for the 
development of MPM. This has been reported in patients receiving therapeutic radiation for 
cancer such as Wilms' tumour or lymphoma and in patients who had previously received 
radiographic contrast medium Thorotrast75,76. The causal association was further supported by 
development of MPM in rat models injected with radioactive material and a review on 
epidemiological studies found statistical significant increase in MPM risk especially with 
Thorotrast and radiation therapy77,78. Although there is no definite causal link between 
radiation and MPM but a possible causal association is evident from the case reports and the 
plausible oncogenic actions of radiation.  
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Polymorphisms in several metabolic genes involved in oxidation processes are implicated in 
conferring an increased risk of MPM. Previous study found genetic polymorphisms in two 
metabolic genes GTSM1 and NAT2 associated with an increased risk of asbestos-induced 
MPM development and the risk is 7-fold higher in the presence of both polymorphisms79. 
Another case-control study identified increased risk of MPM is associated with 
polymorphisms in mEH, combination of mEH and NAT2, mEH and GTSM1; and NAT2 and 
GTSM1 in the presence of asbestos exposure80. However, the studies involved small number 
of cases and these genes have not been reported again in MPM to draw any significant 
associations.  
Genome-wide association study (GWAS) was carried out in an Italian sample involving 407 
MPM cases and 389 controls with a replication Australian study involving 428 MPM cases 
and 1289 controls to identify genetic risk factors in the development of MPM81,82. These did 
not identify any single marker that reached the genome-wide significance threshold and there 
was no replication between the two studies. These could be explained by the small sample 
size as MPM is still a relatively rare cancer and sample heterogeneity. However, five 
chromosomal regions (3q26.2, 4q32.1, 7p22.2, 14q11.2, 15q14) from the Australian study 
showed significant associations with the top single nucleotide polymorphisms (SNP) from the 
Italian study especially in the region of a cell adhesion protein, SDK1. This gene has recently 
been identified through exome data mining to be associated with asbestos exposure83. Thus, 
SDK1 may be an important candidate gene in asbestos-induced disease such as MPM.  
In recent years, germline mutations in BAP1 have been reported in families with a high 
incidence of MPM84,85. Meta-analysis of seven unrelated families found the majority of these 
cases arise in individuals or families with other cancers known as BAP1 cancer syndrome that 
includes atypical melanocytic tumours, uveal melanoma, cutaneous melanomas, renal cell 
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carcinomas and possibly other cancers that have not yet to be classified as part of the 
syndrome85. The prevalence of germline BAP1 mutation is extremely low in sporadic MPM 
and estimated to be between 0-2 %86–88. Sneddon et al also did not identify any history of 
BAP1-associated cancers in sporadic BAP-1 mutant MPM cases suggesting germline BAP1 
mutation and familial BAP1 cancer syndrome is not a common occurrence87. As such, routine 
genetic screening for germline BAP1 mutation is not applicable but could be considered for 
patients with MPM and family history of other BAP1-associated cancer. 
1.5 Diagnostic biomarkers 
Most MPM are readily identified or suspected on routine haematoxylin-eosin (H&E) staining 
where they exhibit three histologic subtypes that are broadly categorized in to epithelioid, 
sarcomatoid or mixed (biphasic) based on cell morphology. A definitive histopathological 
diagnosis of MPM requires immunohistochemistry (IHC) workup. The IMIG recommends the 
use of at least 2 mesothelial and 2 carcinoma antibodies depending on the differential 
diagnoses considered89. The differential diagnoses for epithelioid MPM includes 
adenocarcinomas; for sarcomatoid MPM includes sarcomas and other spindle cell neoplasms; 
and for mixed MPM includes mixed or biphasic tumours such as synovial sarcoma and 
metastatic pleomorphic carcinoma of lung.  
The most established positive mesothelioma markers include calretinin, epithelial membrane 
antigen (EMA), cytokeratin 5/6 (CK5/6), podoplanin (PDP) and Wilms’ tumor-1 protein 
(WT1). As for carcinoma markers, carcinoembryonic antigen (CEA), claudin-4 (CL4), Ber-
EP4 and p63 are useful panels. Initial positive staining for EMA and calretinin together with 
negative staining for CEA and Ber-EP4 support the diagnosis of MPM and exclude 
adenocarcinoma. Any equivocal results will require further MPM antibodies such as PDP and 
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WT-1. PDP is able to differentiate epithelioid MPM from adenocarcinomas but can also be 
expressed in squamous carcinoma. WT1 is a useful MPM diagnostic marker and able to 
differentiate lung adenocarcinoma but not breast adenocarcinoma hence their use may be 
limited to male patients. D2-40 and calretinin are positive markers most consistently 
expressed in sarcomatoid MPM.  In the setting of other suspected cancers, the use of specific 
antibodies such as thyroid transcription factor 1 positivity confirms pulmonary origin of an 
adenocarcinoma. Amongst the negative markers for MPM, CL4 is the most specific while 
EpCAM may show focal positivity and CEA expression is very rare in MPM. The diagnosis 
of benign reactive mesothelial proliferation requires loss of immunoreactivity to EMA and 
positive immunoreactivity to desmin.  
The diagnosis of MPM based on cytological analysis of pleural fluid is non-invasive and has 
lower morbidity rate. Recent evidence has indicated cytopathological diagnosis of MPM can 
be reliable with 100% positive predictive value if carried out in conjunction with other 
ancillary techniques such as IHC, molecular biology, electron microscopy and analysis of 
soluble biomarkers but has lower sensitivity compared to histopathological diagnosis that 
remains as the gold-standard diagnostic tool90. 
Several biomarkers in serum, plasma or pleural effusion have been established as potential 
diagnostic markers in MPM but none can be used solely due to low sensitivity or still 
requiring further validation in larger studies. Soluble mesothelin-related peptides (SMRP) are 
elevated in the serum of patients with MPM with a specificity of 95% and sensitivity of 83% 
compared to controls91. Multivariate analyses showed the sensitivity ranged from 20-70% and 
level of SMRP correlate significantly with age, low BMI, smoking history, cumulative 
asbestos exposure and detection of disease recurrence or progression92. However, the potential 
use of SMRP are limited to epithelioid or biphasic MPM as they are not elevated in 
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sarcomatoid MPM, a subtype that remains a diagnostic challenge. Osteopontin, an 
extracellular cell adhesion protein, has low specificity as a plasma diagnostic marker but in 
contrast to SMRP it may be elevated in sarcomatoid MPM93. Both sensitivity and specificity 
are increased by combining both SMRP and plasma osteopontin for diagnostic accuracy but 
require further validation94. High level of hyaluronate (HA) is secreted into the effusion of 
MPM but high levels are detected in only 50-60% of MPM effusions95. Combining SMRP 
and HA biomarkers with a two-step model to predict MPM showed high specificity but no 
improvement in sensitivity96. Another study identified elevated levels of serum fibulin 3, an 
extracellular glycoprotein, has a sensitivity of 96.7% and specificity of 95.5% in 
distinguishing patients with MPM from those with exposure to asbestos but without the 
disease97. Levels are also significantly higher in pleural effusion due to MPM and together 
with plasma level may be helpful to differentiate effusion due to MPM or other benign 
lesions. However, this could not be validated in a subsequent study that found SMRP to be a 
better serum diagnostic marker compared to fibulin 398. In conclusion, SMRP remains the best 
available biomarker that may be clinically useful to distinguish MPM from other diseases. 
1.6 Molecular changes in MPM 
1.6.1 Chromosomal alterations 
Chromosomal alterations in MPM have been studied on cell cultures and primary tumours 
with comparative genomic hybridization array, SNP array and representative oligonucleotide 
microarray analysis99–105. All studies reported loss of chromosomal regions 1p, 3p, 9p and 
22q. The genes at some of the deleted loci have been identified including 9p21.3 that encodes 
CDKN2A and 22q12 that encodes NF2. The frequent loss of region 3p21 involves tumour 
suppressor gene (TSG) RASSF1A (3p21.3) that is inactivated by allelic loss or methylation. 
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More recently, somatic BAP1 (3p21.1) mutations in MPM have been identified and together 
with loss of chromosome 3p21 lead to biallelic inactivation of BAP1106. Other frequent losses 
are in the region of 4q, 13q and 14q. Gains of chromosomal regions are less common and 
include regions 1q, 5p, 7p, 8q, and 17q. Whole genome sequencing of one primary MPM 
tumour with matched normal tissue using sequencing-by-synthesis and pyrosequencing also 
revealed more large scale genomic alterations, particularly deoxyribonucleic acid (DNA) 
rearrangements involving chromosomes 8, 17 and 21, than point mutations107. The study 
reported one large deletion involving DPP10 at 2q12.3–2q14.2 but loss of this region was not 
detected by earlier studies involving MPM cell lines or tumours. Clearly more samples are 
needed as this study only focused on single tumour genome and the depth of sequencing 
might be biased towards discovery of rearrangement-type mutations.  
1.6.2 DNA methylation 
DNA methylation of clusters of CpG dinucleotides (“CpG islands”) in the promoter regions of 
genes leads to transcriptional silencing. This epigenetic modification plays a major role in 
carcinogenesis through inactivation of tumour suppressor and other growth regulatory 
genes108. Global epigenetic analysis of MPM has shown differences in methylation profile 
when compared to normal pleural or other tumours suggesting the presence of aberrant CpG 
island methylation that is specific and may be involved in the carcinogenesis of MPM. The 
first methylation study on MPM was carried out on 158 MPM and 18 normal pleural samples. 
DNA methylation profile was able to differentiate between MPM and non-malignant pleura 
and was a significant predictor of shorter survival109. Another study compared the methylation 
profile between MPM and lung adenocarcinomas and found 11% of heterozygously deleted 
genes were affected by DNA methylation and/or trimethylated histone H3 lysine 27 in 
MPM110. Amongst these genes, TMEM30B, KAZALD1 and MAPK13 were specifically 
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methylated in MPM and may be useful as differential diagnostic markers. In the same study, a 
subset of patients with low frequency of DNA methylation had longer survival. Other genes 
that have prognostic implications include hypermethylation of LZTS1, SLC6A20, TMS1, HIC-
1 or combination of RARbeta with either RASSF1A or DARK that have been associated with 
shorter survival111–113. Other authors have studied the methylation status in MPM with a more 
directed approach by analysing specific pathway genes. These identified hypermethylation of 
cell cycle genes (APC, CCND2, CDKN2A, CDKN2B, HPPBP1 and RASSF1) was 
significantly associated with higher asbestos burden114. Kohno et al found WNT pathway is 
deregulated in MPM via epigenetic silencing and found promoter methylation of WIF-1 and 
SFRP1, 2 and 4, are common events in MPM115. Epigenetic silencing of miR-34b/c, a direct 
transcriptional target of TP53, by methylation is a crucial event in MPM and forced 
expression of miR-34b/c led to significant antitumor effect116. 
In light of these aberrant epigenetic findings in MPM, several histone deacetylase inhibitors 
(HDACi) have been tested. The largest of the studies was a phase III trial that tested 
vorinostat but did not show any survival benefit compared to best supportive care in patients 
who relapsed after first-line systemic chemotherapy117. A more promising result was achieved 
with valproate, an HDACi, given with doxorubicin that yielded a response rate of 16% in a 
small phase II study. This was further supported by in vitro study that showed tumour growth 
suppression when combined with standard of care chemotherapy regime, pemetrexed plus 
cisplatin118. 
1.6.3 Mirco RNA 
Micro RNA (miR) are involved in regulating gene expression at the post transcriptional level 
and half of known miR are located in cancer-associated genomic regions or in fragile sites, 
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regions of loss of heterozygosity, minimal amplicons or common breakpoints involving TSG, 
oncogenes and genes in specific signalling pathways119. In a study investigating the 
prognostic role of miR in surgically treated patients with MPM, only miR-29c* had 
significant different expression with higher levels correlating with longer time to progression 
and survival120. miR-31 is frequently lost in MPM due to its chromosomal location at 9p21. A 
study showed loss of miR-31 in MPM cell lines is associated with more aggressive phenotype 
and reintroduction of this miR led to inhibition of cell cycle progression121. Several groups 
have identified specific miR that may be of diagnostic value in MPM. Seven miR (miR-141, 
miR-200a, miR-200b, miR-200c, miR-203, miR-205, and miR-429) areshown to be 
downregulated in MPM irrespective of the histologic subtype. Upregulation of miR-484, 
miR-320, hsa-let-7a, and miR-125a-5p are able to discriminate MPM from benign asbestos-
related disease while differential expression of three miR (miR-193, miR-200c, and miR-192) 
are able to distinguish MPM from lung adenocarcinoma122,123. Further miR profiling studies 
and validation of the findings are required to establish their roles in MPM carcinogenesis. 
1.6.4 Gene expression profiling 
Microarray-based transcriptomic studies have led to the identification of deregulated gene 
expression changes relevant to the biology of MPM. Earlier studies on cell lines found gene 
expression changes related to mesothelial cell transformation are involved in DNA repair, cell 
adhesion, cell migration, macromolecule stability and cell cycle124,125. Altered gene 
expression patterns in asbestos-induced tumours in rats found up-regulation of c-myc, Fra-1 
and EGFR at different stages of carcinogenesis and genes involved in integrin-linked signal 
transduction and extracellular matrix (ECM)126.  
Studies analysing gene expression in MPM cells (including cell lines) versus non-malignant 
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mesothelial cells have limited sample size with the largest number of tumour samples being 
53 and utilized different microarray platforms across studies127–134. Collectively, these studies 
showed deregulated genes in MPM are associated with cell cycle, cell proliferation, apoptosis, 
DNA damage repair, cell adhesion, cell migration, invasion and cytoskeletal support 
pathways. Genes driving the different phases of cell cycle including checkpoints have been 
reported by more than two independent studies. The more recent study by Suraokar et al with 
the largest sample size to date revealed mitotic spindle and assembly checkpoint (MSAC) as 
the most significantly altered pathway followed by cytoskeleton/spindle microtubules 
network134. Eighteen up-regulated MSAC pathway component genes were able to classify the 
tumours into three molecular subgroups of potential therapeutic implications. Reynies et al 
analysed the expression profile from 38 MPM cultures as well as the mutation status of genes 
frequently mutated in MPM135. This resulted in a three-gene signature (PPL, UPK3B and 
TFP1) that defined two subgroups that partly correlated with histologic subtype. BAP1 
mutations are frequently detected in subgroup C1 made up of epithelioid subtype and 
epithelial-mesenchymal transition (EMT) pathway is preferentially upregulated in subgroup 
C2 that included sarcomatoid MPM characterised by mesenchymal phenotype. At present, 
molecular classification cannot replace classical histological classification in the clinical 
settings. 
Melaiu et al performed an extensive literature review on transcriptome studies (RTS) in MPM 
combined with data mining (DM)136. A total of 397 significant genes were shared between 
RTS and DM that are significantly involved in pathways associated with focal adhesion, 
MAPK signalling, p53 signalling, ECM-receptor interaction, regulation of actin cytoskeleton, 
cytokine-cytokine receptor interaction, neurotrophin signalling and cell adhesion molecules. 
Notably, genes encoding for matrix components, various cell adhesion molecules such as 
integrins, cytokines, growth factors and growth factor receptors are over-represented in four 
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of the pathways. This suggests cell-cell and cell-matrix interactions in the tumour 
microenvironment appear to be an important biological mechanism in MPM. The same group 
also identified 119 genes from RTS alone that were differentially expressed in at least two 
studies and investigated with reverse transcriptase-quantitative PCR in 15 MPM and 20 non-
MPM tissue samples. Fifty-nine out of the 119 genes were found to be significantly 
deregulated and are associated with cell cycle, focal adhesion, ECM-receptor interaction, 
DNA replication and metabolic pathways137. Of these, nine genes (ACSL1, CCNO, CFB, 
PDGFRB, SULF1, TACC1, THBS2, TIMP3, XPOT) were significantly deregulated in both 
MPM cell lines and 12 genes (ASS1, CCNB1, CDH11, COL1A1, CXADR, EIF4G1, GALNT7, 
ITGA4, KRT5, PTGIS, RAN, SOD1) in at least one MPM cell line.  
Several groups have generated list of gene classifier from microarray gene expression analysis 
to improve prognostic assessments. Pass et al profiled 21 MPM tumour tissues from pre-
surgical patients and constructed a 27-gene classifier that predicted long- and short-term 
survivors post surgery138. Lopez-Rios et al identified higher expression levels of Aurora 
kinases A and B, genes related to cell cycle and mitosis, correlated with shorter survival and 
generated a 29-gene classifier predictive of 1 year survival139. A 22-gene list of prognostic 
genes was published by Gordon et al and validated gene expression ratios of four of the genes 
(KIAA0977, GDIA1, L6, CTHBP) that could predict treatment-related outcomes irrespective 
of histologic subtypes140. In a subsequent study the same group came up with another 
prognostic classifier with a 7-gene list and the expression ratios of four (CD9, 
KIAA1199,THDB, DLG5) of the genes were validated to predict 1 year survival141. Another 
study undertaken by Glinsky et al used 11-gene signature of the polycomb group BMI-1-
driven pathway in several cancer types including MPM that was able to predict therapy failure 
and short survival142. There is a lack of concordance between all these studies with few 
overlapping genes. Three genes were reproducible individually between two studies: BTG2 
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has anti-proliferative function and involved in G1/S transition, SELENBP1 may play a role in 
ubiquitination-de-ubiquitination-mediated protein degradation and CFI is involved in the 
complement cascade.   
1.6.5 Gene mutations and associated pathways 
High-throughput sequencing of DNA such as whole exome sequencing (WES) represents 
another technology that allows a comprehensive characterisation of somatic mutations in 
protein-coding exons in different cancer types. This has led to better understanding of cancer 
biology with advances in cancer diagnosis and treatment resulting in improved clinical 
outcomes.  
Alifrangis et al presented an abstract on WES and copy number analysis of 19 MPM cell lines 
and 6 MPM early passage lines143. Interestingly, they reported absence of mutations in 
oncogenes but MPM cell lines harboured mutations in several TSG including NF2 and 
detected mutations in histone modifying genes such as MLL2 and SETD2. However, no 
mutation in BAP1 was reported. They also performed high-throughput screening across 48 
therapeutic compounds and identified phosphoinositide 3-kinase (PI3K)/mammalian target of 
rapamycin (mTOR) inhibition as the critical pathway to be targeted despite an absence of 
mutations in PI3K-related genes.  
Recently, Guo et al performed WES on DNA of 22 MPM frozen tissues collected prior to 
surgery and matched blood samples144. This study presented the first unbiased overview of the 
molecular landscape in MPM. Other studies have used a more directed approach by 
sequencing genes in specific pathways, known cancer genes and genes with actionable 
mutations145–148. Guo et al identified somatic BAP1 mutations and copy number alterations in 
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41% of cases. Another study by Lo et al analysed 52 known cancer genes with targeted 
sequencing on DNA from 123 formalin- fixed, paraffin-embedded (FFPE) MPM tissues. They 
identified genetic variations in BAP1 in 58% of cases that significantly correlated with loss of 
nuclear BAP1 staining. The frequent mutations in BAP1 from these two studies further 
confirmed previous findings of somatic mutations in BAP1 between 22-61% of MPM 
cases84,106,149. These mutations result in truncated BAP1 protein that inhibits nucleus 
localisation and aberrant deubiquitinase activity. 
BAP1 is a TSG involved in various biologic processes including chromatin dynamics, DNA 
damage response and regulation of the cell cycle and growth. Studies on xenograft models 
showed transfection of BAP1 into a BAP1-null cell line decreased proliferation while 
knockout of BAP1 in adult mice led to myeloid transformation150,151. The mechanisms of how 
loss of BAP1 lead to cell transformation is not well understood. It is known that BAP1 
encodes a nuclear ubiquitin C-terminal hydrolase and has been shown to deubiquitinate 
several proteins including HCF-1 to modulate expression of genes bound by transcription 
factors E2F and YY1152. BAP1 together with human orthologues of additional sex combs 
(ASXL1/ASXL2) form the Polycomb repressive deubiquitinase complex and deubiquitinate 
histone H2A implicated in gene silencing153. BAP1 also interacts with members of the Fox 
transcription factors (FOXK1/FOXK2) that are implicated in cell cycle regulation and 
proliferation. Recent studies revealed repression of FOXK2 target genes by BAP1 but in the 
absence of BAP1 upregulation of FOXK2 target genes is possible only in the presence of 
Ring1B-BMI1 complex, an E3 ubiquitin ligase for histone H2A154. Sacco et al has shown in 
their recent work that BAP1 differentially regulates the expression of class 1 histone 
deactylase expression with downregulation and upregulation of HDAC2 and HDAC1 
respectively in MPM cell lines with genetic BAP1 inactivation155. This may have therapeutic 
implication with HDAC inhibitor for patients with BAP1 mutation. BAP1 loss is associated 
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with more aggressive phenotype and high metastatic potential in uveal melanoma but this has 
not been shown in MPM or associated with any distinct phenotypes except higher smoking 
rates156. 
Both studies by Guo et al and Lo et al also reported frequent NF2 mutations located at 22q12 
in about 50% of cases consistent with previous studies on cell lines and primary MPM 
tumours144,146,157. NF2 inactivation also occurs as a result of small, large and homozygous 
deletions of chromosome 22 or possibly through aberrant splicing leading to altered 
transcripts in tumours that do not harbour mutations or deletions158. These result in loss of 
Merlin, a component of the Hippo signalling pathway, and subsequent transcriptional 
upregulation of YAP1, that is negatively regulated by Merlin through phosphorylation and 
sequestration under physiological state, thus leading to inhibition of cell-cycle arrest and 
apoptosis159. In addition, in vitro study demonstrated loss of Merlin increased motility and 
invasiveness of MPM cells through increased phosphorylation of focal adhesion kinase 
(FAK)160. Interestingly, a recent study revealed common mechanism between NF2 and 
BAP1161. The study identified cullin4A-RING E3 ubiquitin ligase (CRL4) as the major 
binding partner of wild type NF2 to inhibit CRL4-mediated ubiquitination of histones and 
other target proteins. Thus loss of NF2, leads to activation of CRL4 activity including 
promoting cell proliferation.  
Other than NF2, LATS2 is another component of the Hippo pathway that is inactivated by 
deletions or mutations in 22% of MPM cell lines and primary tumours162. A recent study by 
Miyanaga et al analysed the Hippo pathway genes with RNA and targeted exon 
sequencing145. They identified not only mutations in NF2 but also LATS2, RASSF1, and a 
gene fusion involving LATS2-PSEN1. These data indicate aberrant signalling via the Hippo 
pathway is an important event in MPM carcinogenesis. 
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Copy number analysis by Guo et al found the commonest focal deletion (45%) encompassed 
the 9p21 region consistent with a previous study163. Deletion of CDKN2A leads to loss of 
p14ARF and p16INK4A that result in degradation of p53 through activation of MDM2 and 
inactivation of pRB through activation of CDK4 respectively. Therefore, genetic defects in 
p14ARF and p16INK4A lead to deregulated cell cycle control. These alterations are also 
demonstrated in asbestos-induced MPM in mice and in multiwalled carbon nanotubes-
induced MPM as described by Nagai et al62. Combined knockout of INK4A and ARF in mice 
models play a key contributor and displayed accelerated asbestos-induced MPM compared to 
single gene knockout164. 
Despite the absence of mutations in oncogenes, integrative pathway analysis of the somatic 
mutations and copy number alterations identified frequent genetic alterations in MAPK, 
WNT, cell cycle,  p53/DNA repair and PI3K-AKT pathways 144,146. MAPK signalling cascade 
is multilevel and occurs in a specific manner with subsequent phosphorylation of cytosolic 
substrates and translocation to the nucleus to activate transcription factors including c-myc 
and STATs. In vitro studies have demonstrated activation of MAPK signalling as a result of 
asbestos exposure via EGFR-induced ERK activation and via p38 activation that induced a 
chronic immune response59,165. Cell line studies revealed the invasiveness of MPM cells is 
linked to phosphorylation of p38 leading to TGFβ 1-stimulated production of MMP2166. In 
vivo activation of MAPK in MPM is also evident from analysing phosphorylated proteins by 
IHC and Western blot but did not differentiate MPM from reactive mesothelial cells thereby 
questioning its significance in MPM carcinogenesis167. But another study found significant 
ERK phosphorylation by IHC in MPM when compared to normal lung tissues and well 
differentiated lung cancer that may be prognostic168. More recently, an in vitro study showed 
MAPK genes might have different roles in different MPM subtypes and found ERK2 to be 
critical in the transformation and homeostasis of epithelioid MPM169. Thus, MAPK pathway 
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requires further investigations as it is important for cell survival and is deregulated in MPM as 
shown by both exome sequencing and gene expression data. 
Both canonical and non-canonical WNT signalling pathways are involved in determining cell 
fate, cell polarity, cell proliferation and cell death. In the presence of WNT ligands, WNT/ β 
catenin canonical pathway is activated through formation of a protein complex involving Fz, 
LRP5/6 and Dvl leading to LRP6 phosphorylation and activation of Axin complex that 
inhibits degradation of β catenin. Thus β catenin translocates to the nucleus to interact with 
TCF/LEF leading to β catenin- dependent WNT-responsive gene activation170.  
Overexpression of Dvl and cytosolic β catenin has been demonstrated in MPM compared to 
controls and inhibition of Dvl leads to significant antitumor effects both in vivo and in vitro171. 
Gene expression analysis of WNT pathway genes using a WNT-specific microarrays showed 
up-regulation of numerous WNT genes (WNT1, WNT2, WNT5) and WNT-related genes 
(MYC, CCND1, JUN); and down-regulation of WNT antagonists (DKK1, SFRP2, and SFRP4) 
in MPM172. The same study also found WNT2 is frequently upregulated and inhibition of 
WNT2 by siRNA or monoclonal antibody resulted in programmed cell death in MPM cells. 
Further characterization of WNT pathway in MPM has utilized RT-PCR and real time RT-
PCR that confirmed frequent overexpression of WNT3, WNT5A, FZD2, 4, 6 and LEF1; and 
downregulation of WNT4, FZD3, SFRP4, APC and axin2173. The authors also demonstrated 
that WNT3A stimulated MPM cell proliferation and targeting β catenin could modulate and 
sensitise MPM cells to cytotoxic drugs. Several antagonists of WNT signalling (WIF-1, 
SFRP1, SFRP2) are also downregulated in MPM due to promoter hypermethylation as shown 
by Kohno et al115. These results suggest deregulation of the WNT pathway is active and 
relevant in MPM development thus providing means of therapeutic targets and mode of drug 
resistance. 
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The PI3K/AKT/mTOR pathway is a major pathway regulating cell cycle, cell growth, 
migration, invasion and apoptosis in many cancers.  AKT activation plays a central role in this 
pathway that is present in MPM cell lines174,175. Phosphorylated AKT is present in 88% of 
MPM by IHC but not shown to be prognostic176. PTEN is a central negative regulator of AKT 
and cell line study by Suzuki et al reported PTEN homozygous deletion in MPM contributed 
to AKT activation175. Loss of PTEN expression by IHC was observed in 62% of MPM cases 
and significantly correlated with shorter survival independent of histologic subtypes177. A 
recent study exploring PTEN-PI3K pathway and downstream proteins in MPM by IHC 
showed nuclear PTEN loss in only 23% of cases but confirmed overexpression of other genes 
in the pathway including mTOR, AKT, MAPK and FOXO3A178. Low protein expression of 
p36, downstream effector of the pathway, correlated significantly with longer progression-free 
and overall survival. Apart from loss of PTEN, AKT is activated by receptor tyrosine kinase 
(RTK) EGFR, MET and AXL. A cell-line study showed dual targeting of PI3K/mTOR 
pathway with BEZ235 resulted in greater decreased cell viability and similar results are 
achieved with combined RTK inhibition compared to single RTK inhibition179. Infrequent 
mutation in PIK3CA, the activated p110α catalytic subunit that is essential in translocating 
AKT onto the plasma membrane, was identified by Lo et al. Thus, PI3K/AKT pathway is 
active in MPM and represents a critical pathway to be targeted consistent with the findings by 
Alifrangis et al143,146. 
Aberrant cell cycle regulation has been described above and contributes to impaired response 
to DNA damage. DNA repair pathway plays an important role in maintaining genome 
stability and defects in repair process (due to altered gene expression or SNPs) leads to 
carcinogenesis and act synergistically with asbestos while adequate repair leads to chemo-and 
radiotherapy resistance. Roe et al showed up-regulation of three base-excision repair genes 
(PCNA, FEN1 and UNG2) in MPM that represent the major repair system for DNA damage 
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caused by oxidative stress133. The same study also found upregulation of p44 involved in 
nucleotide-excision repair. A case control study revealed association of XRCC1 and ERCC1 
SNPs with MPM in a population exposed to high asbestos level. This suggests increased 
susceptibility to DNA damage favours asbestos-induced carcinogenicity180. In addition, 
polymorphism in ERCC1 may contribute to cisplatin-resistance. There is little evidence on 
defect in mismatch-repair system in MPM except upregulation of MSH6 expression. Genes 
involved in homologous recombinant repair of double-strand breaks are also upregulated in 
MPM including RAD50, RAD54L, RAD21 and BRCA2133.  A cell line study also confirmed 
overexpression of BRCA1/2 that contributes to treatment resistance but sensitivity to cisplatin 
could be restored when BRCA2 level was lowered with ERK2 inhbitors181. Genes involved in 
non-homologous end joining repair are also implicated in MPM and include upregulation of 
XRCC4 expression, Ku80 expression and a point mutation in Ku70 that leads to impair 
dimerization with Ku80125,133,182. 
1.7 Conclusions 
There is no doubt that progress has been made in the past few years that provided broad 
insights into the mechanisms of MPM carcinogenesis but improvement in clinical outcome of 
patients has not been translated. In addition, there are many aspects in MPM carcinogenesis 
thatstill remain unclear and unknown. Transcriptome studies have provided invaluable 
biological mechanisms relevant in MPM carcinogenesis. The lack of reproducible genes 
between microarray studies could possibly be due to experimental or biology variability such 
as different microarray platforms, analytical tools, small sample size, contamination of 
tumour tissues with admixture of non-malignant or stromal tissues.  Application of exome 
sequencing in MPM is still lacking behind compared to other tumours and these are limited 
by similar reasons as described thus limiting a precise delineation of the molecular landscape 
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in MPM. Current sequencing studies have revealed lack of any “driver’” genes in MPM 
possibly as a result of large-scale chromosomal loss in MPM and the observed marked 
heterogeneity in mutation profile between tumours. 
Nevertheless, recent findings have been consistent amongst studies with frequent inactivating 
mutations in BAP1, NF2 and CDKN2A and some of the critical genes or pathways have 
started to emerge as common events in MPM including cell-cell, cell-matrix, Hippo, WNT, 
PI3K/AKT, MAPK and cell cycle/DNA repair pathways. However, more research are still 
required in MPM to look for novel biomarkers and therapeutic targets that can eventually lead 
to clinical benefits. Larger sample size study may be challenging in MPM but the 
establishment of tissue repositories including the UK Mesobank will aim to provide 
accessible tissue samples for research. In the interim, small but well-designed studies are still 
invaluable and by combining datasets from different studies using meta-analysis could lead to 
identification of more robust and significant genes or pathways for further validation.   
In this research, I hope to improve our understanding in the pathogenesis of MPM by 
examining the gene expression and mutational profiles to identify novel candidate genes and 
pathways. This research was performed on an independent cohort of MPM tissues and we 
utilised different data analytical tools compared to published studies for both gene expression 
and exome sequencing data. The weighted gene co-expression network analysis was used for 
functional interpretation of differentially expressed genes and this method has not been 
implemented in MPM study. In terms of whole exome data, candidate variants were selected  
using different filtering algorithm and criteria.  
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1.8 Hypothesis 
I hypothesise that there are important molecular aberrations responsible in driving MPM 
carcinogenesis. 
1.9 Aims 
To identify and validate candidate molecular alterations and pathways in MPM through gene 
expression profiling and whole exome sequencing. 
To correlate these findings with clinical phenotypes for the identification of potential 
diagnostic, prognostic and therapeutic biomarkers. 
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Chapter 2 - Materials and Methods 
2.1 Materials 
Table 2.1. Material and Suppliers 
Material Supplier 
100-bp DNA ladder  New England Biolabs, Herts, UK 
1X Tris-Borate-EDTA buffer Sigma-Aldrich, Dorset, UK 
Affymetrix® Human Gene 2.1 ST Array Plate Affymetrix, California, USA 
Agarose Sigma-Aldrich, Dorset, UK 
Ambion® WT Expression Kit  Life Technologies, California, USA 
BiOstic® FFPE Tissue DNA Isolation Kit  MO Bio Laboratories, California, USA 
Chloroform-isoamyl alcohol  Sigma-Aldrich, Dorset, UK 
Deionised distilled water MilliQ, Hertfordshire, UK 
Ethanol Fisher Scientitfic, Loughborough, UK 
GelRed Biotium, California, USA 
GeneChip® hybridisation, wash and stain kit Affymetrix, California, USA 
GeneChip® WT Terminal Labeling Kit  Affymetrix, California, USA 
HotStarTaq Plus Master Mix Kit Qiagen, Crawley, UK 
HycloneTM Water Fisher Scientific, Loughborough, UK 
Isopropanol Sigma-Aldrich, Dorset, UK 
Membrane Slide 0.17 PEN Carl Zeiss, Cambridgeshire, UK 
Optimal Cutting Temperature compound Fisher Scientific, Loughborough, UK 
Phase Lock Gel 5 Prime, USA 
Phenol Sigma-Aldrich, Dorset, UK 
Proteinase K Qiagen, Crawley, UK 
Qiagen RNeasy® fibrous midi kit  Qiagen, Crawley, UK 
Quant-iT™ PicoGreen® dsDNA Assay Kit  Life Technologies, California, USA 
Revised Primers-SYBR Fast Universal kit  D-Mark Biosciences, Toronto, Canada 
RNA 6000 Nano LabChip kit Agilent Technologies, California, USA 
Sample AdhesiveCap 500 clear (D) Carl Zeiss, Cambridgeshire, UK 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich, Dorset, UK 
SureSelectXT Human All Exon V4  Agilent Technologies, California, USA 
SureSelectXT reagent kit  Agilent Technologies, California, USA 
TissueRuptor Qiagen, Crawley, UK 
TissueRuptor Qiagen, Crawley, UK 
TissueRuptor disposable probe  Qiagen, Crawley, UK 
Tris-HCl Qiagen, Crawley, UK 
Wizard ® Genomic DNA Purification Kit  Promega, Southampton, UK 
Xylene ReAgent, Cheshire, UK 
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2.2 Methods 
2.2.1 Tissue and clinical data collection 
Tissue samples were identified from three institutions (1) the Royal Brompton and Harefield 
NHS Foundation Trust Hospital (RBH), (2) St George’s Hospital (SGH) and (3) the Royal 
Marsden NHS Foundation Trust Hospital (RMH). The use of tissues from RBH was approved 
by the Respiratory Biomedical Research Units (BRU) Heads of Consortia under the ethical 
approval given to the BRU Advanced Lung Disease Biobank and the Brompton and Harefield 
NHS Trust Diagnostic Tissue Bank. A study protocol, Molecular Analyses of Malignant 
Pleural Mesothelioma (MEMO) (Appendix 2.1), was written by me and co-supervised by the 
study’s primary investigator, Dr Popat. This was approved by research ethics committees and 
local research and development department for the use of tissues from SGH and RMH. 
Funding for this project to cover the costs for sample procurement and reagents was 
successfully secured from RBH Respiratory BRU Pump-Priming project and RMH 
Biomedical Research Centre (BRC); both awarded under National Institute for Health 
Research (NIHR). 
Tissue samples identified included frozen tumour tissues stored with or without ribonucleic 
acid (RNA) later and non-malignant frozen pleural tissues stored with or without RNA later 
from RBH. Tissues identified for use under the MEMO study included tumour formalin fixed, 
paraffin-embedded (FFPE) blocks. In addition, frozen tumour tissues with matched peripheral 
blood were contributed from an existing study, EQUALITY (an Imperial College London 
(ICL)-sponsored, prospective study on thoracic cancers undergoing biopsy at SGH (REC 
reference: 10/H0808/53). Written informed consents for use of tissue +/- blood for research 
 47 
were available for all participants whose samples were used.  
A clinical database was created to store patients’ demographic and clinical details collected 
through retrospective review of case notes and electronic patient records. The data was 
anonymised in a link-coded manner and entered into a password protected excel worksheet. 
The following data if available were collected for all patients: 
• date of birth 
• gender 
• date of diagnosis 
• histological subtype 
• date of death or last follow up 
• history of previous cancer or family history of cancer in first degree relatives 
• smoking history and asbestos exposure 
• treatment details including types of treatments received, date when treatment was 
commenced and completed, treatment response and date of disease progression. 
2.2.2 Tissue preparation and quality assessment 
2.2.2.1 Microtomy  
Frozen tissue samples were embedded in Optimal Cutting Temperature (OCT) compound 
followed by cutting five micrometre (µm) sections on a microtome-cryostat. A maximum of 
two sections per sample were obtained and mounted onto a glass slide for haematoxylin and 
eosin (H&E) staining. The remaining frozen tissues were immediately stored back in -80 
degrees Celsius (°C) freezer after removing as much OCT compound as possible. 
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Sections from FFPE samples were prepared using a rotary microtome to cut a maximum of 
two sections of five µm thickness which were mounted onto a glass slide for H&E staining. 
After histologic assessment, a further five sections were prepared for nuclei acid extractions. 
In selected FFPE samples for micro-dissection, a further 5-10 sections were prepared and 
mounted onto a polyethylene napthalate (PEN)-membrane slide. 
2.2.2.2 Haematoxylin and Eosin staining 
H&E staining on the sections was performed according to routine histologic protocol183. 
Briefly, the oxidation product of haematoxylin, haematin, stained the nuclei blue and eosin 
stained the other structures red. Over-staining with eosin was washed out in running water 
before fixing with xylene.  
2.2.2.3 Pathological review 
Sections stained with H&E were examined with a brightfield microscope by me in addition to 
two certified histopathologists (Professor Nicholson and Dr Montero-Fernandez, RBH) for 
histopathological verification and tumour abundance assessment. Tumour samples with a 
minimum arbitrary tumour abundance threshold of 30% viable-appearing tumour cells were 
taken forward for genomic nuclei acid extractions. Non-malignant areas from selected FFPE 
samples were identified and marked for micro-dissection to obtain matched normal tissue 
representative of germline genome. 
2.2.2.4 Laser-capture micro-dissection 
Laser-capture micro-dissection (LCM) on FFPE sections was carried out using the PALM 
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Microbeam (Carl Zeiss, Cambridgeshire, UK) instrument at UCL Cancer Institute and 
Wolfson Institute for Biomedical Research Centre. Each sections from the selected FFPE 
samples for micro-dissection were mounted onto individual PEN-membrane slide which was 
highly absorptive in the UV (ultraviolet)-A range to facilitate laser cutting.  To improve laser 
cutting efficiency, residual paraffin was removed from each section before micro-dissection. 
The de-paraffination procedure involved immersing membrane slide in xylene for five 
minutes repeated twice followed by graduated ethanol washes using 100% ethanol for one 
minute, 96% ethanol for one minute and 70% ethanol for one minute. The deparaffinised 
membrane slides were left to dry in room temperature prior to micro-dissection. The areas for 
micro-dissection in each section were visualised via microscopy (Figure 2.1) and targeted for 
non-contact LCM with each UV laser pulse (Figure 2.2 & 2.3). The dissected non-tumour 
areas from each section were catapulted and pooled into a 500 microlitre (µl) tube with 
adhesive cap for each FFPE sample. The micro-dissected areas ranged from 50 to 100 µm2 
per dissection and each sample had around 300 to 600 micro-dissections pooled together. 
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Figure 2.1. Non-tumour areas identified and visualised via microscopy. 
 
Figure 2.2. Areas for micro-dissection are marked as shown. 
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Figure 2.3. Dissected sections are catapulted and captured into an adhesive cap tube. 
2.2.3 RNA isolation 
2.2.3.1 Frozen tissues 
Total RNA was isolated from frozen tumour and non-malignant pleural tissues with Qiagen 
RNeasy® fibrous midi kit (Qiagen, Crawley, UK) as per manufacturer’s instructions. Each 
piece of tissue was submerged in two millilitres (ml) of Buffer RLT (guanidine thiocyanate 
and beta mercaptoethanol) and ruptured using a TissueRuptor disposable probe and the 
TissueRuptor (Qiagen, Crawley, UK) for just under a minute. Four ml of RNAse free water 
and 65 µl of Proteinase K were added to aid protein digestion and inactivate nucleases 
followed by incubation in a waterbath at 55°C for 90 minutes. The resulting lysate was 
centrifuged at 3273 x g for 10 minutes to pellet the cell debris and the supernatant was 
transferred into a new tube containing three ml of 100% ethanol for RNA precipitation. Three 
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ml of the mixture were transferred at a time to the Midi spin column containing a silica resin 
membrane to bind the RNA. The spin column was centrifuged at 3273 x g (Beckman Coulter 
Allegra® X-12R centrifuge) for five minutes and the flow-through was discarded. This step 
was repeated until all the mixture was transferred. The spin column was then washed by 
adding two ml of Buffer RW1 (Guanidine Thiocyanante and ethanol) to remove biomolecules 
(proteins, fatty acids, carbohydrates) and centrifuged for five minutes at 3270 x g. 
Contaminating deoxyribonucleic acid (DNA) was eliminated by incubation with 160 µl of 
DNase I (140 µl RDD Buffer and 20 µl DNase I) for 15 minutes at room temperature. The 
column was incubated with two ml of RW1 buffer at room temperature for two minutes and 
then centrifuged at 3270 x g for five minutes. This was followed by adding two and a half ml 
of RPE buffer to remove traces of salt then centrifugation at 3270 x g for five minutes. The 
bound RNA was eluted from the column by adding 150 µl RNase-free water. The elute was 
collected from the column following centrifugation at 3270 x g for three minutes and re-
applied to the column to repeat the incubation and centrifugation steps once more. The RNA 
was stored at –80°C until further use. 
2.2.3.2 RNA quantification and purity analysis 
RNA yield and purity were measured using the Thermo Scientific NanoDropTM 1000 
Spectrophotometer (NanoDrop Technologies, Thermo Fisher Scientific, Delaware, USA). 
This records the RNA concentration and the A260/280 ratio. The purity of RNA is determined 
by absorbance at 260 and 280nm with A260/280 ratio of 1.9 to 2.1 being ideal. A lower value 
may indicate the presence of other contaminants such as protein or phenol.   
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2.2.3.3 RNA quality analysis 
The quality of RNA was assessed using one µl of RNA samples, the RNA 6000 Nano 
AssayTM kit and the Agilent 2100 BioanalyserTM. The gel-dye mix was prepared as per 
manufacturer’s instructions. The appropriate well on the RNA chip was loaded with nine μl of 
the gel–dye mix and pressure applied to the well via a one ml syringe on a chip priming 
station. The ladder well and all sample wells were then loaded with five μl of the RNA 6000 
Nano marker.  The RNA samples and one µl of RNA ladder were denatured at 70 °C for two 
minutes and then loaded to the appropriate wells. The mixture in the wells was mixed by 
vortexing for one minute at 2400 rates per minute prior to bioanalyser assessment. The 
integrity of total RNA was assessed using the 2100 Agilent bioanalyser to determine RNA 
size, quality and quantity by electrophoresis.  A software in the bioanalyser classifies total 
RNA by generating a RNA Integrity Number (RIN) score from one to 10. A score of one 
indicates degraded RNA and a score of 10 indicates highly intact RNA. A ratio of 28s to 18s 
ribosomal subunits of 1.9-2.1 also indicates little or no RNA degradation. Figure 2.4 shows 
two RNA samples with high RIN score. 
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Figure 2.4.  Electrophoretic traces generated on Bioanalyser for RNA samples. This 
figure shows traces from two cases showing high quality RNA with distinct 18S and 28S 
rRNA peaks (on the left) and the corresponding gel electrophoresis showing discreet 
bands of high molecular weight RNA.  
 
 2.2.4 Gene Expression Profiling 
RNA samples from tumour and unmatched non-malignant pleural tissues (control) with 
A260/280 ratio of ≥ 1.8 and RIN of ≥ 6.0 were labelled and hybridised in two batches on 
Affymetrix® Human Gene 2.1 ST Array Plate. The Human Gene 2.1 ST Array Plate covers > 
33,500 coding transcripts, > 11,000 long intergenic non-coding transcripts and > 25,000 
RefSeq (Entrez) gene counts. The array provides high coverage of the transcribed genome 
based on data sourced from RefSeq (release51), Ensemble (release 65), lncRNA DB and 
Broad Institute, Human Body Map lincRNAs and TUCP (transcripts of uncertain coding 
potential) catalogue.  The array contains a median of 21 probes per transcript and 25 bases in 
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length for each unique probe measuring a median of 525 bases per transcript.  
The following subsections describe the process of generating amplified sense-strand 
complementary DNA (cDNA) using the Ambion® WT Expression Kit (Life Technologies, 
California, USA) ready for fragmentation and labelling using Affymetrix GeneChip® WT 
Terminal Labeling Kit (Affymetrix, California, USA) before hybridization onto Affymetrix® 
Human Gene 2.1 ST Array Plate (Affymetrix, California, USA). All steps were carried out 
following the manufacturers’ protocols. The starting total RNA quantity was 200 nanogram 
(ng) for tumour and 100 ng for control samples. The Affymetrix® GeneChip® Poly-A RNA 
control kit (Affymetrix, California, USA) was used to prepare Poly-A RNA control dilutions 
for 100 ng and 200 ng of total RNA used. The controls were amplified and labelled together 
with the total RNA samples to monitor the efficiency of the labelling process during the entire 
experiments. 
2.2.4.1 cRNA Amplification 
The synthesis and purification of amplified antisense complementary RNA (cRNA) involved 
a two days' process. The first day involved synthesis of first strand cDNA.  A master mix 
containing one μl of first-strand enzyme mix (oligo (T7) primer) and four μl of first-strand 
buffer mix per reaction was prepared.  Five μl of the master mix was added to total RNA 
made up in three μl nuclease-free water mixed with two μl of diluted Poly-A RNA control.  
The reaction was incubated for one hour at 25 °C then one hour at 42 °C followed by a final 
incubation for at least two minutes at four °C in a Pettier Thermal Cycler–PTC225 DNA 
Engine Tetrad (MJ Research). 
The synthesis of second-strand cDNA was generated by the addition of second-strand master 
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mix containing five μl of second-strand enzyme mix (DNA polymerase and RNase H) mixed 
with 12.5 μl of second-strand buffer mix and re-suspended in nuclease-free water to achieve a 
final total volume of 50µl. The samples were then incubated in the thermal cycler for one 
hour at 16 °C then 10 minutes at 65 °C followed by a final incubation for at least two minutes 
at four °C. Antisense cRNA was synthesized by in vitro transcription (IVT) using 30 μl of the 
IVT master mix containing 6 μl of IVT enzyme mix (T7 RNA polymerase) mixed with 24 μl 
of IVT buffer mix added to each sample. This was left to incubate in the thermal cycler for 16 
hours at 40 °C. 
The second day involved purification of cRNA by removal of contaminants and 
unincorporated nucleotides. This was carried out by isopropanol precipitation using nucleic 
acid binding beads. A master mix containing 10 μl of nuclei acid binding beads and 50 μl of 
nuclei acid binding buffer concentrate for each reaction was prepared. This was added to 
cRNA together with 60 μl of 100% isopropanol and transferred onto a U-bottom plate. The 
plate was gently shaken on a Lab-Line Titer Plate Shaker for two minutes. The plate was then 
placed on a magnetic stand to capture the magnetic beads and the supernatant was discarded. 
The beads were washed twice using 100 μl of nuclei acid wash solution. The purified cRNA 
was then eluted from the nucleic acid binding beads by adding 35 μl of preheated elution 
solution. The concentrations and quality of cRNA were analysed using the NanoDrop-1000 
spectrophotometer and RNA 6000 Nano AssayTM kit with the Agilent 2100 BioanalyserTM. An 
electropherogram of a good cRNA synthesis consisted of a smear of products between 50 and 
4500 nucleotides (nt) long as shown in Figure 2.5.      
  B 
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Figure 2.5. Bioanalyser Electropherogram (A) and Gel Image (B) of cRNA. Based on the 
data from an RNA size reference ladder, the fluorescence of 25 nt is between 20 and 25 
seconds and 4000 nt is detected at 50 seconds as marked. [FU], fluorescence unit; [S], 
second. 
2.2.4.2 cDNA Amplification 
The synthesis of sense-strand cDNA involved reverse transcription of cRNA using random 
primers. Ten μg of purified cRNA was prepared and made up to a volume of 22 μl with 
nuclease-free water. On ice, two μl of random primers were added to each sample followed by 
denaturing of cRNA in the thermal cycler for five minutes at 70 °C, five minutes at 25 °C and 
two minutes at four °C. After the incubation, the second cycle master mix was prepared using 
eight μl of 2nd-Cycle Buffer Mix and eight μl of 2nd-Cycle Enzyme Mix for each reaction. 
Sixteen μl of the master mix was added to each sample followed by incubation in the thermal 
cycler for 10 minutes at 25 °C, then 90 minutes at 42 °C and two minutes at four °C. This was 
followed by the addition of two μl of RNase H to degrade cRNA template leaving only single-
stranded cDNA and left to incubate in the thermal cycler for 45 minutes at 37 °C, five minutes 
at 95 °C and two minutes at four °C. 
The purification of cDNA involved ethanol precipitation using nucleic acid binding beads. A 
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master mix containing 10 μl of nuclei acid binding beads and 50 μl of nuclei acid binding 
buffer concentrate for each reaction was prepared. This was added to cDNA together with 120 
μl of 100% ethanol and transferred onto a U-bottom plate. The plate was gently shaken on a 
Lab-Line Titer Plate Shaker for two minutes. The magnetic beads were captured with the use 
of magnetic stand and discarding the supernatant. The beads were washed twice using 100 μl 
of nuclei acid wash solution. The cDNA was eluted from the nucleic acid binding beads by 
the addition of 30 μl of pre-heated elution solution. The concentrations and quality of purified 
cDNA were analysed using the NanoDrop-1000 spectrophotometer and RNA 6000 Nano 
AssayTM kit with the Agilent 2100 BioanalyserTM. The median cDNA profile size should be 
around 400 nt. The figure below, Figure 2.6, shows an example of a cDNA profile. 
A          B 
 
Figure 2.6. Bioanalyser Electropherogram (A) and Gel Image (B) of cDNA. [FU], 
fluorescence unit; [S], second. 
2.2.4.3 Fragmentation, Labelling and Hybridization 
The process of cDNA fragmentation, labelling and hybridisation was all carried out on the 
same day. The Affymetrix GeneChip® WT Terminal Labeling Kit (Affymetrix, California, 
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USA) was used for cDNA fragmentation and labelling. The fragmentation step involved using 
five and a half μg of single-stranded cDNA made up to a total volume of 31.2 μl with 
nuclease-free water. The fragmentation master mix was prepared with 10 μl of RNase-free 
water, 4.8 μl of 10X cDNA fragmentation buffer, one μl of UDG (10 U/μl) and one μl of APE 
1 (1,000 U/μl) for each reaction. This mixture was added to each sample and left to incubate 
in the thermal cycler for 60 minutes at 37 °C, two minutes at 93 °C and two minutes at four 
°C. The quality of fragmented cDNA was analysed using RNA 6000 Nano AssayTM kit with 
the Agilent 2100 BioanalyserTM. For successful fragmentation, the expected range in peak size 
of the fragmented samples should be approximately 40 to 70 nt. Figure 2.7 shows an example 
of a successful cDNA fragmentation. 
A         B 
  
Figure 2.7. Bioanalyser Electropherogram (A) and Gel Image (B) of fragmented ss 
cDNA. [FU], fluorescence unit; [S], second. 
The labelling master mix was prepared using 12 μl of five X TdT buffer, two μl of TdT and 
one μl of DNA labelling reagent for each reaction. This was added to 45 μl of fragmented 
single-stranded cDNA samples followed by incubation in the thermal cycler for 60 minutes at 
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37 °C, 10 minutes at 70 °C and four °C for at least two minutes.  
The hybridisation step involved the use of the GeneChip® hybridisation, wash and stain kit 
(Affymetrix, California, USA). The 20X eukaryotic hybridisation controls (bioB, bioC, bioD, 
cre) were denatured at 65 °C for five minutes on a heating block. Hybridization cocktail was 
prepared and consisted of 1.2 μl of control Oligonucleotide B2, six μl of denatured 20X 
eukaryotic hybridisation controls, 24 μl of 5X WT Hyb Add 1 and eight μl of 15X W Hyb 
Add 4 for each array/sample. This cocktail mix was added to 32.8 μl of the fragmented and 
labelled cDNA. The cocktail was denatured in the thermal cycler for five minutes at 95 °C 
followed by 45 °C for five minutes and centrifuged for one minute at 5000 rpm at room 
temperature. 
The GeneTitanTM Multi-Channel Instrument was used to process the array plate from target 
hybridisation to data generation using a combination of a hybridisation oven, fluidics 
processing and imaging device. Prior to hybridisation process, the setup of the GeneTitanTM 
Instrument involved deionising stain trays and lids, filling up the trays with the recommended 
buffer, filling up the bottles for washing and emptying the bottle for rinsing. This was 
followed by loading 90 μl of the centrifuged supernatant hybridisation mix into the 
appropriate well of the Affymetrix® Human Gene 2.1 ST Array Plate. The hybridisation 
process and scanning of the array plate took approximately 16 hours on the GeneTitanTM 
Instrument.  
2.2.4.4 Pre-processing of raw microarray data 
Raw microarray data from Affymetrix was generated with the extension CEL format. The 
CEL file contained the raw probe data from measured probe intensities in the hybridised 
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microarray. Data analysis was carried with R studio software and the relevant packages. 
The preprocessing steps of Affymetrix probe-level expression data consisted of quality 
assessment, background adjustment, normalization, and summarization at the probe set level 
as a measure of the expression level of corresponding messenger RNA (mRNA). The 
assessment of raw data quality was performed using arrayQualityMetrics (version 3.2)184. 
This package produces a comprehensive report in a specified directory and an HTML page. 
The report contains a metadata table about the quality of the arrays and for outlier detection. 
The quality assessment is based on comparison between arrays, array intensity distributions 
and individual array quality.  
After removing outlier arrays, the apt-probeset-summarize programme (Affymetrix Power 
Tools) was used for background correction, normalisation and summarising probe data from 
CEL files. Probe intensities was adjusted for background intensities (none or nonspecific 
hybridisation and fluorescent artefacts) to give a more accurate measure of spot intensity. 
Normalisation was performed to correct for differences in probe intensities between samples 
based on the assumption that the distribution of intensities was constant and taking into 
account housekeeping genes and spike in controls.  The random multiple access (RMA) 
procedure was used for both background adjustment using only perfect match (PM) probe 
intensities and for probe-level data normalisation with quantile normalisation method185,186. 
This was followed by median polish procedure to summarise the PM intensities. Expression 
values of each probe set were calculated by using the rmasummary function that summarised 
the probe set intensity summaries on a logarithm of 2 scale. Transcripts with expression level 
that were below the median expression value in all samples were identified and removed. 
Next, the variability of experimental effects was quantified using principal variance 
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component analysis (PVCA) (version 1.10 R package) method187. Variables from the 
phenotype file were specified and included for PVCA analysis to identify the prominent 
sources of variability. This method involves principal component analysis to reduce data 
dimension while retaining the maximum variability of the data, and variance components 
analysis to fit a mixed linear model to each principal components using a number of factors as 
random variables.  The proportion of total variance was estimated by standardising the 
corresponding eigenvalues as weights.  
2.2.4.5 Differential Gene expression analysis 
After pre-processing and filtering steps, the gene expression data was analysed using 
unsupervised 2-dimensional hierarchical clustering algorithm to assess clustering of samples. 
Differentially expressed genes were identified by applying parametric tests to rank genes with 
respect to the resulting probability (p)-value using the limma package (version 3.2)188. First, a 
design matrix representing the gene expression data and the contrast matrix representing the 
coefficients of the design matrix that modelled the contrasts of difference between the 
tumours and controls were specified. A linear model was used to model the data set and the 
contrast matrix allowed the fitted coefficients to be compared and to generate moderate t-
statistics using the empirical Bayes method. The raw p-values were adjusted for multiple 
testing using the Benjamini & Hochberg method to control for expected false discovery rate 
(FDR)189.Transcript clusters were then annotated using HuGene-2_0-st-v1 Transcript Cluster 
Annotations (Affymetrix, California, USA). Genes with an adjusted p-value of ≤ 0.01 and 
fold change (FC) in the level of expression of ≥ two were selected and analysed using 
WebGestalt Gene Set Analysis ToolKit to identify enriched Gene Ontology (GO) terms and 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways190.  
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2.2.4.6 Weighted gene co-expression network analysis 
The weighted gene co-expression network analysis (WGCNA, version 1.49) was used to 
construct MPM-associated gene co-expression networks and identification of potential hub 
genes (genes with high connectivity) contributing to MPM carcinogenesis191. Differentially 
expressed genes with an adjusted p-value of ≤ 0.05 were selected together with 
clinicopathological variables for WGCNA analysis.  
Firstly, gene expression profiles were converted into connection weights using a Pearson 
correlation to relate every pairwise gene-gene relationship. These were then transformed into 
an adjacency matrix by using a soft thresholding power β. A power β of nine was chosen 
based on the network exhibiting approximate scale-free topology criteria and high 
connectivity.  The adjacency was then transformed into a network distance measure known as 
the topological overlap matrix (TOM) to allow identification of genes that form highly 
integrated clusters of co-expressed genes (modules). Modules containing genes with high 
topological overlap were identified by (1) calculating the corresponding TOM dissimilarity 
measures (TOM-1), (2) hierarchical clustering analysis to produce a clustering dendrogram of 
genes based on TOM dissimilarity, (3) dynamic tree-cut algorithm to calculate the module 
eigengenes and clustering them based on a height cut of 0.25 corresponding to a correlation of 
0.75.  
Next, the module eigengenes (MEs) were computed by retaining the first principal component 
following principal components analysis of the log2 expression data for each module. MEs 
represent a summary measure for the overall co-expression network in that module. The MEs 
were then tested for association with clinicopathological variables adjusted for age and gender 
using the linear regression model. The resulting p-values were adjusted for multiple testing by 
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Benjamini & Hochberg method. For each gene, an intramodular connectivity (kme) was 
calculated that measured its connectivity with respect to other genes in a particular module. 
Module membership (MM) of a gene was derived from Pearson’s correlation coefficient 
between the expression profile of that particular gene and the MEs.  
The biological significance of a gene to a clinical variable known as gene significance (GS) 
was calculated for each gene. The linear regression model was used to regress the 
clinicopathological variables and individual gene expression profile adjusted for age and 
gender. The GS measure was defined as minus the logarithm of the resulting adjusted p-value. 
To assess associations with survival data, Cox proportional hazards model was used to regress 
survival time on individual gene expression profile adjusted for age and gender. The hazard 
ratio was computed with the corresponding p-value for each genes and the prognostic GS of a 
gene was defined as minus the logarithm of the p-value. The ModuleEnrichment function was 
used to generate bar plot, 95% confidence interval of the mean and a Kruskal Wallis p-value 
to identify modules enriched with genes associated with survival. Spearman’s correlation was 
used to relate the GS and kme or MM that allowed us to identify potential hub genes that have 
high GS for the clinical variable of interest and high connectivity within the module.  
The network from WGCNA analysis was visualised through Cytoscape Software 3.0.1192. 
Reactome Cytoscape Plugin was used for functional enrichment analysis for GO terms and 
associated pathways. CyTargetLinker from Cytoscape was used to generate biological 
networks with regulatory and drug-target interactions. Regulatory data was extracted from 
homosapiens Regulatory Interaction Networks, Cytoscape. 
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2.2.5 DNA isolation 
2.2.5.1 Frozen tissues 
Total genomic DNA was isolated from frozen tumour tissues containing 30% or more viable-
appearing tumour cells using the phenol-chloroform method. Each piece of tissue was 
ruptured in 2710 µl re-suspension buffer (0.075M NaCl, 0.024M EDTA pH 8, deionised 
distilled water) and 271µl 10% SDS using a TissueRuptor disposable probe and the 
TissueRuptor (Qiagen, Crawley, UK) for approximately one minute. This was followed by 
adding 22µl of Proteinase K to aid protein digestion and the resulting lysate was left to 
incubate overnight in a water bath at 37°C.  
On the following day, three ml of the clear lysate was transferred to a pre-spun light phase 
lock gel tube containing an equal volume of buffered phenol solution, mixed thoroughly and 
centrifuged for 10 minutes at 2000 x g (Beckman Coulter Allegra® X-12R centrifuge) to 
yield a lower organic protein-containing phase and an upper nuclei acid containing aqueous 
phase. Next, three ml of phenol:chloroform:isoamyl solution (25:24:1) were added and 
centrifuged for 10 minutes at 2000 x g.  In order to partition the remaining lipids, three ml of 
chloroform:isoamyl (24:1) were added and centrifuged for 10 minutes at 2000 x g. The 
aqueous phase was decanted into a new tube containing 300µl Sodium Acetate and six ml of 
100% ethanol for precipitation and cooled for 90 minutes at -20°C. DNA pellet was separated 
from the supernatant by centrifugation at 1800 x g and at four °C for one hour. The 
supernatant was removed and the pellet was left to dry at room temperature for 20 - 30 
minutes to remove traces of ethanol. Finally, DNA was re-suspended in 250µl 10mM Tris-
HCL (Qiagen, Crawley, UK) and stored overnight at four °C. DNA was assessed for quality 
and yield the next day and the remaining samples were stored at -80°C until further use. 
 66 
2.2.5.2 Blood 
DNA isolation from whole blood samples identified from EQUALITY study was carried out 
using Wizard ® Genomic DNA Purification Kit (Promega, Southampton, UK) following the 
manufacturer’s instructions. Blood sample was transferred into a 50 ml centrifuge tube 
containing 30 ml of Cell Lysis solution for red blood cells lysis. These were mixed thoroughly 
by inverting the tube several times. The mixture was incubated at room temperature for 30 
minutes on a rocker set at medium speed. This was followed by centrifugation at 2000 x g for 
10 minutes at room temperature. The supernatant was discarded leaving behind the white 
blood cells pellet with approximately 1.4ml of residual liquid. The white blood cells were re-
suspended by vortexing the tube vigorously followed by the addition of 10ml of Nuclei Lysis 
solution to lyse the white blood cells. The mixture was incubated in a water bath at 37°C for 
two hours. The cellular proteins were removed by salt-precipitation method involving the 
addition of 3.3 ml of Protein Precipitation Solution and centrifugation at 2000 x g at room 
temperature for 10 minutes. This resulted in a lower protein-containing phase and an upper 
genomic DNA-containing phase. The supernatant was transferred to a fresh tube containing 
10 ml of isopropanol to concentrate and desalt the genomic DNA. By gently inverting the 
tube, DNA was visible as thread like strands and DNA pellet was obtained by centrifugation 
the mixture at 2000x g for two minutes at room temperature. After discarding the supernatant, 
10 ml of 70% ethanol was added to wash the DNA pellet followed by centrifugation at 2000 x 
g for 2minutes. The ethanol was discarded and DNA pellet was left to air dry for 10 minutes. 
Finally, the DNA was re-suspended in 800 µl of rehydration solution and left to incubate for 
few days at four °C before assessing the quality and yield.  
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2.2.5.3 FFPE 
DNA was isolated from five micro-dissected FFPE sections of five µm thickness using the 
BiOstic® FFPE Tissue DNA Isolation Kit (MO Bio Laboratories, California, and USA). This 
was carried out by collaborators at McGill University and Genome Quebec Innovation 
Centre, Canada. Briefly, paraffin wax from samples was melted away using an optimised wax 
melting buffer without the use of organic solvent, xylene, and the addition of proteinase K to 
aid tissue digestion. This was followed by a 90°C heating step to remove cross-linking in 
DNA. The sample was then mixed with a salt binding buffer and 100% ethanol for binding to 
silica filters. Impurities were washed from the column and pure DNA was eluted in a low salt 
buffer. 
2.2.5.4 DNA quantification and purity analysis 
DNA yield and purity were assessed using the Thermo Scientific NanoDropTM 1000 
Spectrophotometer (NanoDrop Technologies, Thermo Fisher Scientific, Delaware, USA). 
This records the DNA concentration and the A260/280 ratio. DNA concentration is 
determined by absorbance at 260 nm, the peak for DNA, and the modified Beer Lambert 
equation (a reading of 1.0 at 260 nm corresponded to 50 µg/ml of double-stranded DNA). 
Purity is estimated by the ratio of absorbance at 260 and 280 nm. The absorbance at 260 nm 
measures not only double-stranded DNA but also single-stranded DNA and other 
contaminants such as proteins and extraction buffers. A ratio around 1.8 indicates good 
quality DNA. Lower values indicate protein contamination and higher values of 2.1 or more 
indicate RNA contamination.  
DNA quantification was also performed by fluorometry using Quant-iT™ PicoGreen® 
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dsDNA Assay Kit (Life Technologies, California, USA). This was carried out by 
collaborators at McGill University and Genome Quebec Innovation Centre, Canada, on DNA 
isolated from frozen samples sent for whole exome sequencing and from micro-dissected 
FFPE sections. PicoGreen® quantified double-stranded DNA with high sensitivity. The 
fluorescent dye exhibits an emission peak at 530 nm and fluorescent enhancement is 
exceptionally high when bound specifically to double-stranded DNA. 
2.2.6 Whole exome sequencing 
Whole exome sequencing of genomic DNA was carried out by collaborators at McGill 
University and Genome Quebec Innovation Centre, Canada, with Illumina HiSeq platform. 
This platform utilises sequencing by synthesis technology to generate exome data193. The 
technology enables detection of single bases when added to DNA strands using fluorescent 
reversible terminator deoxyribonucleotides. The images of fluorescent terminator are captured 
as deoxyribonucleotide triphosphate (dNTP) is added, and then cleave so that the next base 
could be added and imaged. The presence of four reversible terminator-bound dNTPs 
minimises incorporation bias present during each sequencing cycle.  
Libraries were generated robotically using SureSelectXT reagent kit (Agilent Technologies, 
California, USA) following the SureSelectXT Target Enrichment System for Illumina Paired-
End Multiplex Sequencing protocol. Briefly, three μg of concentrated and purified genomic 
DNA was fragmented to around 200 base pairs (bp) using the Covaris instrument. After end-
repair and A-tailing, sequencing adapters were ligated onto the DNA fragments followed by 
PCR amplification of the adaptor-ligated library. After purification with AMPure XP beads, 
the adapter-ligated DNA libraries were concentrated for hybridisation using SureSelectXT 
Human All Exon V4 baits (Agilent Technologies, California, USA). The captured product was 
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amplified with indexing primers by PCR and purified with AMPure XP beads. The 
concentration of the sequencing libraries was quantified using the Quant-iT™ PicoGreen® 
dsDNA Assay Kit (Life Technologies, California, USA) and the Kapa Illumina GA with 
Revised Primers-SYBR Fast Universal kit (D-Mark). Average size fragment was determined 
using a LaChip GX (PerkinElmer) instrument. Each captured library was loaded on the 
Illumina HiSeq2000 for sequencing according to standard protocols 
2.2.6.1 Data processing and quality control 
Raw image files were processed with Illumina base calling software 1.7 for base calling using 
default parameters and the sequences of each library were generated as 90 bp paired-end 
reads. The target regions were sequenced to 100-160X mean coverage in each sample. These 
were trimmed from the 3’end to give a base quality score of at least 30 as encoded in phred 
33. Sequencing adapters were clipped off to generate all reads with a length of at least 50 bp. 
The reads were then mapped to the reference human genome (UCSC hg19) using Burrows–
Wheeler aligner194. A single global Binary Alignment Map (BAM) file for each tumour and 
normal samples was generated using the Picard software195. Data quality control was 
processed with GATK software as suggested by the Broad Institute and these include 
realignment of short insertions and deletions (indels), recalculation of the realigned read mate 
coordinates, marking of read duplicates and base quality recalibration to generate a more 
accurate quality score based on covariates such as reported quality score, position within the 
read accounting for the preceding and current nucleotide.  
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2.2.6.2 Variant analysis 
GATK Unified Genotyper variant discovery tool was used for calling variants from the 
processed BAM files196 . This was followed by variant score recalibration for single 
nucleotide variants (SNVs) and indels separately to generate variant call format (VCF) files 
for SNVs and indels respectively. The VCF files were annotated using ANNOVAR197 to 
obtain gene-based (e.g. functional consequences on genes), region-based (e.g. conserved 
regions) and filter-based annotations (e.g. 1000 Genomes Project, dbSNP) for each variant. 
In order to identify candidate SNVs and indels, the annotated files were subjected to a series 
of filtering steps. Somatic variants were identified after removing variants present in the 
matched normal samples. Common single nucleotide polymorphisms (SNPs) present in 
dbSNP138, 1000 Genomes Project and NHLBI GO Exome Sequencing Project 6500 were 
filtered out. The functional significance of each variant was assessed using Polyphen-2 
(genetics.bwh.harvard.edu/pph2/), SIFT (sift.jcvi.org/) and MutationTaster 
(www.mutationtaster.org/) programs, which score variants by the predicted effect on protein 
functions. Variants with non-deleterious or non-damaging functional consequences were 
removed.  
Potential driver mutations were identified from one of the following criteria: 
• somatic non-synonymous SNV predicted to alter protein function by one of the three 
algorithms: Polyphen-2 (genetics.bwh.harvard.edu/pph2/), SIFT (sift.jcvi.org/) and 
MutationTaster (mutationtaster.org/) 
 
• recurrent somatic mutations that cluster in a specific domain of the gene (mutation 
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hotspots) or recurrent somatic mutations distributed along a gene 
• genes implicated in other types of malignancy 
Pathways enrichment of somatic mutations (nonsense, damaging or deleterious missense, 
splicing mutations and indels) were analysed with NetworkAnalyst tool whereby genes from 
our exome data were used as priory and mapped to a manually curated protein-protein 
interaction database to construct non-random networks198. 
2.2.6.3 Polymerase chain reaction and Sanger sequencing   
Candidate point mutations or indels identified from whole exome sequencing were chosen for 
confirmation by amplifying the region of interest using polymerase chain reaction (PCR) 
followed by DNA sequencing with chain-terminating inhibitors method, Sanger sequencing. 
This method is based on the incorporation of 2’,3’dideoxynucleotides (ddNTP’s) by DNA 
polymerase at the 3’ end of the growing chain during in vitro DNA replication. Chain 
elongation is terminated selectively at A, C, G or T due to the lack of 3’-hydoxyl group199. 
First, the genomic sequence of the candidate variants was obtained from UCSC Genome 
Browser (UCSC Genome Bioinformatics). PCR primers of at least 200 bases long were 
designed using the Primer3web (version 4.0.0) or ExonPrimer 
(http://ihg.gsf.de/ihg/ExonPrimer.html) programme and checked for sequence specificity with 
In-Silico PCR (UCSC Genome Bioinformatics). A working solution of 10 micro-molar (µM) 
for each primer pair was prepared using five µl of 50 µM stock solution of the forward primer 
and five µl of 50 µM stock solution of the reverse primer in 15 µl of Hyclone TM molecular 
biology grade water (Fisher Scientific, Loughborough, UK). The primer pairs were initially 
tested on one µl of control DNA (10ng/µl). Next, DNA from tumour +/- normal (10ng/µl) 
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samples with the candidate mutations was subjected to PCR using the specific primer pairs.  
Each 20 µl of the PCR reactions consisted of 10 µl of the HotStarTaq Plus Master Mix 
(HotStarTaq Plus DNA polymerase, PCR Buffer with 3mM MgCl2 and 400 µM of each dNT, 
HotStarTaq Plus Master Mix Kit, Qiagen, Crawley, UK), eight µl of RNase-Free Water 
(HotStarTaq Plus Master Mix Kit, Qiagen, Crawley, UK), one µl of tumour+/-normal DNA 
(10ng/ µl) and one µl of the primer pair working solution. 
PCR was carried out using Pettier Thermal Cycler–PTC225 DNA Engine Tetrad (MJ 
Research). The PCR cycling conditions were optimised and consisted of an initial activation 
of HotStarTaq Plus DNA polymerase at 95°C incubation step for five minutes followed by 35 
cycles of denaturing at 95°C for 15 seconds, annealing at 56 °C for 30 seconds, extension at 
72 °C for 30 seconds and a final hold at 4 °C. 
Gels were prepared using two grams (gm) of 2 % agarose (Sigma-Aldrich, Dorset, UK) in 
100 ml of 1X Tris-Borate-EDTA buffer (Sigma-Aldrich, Dorset, UK) and dissolved in a 
microwave. One µl of GelRedTM (Biotium, California, USA)! was then added to the gel 
solution. The solution was poured into a gel-casting tray with comb inserted and allowed to 
set at room temperature for 30 minutes. A 100-bp DNA ladder (New England Biolabs, Herts, 
UK) was used as the molecular size marker and samples were loaded into individual wells 
and electrophoresed in 1X Tris-Borate-EDTA buffer at 100 voltages for 45 minutes. The 
agarose gel was then inspected under ultraviolet light (FirstLight UV illuminator, Ultra Violet 
Products Inc., BioDoc-It TM imaging system) to visualize the bands of the amplicons.  
The amplicons were subjected to Sanger sequencing provided by Eurofins Genomic. The 
results were available in SEQ file and analysed using SEQUENCHER (Gene Codes 
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Corporation) that allowed editing, trimming and quality checks of the sequences to detect the 
mutation of interest. 
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Chapter 3 - Global Gene Expression Profiling of 
Malignant Pleural Mesothelioma 
3.1 Introduction 
Gene expression profiling using high-throughput array-based technologies allows 
simultaneous analysis of many genes from multiple samples. Studying the altered expression 
of genes, including oncogenes and tumour suppressor genes, and correlations with cellular 
and physiological state would lead to better understanding of cancer biology. Cancers 
including malignant pleural mesothelioma (MPM) are classified primarily based on 
histopathological features of the tumour but similar morphological subtypes show clinical 
heterogeneity in terms of prognosis and response to therapies. Global gene expression 
profiling allows identification of new subtypes based on gene signatures to improve class 
classification, prognosis and response to treatment prediction200. This is particularly important 
in clinical setting as it could potentially lead to personalised therapies based on the molecular 
signatures of the cancer such as in breast cancer and diffuse large B-cell lymphoma201,202.  
Till date numerous microarray studies on gene expression in MPM have been conducted and 
reviewed by Melaiu et al136. These studies were carried out on cell lines and on human MPM 
tissues to improve diagnosis, histological classification and identification of predictive 
biomarkers for this fatal disease. These have identified deregulated oncogenes, tumour 
suppressor genes and other genes of prognostic value. However, these biomarkers have not 
proven to be of clinical value as majority of them have not been reproducible between various 
studies. These could be due to several reasons including relatively small sample size, 
contamination of tumour samples with normal stromal cells that prevents precise delineation 
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of deregulated genes, use of different microarray platforms and inconsistent statistical 
methodologies. Nevertheless, data from further microarray studies could be still be useful in 
identifying novel biomarkers and could be integrated with existing data to increase statistical 
power for meta-analysis.  
The first objective of this chapter is to identify genes that are deregulated in MPM compared 
to non-malignant pleura (controls) and their associated enriched pathways. Secondly, we 
applied weighted gene co-expression network analysis (WGCNA), a ‘guilt-by-association’-
based method which has not been performed in MPM gene expression studies, to detect 
clusters of genes that are coexpressed or coregulated (modules) independent of the clinical 
phenotypes across the MPM cases203. This methodology has been applied successfully in 
cancer research and has led to the identification of several molecular targets including ASPM 
gene in glioblastoma204. Genes that are coexpressed may share similar biological process and 
provide further biological information about the genes that are differentially expressed 
between MPM and controls. The identified modules are then tested for association with 
clinical phenotypes including histological subtypes and survival outcome. The pathways and 
networks of these clusters will be interrogated to reveal their roles in the pathogenesis of 
MPM.  
3.2 Materials and methods 
3.2.1 Tissues acquisition 
Tissues used for total ribonucleic acid (RNA) extractions were provided by Biomedical 
Research Units (BRU) Advanced Lung Disease Biobank and the Brompton and Harefield 
NHS Trust Diagnostic Tissue Bank. The use of these tissues had been ethically approved and 
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written informed consents from patients were verified. A total of 26 MPM and 10 control 
frozen tissues stored with or without RNA later were identified. Tissues not stored in RNA 
later were subjected to pathological review using newly prepared haematoxylin and eosin 
(H&E) stained sections to confirm diagnosis and tumour abundance (Chapter 2 section 2.2.2.2 
and 2.2.2.3). For all other tissues, histopathological reports were checked and verified. 
Tissues used as controls were taken from patients who underwent surgical procedures for 
pneumothorax and the histology was non-malignant reactive pleura. 
3.2.2 RNA isolation, quantification and quality assessments 
Total RNA was extracted from the collected tissues using Qiagen RNeasy® fibrous midi kit 
(Qiagen, Crawley, UK) as described in Chapter 2 section 2.2.3.1. RNA concentration and 
yield were quantified with Thermo Scientific NanoDropTM 1000 Spectrophotometer 
(NanoDrop Technologies, Thermo Fisher Scientific, Delaware, USA). The quality of RNA 
was assessed with RNA 6000 Nano AssayTM kit and the Agilent 2100 BioanalyserTM (Agilent 
Technologies, California, USA) (Chapter 2 section 2.2.3.3). A RNA Integrity Number (RIN) 
score was generated to assess the quality of each RNA samples.  
3.2.3 Gene expression profiling 
Section 2.2.4 in Chapter 2 described in detail the process of gene expression profiling carried 
out with Affymetrix® Human Gene 2.1 ST Array Plate (Affymetrix, California, USA). Briefly, 
this involved generating amplified sense-strand complementary deoxyribonucleic acid 
(cDNA) with the Ambion® WT Expression Kit (Life Technologies, California, USA) for 
fragmentation and labelling processes using Affymetrix GeneChip® WT Terminal Labeling 
Kit (Affymetrix, California, USA). The sense-strand cDNA was then hybridised onto 
 77 
Affymetrix® Human Gene 2.1 ST Array Plate (Affymetrix, California, USA) and processed 
with GeneTitanTM Multi-Channel Instrument. 
3.2.4 Data pre-processing and analysis 
The quality assessment of raw probe level intensity data was carried out with Expression 
Console (EC) software (Affymetrix, California, USA) and arrayQualityMetrics (version 3.2) 
as described in Chapter 2 section 2.2.4.4 The preprocessing steps included background 
adjustment, normalisation, and summarisation at the probeset level as a measure of the 
expression level of corresponding mRNA with the apt-probeset-summarize programme 
(Affymetrix Power Tools).  
Differentially expressed probesets with a false discovery rate (FDR) of 1% and fold change 
(FC) in expression level of ≥ 2 in MPM compared to controls were identified using the 
empirical Bayes method (Chapter 2 section 2.2.4.5). The genes were interrogated for gene 
ontology (GO) terms and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways 
enrichment using WebGestalt Gene Set Analysis ToolKit205. We then applied weighted gene 
co-expression network analysis (WGCNA version 1.49) on the differentially expressed 
probesets with a FDR of 5% to identify clusters of co-expressed genes (modules) based on 
topological overlap matrix (TOM) dissimilarity measure (Chapter 2 section 2.2.4.6). The 
associations between modules and clinical variables including survival time were assessed 
using linear regression model adjusted for gender and age. 
3.3 Results 
Total RNA was extracted from 26 MPM and 10 non-malignant pleural tissues (controls). The 
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mean RNA yield and RIN were 74.4 µg and 8.2 respectively for MPM, and 47.7 µg and 7.6 
respectively for controls.   The table (Table 3.1) below shows the results of the total RNA 
yield and RIN obtained. 
Table 3.1. Total RNA results. Control samples denoted by C, Epithelioid MPM by E, 
Biphasic MPM by B, Sarcomatoid MPM by S. 
Sample ID Histology Cx (ng/ul) Yield (µg) RINS 
C2 C 117.8 17.7 8.8 
C3 C 37.6 5.6 7.2 
C4 C 146.9 22.0 7.1 
C5 C 1081.3 162.2 7.9 
C8 C 862.2 129.3 6.8 
C10R C 376.3 56.4 7 
C11 C 34.5 5.2 6.5 
C12R C 43.9 6.6 8.4 
C13 C 72.1 10.8 8.6 
C14 C 406.4 61.0 7.4 
M1 E 1802.2 270.3 9.2 
M2 B 1461.2 219.2 6.4 
M3 E 1234 185.1 9.2 
M4 E 1163.1 174.5 8.5 
M5 E 784.3 117.6 8 
M6 B 551.8 82.8 8.7 
M7 E 550.8 82.6 8.5 
M8 E 497.8 74.7 9.3 
M9 E 465 69.8 7.9 
M10 E 429.1 64.4 8.9 
M11 E 378 56.7 6.6 
M12 B 368.9 55.3 9 
M13 E 356.2 53.4 8.2 
M14 E 343.5 51.5 8.5 
M15 E 310.7 46.6 9.1 
M16 E 291.7 43.8 7.6 
M17 E 287.9 43.2 8.2 
M18 E 269.5 40.4 8.8 
M19 S 261.8 39.3 7.1 
M20 E 219.5 32.9 7.7 
M21 B 208.7 31.3 9.1 
M22 E 168.9 25.3 8.1 
M23R E 154.9 23.2 7.6 
M24 B 132.6 19.9 7.1 
M25 E 106.3 16.0 7.8 
M26 E 93.8 14.1 7.7 
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3.3.1 Quality assessment and microarray preprocessing steps 
The Expression Console software (Affymetrix, California, USA) was used to monitor assay 
data quality by assessing control probes such as target prep or hybridisation controls. Each 
array contains probe sets for Poly-A RNA controls from B. subtilis genes (lys, phe, thr and 
dap) that are absent in eukaryotic samples. The Poly-A RNA controls were spiked in to total 
RNA samples and evaluated like internal control genes to monitor the labelling process during 
the entire experiments. The signals should be present for all of the Poly-A controls with 
ascending values in the order of lys, phe, thr and dap as shown in Figure 3.1.  
The hybridisation controls (BioB, BioC, BioD and Cre) were mixed in to the hybridisation 
cocktail after target preparation. This allows evaluation of hybridisation efficiency 
independent of the prior target preparation steps. Bio B (red) should be present at least 70% of 
the time and the signals for the others should be in the ascending order of Bio C (blue), Bio D 
(green) and cre (pink) as shown in Figure 3.2.
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Microarray data quality was assessed with arrayQualityMetrics (version 3.2). Homogeneity of 
probe intensity levels between arrays was assessed and compared with boxplot and density 
plot. The raw data was transformed to a logarithm of 2 scale with the upper and lower quartile 
represented on either end of the box and the median was represented as the line in the middle 
of the box as shown in Figure 3.3. The intensity distributions were visualised using a density 
plots showing similar shapes and ranges for each array as shown in Figure 3.4. Outlier arrays 
were detected based on Kolmogorov-Smirnov statistic Ka computed between each array’s 
distribution and of the pooled data. The results did not indicate the distributions in any of the 
36 arrays were drastically different from each other. 
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Figure 3.4. Density (x-axis) plots of log-intensity (y-axis) distributions. This figure shows 
the density plot of each array superimposed on a single graph as shown for better 
comparison between arrays and identification of arrays with different distribution.  
Distance (dab) between two arrays (a and b) was computed according to the formula dab = 
mean | Mai where Mai was the value of the i-th probe on array a. These were represented in a 
heatmap (Figure 3.5) and outliers were detected if the sum of distances to all other arrays was 
exceptionally large. The results showed array 2 and 7 (marked with an asterisk *) were 
flagged as outlier samples.  
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Figure 3.5. Colour heatmap of distances between arrays. The distance between arrays is 
denoted by different colour scheme as shown on the bar chart on the left. Array 2 and 7 
with large distances to other arrays are identifed as outliers as shown above.   
MA plots allow the identification of intensity-dependent biases by plotting the log-ratio 
intensity of one array compared to a reference “pseudo” array.  The plot shows the logarithm 
of the relative expression between the two arrays (M) on the Yaxis against the average log-
intensity of both arrays (A) on the X axis. Outliers are detected based on Hoeffding’s statistics 
Da computed on the joint distribution of A and M for each array. The M values should centre 
on zero indicating no dependency between the intensities and the log-ratio. Figure 3.6 shows 
4 arrays with the highest Da on the top panel and four arrays with the lowest Da on the 
bottom panel. No arrays were detected with a Da of more than 0.15 that would have otherwise 
been flagged as outliers.  
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Figure 3.6. MA plots of arrays. This shows the logarithm of the relative expression 
between the two arrays (M) on the y-axis against the average log-intensity of both arrays 
(A) on the x-axis. The arrays with the highest (top panel) and lowest (bottom panel) Da 
are displayed in this figure. 
 In summary, two arrays from control samples C3 and C11 were identified as outliers by 
arrayQualityMetrics and were removed. The remaining 34 arrays were subjected to 
background adjustment, normalisation and summarisation using random multiple access 
(RMA) procedure. Figure 3.7 displays the boxplots of RMA treated data showing no 
deviation indicating the raw intensities were corrected by normalisation. 
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After the pre-processing steps, probe sets with expression levels below the median across all 
samples were removed from the dataset. This reduced the probe sets from 53,617 to 38,139.   
The principal variance component analysis (PVCA, version 1.10) analysis identified age as 
the most prominent source of variability accounting for 10% of the total variance in the data 
as shown in Figure 3.8. The experiments were done in two batches and PVCA revealed that 
this explained 2.5% (denoted by GT in Figure 3.8) of the overall variation in the RMA treated 
data.  
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In order to reduce variation due to age, three control samples (C10, C12 and C13) with much 
younger age compared to the others were removed. Sarcomatoid subtype was only 
represented by tumour sample M19 and was removed from subsequent analyses. This reduced 
the variance due to age from 10.1% to 1.7% and for tissue subtypes from 8.6% to 4.6%.  
3.3.2 Differential gene expression 
The expression data from a total of 25 tumour samples and five control samples were 
analysed for differential gene expression. The table below (Table 3.2) shows the clinical 
profiles for the 30 samples. 
Table 3.2. Demographics and clinical data for 25 tumours and 5 control samples. E= 
epithelioid, B= biphasic. 
Clinical variables Tumour Control 
Age 55-82 (median 67) 51-78 (median 68) 
Gender 20 Males: 5 Females 5 Males 
Histology 20 E-MPM 
5 B-MPM 
5 Non-malignant reactive pleura 
Asbestos exposure 
 
Yes 
No 
Not known 
 
 
 
21 
3 
1 
 
 
3 
2 
0 
Smoking history 
 
Ever smoked 
Never smoked 
Not known 
 
 
 
13 
10 
2 
 
 
4 
1 
0 
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Prior to testing for differential gene expression, clustering of the samples was assessed with 
unsupervised two dimensional hierarchical clustering algorithm (HCA) (Figure 3.9) and 
principal component analysis (PCA) (Figure 3.10). Both HCA and PCA successfully 
segregated the tumours from the controls and demonstrated molecular homogeneity shared 
amongst the tumour samples. Thus, subsequent statistical analysis to test for differentially 
expressed genes was carried out without splitting the tumour samples into their respective 
subtypes.   
 
Figure 3.9. Unsupervised hierarchical cluster analysis of the final 30 samples. The 
analysis shows clear separation of tumour from control samples. Control samples are 
denoted by letter C## and tumour samples denoted by letter M##E for E-MPM and 
M##B for B-MPM. 
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Figure 3.10. Scatter plot for the first two principal components (PC)of the full dataset. 
Each sample is represented by a dot on the plot and control samples in green appear to 
cluster together.  
We applied the empirical Bayes method (as described in section 2.2.4.5) to detect 
differentially expressed genes between tumour and control samples (Appendix 3.1). The 
analysis identified 643 genes (651 probesets) with an adjusted p-value of ≤ 0.01 and absolute 
FC in the level of expression of ≥ 2.  
3.3.2.1 Upregulated genes 
A total of 291 differentially expressed genes were upregulated in tumours compared to 
controls with an absolute FC level ranging from 2.00-87.61 (Appendix 3.1). Table 3.3 shows 
the top 20 upregulated genes with the highest FC in the level of expression. Twelve of these 
are transmembrane genes involved in cell-cell communications, transmembrane signalling, 
 93 
ions transport and maintenance of cell structure.  
Table 3.3. Top 20 statistically validated differentially expressed genes with the highest 
fold change (FC) in the level of expression. 
Gene 
symbols 
Gene.names Gene.ID adj.P.Val FC 
ITLN1 intelectin 1 (galactofuranose binding) 55600 0.000467 87.43 
UPK1B uroplakin 1B 7348 6.16E-05 64.45 
UPK3B uroplakin 3B 80761 1.39E-05 47.50 
CALB2 calbindin 2 794 5.17E-05 41.36 
LRRN4 leucine rich repeat neuronal 4 164312 4.83E-05 40.22 
BNC1 basonuclin 1 646 1.18E-07 39.67 
PLLP Plasmolipin 51090 2.45E-05 35.02 
CTSE cathepsin E 1510 0.000194 32.45 
LRP2 low density lipoprotein receptor-related protein 2 4036 0.001847 30.48 
FLRT3 fibronectin leucine rich transmembrane protein 3 23767 0.000103 23.43 
SLPI secretory leukocyte peptidase inhibitor 6590 0.000456 21.41 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 999 0.000864 20.39 
CACNG4 calcium channel, voltage-dependent, gamma subunit 4 27092 0.00031 20.25 
MMP24 matrix metallopeptidase 24 (membrane-inserted) 10893 5.68E-05 18.64 
KRT5 keratin 5 3852 1.55E-05 18.51 
ANXA3 annexin A3 306 3.57E-05 17.63 
MUC16 mucin 16, cell surface associated 94025 0.001016 17.39 
C19orf33 chromosome 19 open reading frame 33 64073 1.41E-05 17.03 
HNRNPA1P
33 
heterogeneous nuclear ribonucleoprotein A1 pseudogene 
33 
728643 0.000153 16.00 
MAL2 mal, T-cell differentiation protein 2 (gene/pseudogene) 114569 0.000295 15.56 
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Next, we focused on the top five upregulated genes: ITLN1, UPK1B, UPK3B, CALB2 and 
LRRN4. ITLN1 is a galactose-binding lectin expressed mainly in small intestine, renal 
collecting tubule cells and some mesothelial cells. Studies have shown over-expression of 
ITLN1 by immunohistochemistry (IHC) in 80% of epithelioid MPM but rarely in biphasic or 
sarcomatoid MPM; and no expression was seen in reactive mesothelial cells or lung 
adenocarcinomas206,207. Tsuji et al also detected higher concentrations of ITLN1 in pleural 
effusions of MPM compared to lung adenocarcinomas207. The exact role of ITLN1 in 
tumorigenesis is not fully understood. Human mesothelial cells exposed to crocidolite 
asbestos and transfected with simian virus 40 resulted in over-expression of ITLN1208. 
Another study using immortalised human mesothelial cell line showed induction of ITLN1 
resulted in marked increase in cell growth, invasiveness and chromosomal aberrations with 
translocation events209. These suggest involvement of ITLN1 in MPM tumorigenesis might be 
an early event and could be a potential diagnostic biomarker for MPM. 
CALB2 is a member of the EF-hand family of calcium binding proteins that encodes 
calretinin, a validated IHC marker for diagnosing MPM. The protein is detected in virtually 
all mesothelioma of epithelioid and biphasic subtypes but only in less than 10% of lung 
adenocarcinomas210. The involvement of CALB2 in tumorigenesis has not been well studied. 
However, calretinin has been shown to interact with cytoskeletal elements and cell 
proliferation in colon cancer cells211. The role of CALB2 in MPM has been investigated by 
one study and found elevated calretinin levels strongly correlated with increased resistance of 
mesothelial cells to asbestos cytotoxicity in vitro.  In addition, this protective effect could be 
inhibited with phosphoinositide 3-kinase (PI3K) inhibitor212. This suggests CALB2 might 
contribute to MPM carcinogenesis possibly through up-regulation of PI3K signalling 
resulting in increased cell survival from asbestos cytotoxicity.  
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UPK1B and UPK3B are transmembrane proteins that are specific for urothelial lineage. 
Previous study found over-expression of both uroplakins in epithelioid compared to 
sarcomatoid MPM139. Another transcriptomic microarray study identified UPK3B as one of 
the three predictive genes that was able to distinguish the different molecular subtypes of 
MPM135. In addition, UPK3B and LRRN4 have recently been identified as novel mesothelial 
lineage markers and both showed heterogeneous expression in epithelioid mesothelioma cell 
lines213. LRRN4 is a leucine rich repeat neuronal protein and has not been implicated in cancer 
but shown to be dysregulated in response to lung injury raising a possible role in 
inflammation214. Little is known about these three genes and in view of their significant 
upregulation in our study, further studies are required to elucidate their roles in MPM 
pathogenesis.  
It is also worth noting BNC1, the most statistically significant upregulated gene in our data 
and has not been described in MPM. BNC1 was first discovered in keratinocytes and found to 
be associated with proliferation, cell-adhesion, intracellular transport and ion-channels. 
Studies found opposing roles of BNC1 in tumorigenesis depending on cell types; reduced 
expression in renal cell carcinoma cell lines conferred survival advantage but elevated 
expression in breast cancer was associated with tumour invasiveness and its expression was 
positively regulated by p63 in squamous carcinoma215–217. Recent evidence identified further 
oncogenic role of BNC1 in epithelial dedifferentiation through modulation of transforming 
growth factor beta 1 (TGF-ß1) responsive genes including epithelial-mesenchymal transition 
(EMT)-related transcription factors218. TGF-ß production can be stimulated by MPM and 
interacts with Hippo pathway to promote tumour growth219. Furthermore, EMT process has 
been described in MPM suggesting potential role for BNC1 in promoting this process and 
tumour growth in MPM220.  
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To gain further biological insights, we interrogated the list of differentially expressed 
upregulated genes for enriched GO terms and KEGG pathways as described in Chapter 2 
section 2.2.4.5. The analysis identified cell junction organisation as the top over-represented 
GO terms (Table 3.4) and the genes are enriched in cancer pathways, Hedgehog signalling, 
cell cycle and pathways involved with cell junction organisation (Table 3.5). 
Table 3.4. Top enriched GO terms for upregulated genes. 
GO category Category name GO ID No of genes adj.P value 
biological process cell junction organisation GO:0034330 19 1.29E-06 
biological process cell junction assembly GO:0034329 16 2.59E-05 
cellular component cell junction GO:0030054 32 3.77E-05 
 
Table 3.5. KEGG pathway analysis of upregulated genes. 
PathwayName Genes adj.P value 
Pathways in cancer FGF9, WNT9A, NKX3-1, ITGA3, CDH1, SKP2, CKS1B, 
BMP4, WNT3, MET, RAC3, LAMC2, EGFR, WNT2B, 
FGF18, ARNT2, LAMA5 
0.0005 
Adherens junction PTPRF, MET, CDH1, RAC3, EGFR, BAIAP2, SSX2IP 0.0027 
ECM-receptor interaction HMMR, ITGB4, ITGA3, AGRN, LAMC2, LAMA5, SDC4 0.004 
Regulation of actin cytoskeleton FGF9, SSH3, ITGA3, FGF18, EZR, ITGB4, PFN2, 
RAC3, PAK4, BAIAP2, EGFR 
0.004 
Cell cycle MCM4, MAD2L1, CDC6, MCM2, CCNB1, CCNB2, 
SFN, SKP2 
0.0065 
Hedgehog signalling pathway BMP4, WNT9A, WNT3, LRP2, WNT2B 0.0162 
Cell adhesion molecules (CAMs) PTPRF, CDH4, CDH3, F11R, CLDN15, CDH1, SDC4 0.0228 
Axon guidance EFNA5, SEMA3C, EFNA1, MET, PAK4, RAC3, PLXNB1 0.0228 
Focal adhesion ITGA3, MET, ITGB4, RAC3, LAMA5, LAMC2, PAK4, 
EGFR 
0.0461 
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The upregulated genes implicated in cancer pathways include proto-oncogenes (EGFR, MET, 
RAC3), potential tumour suppressor gene (NKX3-1), genes associated with proliferation 
(FGF9, FGF18), cell cycle/survival genes (SKP2, CKS1B, ARNT2, RAC3), cell-cell 
interactions (CDH1), extracellular matrix (ECM) interactions and cytoskeletal remodelling 
(ITGA3, LAMA5, LAMC2, BMP4, RAC3 and components of WNT).  
Eight of the upregulated genes are associated with cell cycle pathway of which CCNB1, 
CCNB2, CDC6 and MAD2L1 are regulators of cell cycle check points and have been 
described in MPM134,221,222. CCNB1 is involved in G2/M transition of the cell cycle by 
interacting with CDC2 to form mitosis-promoting factor kinase complex. Both CCNB1 and 
MAD2L1 regulate mitotic spindle checkpoint and chromosome segregation; and 
overexpression of these genes are linked to chromosomal instability223,224. CDC6 regulates 
G1/S transition of the cell cycle and is needed for the loading of DNA replicative helicase 
minichromosome maintenance proteins (including MCM2 and MCM4) onto the origins of 
replication. CDC6 over-expression promotes persistent DNA replication and may confer 
resistance to accumulation of DNA damage and cell entry into senescence225. Over-expression 
or amplification of SKP2 has been detected in a variety of cancers. SKP2 has not been 
described in MPM but abnormalities in chromosome 5p that encodes for SKP2 (5p13) was 
overrepresented in MPM cell lines and cultures226. CKS1B is a member of the cyclin-
dependent kinases (CDK) that regulates mitosis and together with SKP2 form the 
SCFSKP2_CKS1 ubiquitin ligase complex that regulates proteasome degradation of p27Kip1
 
(CDK 
inhibitor), FOXO1 and RASSF1A thereby abolishing their tumour suppressor functions 
including cell cycle arrest and death227–229. 
Both enrichment analyses identified overrepresentation of genes involved in cell junction 
organisation including adherens junction, actin cytoskeleton, ECM-receptor interactions and 
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axon guidance. Integrins are α/ß heterodimeric transmembrane receptors that promote cell-
ECM interactions by binding to a wide variety of ECM proteins including the laminin family. 
Upon ligand binding, they cluster on cell surface area termed as focal adhesion site. This 
forms an important connection between ECM and actin cytoskeleton; and is an important 
mediator of focal adhesion kinase (FAK) activation by promoting its recruitment, 
phosphorylation and formation of FAK-Src complex. Phosphorylated FAK also forms a 
complex with GRB2 that binds to SOS to activate RAS and downstream MAPK and PI3K/Akt 
pathways230. 
We identified overexpression of two integrin receptors: ITGA3 and ITGB4; and two laminin 
members: LAMA5 and LAMC2 that have been shown to promote cell invasion. ITGA3 forms 
an integrin complex (α3β1) with the beta-1 subunit and is a major receptor for laminin-5. 
Silencing of ITGA3 expression using RNAi reduced adhesion, spreading and proliferation of 
4T1 murine cancer cell in vivo231. Functional in vitro study showed the interaction of α3β1 
and laminin-5 promoted cell growth via activation of MAPK pathway232. Upregulation of 
ITGB4 was observed in invasive xenograft pancreatic cancer model and knockdown of ITGB4 
reduced cancer cells migration and invasion233. LAMC2, γ2 chain of laminin-5, exerts its 
oncogenic role via the EGF-like repeats in domain III that allows interaction with EGFR. In 
vitro study using breast cancer cell line demonstrated the binding of LAMC2 to EGFR 
increased MMP2 expression and enhanced cell migration234. LAMA5 is a subunit of laminin-
10, -11 and -15 that also binds to α3β1integrin. Study using LAMA5 knockout mouse model 
and RNAi demonstrated involvement of LAMA5 in cell survival and epithelial cells 
differentiation via activation of PI3K/Akt235.  
Axonal guidance molecules include the Slit, Netrin, Eph/erin and Semaphorin families act as 
repulsive or attractive force to guide axonal growth and migration236. Aberrant expression of 
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these molecules and their associated partners is linked with the initiation and progression of 
cancers and recent study found several genes associated with axon guidance were mutated in 
pancreatic cancer237. Recent data also suggested FAK as the main effector of Eph-ephrin and 
Semaphorin signalling pathways238,239. Two ephrin ligands (EFNA1 and EFNA5) are 
identified in our study. EFNA1 is overexpressed in HCC and promoted proliferation in 
EFNA1-deficient cell line240. Furthermore, gene expression analysis revealed EFNA1 induced 
overexpression of genes associated with cell cycle, angiogenesis and invasion241. The role of 
EFNA5 in tumorigenesis was demonstrated by increased invasion, anchorage-independent 
growth and morphogenetic changes in EFNA5-expressing murine fibroblasts242. Of the 
semaphorin members, we identified upregulation of SEMA3C and PLXNB1, receptor for 
SEMA4D that have also been shown to be involved in cancer progression and 
vascularity243,244. These studies showed tumour growth and micro vessel density examined in 
vivo were reduced after SEMA3C silencing while inactivation of PLXNB1 in HER2 
overexpressing breast cancer reduced invasiveness and number of metastases. 
Actin reorganization is another important element contributing to cell motility. 
Overexpression of EZR, a membrane cytoskeleton linker, promotes cell motility and survival 
through PI3/Akt pathway245,246. EZR has been shown to trigger activation of FAK through 
phosphorylation of FAK at Tyr-397 independently of cell-matrix adhesion247. The downstream 
effectors of FAK signalling include the small GTPases of the Rho family that regulate 
dynamic reorganization of the actin cytoskeleton. RAC3, one of the Rho GTPases, is 
implicated in reorganising the actin cytoskeleton through formation of lamellipodia necessary 
for cell dissemination but also activation of extracellular-signal-regulated kinases (ERK) / 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) leading to increase 
cell survival and proliferation248. PAK4, one of the PAK serine/threonine kinases that are 
important effectors of Rho family GTPases, together with CDC42 induced actin 
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polymerisation and formation of filipodia249. In vitro study showed PAK4 is required for Ras 
driven anchorage-independent cell transformation250. Taking all these data together, FAK and 
mitogen-activated protein kinases (MAPK) signalling pathways may be important mediators 
of MPM cells migration and invasion. 
Five genes (LRP2, BMP4, WNT9A, WNT3, WNT2B) are involved in Hedgehog and WNT 
signalling pathways. The hedgehog pathway involves ligand binding to PTCH1/2 that relieves 
the repression of SMO and activates signal transduction to SUFU-GLI complexes leading to 
activation of GLI transcription factors. LRP2, a member of the LDL receptor gene family, has 
recently been identified as a binding protein for sonic hedgehog and controls internalisation, 
cellular trafficking of sonic hedgehog-patched 1 complexes. A mice model study showed 
overexpression of LRP2 is critical for hedgehog signalling and lack of LRP2 resulted in 
failure to respond to sonic hedgehog despite functional expression of PTCH1 and SMO251.  
Aberrant WNT signalling is active in malignant mesothelioma and targeting WNT signals 
using siRNA or antibodies against WNT1 or 2 and dominant-negative Dvl led to suppression 
of mesothelioma cells growth in vitro171,173,252,253. Two WNT ligands, WNT2B and WNT3, 
identified in our study have been reported by Fox et al to be upregulated in MPM. Both genes 
are involved in positive regulation of WNT canonical pathway through binding with frizzled 
receptors to activate Dvl that inhibits phosphorylation of GSK-3ß thereby reducing the 
binding affinities of AXIN1 and APC for CTNNB1 that promotes its degradation. 
Unphosphorylated CTNNB1 translocate into the nucleus and displaces Groucho/TLE from 
TCF/LEF binding sites to activate transcription of genes involved in several biological 
process such as cell growth and proliferation (c-myc, cyclin D) and cell invasion/migration 
(MMP7, UPAR, SLUG, LAMA5).  
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The involvement of WNT and hedgehog signalling pathways in MPM is further supported by 
overexpression of BMP4 in our study. The expression of BMP4 is regulated and can be 
induced by both pathways254,255. BMP4, a member of the TGF-ß superfamily, has opposing 
roles in cancer pathogenesis. This was reviewed and majority of studies demonstrated 
suppression of cell growth in vivo and in vitro by BMP4 but is capable of initiating 
morphological changes and EMT process256. In MPM, BMP4 has been shown to be 
overexpressed in a molecular subtype associated with genes involved in ECM components 
suggesting an invasion role in MPM130.  
3.3.2.2 Downregulated genes 
A total of 352 differentially expressed genes were downregulated in tumours compared to 
controls (Appendix 3.1). The absolute FC in expression level for downregulated genes was 
much smaller (ranged from 2.00-7.65) compared to upregulated genes. MMRN1, a novel gene 
in MPM has the highest FC in expression level amongst the downregulated genes.  MMRN1 is 
a soluble protein found in platelets and in the endothelium of blood vessels that has been 
shown to function as an adhesive ligand promoting platelet adhesion at sites of vascular 
injury257. In vitro study showed MMRN1 adhesion to cellular receptors enhanced its formation 
of large, branching ECM fibres258. In addition, proteomic analysis identified direct interaction 
of MMRN1 with tumour suppressor, CDKN2A259. This raises the possibility that 
downregulation of MMRN1 might contribute to MPM tumorigenesis through tumour-driven 
vascular permeability, destabilisation of ECM and possibly cell-cycle progression.  
MYH11, another top downregulated genes, encodes for a major contractile protein, smooth 
muscle myosin heavy chain 11, that utilises the energy of ATP hydrolysis to move actin 
filaments and produce muscle force. Recent evidence indicated the potential roles of MYH11 
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in tumorigenesis including cell migration, adhesion and control of cell shape, as well as in 
cell-signalling pathways such as interaction with Rho and the pro-apoptotic protein Bmf 
(BCL2-modifying factor)260–262. In addition, MYH11 is underexpressed in breast cancer cell 
lines compared to hybrids and in microsatellite stable hereditary nonpolyposis colorectal 
cancer263,264. Low expression of MYH11 by IHC correlated with poorer survival in patients 
with colorectal cancer265. MYH11 has not been reported in MPM and it is possible that it 
contributes to MPM carcinogenesis through modulation of cell adhesions and migrations.  
Enrichment analysis identified regulation of immune system as the top overrepresented GO 
terms (Table 3.6). This consists of 78 genes involved in several functions including T cell 
activation (BCL11A, CD28, IKZF1, DOCK2, IRF4, PTPN22, PTPRC, RHOH, THEMIS), B 
cell activation (BCL11A, BANK1, CD40LG, CD40, IKZF1, CXCR5, PLCG2, PTPRC), cell 
adhesion and recognition molecules and cytokine-cytokine receptor interactions. The top 
enriched KEGG pathways include cell adhesion, immune deficiency and cytokine-cytokine 
receptor interactions (Table 3.7). 
Table 3.6. Top enriched GO terms for downregulated genes. 
 
GO category Category name GO ID No of genes adj.P value 
biological process immune system process GO:0002376 78 2.26E-11 
biological process regulation of immune system process GO:0002682 50 4.69E-11 
biological process cell adhesion GO:0007155 51 2.81E-10 
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Table 3.7. KEGG pathway analysis of downregulated genes. 
PathwayName EntrezGene adj.P val 
Cell adhesion molecules 
(CAMs) 
PTPRC,CD99, CD40LG, CDH5, PTPRM, SELE, CD40, ICAM2, 
CD28, ESAM, SELL, CD34 
0.0004 
Primary 
immunodeficiency 
PTPRC, CD40, JAK3, CD40LG, CD19, CIITA 0.0007 
Cytokine-cytokine 
receptor interaction 
CSF2RB, IL12RB2, CCR6, CXCR5, CD40LG, IL6, LEP, IL2RA, 
CD40, NGFR, IL21R, IL3RA, PDGFRB 
0.0009 
 
The cell adhesion genes that are associated with recruitment of immune cells included SELE, 
SELL, CD34, CD99, ICAM2 and ESAM. Downregulation of these genes might suggest 
impaired infiltration of immune cells to the tumour microenvironment in mediating effective 
anti-tumour immune response. 
Downregulation of SELE results in interrupted attachment of T cells to the tumour 
vasculature. Treatment with imiquimod, a TLR7 agonist, is associated with induction of SELE 
on tumour vasculature, increased infiltration of CD8+ T cells, inhibition of tumour associated 
Treg cells and  tumour regression266. TLR7 agonist has been tested in murine MPM model 
and resulted in induction of CD8+ T-cell, type I IFN anti-tumour responses and primary 
tumour growth retardation267. The authors also showed the combinations of TLR7 agonist and 
agonistic anti-CD40 antibody to mimic CD4+ T-cell assistance led to higher systemic immune 
response and inhibition of growth in not only the primary tumour but also distant metastatic 
lesion268.  
SELL and CD34 are known to promote tethering and rolling of immune cells on the 
endothelia269. Downregulation of SELL in knockout mouse model resulted in improper 
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adhesion and migration of lymphocytes that might represent another immune escape 
mechanism270. CD34-/- animal models exhibited increased tumour growth at later stage of 
cancer development and are associated with impaired homing of mast cells271. CD99 is a cell 
surface glycoprotein expressed on both leucocytes and endothelial cell contacts allowing its 
participation in transendothelial migration of monocytes and lymphocytes to sites of 
inflammation272. Loss of CD99 and lower protein level in tumour stromal are associated with 
poor prognosis in several tumour types including lung cancer273.  
ICAM2 stimulates the migration and cytotoxicity of natural killer (NK) cells upon binding to 
leucocyte adhesion LFA-1 protein274. In cancer cells, ICAM2-transfection enhanced adhesion, 
activation of NK cells and reduction in metastasis275. ESAM, a member of the 
immunoglobulin superfamily is expressed on endothelial tight junctions and is involved in 
maintaining the integrity of endothelial cells. Targeted deletion of ESAM in knockdown 
mouse models reduced tumour angiogenesis and growth but conversely disruption in vascular 
permeability might modulate transendothelial migration of cells including tumour and 
immune-related cells276,277.  
Apart from immune cells recruitment, activation of lymphocytes is also crucial in initiating 
anti-tumour process. Several genes involved in this process are downregulated in our study. 
CD40 belongs to the superfamily of TNF receptors and are expressed on endothelial cells and 
antigen-presenting cells such as B cells, macrophages and dendritic cells. CD40 together with 
its ligand CD40L are important for clonal B cell expansion, differentiation and germinal 
centre formation. The role of CD40-activated B cells in anti-tumour immunity has been 
reviewed278. In vitro and in vivo studies showed signalling via CD40 activates host antigen-
presenting cells to evoke an effective cytotoxic T cell response; and direct tumour cytotoxicity 
was observed upon CD40L ligation on CD40 expressing tumours. In MPM, enhancing CD40 
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activation with agonist anti-CD40 antibody injected into mice model resulted in tumour 
regression but unexpectedly with no increase in CD8+ tumour-specific T cells; and instead 
promoted follicular B-cell activity suggesting the role of memory B cells in recognizing auto-
antigens on MPM cells279.  
The role of PTPRC (CD45) in modulating the immune system has been reviewed280. CD45 is 
a key regulator of T-cell and B-cell receptors signalling through dephosphorylation of the 
negative regulatory Src family kinases Lck and Lyn respectively. CD19 is critical for 
mounting an optimal immune response through antigen-independent development and 
immunoglobulin-induced activation of B cells281. In addition, CD19 deficient mice exhibited 
impaired response to transmembrane signals and T-cell dependent humoral responses. 
JAK3 activating mutation and over-expression are associated with several haematopoietic and 
solid malignancies but also has a key role in T cell development and regulation of immune 
system282. Previous studies demonstrated  the involvement of COX in MPM pathogenesis and 
observed significant production of PGE2 by asbestos from alveolar macrophages that inhibits 
mesothelial cell-mediated cytotoxicity283. Another study found PGE2 inhibited upregulation 
of JAK3 in naïve T cells and downregulated JAK3 expression in primed T cells resulting in 
inhibition of T cell proliferation through impaired activation of STAT5 and decreased 
induction of c-myc and c-Jun284. 
Downregulation of several cytokines and its receptors identified in our study (Table 3.7) such 
as IL2RA, IL3RA, IL21R, might also contribute to impaired anti-tumour immunity. IL2 is an 
important growth factor for lymphocytes and IL2RA has a key function in mediating its effect 
by forming a complex with IL2, IL2R! and γc285. In vitro study showed IL2RA expression is 
suppressed by cancer derived immunosuppressive factor thereby markedly suppressing T cell 
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proliferation286. As such, it is plausible that the function and expansion of cytotoxic T 
lymphocytes can be inhibited due to the repressed expression of IL2RA. Downregulation of 
IL3RA, a subunit of the receptor for IL3, might contribute to reduction in infiltration of 
immune cells through impaired IL-3 signalling as demonstrated in murine tumour model 
resulted whereby IL3 overexpression resulted in slower tumour growth due to increased 
immunogenicity and host-cell infiltration by macrophages287. IL-21R is the receptor for IL21 
cytokine that exerts its antitumour effect by promoting both T cell-mediated and NK cell-
mediated cytotoxicity. IL-21-primed CD8+ T cells have characteristics of memory T cells and 
exerts its anti-tumour effects not only by inducing CD8+T cells but also NK cells and able to 
suppress the expression of FOXP3 and expansion of regulatory T cell288,289.  
Tumour cells can also acquire defects in antigen processing and presentation that facilitate 
evasion from the adaptive immune system. Effective T-cell priming requires co-stimulatory 
receptors on naïve T-cells and the most important of which is CD28 that is normally 
expressed in 95% of CD4+T cells and approximately 50% of CD8+T cells. Interactions of 
CD28 and its ligands are crucial in the regulation of adaptive cellular immunity. Down-
regulation of CD28 leads to decreased binding with its ligands B7 on antigen presenting cells 
thereby impairing antigen/MHC complex presentation290,291. CIITA is a major transcriptor of 
major histocompatibility complex (MHC) class II genes and downregulation of CIITA results 
in impaired antigen presentation. Results from melanoma cell line study demonstrated greater 
anti-tumour responses in a dose-dependent manner with exosomes from CIITA-transduced 
tumour cells compared to exosomes from parental tumour cells292. This represents another 
novel strategy to genetically modified tumour cells to express MHC class II gene products. 
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3.3.3 Weighted gene co-expression network analysis 
We selected 3,227 probesets (3,092 genes) with a FDR of 5% from the list of differentially 
expressed genes (Appendix 3.1) for WGCNA as described in Chapter 2 section 2.2.4.6 to 
construct MPM-associated co-expression network and identify modules of highly connected 
genes.  
A soft-thresholding power (β) of 9 (Figure 3.11) to which co-expression similarity was raised 
to calculate adjacency was chosen to construct the weighted gene network.  At this β level, the 
scale free topology fit was approximately satisfied with a R^2 threshold of 0.95. By 
increasing the R^2 value further would lead to networks with low connectivity.  
 
Figure 3.11. Analysis of network topology for various soft-thresholding powers. The left 
panel showed the scale-free fit (y-axis) as a function of the soft-thresholding power (x-
axis). The right panel showed the mean connectivity (y-axis) as a function of the soft-
thresholding power (x-axis). 
A total of 14 modules (Figure 3.12) were detected with module sizes ranging from 51 to 605 
genes (Table 3.8). The grey module contained genes that do not share similar co-expression 
with other genes in the network and therefore was not included in the dendrogram. A heatmap 
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is generated to visualise the weighted network as shown in Figure 3.13. 
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Table 3.8. Modules and corresponding number of genes (modSize). 
Module No of genes in module (modSize) 
Black 129 
Blue 436 
Brown 353 
Green 177 
Green-yellow 74 
Grey 500 
Magenta 90 
Pink 113 
Purple 76 
Red 119 
Salmon 51 
Tan 64 
Turquoise 605 
Yellow 305 
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The proportion of variance explained by the first three principal components for each module 
are summarised in Table 3.9. On average, the first principal component, also known as 
module eigengenes (MEs), explained approximately 44% of the total variance for each 
associated module. 
 
Table 3.9. Proportion of variance explained by the first 3 principal components (PC) for 
each module. 
MEs PC 1 PC 2 PC 3 
MEblack 40.19% 7.65% 5.66% 
MEblue 44.65% 7.17% 5.13% 
MEbrown 45.98% 7.05% 4.69% 
MEgreen 48.18% 6.09% 5.76% 
MEyellow 42.40% 7.69% 6.07% 
MEmagenta 39.89% 7.04% 5.61% 
MEpink 50.89% 7.48% 4.56% 
MEpurple 42.28% 10.02% 5.47% 
MEred 39.45% 7.51% 6.25% 
MEsalmon 50.71% 7.48% 5.87% 
MEtan 44.47% 7.17% 5.66% 
MEturquoise 37.27% 8.13% 5.41% 
MEyellow 41.20% 8.01% 4.92% 
 
The MEs in each module were tested for association with histological subtypes, smoking 
status and asbestos exposure using linear regression model adjusted for age and gender (as 
described in Chapter 2 section 2.2.4.6). The analysis found statistically significant association 
between the blue module (436 genes) with histological subtypes (adjusted p-value= 0.003). 
None of the MEs were significantly associated with either smoking status or asbestos 
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exposure. GO analysis (Table 3.10) revealed the blue module was enriched in genes involved 
in biological processes of cell junction organisation.  
Table 3.10. Top enriched GO terms for blue module associated with histological 
subtypes. 
GO category Category name GO ID No of genes adj.P value 
biological process cell junction organization GO:0034330 18 0.0137 
biological process tight junction assembly GO:0070830 8 0.0137 
biological process morphogenesis of embryonic epithelium GO:0016331 14 0.0197 
 
In order to identify genes in the blue module with high connectivity and strong association 
with histological subtypes, the module membership (MM) for each gene in the blue module 
and gene significance (GS) of each gene associated with histological subtypes were calculated 
as described in Chapter 2 section 2.2.4.6. Figure 3.14 shows a statistically significant positive 
correlation between GS for histological subtypes and MM of genes in the blue module 
indicating that genes with high connectivity are also significantly associated with histological 
subtypes. An arbitrary GS value of ≥ 1.0 and MM value of ≥ 0.7 were chosen to identify hub 
genes with strongest connectivity and link with histological subtypes. This resulted in 31 hub 
genes (Table 3.11) and a visualisation of this network with Cytoscape Software 3.0.1 is shown 
in Figure 3.15. 
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Table 3.11. Top hub genes in the blue module. These hub genes are defined by an 
absolute Module membership (MM) ≥ 0.7and gene significance (GS) ≥ 1.0 with 
corresponding fold change (FC) and adjusted p value from differential gene expression 
analysis. 
 Gene GS  MM  FC adj. p value 
CARNS1 1.91 0.9 5.02 0.002105113 
PLLP 1.08 0.89 35.08 2.44908E-05 
PTPRF 1.06 0.89 5.33 1.58227E-05 
PRR15 3.29 0.88 12.25 0.000197445 
KLK11 1.78 0.88 5.84 0.000218948 
LRRN4 1.54 0.88 40.30 4.83018E-05 
CCDC64 1.54 0.88 4.70 0.013362278 
BNC1 1.54 0.86 39.62 1.17508E-07 
LRRC1 1.43 0.84 6.51 0.001049806 
PDZD2 1.26 0.84 6.65 0.001794995 
REC8 1.05 0.84 4.93 0.000545429 
KLHL31 1.04 0.84 5.34 0.002498679 
UPK3B 1.54 0.82 47.56 1.3889E-05 
C19orf33 1.54 0.81 17.09 1.41006E-05 
TM4SF1 1.33 0.81 2.73 0.01108929 
SELENBP1 1.54 0.79 2.47 0.0421346 
MMP24 1.01 0.79 18.66 5.68068E-05 
CMTM8 1.21 0.78 4.76 4.12692E-06 
TMEM151A 1.33 0.76 5.03 0.002740044 
HOOK1 1.54 0.75 2.63 0.048263673 
KLK10 1.43 0.75 2.78 0.02259675 
IGSF9 2.39 0.74 4.45 0.001196221 
CYSTM1 1.33 0.74 1.78 0.04086658 
SLPI 1.59 0.72 21.47 0.000456269 
MIR181A1HG 1.13 -0.72 1.75 0.038039179 
RASGRP3 1.05 -0.75 2.26 0.000429178 
GLRX 1.04 -0.76 1.75 0.038329462 
ADAM19 1.09 -0.78 2.96 0.01631073 
IMPDH1 1.09 -0.81 1.73 0.029372633 
ADAMTS6 2.84 -0.83 3.40 0.028963716 
ANXA6 1.17 -0.85 1.99 0.01202954 
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Figure 3.15. Cytoscape visualisation of the top hub genes in blue module with high 
connectivity and gene significance (GS). Nodes with high degree of intramodular 
connectivity appear larger and darker in colour. Strong connections between nodes are 
represented by darker and wider edges.  
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Figure 3.16. Hierarchical cluster analysis of the expression level of the hub genes. The 
analysis identified 3 clusters (CL) of MPM cases (M) with epithelioid denoted by E and 
biphasic by B. Columns correspond to MPM cases and rows correspond to 31 hub genes 
associated with subtype classifications. 
Using the expression profiles of the 31 hub genes we reclassified the tumours into three 
molecular subtypes. Cluster 1 consisted of four out of the five biphasic MPM, cluster 2 
included one biphasic MPM and 4 epithelioid MPM; and the remaining epithelioid MPM are 
grouped together in cluster 3 (Figure 3.16).  Amongst these hub genes, CARNS1 has the 
strongest connectivity and PRR15 is the gene most significantly associated with histological 
subtypes (Table11).  
CARNS1 is a member of the ATP-grasp family of ATPases and catalyses the formation of 
CL 1     CL2        CL3 
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carnosine and harmocarnosine present mainly in skeletal muscle and the central nervous 
system respectively. Little is known about the role of carnosine in cancer but has been 
suggested to have a protective effect against oxidative stress293. Recent evidence 
demonstrated potential tumour suppressive function of CARNS1 by inhibiting the 
proliferation of malignant glioma cells in vitro and reducing growth in vivo in a NIH3T3-
HER2/neu mouse model294,295. Another study demonstrated CARNS1 as a Mapsin-dependent 
tumour suppressor in claudin-low breast carcinoma296. The expression of Mapsin, a tumour 
suppressor gene, is regulated by transcription factors or epigenetic modifiers and is expressed 
at higher levels in epithelial cells and downregulated in mesenchymal cells.  In vivo induction 
of Mapsin not only significantly upregulated CARNS1 but was able to revert aggressive 
claudin-low breast carcinomas towards a more differentiated ‘epithelial-like phenotype’. 
Interestingly, claudins are not frequently expressed in MPM; and their  expression by IHC are 
lower in sarcomatoid and biphasic MPM compared to epithelioid MPM297. The differential 
expression of CARNS1 across the 3 clusters in our study suggests possible downregulation of 
tumour suppressor Mapsin in the biphasic tumours (CL1). 
PRR15 encodes a protein of unknown function and its expression is restricted to post mitotic 
epithelial cells in mouse model and the pattern of expression is similar to negative cell cycle 
regulators suggesting a role in regulating cell proliferation298. PRR15 expression by in situ 
hybridisation was studied in mouse and human gastrointestinal tumours. The study found 
PRR15 was detected in tumours harbouring APC mutations suggesting its involvement in 
defective WNT signalling299. Thus the higher expression of PRR15 in CL1 compared to CL3 
suggests this pathway may be more active in epithelioid than biphasic subtypes. 
The expression level of seven hub genes is higher in CL1 as depicted in the heatmap in Figure 
3.16.  These include ADAMTS6, ADAM19, ANXA6 and RASGRP3 that are involved in ECM 
 119 
degradation and cell invasion; IMPDH1 and GLRX are involved in cell proliferation while the 
role of MIR181A1HG is unknown but has been shown to be highly expressed in acute 
promyelocytic leukaemia300. Amongst these genes, ANXA6 has the strongest connectivity and 
ADAMTS6 is the gene most significantly associated with histological subtypes (Table 3.11). 
ANXA6 is a member of the annexin family of calcium-dependent phospholipid binding 
proteins. Study in breast cancer tumours demonstrated downregulation of ANXA6 in tumour 
compared to normal breast tissue correlated with enhanced tumour cell proliferation mainly 
due to increased cytosolic calcium in cells expressing low level of ANXA6301. On the contrary, 
the study showed depletion of ANXA6 in invasive breast cancer cell line reduced tumour cell 
invasion/migration that might be attributed to the inhibition of FAK and PI3kinase/Akt 
pathway activation. The role of ANXA6 in promoting cell invasion/migration is further 
supported by increased NF-Kß activity and MMP-13 expression that promotes ECM 
degradation in ANXA6-overexpressing chondrocytes302. Taking all these together, 
downregulation of ANXA6 in cancer cells promotes cell proliferation while upregulation gives 
rise to a more invasive phenotype corresponding to the biphasic tumours in CL1 in Figure 
3.16. ADAMTS6 is a newly described ADAMTS (a disintegrin and metalloprotease with 
thrombospondin motifs) family members but its exact function is not well understood. 
However, there is evidence suggesting its role in compromising ECM structure from a retinal 
pigment epithelium derived cell line study303. 
It is also worth noting ADAM 19 and IMPDH1. ADAM19 is an endopeptidase that degrades 
ECM to promote invasion and is also capable of releasing several growth factors and 
cytokines including tumour necrosis factor (TNF)-alpha and TNF-alpha-related activation-
induced cytokine. It is upregulated in several malignancies and correlated with tumour 
invasiveness in primary brain tumour304. Cell line study identified ADAM19 as a downstream 
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target of TGF-ß pathway whereby stimulation of ovarian cancer cells with TGF-ß1 resulted in 
binding of SMAD4 to ADAM19 gene promoter sites accompanied by an increase in ADAM19 
mRNA levels305. IMPDH1 together with IMPDH2 are involved in the rate-limiting step for 
GTP and dGTP biosynthesis. IMPDH is implicated in cell proliferation and inhibition of 
IMPDH reduced guanine nucleotide pools thereby interrupting DNA synthesis and cell cycle 
progression by arresting cells in G1306. IMPDH is a recognised target for anticancer and 
immunosuppressive drugs and therefore potentially could be an attractive target in biphasic 
MPM tumours307. 
Next, we investigated the role of epithelial-mesenchymal transition (EMT) across the 
subtypes based on the findings of higher expression of genes associated with invasion, 
degradation of ECM and TGF-ß signalling in CL1. The boxplots below (Figure 3.17) display 
the differences in expression level of EMT markers (CDH1, SNAI1, SNAI2, ZEB1, ZEB2, 
TWIST1) across the 3 clusters. The results showed the mesenchymal transcriptional regulators 
are consistently more overexpressed in biphasic MPM tumours in CL1 with lower expression 
of epithelial marker, CDH1. The differences across the 3 clusters are statistically significant 
for SNAI1, SNAI2, ZEB2, TWIST1 and CDH1. Although not statistically significant, 
expression of ZEB1 also showed an upward trend from CL3 to CL1.  
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Survival data were available for each of the 25 tumour cases. Using Cox proportional hazards 
model to regress survival time on individual gene expression profile (adjusted for age and 
gender), a GS for survival was defined as minus logarithm of the hazard ratio probability 
value (described in Chapter 2 section 2.2.4.6). The diagram below (Figure 3.18) shows the 
turquoise module (605 genes) is significantly enriched with genes associated with survival 
time.  
 
Figure 3.18. Modules associated with survival time. Bar plots for each module (x-axis) 
and the corresponding gene significance (GS) for survival time (y-axis). The analysis 
shows turquoise module has the highest mean value of GS for survival time with a 
Kruskal Wallis p-value of 2.6e-59.  
Enrichment analysis revealed cell cycle process as the top over-represented GO terms for the 
turquoise model (Table 3.12). 
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Table 3.12. Top enriched GO terms for turquoise module associated with survival time. 
 
A statistically significant positive correlation is observed between GS for survival time and 
MM for genes in the turquoise module (Figure 3.19) indicating genes with high connectivity 
are also strongly linked with survival time. Twenty-five hub genes associated with survival 
time in the turquoise module are identified using an arbitrary GS value of ≥ 2.0 and MM 
value of ≥ 0.7 (Table 3.13). The interactive network amongst the hub genes is displayed using 
Cytoscape Software 3.0.1 as shown in Figure 3.20. 
GO category Category name GO ID No of genes adj.P value 
biological process cell cycle process GO:0022402 112 1.24E-22 
biological process cell cycle GO:0007049 126 7.93E-22 
biological process cell cycle phase GO:0022403 37 1.41E-20 
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Table 3.13. Top hub genes in the turquoise module. These hub genes are defined by 
absolute MM ≥0.7 and GS ≥ 2.0 with corresponding FC and adjusted p value identified 
from differential gene expression analysis. 
Gene GS survival MM turquoise FC adj.p value 
PDRG1 2.67 0.89 1.62 0.01065877 
E2F1 2.62 0.87 2.06 0.043738806 
TIMM50 2.03 0.85 1.56 0.017060413 
PSMD8 2.03 0.85 1.34 0.041059079 
MCM7 2.85 0.83 1.87 0.008922121 
GSG2 2.1 0.83 2.04 0.042485814 
PXMP4 2.97 0.83 1.53 0.043561541 
MOCS3 2.43 0.8 1.93 0.014510297 
NSDHL 2.64 0.8 1.80 0.00287891 
SGOL1 2.79 0.79 2.98 0.020787539 
CCT4 2.74 0.78 1.59 0.006244544 
CDCA8 2.29 0.78 2.72 0.017160609 
CENPH 2.19 0.78 1.70 0.026323983 
CCT5 2.16 0.77 1.44 0.035352582 
PBK 2.36 0.76 3.41 0.002567779 
CDC20 2.02 0.74 2.69 0.036215521 
NR2C2AP 2.19 0.74 2.07 0.014312739 
DAGLA 2.72 0.73 2.00 0.004631814 
TPX2 2.48 0.72 3.25 0.012000329 
BUB1 2.35 0.72 2.55 0.041013206 
SKA3 2.6 0.72 2.46 0.046605563 
POLD2 2.52 0.72 1.59 0.031978027 
MRPS17 2.08 0.71 1.50 0.032925202 
RFC3 3.29 0.71 1.51 0.047574394 
CKAP2L 2.5 0.7 2.89 0.013096869 
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Figure 3.20. Cytoscape visualisation of the top hub genes in turquoise module with high 
connectivity and gene significance (GS). Nodes with high degree of intramodular 
connectivity appear larger and darker in colour. Strong connections between nodes are 
represented by darker and wider edges.  
The hub genes associated with survival time are enriched in pathways involved in regulation 
of the cell cycle, in particularly the mitotic phase (Table 3.14). The hub genes are also 
involved in PLK1 and Aurora B signalling pathways that have several important functions in 
the mitotic phase of the cell cycle such as regulation of centrosome maturation, spindle 
assembly, mitotic exit and cytokinesis.  
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Table 3.14. Top pathways enriched by 25 hub genes associated with survival time. 
 
The expression profiles of the 25 hub genes stratified the tumours into three clusters (Figure 3.21) with different 
prognostic outcomes as shown in the Kaplan-Meier survival plots in Figure 3.22. 
 
 
Pathway FDR Nodes 
Mitotic Metaphase and 
Anaphase 
<1.000e-03 CDCA8,BUB1,PSMD8,SGOL1,CDC20,CENPH 
PLK1 signalling events <5.000e-04 BUB1,SGOL1,TPX2,CDC20 
Mitotic Prometaphase 3.33E-04 CDCA8,BUB1,SGOL1,CDC20,CENPH 
Synthesis of DNA 2.75E-03 MCM7,PSMD8,RFC3,POLD2 
DNA replication 3.00E-03 MCM7,RFC3,POLD2 
Aurora B signalling 3.67E-03 CDCA8,BUB1,SGOL1 
Cell Cycle Checkpoints 3.57E-03 MCM7,PSMD8,CDC20,RFC3 
S Phase 3.63E-03 MCM7,PSMD8,RFC3,POLD2 
Cell cycle 3.33E-03 E2F1,MCM7,BUB1,CDC20 
Regulation of DNA 
replication 
1.49E-02 E2F1,MCM7,PSMD8 
M/G1 Transition 1.62E-02 E2F1,MCM7,PSMD8 
Mismatch repair 2.78E-02 RFC3,POLD2 
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Figure 3.21. Hierarchical cluster analysis of the expression level of the hub genes 
associated with survival time. The analysis identified 3 clusters (CL) of MPM cases. 
Rows correspond to 25 hub genes associated with survival time and columns correspond 
to MPM cases (M). 
  
Chisq= 13.5 on 2 degrees of freedom, p= 0.001 
Figure 3.22. Kaplan-Meier overall survival plot for cluster (CL) 1, 2 and 3. This 
demonstrates CL1 has the worst prognosis while CL2 has the best prognosis.  
CL 1     CL2        CL3 
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The top three genes with the highest intra-modular connectivity are PDRG1, E2F1 and 
TIMM50 (Table 3.13). PDRG1 may have a role in DNA damage response and study found its 
mRNA level is up and downregulated by ultraviolet radiation and p53 respectively308. In 
addition, knockdown of PDRG1 in colon cancer cell suppressed tumour cell growth and 
PDRG1-associated proteins are involved in apoptosis and cell cycle demonstrating its 
participation in cell growth regulation.  
The expression of E2F1, a pivotal transcription factor involve in cell cycle, DNA synthesis, 
repair, proliferation and apoptosis, has been shown to be positively correlated with cancer cell 
proliferation309. The role of E2F1 in MPM has been previously studied that demonstrated 
knock down of E2FI using small interfering RNA (siRNA) in MPM cell lines and in 
xenograft models treated with arsenic trioxide (ATO)  significantly inhibited cell viability and 
proliferation310.  
TIMM50 facilitates transfer of proteins to the inner mitochondrial membrane required for 
normal mitochondrial function. TIMM50 plays an active role in modulating growth and 
development while knockdown of TIMM50 by siRNA increased the sensitivity of human cell 
lines to apoptosis by stimulating the release of mitochondrial apoptotic proteins that activate 
the caspase-dependent and –independent cell death pathways311.  
Seven of the hub genes associated with survival time (CDCA8, BUB1, PSMD8, SGOL1, 
CDC20, CENPH, TPX2) are related to mitotic spindle assembly checkpoint (MSAC). 
Overexpression of BUB1 has been previously described in MPM and is identified as one of 
the 11 genes in the prognostic classifier list associated with poor prognosis142. This 
serine/threonine protein kinase is a key component in mitotic checkpoint that regulates 
APC/C activity through recruitment of MAD1-MAD2 and inhibits APC/C activity by forming 
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a complex with other proteins to bind and phosphorylate an E3 ubiquitin ligase CDC20 that 
regulates separation of chromosomes for degradation at specific mitotic stages312. BUB1 also 
interacts with another novel gene in MPM, SGOL1, a protein-coding gene that maintains 
chromosome cohesion during mitosis313. This in turn allows SGOL1 to recruit a protein 
phosphatase, PP2, that retains cohesin at centromeres by counteracting PLK1 kinase activity 
to protect sister chromatids from early separation and maintain chromosomal stability. Several 
spliced variants of SGOL1 have been identified and their overexpression resulted in aberrant 
chromosome alignment and resistance to taxane chemotherapy314,315. Overexpression of 
CDCA8, a new component required for chromatin-induced microtubule stabilization and 
spindle formation is phosphorylated by AURKB and inhibition of CDCA8 resulted in growth 
suppression of lung cancer cell in vitro316.  
Four other genes (MCM7, PSMD8, RFC3, POLD2) are related to DNA synthesis/replication. 
PSMD8 is a 26S proteasome involved in activation of cyclin dependent kinase, CDC28, and 
shown to be upregulated in breast cancer317. Overexpression of MCM7 in body cavity fluid of 
patients with mesothelioma  correlated positively with Ki-67 and TOP2A (also identified in 
the turquoise module with MM=0.69 and GS 2.12); and together are able to distinguish 
reactive mesothelial cells from malignant mesothelioma cells318.  
Both POLD2 and RFC3 are involved in DNA repair. POLD2 is a subunit of the DNA 
polymerase delta complex whose expression is negatively regulated by tumour suppressor, 
PTEN. POLD2 is known to be involved in ovarian carcinogenesis and is associated with poor 
survival in gliomas319,320. RFC3 is a novel gene in MPM and has the highest GS value 
associated with survival time. RFC3 is a potential oncogene whose expression is upregulated 
by cancer promoter genes, MYCN and SHH; and downregulated by tumour suppressors TP53 
and CDKN2A of which the latter is frequently lost in MPM321–324. In addition, E2F1 is able to 
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promote RFC3 expression by binding to the RFC3 gene promoter region325. 
3.4 Discussions 
MPM is a highly aggressive tumour with poor prognosis and limited treatment options. MPM 
is categorized into three broad histological subtypes (epithelioid, sarcomatoid and biphasic) 
according to the presence and relative amount of epithelioid and spindle cell components. 
Histological subtype is one of the main prognostic factors in MPM but this is not always the 
case326. Gene expression profiling has successfully reclassified tumours into different 
subtypes and prognostic groups with more precision327. This is based on molecular signatures 
identified from gene expression variations that correlate with cellular and physiological state 
of the disease. 
Our global gene expression profiling study of MPM compared to non-malignant pleura 
revealed diverse molecular events that may contribute to the phenotype of this disease. Our 
data identified aberrant expression of genes involved in biological functions such as cell 
junction organization including cell morphology, movement and interactions with ECM, cell 
cycle process, and immune system regulation. The top five differentially expressed genes 
(ITLN1, UPK1B, UPK3B, CALB2 and LRRN4) with the highest absolute FC in expression 
level in our study are notable as potential diagnostic biomarkers (except CALB2 which is an 
established validated IHC marker for the diagnosis of MPM) and their roles in the 
pathogenesis of MPM require further studies.  
Uncontrolled cell growth and proliferation due to aberrant cell cycle regulation is one of the 
hallmarks of cancer. The CDKN2A locus that encodes p16INK4A and p14ARF (components of 
pRb and p53 cell cycle regulatory pathways); and CDKN2B are frequently deleted in MPM 
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leading to uncontrolled cell cycle progression328. Our study further supports the role of cell 
cycle genes in MPM progression and maintenance. We identified genes associated with cell 
cycle checkpoint, MSAC, and tumours with high expression of MSAC genes could 
potentially be targeted with nontaxane molecular inhibitor, epithilone B, as shown by 
Suraokar et al134. 
Cell junctions comprise of adhesive protein complexes that provide contact and signalling 
between neighbouring cells or between cell and the ECM thereby regulating cell morphology, 
adhesions and mobility. Abnormal expression of genes involved in these processes is 
implicated in tumorigenesis including malignant transformation, migration/invasion and 
metastasis329. We observed FAK, a cytoplasmic tyrosine kinase and a multifunctional 
regulator of cell signalling within the tumour microenvironment, is at the intersection of many 
of the genes and pathways associated with cell morphology, adhesions and migration. In 
addition, several upregulated growth factors and/or their receptors identified in our study 
including EGFR, FGF9, FGF18, MET and HMMR are capable of activating FAK. The amino-
terminal domain of FAK interacts with intracellular domain of EGFR and is an important 
signalling integrator for EGF-EGFR mediated cell migration330. The fibroblast growth factors 
are also implicated in phosphorylation of FAK at Ser-910331. MET has also been shown to 
have direct interaction with FAK independently of its ligand HGF332. Hyaluronan, a 
glycosaminoglycan of the ECM, binds to its receptor HMMR and are able to induce epithelial 
cell lines to undergo transformation to mesenchymal-like phenotype and activation of 
PI3K/Akt pathway via FAK333. 
In addition, we identified genes involved in Hedgehog and WNT signalling pathways.  
Deregulated Hedgehog signalling is active in MPM with significant increase in expression of 
GL1, sonic hedgehog and human hedgehog interacting protein detected by q-PCR and in situ 
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hybridisation in tumour samples334. LRP2 an important regulator of Hedgehog signalling is 
one of the top 20 up-regulated genes (adj. p value= 0.002, FC= 30.48) in our study. Aberrant 
WNT signalling is active in MPM and targeting WNT signals using siRNA or antibodies 
against WNT1 or 2 and dominant-negative Dvl led to suppression of mesothelioma cells 
growth in vitro171,173,252,253. Our findings further support the involvement of these two 
pathways in MPM carcinogenesis that may have potential therapeutic implications. 
Interestingly, recent studies have identified interactions between both Hedgehog and WNT 
pathways with FAK signalling. In vitro study on hepatoma cell line showed Sonic hedgehog 
mediated cell migration and invasion by regulating FAK/AKT signalling pathways. 
Enhancing Hedgehog signalling by rSHH-N led to increased phosphorylation of AKT and 
FAK while Hedgehog signalling inhibitor resulted in decreased AKT and FAK activities335. 
On the contrary, FAK appears to act upstream of WNT signalling as demonstrated in MCF-7 
breast cancer cell line whereby suppression of FAK led to reduced WNT3/3A expression 
levels336.  
As described, many of the genes and pathways identified are linked to FAK signalling. 
However, PTK2 that encodes FAK was not identified as one of the differentially expressed 
genes in our data. The Cancer Genome Atlas showed high messenger RNA (mRNA) levels of 
FAK in several cancer types and activation of FAK identified with antibody recognition of the 
FAK Y397 auto-phosphorylation site correlated with tumour progression337. Other study 
observed increased FAK activity is associated with PTK2 amplification or copy number gain 
but does not always correlate with FAK mRNA expression and mRNA level does not always 
translate into FAK protein level338. In MPM, NF2 that encodes Merlin is frequently 
inactivated and Merlin is required to inhibit tumour growth and cell contact through reduction 
of several signalling pathways including FAK-Src339. Merlin negative MPM cell lines depend 
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on cell-ECM induced FAK signalling and are particularly sensitive to FAK inhibitor in vivo 
and in vitro340. Taking all these together, our data suggest the role of FAK in MPM require 
further exploration and in fact FAK inhibitors have already been tested in patients with MPM 
showing positive results341.  
Our analysis revealed 78 out of 352 downregulated genes are associated with immune system 
regulation suggesting contribution of dysfunctional immune system to the transformation and 
progression of this disease.  The interaction of cancer and the immune system is complex and 
involves the interactions between tumour immunogenicity, cooperation of all known effectors 
in both innate and adaptive immunity that regulates host’s immune response and capabilities 
of cancer cells to evade the immune system342.  
MPM is considered weakly immunogenic but a case report of spontaneous tumour regression 
provided evidence for anti-tumour response mounted by modulation of the immune system343. 
Subsequently, studies showed the presence of tumour-infiltrating CD8+ T cells in MPM 
tumours is associated with better prognosis in patients undergoing surgery and higher CD8+ T 
cells is also associated with reduced metastases in patients with MPM receiving 
chemotherapy344,345. Our data demonstrated downregulation of several immune-related genes 
that might result in impaired anti-tumour immune response. These genes are involved in 
recruitment, activation and expansion of immune cells including CD8+ T cells and genes 
involved in antigen processing and presenting.  Modulating the immune system with 
recombinant viral proteins, vaccines or antibody and dendritic-cell based applications is an 
appealing approach in targeting tumours including MPM. This strategy involves inducing 
antigen-specific immune response to activate cytotoxicity and eventually generate 
immunological memory to ensure long-term remission.  In fact, preclinical data and clinical 
studies in MPM have shown promising cytotoxic result with antibodies against immune check 
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point receptors such as cytotoxic T lymphocyte antigen-4 and programmed cell death protein-
1346–348. In addition, other immune-related genes (SELE, CD40 and CIITA) that could 
potentially be modulated with immunotherapy have also been identified from our study. 
WGCNA allows the identification of groups of genes (modules) that are co-expressed 
independent of phenotypes and share similar biological process. This methodology has 
successfully revealed molecular targets including ASPM gene in glioblastoma and networks 
associated with survival in breast cancer204,349. We used WGCNA to assess the data set 
containing 3092 differentially expressed genes with an adjusted p-value of ≤ 0.05. This 
identified 14 modules of which the blue module (436 genes) and the turquoise module (605 
genes) are significantly associated with histological subtypes and survival time respectively. 
We then chose the hub genes (genes with high connectivity in the respective module as 
measured by MM and high significance for the respective clinical trait as measured by GS) 
with an arbitrary cut off values of MM and GS to stratify histological subtypes and prognosis. 
We identified 31 hub genes in the blue module of which 26 have a FC in expression level of ≥ 
2.  Seven (PLLP, PRR15, LRRN4, BNC1, UPK3B, MMP24, C19orf33) out of these 26 genes 
are in the top 20 differentially expressed genes with the highest FC in expression level. These 
hub genes are able to distinguish 4 out of the 5 biphasic tumours from the epithelioid 
subtypes. One of the biphasic tumour is grouped with 8 epithelioid subtypes in CL2 and the 
remaining 12 epithelioid subtypes are grouped in CL3.  CARNS1 has the highest connectivity 
in the module and is associated with tumour suppressor Mapsin. Its differential expression 
across the three clusters suggests a tumour suppressive function of Mapsin in the pathogenesis 
of the different MPM subtypes. Interestingly, a recent study revealed the role of Mapsin in 
modulating the immune system towards tumour elimination by depleting cancer cells of the 
stemness and regulating the HDAC1-dependent cytokine expression profile to reduce immune 
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suppression1. Thus, Mapsin- based therapies may have an important therapeutic implication in 
MPM. 
PRR15 has the highest GS value associated with histological subtypes and its up- and down-
regulation are associated with TGF-ß and WNT signalling respectively. Based on the 
differential expression of PRR15 in the 3 molecular subtypes, we hypothesised these two 
pathways may be preferentially activated across the different subtypes which could explain 
the more aggressive and invasive phenotype of biphasic tumours in CL1 compared to 
epithelioid tumours in CL3. In addition, the expression of ADAM19, one of the hub genes that 
is a downstream effector of TGF-ß, is higher in CL1. This further supports our assumption 
that TGF-ß might be the preferential pathway in CL1.  We interrogated the other genes in the 
blue module and identified an additional 9 genes (TGFB2, WNT9A, WNT7B, WNT2B, CDH1, 
INADL, PARD6B, MPP5 and PRKCI) that are associated with these two pathways.  
TGF-ß is a recognised stimulator of EMT process that was first observed in cell culture and 
subsequently several in vitro studies demonstrated similar findings350–352. TGF-ß-induced 
EMT occurs not only via Smad-dependent pathway but also via activation of MAPK pathway 
and small GTPases of the Rho family to regulate transcription of regulators of EMT and cell 
proliferation353–355. The involvement of EMT process is further supported by the 
overexpression of other hub genes: ANXA6, ADAMTS6 and RASGRP3; that are involved in 
ECM degradation. The process of physiological EMT involves a defined sequence of events 
for the conversion of epithelial tissue into a mesenchymal phenotype but this coordination is 
lost and occurs in a haphazard manner in cancer. Cancer cells undergo EMT to promote 
migration and invasion involving the transcriptional downregulation of genes that maintain 
epithelial apical-basolateral polarity, cytoskeletal organisation, cell-cell contact (tight 
junctions, adherens junctions and desmosomes); and upregulation of genes associated with 
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ECM-remodelling, mesenchymal cytoskeleton and cell migration. We examined the 
expression profiles of mesenchymal markers SNAI1, SNAI2, TWIST, ZEB1 and ZEB2. These 
genes have been shown to be the main regulators of EMT that induce epigenetic silencing of 
CDH1 by binding to its promoter region356–359.  The expression of SNAI1, SNAI2, TWIST and 
ZEB2 are consistently higher in CL1 and the differences in expression level are statistically 
different across the three clusters. We demonstrated EMT process might have an important 
role in governing the morphological differences across the subtypes and these observations 
are in keeping with a published study in MPM360.  
We identified 25 hub genes in the turquoise module that are significantly associated with 
survival time. Further interrogation into these genes revealed their significant association with 
cell-cycle process. Aberrant cell cycle regulation is a common oncogenic event in many 
tumour types including MPM. These hub genes are able to categorise the tumours into three 
prognostic groups. PDGR1 has the highest connectivity with other genes in the turquoise 
module. This gene has not been reported in MPM and is implicated in defective DNA repair 
pathway. This is particularly relevant in MPM as 80% of MPM is attributed to asbestos that is 
capable of inducing DNA damage. Lam et al demonstrated the expression level of E2F1, one 
of the top hub genes associated with survival time, together with SKP2 could be 
downregulated by ATO. Thus, further studies are warranted to investigate the clinical use of 
ATO in MPM.  
Seven of the 25 prognostic hub genes are also associated with MSAC and 5 of these (CDCA8, 
PSMD8, SGOL1, CDC20, CENPH) have not been reported in MPM. Similar findings on 
deregulation of MSAC pathway were also reported by Crispi et al and Suraokar et al134,222. 
These further support the importance of MSAC genes in the pathogenesis of MPM. 
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Four prognostic hub genes (BUB1, SGOL1, TPX2 and CDCA8) are associated with Aurora 
kinase signalling that could have therapeutic implications. It is worth noting that the 
prognostic role of BUB1 in MPM is further supported by 2 other published studies and is 
included in the 11 prognostic classifier gene list by Glinski et al142,222. In vitro study showed 
promising activity of aurora kinase inhibitor in inhibiting MPM cell growth and trials have 
been set up testing several commercially available aurora kinase inhibitors in MPM361.  
There are few limitations identified from our study. Firstly, our sample size might not be the 
largest to date and this is mainly due to the low incidence of MPM compared to other solid 
tumours and the small tissue size obtained for diagnostic purpose results in inadequate surplus 
tissues for research. The latter can also affect the quality and yield of RNA obtained. In 
addition, majority of the frozen tumour samples used in our study were not stored in 
RNAlater that might affect the integrity of RNA. This explains the reason for the need to use 
higher RNA quantity for the tumour samples compared to controls in generating cDNA.  
Gene expression microarray experiments can be affected by a number of non-biological 
variables that can have an impact on the results362. These variables are termed batch effects 
and include differences such as reagents lot, the time, place and technicians carrying out the 
experiments. Of the batch effects identified in our study, the number of array plates used 
accounted for 2.5% of the variance in the RMA treated data. Lastly, treatment data for the 
majority of the tumour cases were not available and therefore the survival time could be 
confounded by treatments received along the course of the disease.  
In conclusion, our study identified simultaneous aberrant expression in genes involved in cell 
migration, invasion, cell cycle and the immune system that support the malignant phenotype 
of this disease. To our knowledge, WGCNA methodology has not been applied in MPM 
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transcriptome data. Through this approach, we identified hub genes that are able to stratify 
tumours into three distinct molecular subtypes and prognostic groups. Our analyses identified 
several pathways including FAK (and its downstream pathways including MAPK and PI3K), 
TGF-ß, Hedgehog, WNT, MSAC and Aurora kinase that might contribute to the pathogenesis 
of MPM and these should be evaluated further for potential therapeutic targets.  
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Chapter 4 - Whole Exome Sequencing of Malignant 
Pleural Mesothelioma 
4.1 Introduction 
Approximately 85% of human diseases occur as a result of mutations in the protein coding 
regions of the genome. Therefore, selective sequencing of protein coding regions, the exome, 
allows identification of mutations relevant to the disease. Whole exome sequencing provides 
higher sequence coverage, manageable output data, lower costs and higher sensitivity to 
detect mutations with low allele frequencies compared with whole-genome sequencing. These 
benefits generally outweigh the limitations of exome sequencing, which rely on an initial 
hybridization step and therefore can lead to exome “dropout” and failure to capture anything 
not included in the original exome probe library.  
In recent years, whole exome sequencing has successfully revealed the molecular landscape 
in a variety of cancer types363. This has provided key understanding in the biological 
mechanisms relevant to the disease with improvement in personalised medicine to inform 
treatment choices, early diagnosis and other potential therapeutic discovery.  
Little is known about the full genetic landscape of malignant pleural mesothelioma (MPM) 
but previous studies have consistently identified several genetic alterations in MPM. These 
include frequent losses of chromosome arms 1p, 3p, 9p and 22q; gains in chromosome 1q, 5p, 
7p, 8q, and 17q; and inactivation of CDKN2A, NF2 and BAP1106,364. The use of next-
generation sequencing in MPM is rare compared to other tumour types. Thus far, whole 
genome sequencing of a single MPM tumour and matched normal tissue has been reported 
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and uncovered chromosomal rearrangement events as the dominant type of molecular 
aberrations107. These included 15 rearrangements that disrupted 17 genes and one of these 
resulted in a large deletion in DPP10 of which its expression was associated with significantly 
better survival compared to patients whose tumours lacked DPP10 expression. Two other 
groups have carried out whole exome sequencing with MPM cell lines and identified 
molecular aberrations in genes associated with mammalian SWI/SNF chromatin remodelling 
complexes and histone modifiers143,365. The first comprehensive overview of the molecular 
landscape in MPM was revealed by Guo et al who performed whole exome sequencing 
together with copy number alteration analysis on 22 MPM frozen tissues and matched blood 
samples144. They confirmed frequent genetic alterations in previously described genes 
including CDKN2A, NF2, BAP1 and a novel gene, CUL1. To explore further the molecular 
alterations underlying MPM, we performed whole exome sequencing on a discovery cohort 
consisted of seven matched pairs of MPM frozen tissues and whole blood; and a validation 
cohort of 29 MPM frozen tissues without matched normal counterparts. 
4.2 Materials and Methods 
4.2.1 Tissues acquisition and preparation 
A total of eight frozen tumour tissues and matched blood samples (discovery cohort) were 
identified from EQUALITY study, an Imperial College London-sponsored, prospective study 
on thoracic cancers undergoing biopsy at St George’s Hospital (REC reference: 
10/H0808/53). A further 29 frozen tumour tissues without matched blood samples (validation 
cohort) were provided by National Institute for Health Research-Biomedical Research Units 
(NIHR-BRU) Advanced Lung Disease Biobank and Royal Brompton and Harefield (RBH) 
NHS Trust Diagnostic Tissue Bank. Tissues were collected during diagnostic procedure prior 
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to any anti-cancer treatment. In addition, 13 formalin fixed, paraffin-embedded (FFPE) 
tumour blocks from the validation cohort were identified and selected to undergo laser 
microdissection (LCM) (Chapter 2 section 2.2.2.4) or microtomy section (Chapter 2 section 
2.2.2.1) to isolate adjacent non-tumour cells for matched normal DNA.  
Tumour frozen tissues and FFPE were sectioned, stained with routine haematoxylin and 
eosin, and reviewed by two certified pathologists to verify tumour histology, abundance and 
to identify adjacent non-tumour areas in the FFPE sections (Chapter 2 section 2.2.2.2 and 
2.2.2.3). Tumour tissues with a minimum arbitrary threshold of 30% viable-appearing 
malignant cells were selected for genomic deoxyribonucleic acid (DNA) isolation. 
4.2.2 DNA isolation plus quantity and quality assessments 
Total genomic DNA was isolated from frozen tumour tissues using the phenol-chloroform 
method as described in Chapter 2 section 2.2.5.1. Briefly, equal volume of phenol-chloroform 
was added in a stepwise manner to an aqueous solution of homogenised tissue. By mixing the 
two phases and separating them by centrifugation yielded the lower organic phase and the 
upper DNA-containing aqueous phase.  DNA was then precipitated with 100% ethanol and 
the pellet was isolated by centrifugation.  
DNA isolation from whole blood samples was carried out with Wizard ® Genomic DNA 
Purification Kit (Promega, London, UK) following the manufacturer’s instructions (Chapter 2 
section 2.2.5.2). Briefly, red blood cells were lysed followed by lysis of white blood cells and 
their nuclei. The cellular proteins were removed by salt-precipitation method that resulted in a 
lower protein-containing phase and an upper DNA-containing phase. DNA was precipitated 
with isopropanol and pellet was obtained by centrifugation. DNA from non-tumour FFPE 
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sections was isolated with BiOstic® FFPE Tissue DNA Isolation Kit (MO Bio Laboratories, 
California, USA) as described in Chapter 2 section 2.2.5.3. 
DNA yield and purity were assessed using the Thermo Scientific NanoDropTM 1000 
Spectrophotometer (NanoDrop Technologies) and Quant-iT™ PicoGreen® dsDNA Assay Kit 
(Life Technologies, California, USA). 
4.2.3 Whole exome sequencing 
Genomic DNA from tumour and blood samples were fragmented and hybridised as per 
SureSelectXT Target Enrichment System for Illumina Paired-End Multiplex Sequencing 
protocol (Chapter 2 section 2.2.6). The captured libraries were sequenced on Illumina 
HiSeq2000 according to the standard protocol.  
4.2.4 Data processing and quality control 
Read alignment and data quality control were processed with GATK software from the Broad 
Institute. Variant calling was carried out with GATK Unified Genotyper variant discovery 
tool196. The variants were annotated with ANNOVAR to obtain gene-based (e.g. functional 
consequences on genes), region-based (e.g. conserved regions) and filter-based annotations 
(e.g. 1000 Genomes Project, dbSNP) for each variant. 
4.2.5 Candidate somatic variants  
After removing germline variants, the annotated file was subjected to a series of filtering steps 
to identify candidate somatic variants. Single nucleotide variants (SNV) and 
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insertions/deletions (indels) with a quality score of <50 or present in either dbSNP138, 1000 
Genomes Project or NHLBI GO Exome Sequencing Project were filtered out. Potential driver 
mutations were identified from one of the following criteria: 
• somatic non-synonymous SNV predicted to alter protein function by one of the three 
algorithms: Polyphen-2 (genetics.bwh.harvard.edu/pph2/), SIFT (sift.jcvi.org/) and 
MutationTaster (mutationtaster.org/) 
 
• recurrent somatic mutations that cluster in a specific domain of the gene (mutation 
hotspots) or recurrent somatic mutations distributed along a gene 
 
• genes implicated in other types of malignancy 
4.2.6 Pathway analysis 
Somatic mutations (nonsense, damaging or deleterious missense, splicing mutations and 
indels) were analysed for pathway enrichment with NetworkAnalyst tool whereby genes from 
our exome data were used as priory and mapped to a manually curated protein-protein 
interaction database to construct non-random networks198.  
4.2.7 Validation of candidate mutations 
Specific primers were designed with Primer3web (version 4.0.0) or ExonPrimer 
(http://ihg.gsf.de/ihg/ExonPrimer.html) to amplify candidate SNV or indels using polymerase 
chain reaction (PCR) with HotStarTaq Plus Master Mix kit (Qiagen, Crawley, UK) followed 
by Sanger sequencing (Chapter 2 section 2.2.6.3).  
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4.3 Results 
4.3.1 Cases demographic and clinical characteristics 
Genomic DNA was isolated from a total of 37 frozen tumour tissues with and without 
matched blood samples (discovery cohort = 8 matched pairs of tumour tissues and blood, 
validation cohort = 29 frozen tissues) and whole exome was sequenced successfully for all 
but one (MESOEQ15) from discovery cohort. Table 4.1 summarises the cases and tumour 
characteristics. The majority of the cases were of male gender and 35% of the cases were 
above 70 years of age. About 70% of cases had a documented exposure to asbestos and 62% 
of cases had ever smoked. Stage of disease was not or poorly recorded and was unreliable in 
this dataset hence it was not included. Epithelioid MPM was the predominant subtype and no 
sarcomatoid MPM was identified from both cohorts. The mean tumour abundance was lower 
in the discovery cohort compared to the validation cohort and a total of 17 tumour samples 
(see Table 4.2 and 4.3) had less than the minimum 60% tumour abundance requirement 
according to the International Cancer Genome Consortium guidelines366. Treatment data were 
not available for majority of the cases as further oncological management was undertaken by 
the referring hospitals after completing the diagnostic procedures. 
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Table 4.1. Baseline demographics and clinical characteristics of discovery and validation 
cohorts. CT=chemotherapy, RT=radiotherapy. 
 Characteristics Discovery cohort (n=7) Validation cohort (n=29) 
Age, years 
Median 
Range 
≤ 70 
> 70 
 
68 
60-80 
5 (71%) 
2 (29%) 
 
67 
52-82 
18 (62%) 
11 (38%) 
Sex 
Male 
Female 
 
5 (71%) 
2 (29%) 
 
23 (79%) 
6 (21%) 
Smoking 
Ever smoked 
Never smoked 
Not known 
 
6 (86%) 
0 
1 (14%) 
 
17 (59%) 
9 (31%) 
3 (10%) 
Asbestos exposure 
Yes 
No 
Not known 
 
4 (57%) 
2 (29%) 
1 (14%) 
 
22 (76%) 
6 (21%) 
1 (3%) 
Histological subtypes 
Epithelioid MPM 
Biphasic MPM 
Sarcomatoid MPM 
 
6 (86%) 
1 (14%) 
0 
 
21 (72%) 
8 (28%) 
0 
Tumour abundance (%) 
Mean 
Range 
 
50 
30-80 
 
65 
30-95 
Treatment 
CT 
RT 
CT+RT 
None 
Not known 
 
 
 
 
 
7 (100%) 
 
4 (14%) 
2 (7%) 
3 (10%) 
4 (14%) 
16 (55%) 
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4.3.2 DNA results 
From the discovery cohort, the median DNA yield from tumour and matched blood was 67.1 
micrograms (µg) (ranged from 12.7-273.1 µg) and 79.4 µg (ranged from 35.3-111.7 µg) 
respectively (Table 4.2). 
Table 4.2. Total DNA results of discovery cohort. Tumour samples denoted by 
MESOEQ♯♯TF and matched blood samples denoted by MESOEQ♯♯BL. DNA 
concentration (Cx) in ng/μl and 260/280 ratio quantified by Thermo Scientific 
NanoDropTM 1000 Spectrophotometer (NanoDrop Technologies). NA= not applicable. 
 Sample ID Tumour % Cx (ng/μl) volume (μl) Yield(µg) 260/280 
MESOEQ13TF 30 496.2 250 124.1 1.9 
MESOEQ21TF 70 268.3 250 67.1 1.9 
MESOEQ22TF 30 50.6 250 12.7 1.8 
MESOEQ30TF 30 172.3 250 43.1 2.0 
MESOEQ36TF 80 1092.4 250 273.1 2.0 
MESOEQ38TF 50 631.7 250 157.9 1.9 
MESOEQ40TF 70 174.7 250 43.7 2.0 
MESOEQ13BL NA 44.1 800 35.3 2.1 
MESOEQ21BL NA 52.2 800 41.8 1.9 
MESOEQ22BL NA 52.3 800 41.8 2.0 
MESOEQ30BL NA 129.9 800 104.0 1.9 
MESOEQ36BL NA 101.0 800 80.8 1.9 
MESOEQ38BL NA 99.2 800 79.4 1.9 
MESOEQ40BL NA 139.6 800 111.7 1.9 
 
The median DNA yield was 100 µg (ranged from 14.7-562.5 µg) in the validation cohort 
(Table 4.3). 
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Table 4.3. Total DNA results of validation cohort. Tumour samples denoted by 
MESOD♯♯. DNA concentration (Cx) in ng/μl and 260/280 ratio quantified by Thermo 
Scientific NanoDropTM 1000 Spectrophotometer (NanoDrop Technologies). 
 Sample ID Tumour % Cx (ng/μl) Yield(µg) 260/280 
MESOD1 30 58.7 14.7 1.6 
MESOD2 30 61.6 15.4 1.6 
MESOD3 55 77.9 19.5 1.6 
MESOD5 80 108.6 27.1 1.7 
MESOD6 30 133.1 33.3 1.9 
MESOD8 40 166.8 41.7 1.8 
MESOD10 90 215.6 53.9 1.9 
MESOD12 95 238.9 59.7 1.9 
MESOD13 50 270.9 67.7 1.9 
MESOD14 80 281.2 70.3 1.7 
MESOD15 40 336.3 84.1 1.9 
MESOD16 95 348.4 87.1 1.9 
MESOD17 70 388.4 97.1 1.9 
MESOD18 90 389.4 97.3 1.9 
MESOD19 70 402.9 100.7 2.0 
MESOD21 30 419.2 104.8 1.9 
MESOD22 90 443.8 111.0 2.0 
MESOD24 50 483.9 121.0 1.9 
MESOD25 95 533.5 133.4 1.9 
MESOD26 70 596.9 149.2 1.9 
MESOD27 70 602.0 150.5 2.0 
MESOD28 35 624.2 156.1 1.9 
MESOD29 80 927.9 232.0 1.9 
MESOD30 40 1134.1 283.5 2.0 
MESOD31 90 1196.6 299.2 2.0 
MESOD32 90 1422.7 355.7 1.9 
MESOD33 40 1794.1 448.5 2.0 
MESOD34 80 2250.0 562.5 1.9 
MESOD35 90 479.5 119.9 2.0 
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In an attempt to obtain matched normal for the validation set, LCM and microtomy section of 
adjacent non-malignant areas were carried out on eight and five FFPE tumour blocks 
respectively. The DNA yield was virtually zero for the LCM samples while the DNA yield 
from two of the samples sectioned with microtome was critically low (Table 4.4). The DNA 
from the remaining three sectioned samples was not taken forward for whole exome 
sequencing. 
Table 4.4. Total DNA results of matched normal from validation cohort. DNA 
concentration (Cx) in ng/μl quantified by Quant-iT™ PicoGreen® dsDNA Assay Kit 
(Life Technologies, California, USA). 
Sample ID Cx (ng/μl) volume (μl) Yield (µg) 
MESOD35N -0.03 16 nil 
MESOD30N -0.03 16 nil 
MESOD19N 0.02 16 0.3 
MESOD14N 0.38 16 6.1 
MESOD2N 0.01 16 0.2 
MESOD32N 0.30 16 4.9 
MESOD6N -0.05 16 nil 
MESOD29N -0.06 16 nil 
MESOD24N 2.07 40 82.8 
MESOD28N 5.17 40 206.9 
MESOD33N 5.10 40 204.1 
MESOD3N 2.37 40 94.7 
MESOD6N 4.25 40 170.1 
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4.3.3 Overview of somatic mutations in discovery cohort 
The exomes were successfully sequenced for all 7 matched pairs of tumour and blood DNA 
except MESOEQ15. An average of 3.5Gb sequencing data were generated for each sample 
with a mean coverage of 164X for tumour and 106X for normal (blood) (Table 4.5 and 
Appendix 4.1). On average, 98.5% of the bases sequenced achieved 10X coverage.  
Table 4.5. Total number of bases sequenced and mean coverage results. 
Case ID Tumour bases 
sequenced 
Normal bases 
sequenced 
Mean tumour 
exome coverage 
Mean normal 
exome coverage 
MESOEQ13 5.10E+07 5.10E+07 214.9 78.3 
MESOEQ21 5.10E+07 5.10E+07 188.8 83.4 
MESOEQ22 5.10E+07 5.10E+07 139.6 101.0 
MESOEQ30 5.09E+07 5.09E+07 105.1 144.9 
MESOEQ36 5.10E+07 5.10E+07 114.2 143.0 
MESOEQ38 5.10E+07 5.10E+07 162.2 82.2 
MESOEQ40 5.09E+07 5.09E+07 224.4 106.6 
 
After filtering, we identified a total of 1,226 somatic mutations in 1,074 genes of potential 
biological significance distributed predominantly in the protein coding (97.7%) and to a lesser 
extent in the splice site (2.3%) regions. These included 334 synonymous mutations, 765 
missense mutations, 84 nonsense mutations including 83 stop-gain and 1 stop-loss mutation, 
28 splice site mutations and 15 insertions/deletions including 12 indels causing frameshift 
mutations and 3 indels that did not alter reading frame. A median of 78 somatic mutations in 
exonic/splice site regions per tumour sample was observed with MESOEQ38 harbouring 
small numbers of somatic mutations and MESOEQ22 having a higher rate of somatic 
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mutations compared to the rest (Table 4.6). The observed ratio of non-synonymous to 
synonymous change was 2.5 with 88.3% of the SNV occurring at G:C base pairs. The 
observed somatic mutation spectrum in the seven tumour samples showed G:C>A:T as the 
predominant transition and transversion was dominated by G:C > T:A as noted in other 
cancers such as non-small cell and small cell lung cancers367,368. 
Table 4.6. Distribution of somatic mutations across each sample. 
Mutation 
types 
MESOEQ 
13 
MESOEQ 
21 
MESOEQ 
22 
MESOEQ 
30 
MESOEQ 
36 
MESOEQ 
38 
MESOEQ 
40 
Silent 26 19 210 59 19 9 51 
nonsense 3 0 69 11 1 0 3 
missense 31 55 509 123 18 16 91 
splicing 2 3 16 4 1 1 4 
indels 0 1 1 9 1 0 3 
Total 62 78 805 206 40 26 152 
 
After removing non-silent mutations, a total of 892 somatic mutations across 821 genes were 
identified. A median of 69 non-synonymous mutations per tumour sample was observed. 
These are much lower compared to solid tumours with known mutagens such as lung cancer 
and melanoma where 200 missense mutations per tumour have been observed369. We used 
three functional prediction algorithms to evaluate missense mutations for the identification of 
potential driver mutations. Of the 765 missense mutations, functional impact could not be 
predicted for 22 variants using all three algorithms possibly due to non-availability of suitable 
transcripts. The remaining 743 missense variants, 208 (28.0%) missense mutations were 
predicted by all three algorithms, 205 (27.5%) were predicted by two out of the three 
algorithms and 185 (24.9%) were predicted by one out of the three algorithms to be at least 
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probably damaging or deleterious (Appendix 4.2). 
4.3.4 Overview of mutations in validation cohort 
In the validation cohort of 29 tumour samples, each sample was sequenced at a mean 
coverage of 149X and an average of 98.9% bases were covered at 10X. After filtering, a total 
of 4,684 mutations were identified comprising of 1,253 synonymous mutations, 2,764 
missense mutations, 110 nonsense mutations and 553 indels or substitution of which 305 
indels and substitution altered the reading frame. By excluding non-silent mutations, there 
were a total of 3,431 mutations distributed across 2,764 genes. 
4.3.5 Candidate genes 
Candidate genes were selected based on any one of these criteria: (a) nonsense, splicing, 
indels and missense mutations with protein alteration predicted to be probably damaging or 
deleterious by one of the three functional algorithms (b) overlapping variants present in one or 
more tumour sample in discovery cohort and validation cohort (c) genes reported to be 
associated with cancers. We selected several variants and confirmed the presence of the 
mutations with Sanger sequencing (Appendix 4.3). 
We found the mucin family genes, in particularly MUC4 and MUC12, frequently mutated in 
more than 70% of the tumours in both cohorts. These results should be interpreted with 
caution since the mucin genes encode for extremely large proteins and the statistical tests in 
variant calling have not taken into account larger target size. Thus, these variants are likely to 
be false positives. 
Other mucin genes that were less frequently mutated included MUC5B and MUC16 in 14% of 
 154 
all tumours. The somatic status was determined in two out of nine MUC5B variants and four 
out of six MUC16 variants The role of MUC5B in cancer has not been studied extensively but 
results from breast cancer cell lines demonstrated its capability in promoting tumour 
proliferation and invasion370. Interestingly, MUC16 is known to bind to mesothelin, frequently 
overexpressed in  epithelioid MPM and promotes MPM cell invasion by inducing MMP-9371. 
However, it is not known how mutations in MUC16 might alter MSLN-MUC16 molecular 
interaction contributing to carcinogenesis. 
SAFB2, scaffold attachment factor B2, and its paralog SAFB1 act as transcriptional repressor 
regulating genes involved in apoptosis and the immune system372. Four mutations were noted 
in SAFB2 and of these a somatic non-synonymous mutation resulting in T950P protein change 
occurred in 61% of all tumours. It is uncommon for a hotspot mutation to occur at such high 
frequency and further interrogation revealed the variant is present in Exome Aggregation 
Consortium (ExAC) data set with an allele frequency of 0.007. This is unlikely to be a 
disease-causing variant as it would imply the incidence of MPM to be 1 in 142. Two other 
recurrent mutated genes in the discovery cohort include SRCAP and SHANK3 but these are 
considered not significant in MPM as the variants are also present in ExAC database. 
Two other novel genes not described previously as mutated in MPM are AIDA and SPDYE6. 
Somatic mutations in AIDA, an Axin-interacting protein, are present in two tumours and also 
mutated in an additional tumour in the validation cohort accounting for 8.3% of all tumours. 
SPDYE6, one of the speedy/RINGO family members E, mutations were also observed in 
8.3% of all tumours. A somatic missense mutation resulting in protein change p.R337H 
occurred in two tumours and an additional mutation (p.R305C) was present in one tumour in 
the validation set. The speedy/RINGO family members E have been shown to activate cyclin 
dependent kinases CDK1, CDK2 and CDK5 but their interactions resulted in slow G2-M 
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transition of the cell cycle373. 
Next, we compared non-silent mutations present in discovery cohort to genes from the 
Catalogue of Somatic Mutations in Cancer (COSMIC) database and genes implicated in 
cancer as reported by Vogelstein et al and Leiserson et al369,374.These revealed somatic 
mutations in 40 genes implicated in human cancers across the tumours in discovery cohort 
except MESOEQ21 and MESOEQ38 (Appendix 4.4). The majority of the mutations occurred 
in not more than one tumour except mutations in NF2 and XPC present in two out of seven 
tumours. Twelve of these genes were also mutated in the validation cohort including BAP1 
and NF2 (Appendix 4.5). 
BAP1 mutations occurred in 25% of all tumour samples combined (one from discovery cohort 
and eight from validation cohort). Eleven variants of different mutation types (Table 4.7) were 
distributed across BAP1 with the majority occurring in the ubiquitin carboxy-terminal 
hydrolase and nuclear localisation signal domains that might result in loss of BAP1 
ubiquitinase activity (Figure 4.1). Tumour MESOEQ22 and MESOD25 each harboured two 
BAP1 mutations. We were not able to determine the somatic status of these mutations except 
for a stop codon (p.E373X) in MESOEQ22 that also harboured a germline BAP1 mutation 
(p.R227C). Three variants were confirmed with Sanger sequencing including the germline 
mutation in MESOEQ22. Interestingly, C/G to T/A transition in exon 16 that results in a stop 
codon (p.Q684X) in MESOD18 has been reported as a germline mutation in a family with 
individuals diagnosed with MPM and skin cancers84. Germline BAP1 mutation has been 
identified to predispose individuals to a hereditary cancer syndrome including MPM, uveal 
melanoma, cutaneous melanoma, and renal cell carcinoma85. There was a strong family 
history of cancers in MESOD18 with individuals diagnosed with MPM, lung and oesophageal 
cancer while there was only one family individual with head and neck cancer for 
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MESOEQ22. The phenotype of BAP1 cancer syndrome is still not fully characterised and it is 
not known if the family history of cancers in these two cases represent part of the syndrome. 
Table 4.7. BAP1 mutations in both discovery and validation cohort. E= epithelioid 
MPM, B= biphasic MPM. 
Samples ID Mutation types Protein 
change 
Somatic / 
Germline 
Validation: 
Sanger 
sequencing 
Subtype 
MESOEQ22 nonsynonymous p.R227C germline yes E 
MESOEQ22 stopgain p.E373X somatic no E 
MESOD27 frameshift deletion p.56_62del, unknown not done E 
MESOD22 frameshift deletion p.R114fs, unknown not done E 
MESOD17 frameshift deletion p.558_560del, unknown not done E 
MESOD14 frameshift deletion p.162_162del, unknown not done B 
MESOD10 frameshift deletion p.146_147del, unknown not done E 
MESOD25 frameshift insertion p.K658fs, unknown not done B 
MESOD25 nonframeshift deletion p.659_659del, unknown not done B 
MESOD13 nonsynonymous p.H141P, unknown yes E 
MESOD18 stopgain p.Q684X, reported germline yes E 
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The baseline clinical characteristics of patients with and without BAP1 mutations are 
displayed in Table 4.8. Data on smoking history and asbestos exposure were not available in 
four and two patients respectively. The relationship between BAP1 mutation status and 
clinical characteristics was assessed using Fisher’s exact test. We did not identify any 
significant association between BAP1 mutation with age (p=0.438), gender (p=1.0), 
histological subtype (p=1.0), asbestos exposure (p=1.0), smoking status (p=0.17) and personal 
and family history of malignancy (p=1.0).  
Table 4.8. Baseline clinical characteristics of patients with and without BAP1 mutations 
 Clinical characteristics BAP1 mutant (N=9) BAP1 wild-type (N=27) 
Median age 66 68 
Age≤70 7 (78%) 16 (59%) 
Age≥71 2 (22%) 11 (41%) 
Male 7 (78%) 21 (78%) 
Female 2 (22%) 6 (22%) 
Epithelioid 7 (78%) 20 (74%) 
Biphasic 2 (22%) 7 (26%) 
Asbestos exposure 7 (78%) 19 (70%) 
Ever smoked 4 (44%) 19 (70%) 
Personal history of cancer  0 (0%) 2 (7%) 
Family history of MPM 1 (11%) 1 (4%) 
Family history of cancer 3 (33%) 9 (33%) 
 
Survival wasdefined as time from date of diagnosis to time of death and these data were 
available for all patients except three with no follow-up data. Overall survival (OS) was 
 159 
estimated using the Kaplan-Meier method and one patient was censored at the time of the last 
available follow-up. There was no significant difference in OS associated with BAP1 mutation 
status (HR= 0.806, 95%CI 0.35-1.85, p=0.325) (Figure 4.2). The median survival for patients 
with BAP1 mutant tumours was 13.8 months (95%C1 5.8-NA) and for those with BAP1 wild-
type tumours was 12.3 months (95%CI 9.3-26.8). 
 
Figure 4.2. Kaplan-Meier survival curves for patients with BAP1 mutations (red line) 
and BAP1 wild-type (green line). The hazard ratio = 0.806 (95%CI 0.35-1.85, p=0.325). 
We also observed frequent NF2 mutations with six variants identified (Table 4.9). NF2 
mutations   occurred in 16.7% (6 out of 36 tumours) of all tumour samples. The somatic status 
was confirmed for two variants, a non-frameshift deletion and a splice site mutation. Two 
mutations that resulted in protein change p.R221X and p.76_76del were validated with Sanger 
sequencing. One of the mutations of unknown somatic status that resulted in a stop codon 
(p.R221X) is a pathogenic single nucleotide polymorphism (SNP) (rs74315496)  previously 
reported in a patient with neurofibromatosis 2375. This potentially suggests a common 
pathway between  MPM and neurofibromatosis 2 that may be of interest. 
 160 
Table 4.9. NF2 mutations in both discovery and validation cohort. E= epithelioid MPM, 
B= biphasic MPM. 
Samples ID Mutation types Protein 
change 
Somatic / 
Germline 
Validation: 
Subtype Sanger 
sequencing 
MESOEQ40 nonframeshift deletion p.76_76del, somatic yes E 
MESOEQ13 splicing  somatic not done B 
MESOD16 frameshift deletion p.A354fs, unknown not done E 
MESOD12 frameshift deletion p.F35fs, unknown not done B 
MESOD30 frameshift insertion p.P129fs, unknown not done E 
MESOD14 stopgain SNV p.R221X, unknown yes B 
 
XPC mutations occurred in two out of the seven tumours in the discovery set but none in the 
validation set. XPC plays a key role in nucleotide excision repair (NER), in particularly global 
genome-NER by recognising and eliminating helix distorting lesions. Asbestos generates 
extracellular high molecular group binding protein 1 (HMGB1) that releases reactive oxygen 
and nitrogen species leading to DNA damage and strand breaks58. Defective XPC function 
results in carcinogenesis as demonstrated in homozygous mutant mice model and thus may 
play a role in asbestos-induced malignancy such as MPM376. In addition, polymorphisms in 
XPC confer sensitivity to platinum compound which is the main chemotherapy agent in 
MPM377. However, it has not been possible to test for this association due to insufficient 
treatment data in our study. 
Other genes implicated in cancer that were mutated in both cohorts include AR, FOXK1, 
GATA3, GNA11, NAB2, NOTCH1, RNF213, SETD2 and USP6 (Appendix 4.5). USP6 is 
implicated in aneurysmal bone cyst tumour that exerts its oncogenic effect through 
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juxtaposition of its coding sequence with several partner genes. Three non-synonymous 
mutations in USP6 were identified and 26 tumours in the validation set harboured two of the 
variants. Two of the variants are present in ExAC database with allele frequency of around 
25% and hence are highly unlikely to be pathognomonic of MPM.  
AR regulates androgen-dependent signalling network and this pathway has not been reported 
to play a role in MPM.  AR expression assessed by IHC was positive in 65% of peritoneal 
mesothelioma cases but absent in 100% of pleural MPM378,379. Mutations in AR have not been 
described in MPM and currently there is insufficient evidence to suggest its role in MPM 
carcinogenesis. The high frequency (61% of all tumours) of mutations observed in our study 
need to be interpreted with caution as these might represent false-positive findings.  
The forkhead transcription factor, FOXK1, was mutated in 44% of our MPM cases. This gene 
resides in chromosome region 7p22.2 that was replicated in two genome-wide association 
studies identifying genetic predisposition to MPM81,82. Interestingly, FOXK1 has been shown 
to interact with BAP1 that is frequently mutated in MPM380. 
Our study observed the presence of NOTCH1 mutations in 29% of tumours. One of the two 
variants that resulted in a c. 580A>C was present in nine tumours in the validation set and 
reported in COSMIC database. Activating NOTCH1 mutations are implicated in acute 
lymphoblastic T-cell leukaemia and the highly conserved Notch signalling is deregulated in 
several cancers including MPM381. A study demonstrated  NOTCH1 activation was required 
for simian virus 40-induced mesothelial cell transformation while its inhibition led to cell 
growth arrest67. In addition, NOTCH1 activation promoted MPM cell survival via 
downregulation of PTEN and Akt phosphorylation382. The role of NOTCH1 in MPM 
carcinogenesis and as a potential actionable target requires further exploration. 
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RNF213, a specialised type of zinc finger, was mutated in 8.3% of our MPM cases. It has 
been identified as a translocation partner with ALK in anaplastic large cell lymphoma383. The 
gene function is not well understood but has probable E3 ubiquitin ligase activity and 
involvement in angiogenesis384. It is not known if RNF213 may have any interactions with 
BAP1, a frequently altered gene in MPM with similar function.  
GATA3 is the master regulator of luminal epithelial cell differentiation and possibly has a 
tumour suppressive effect. GATA3 is mutated in approximately 10% of breast cancer and in 
5.5% of MPM from our data385. Interestingly, the study by Hattori et al also assessed the 
expression of GATA3 by immunohistochemistry (IHC) and found positivity in only 2.4% of 
MPM but a different study observed positivity in 58% of epithelioid and sarcomatoid 
MPM379. 
GNA11, one of the guanine-nucleotide binding proteins involved in transmembrane signalling, 
is frequently mutated in uveal melanoma and tumours with coexisting BAP1 loss have higher 
propensity for metastasis and activation of mitogen-activated protein kinase (MAPK) 
pathway386,387. Two tumours from our study harboured mutations in GNA11 but both had no 
mutations in BAP1. This might suggest the interactions between GNA11 and BAP1 may not 
apply in MPM. However, whole exome sequencing will not identify other alterations in BAP1 
such as loss in copy number or whole gene deletion. 
NAB2 was mutated in 5.5% of MPM in our data and its implication in carcinogenesis is not 
known but a gene fusion involving the repressor domain of NAB2 replaced with a carboxy-
terminal transactivation domain from STAT6, is a molecular hallmark of solitary fibrous 
tumour388. 
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SETD2 is a histone H3 lysine 36 methyltransferase and both somatic and germline variants 
have been described in MPM143,365. Depletion of SETD2 has been shown in renal cell cancer 
to result in genome instability through impaired DNA repair, nucleosome reassembly and 
suppression of replication stress389. 
4.3.6 Altered pathways 
Integrative network analysis of somatic missense, nonsense and splice site mutations revealed 
pathway involving focal adhesion as significantly altered (adj. p value=6.61E-16). Fourteen 
genes from our dataset (COL2A1, COL1A2, PIK3CB, PARVB, LAMA5 8, DOCK1 2, SHC2, 
KDR, BCAR1, TNXB, FLNB, VEGFB, ITGA9 1, ACTN1) were implicated in this pathway in a 
total of 11 tumours (two in discovery and nine in validation cohort). Interestingly 13 of these 
genes were mutated exclusively in MESOEQ22 that harboured germline mutation in BAP1. 
The interactions between the focal adhesion genes and BAP1 are displayed in Figure 4.3 
created with NetworkAnalyst198. However, this exclusivity is not obvious in the validation 
cohort as only ITGA9 and LAMA5 were identified in BAP1 mutated tumours.  
Cell cycle pathway was also significantly altered (adj. p= 2.48E-15) involving five genes 
(CDC14A, CDC25A, DBF4, PRKDC, SKP1) mutated in only two tumours in the discovery 
cohort. 
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Figure 4.3. Network visualization of genes involved in focal adhesion pathway and their 
interactions with BAP1. The network was created with NetworkAnalyst showing 
protein-protein interactions between the genes identified from WES data (highlighted 
with an outer yellow ring)..  
Eleven genes from our data (ATF4, CACNA1B, CACNA1A, FLNB, HSPA8, MAP4K1, 
MAPK13, PLAG2G6, RPS6KA6, STK4, RASGRP4, SMYD3) were implicated in MAPK 
pathway (adj. p=2.88E-14). They were present in four tumours from the discovery cohort 
while four tumours in the validation cohort also harboured mutations in CACNA1A, 
CACNA1B, SMYD3 and HSPA8. 
In addition, the WNT pathway was also significantly deregulated (adj. p=1.08E-05) involving 
three genes (FZD2, TBL1XR1 and CHD8). We also observed mutations in LRP2 that might be 
related to WNT pathway.  These alterations were observed in two tumours in the discovery 
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cohort while five tumours in the validation cohort had mutations in FZD2 and LRP2. 
Further enrichment analysis identified somatic mutations in 13 genes involved in chromatin 
modification. Except for SETD2, these genes have not been described as being mutated in 
MPM. Interestingly, these genes were only observed in tumours without BAP1 mutation 
(Figure 4.4). Four genes (JMJD1C, SETD2, ASH1L and SMYD3) were also mutated in the 
validation set and exclusively in BAP1 wild-type tumours except ASH1L. 
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4.4 Discussions 
This whole exome sequencing study analysed the somatic mutations of seven MPM tumours 
and matched blood samples with GATK UnifiedGenotyper algorithm. This has similar 
sensitivity in identifying high allelic fraction SNVs compared to other popular algorithms 
such as Mutect390.  
Our results detected a total of 1,226 somatic mutations in 1,074 genes in at least one tumour 
sample from the discovery cohort.  We also demonstrated MPM tumours harbour mutational 
burden (median nonsynonymous mutations per tumour was 69) comparable to other tumour 
types such as oesophageal squamous cancer, Non-Hodgkin lymphoma, colorectal cancer and 
head and neck cancer as depicted by Vogelstein et al (Figure 4.5)369. However, the mutational 
load was lower compared to tumours with known potent mutagens such as cigarette smoking 
and lung cancer; and ultraviolet light and melanoma. This is somewhat surprising since 
asbestos is a well-known mutagen and remains the main risk factor for developing MPM37. 
On the other hand, the mutational analyses in the other tumours reported by Vogelstein et al 
were done with whole genome sequencing data instead of whole exome. It would be 
interesting to compare the mutational burden between the exomes and genomes in MPM to 
see if this accounts for our unexpected finding. 
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Figure 4.5. Number of somatic mutations in representative human cancers detected by 
genome-wide sequencing studies (adapted from Vogelstein et al). The estimated position 
of  MPMis depicted by the blue arrow. 
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We found BAP1 and NF2 are frequently altered in MPM. In addition, we have also identified 
multiple mutated genes that have not been previously described in MPM that might provide 
new genetic insights into the carcinogenesis of MPM.  
BAP1 is a deubiquitinating enzyme and a tumour suppressor gene implicated in various 
biologic processes including chromatin dynamics, DNA damage response and regulation of 
cell cycle and growth. BAP1 is increasingly recognised as an important gene that is frequently 
mutated and lost in cancers especially uveal melanoma, clear cell renal carcinoma and MPM. 
Recently, a pancancer sequencing study identified mutations in BAP1 as one of the seven 
genes associated with detrimental survival outcome391. We found BAP1 was mutated in 25% 
of tumours across both discovery and validation cohorts consistent with previous reports106. 
There were two germline and one somatic mutations while the somatic status for the 
remaining eight variants in the validation cohort was not known. Previous studies identified 
somatic BAP1 mutation was associated with age, E-MPM subtype and smoking106,149,156. We 
did not detect any significant associations of BAP1 mutation status with the predefined 
clinical characteristics including survival. This might be due to small sample size that limits 
the detection of any significant associations. Interestingly, we also identified mutations in 
FOXK1, a BAP1 interacting partner. FOXK1 regulates cell cycle progression but has been 
found to co-precipitate with BAP1 and together with HCF-1, ASXL1 and/or ASXL2, OGT 
and/or FOXK2 form a BAP1 complex that might have potential roles in regulating BAP1 
function380. 
We also identified six genetic alterations involving NF2 that encodes for Merlin, the key 
regulator of Hippo signalling pathway. Around 40-50% of MPM are reported to exhibit 
homozygous disruption of the NF2 by mutation and/or deletion resulting in lack of expression 
of functional Merlin protein158. Interestingly, we identified and confirmed a novel gene, 
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INADL, missense mutation in the discovery cohort and a nonframeshift insertion in the 
validation cohort.  INADL forms a stable tight junction protein complex with Angiomotin and 
Pals1 that associate with Merlin in regulating mitogenic signalling392. Thus, deregulated form 
of INADL might imply failure of Merlin to bind properly to the complex and this requires 
further exploration. The loss of Merlin leads to dysfunctional Hippo pathway and subsequent 
increased in YAP/PDZ-binding motif activity capable of inducing oncogenic transformation 
due to the activation of transcription factors including transcription enhancers activation 
domain (TEAD) family members. This in turn up-regulates the expression of several growth 
promoting factors, including genes involved in survival and cell cycle such as c-myc and 
survivin respectively393. An in vitro study demonstrated that loss of Merlin increased the 
motility and invasiveness of MPM cells through increased phosphorylation of focal adhesion 
kinase (FAK)160.  
FAK is a non-receptor cytosolic protein tyrosine kinase with a central catalytic domain 
flanked by large N- and C-terminal domains that indirectly localizes at contact points of cells 
with extracellular matrix through interactions with integrin-associated proteins394. It has 
important roles in regulating cell survival, motility, metastasis, invasion and angiogenesis395–
398
. The importance of FAK signalling and as a potential therapeutic target in MPM was 
further supported by significant deregulation of focal adhesion pathway from our exome data. 
In addition, we also identified upregulated genes and associated pathways involving cell 
morphology, adhesions and migration from our gene expression study (Chapter 3) that are 
linked to FAK signalling.  
A study using in vitro and xenograft models demonstrated MPM cells with low Merlin 
expression had increased sensitivity to FAK inhibitor. Targeting FAK has also been shown to 
inhibit self-renewal of cancer stem cells (CSC) that are linked to metastases and recurrence340. 
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This led to the evaluation of FAK inhibitors in MPM in the clinical setting including GSK 
compound, GSK2256098, in patients with relapsed disease and the result was encouraging 
with improvement in median progression-free survival (PFS) of 4.5 months compared to 
historical control of 1.5 months341. There was also increased activity seen in a subset of 
patients with Merlin negative MPM achieving a median PFS of 6 months. However, the 
Verastem FAK inhibitor defactinib (VS6063) demonstrated no efficacy over placebo in a 
randomized trial in the first-line maintenance setting for MPM in both the intent-to-treat 
population and in patients with low Merlin expressing tumours399. It is currently unclear 
whether this was related to trial design, a drug related-issue or a true finding that FAK may 
not be a key driver despite the preclinical evidence. 
MAPK and WNT are the other two pathways that were also significantly altered in our data 
that further support the findings by Guo et al144. MAPK activation is important for cell 
survival and apoptotic events. Significant protein phosphorylation of the MAPK cascade in 
MPM has been shown in previous studies168. Both in vivo and in vitro studies have also 
demonstrated activation of extracellular-signal-regulated kinases (ERK) and p38 in MPM 
cells exposed to asbestos59,165. Our study did not identify any known oncogenes such as KRAS 
and BRAF in this pathway but we found somatic mutations in 11 genes encoding the MAPK 
cascade. Mutations in CACNA1A, CACNA1B, HSPA8 and SMYD3 were also present in the 
validation cohort. Both CACNA1A and CACNA1B belong to voltage-gated calcium channel 
family that regulates the balance between extracellular and intracellular calcium levels that 
are crucial in regulating many signalling processes including cell cycle, proliferation and 
migration. Studies have shown calcium influx through the voltage-gated calcium channels can 
have direct and indirect effect on MAPK signalling400. A meta-analysis of microarray datasets 
revealed overexpression of CACNA1A in most cancers and correlated with poor survival in 
lung and ovarian cancers suggesting possible involvement in the onset and progression of 
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certain malignancies401. The role of CACNA1B in cancer is less well understood but the same 
study found it is significantly overexpressed in breast cancer. HSPA8 belongs to heat shock 
protein 70 family and knockdown with RNA interference in tumour cells revealed anti-
proliferative property402. SMYD3, a histone methyltransferase, plays a key role in regulating 
oncogenic Ras signalling through methylation of MAP3K2 at lysine 260 and is a potential 
drug target403. 
The importance of MAPK signalling in MPM is further supported by the findings from our 
gene expression profiling study of 25 MPM tumours (Chapter 3). Several genes involved in 
MAPK pathway including EGFR, MET, PAK4, RAC3, LAMA5, LAMC2, ITGA3 and ITGB4 
were significantly over-expressed in MPM. Figure 4.6 displays the interactions of the mutated 
and over-expressed genes with other components in the MAPK pathway. 
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Figure 4.6. MAPK signalling pathway.  The network was created with NetworkAnalyst 
showing protein-protein interactions between the genes identified from WES and gene 
expression data (highlighted with an outer yellow ring) with components encoding 
MAPK pathway 
The highly conserved WNT family of secreted proteins and downstream effectors are crucial 
for cell-cell communication events including cell fate determination, migration, polarity, 
neural patterning, and organogenesis during embryonic development and maintenance of stem 
cells.  Thus perturbations in WNT signalling are important for cancer initiation and 
progression including cell survival, proliferation, invasion and metastases. These are 
frequently observed in cancers including MPM and studies have demonstrated accumulation 
of CTNNB1 protein level, deregulated expression of several WNT ligands, frizzled receptors 
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(receptor for WNT proteins), APC and AXIN2 in MPM173,404. Targeting components of WNT 
pathway such as siRNA knockdown of dishevelled proteins downstream of WNT have 
resulted in suppression of MPM cell growth405.  We identified somatic mutations in FZD2, 
TBL1XR1, CDH8, LRP2 and AIDA that are implicated in WNT pathway. AIDA, FZD2 and 
LRP2 mutations were also present in the validation cohort. AIDA has a potential tumour 
suppressor role identified to block Axin-mediated JNK activation by disrupting Axin 
homodimerization and subsequent inactivation of non-canonical WNT pathway406. FZD2 has 
been shown to be overexpressed in late stage mesenchymal-type cancer cell lines and 
tumours407. Both in vivo and in vitro studies have identified a novel non-canonical WNT 
pathway driven by FZD2 that drives the epithelial-mesenchymal transition process and is 
associated with metastasis and poor survival outcome. Targeting FZD2 in xenograft model 
has shown promising inhibition of tumour growth and metastasis making it a potential 
therapeutic target in MPM. LRP2 is a member of the lipoprotein-related protein (LRP) family 
but only LRP5 and LRP6 are LRP-family WNT-associated receptors. LRP2 encodes megalin 
that is involved in intracellular transporter of sonic hedgehog (SHH)408. Deregulation in 
hedgehog signalling is implicated in various cancers and plays a key role in proliferation and 
differentiation. Studies have also demonstrated an interaction between SHH and WNT 
signalling in tumours to coordinate and regulate cell cycle progression409. This suggests LRP2 
may have an indirect role in WNT signalling. 
Deregulated expression of genes involved in WNT signalling was one of the main findings 
from our gene expression study in MPM (Chapter 3). Our findings revealed significant over-
expression of WNT ligands WNT2B, WNT3, WNT9A and transforming growth factor β 
member, BMP4 in MPM compared to non-malignant pleural. A visual representation of the 
interactions between the mutated and over-expressed genes involved in WNT signalling is 
shown in Figure 4.7.  Taking all together, our data supports previous findings that WNT 
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signalling is active in MPM and may offer new avenues for intervention and development of 
therapeutic targets. 
 
Figure 4.7. WNT signalling pathway.  The network was created with NetworkAnalyst 
showing protein-protein interactions between the genes identified from WES and gene 
expression data (highlighted with an outer yellow ring) with components encoding WNT 
pathway.  
Chromatin is important in regulating gene transcription and maintaining genome stability. 
Recent next generation sequencing studies in cancer have revealed molecular alterations in 
genes encoding chromatin regulatory factors and enzymes that result in disruption of 
chromatin remodelling.  
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Our study identified somatic mutations in 13 genes participating in chromatin regulation that 
could be associated with MPM carcinogenic events through alterations in gene transcriptions. 
Five of these genes (SETD1B, SETD2, SETD6, SMYD3, WHSCIL1 and ASH1L) encode 
histone lysine methyltransferase enzymes and were mutated in a total of 7 out of 36 tumours. 
Histone lysine methyltransferases play a key role in regulating chromatin processes including 
transcription and DNA repair410. Lysine methylation occurs mainly within the tails of histone 
H3 and H4 resulting in transcriptional activity or repression depending on the target 
residues411. Its deregulation has emerged as a common factor in cancer pathogenesis.  
SETD2 is located close to 3p21 locus that also encodes BAP1 and this region is frequently lost 
in several tumour types including MPM99. Thus a combination of loss of copy number in this 
region and SETD2 mutation might potentially lead to its loss of function. Depletion of SETD2 
has been shown in renal cell cancer resulting in genome instability through impaired DNA 
repair, nucleosome reassembly and suppression of replication stress389. SETD6 mediates 
monomethylation of the p65 subunit of Nuclear Factor Kappa-light-chain-enhancer of 
activated B cells (NF-κB) resulting in inhibition of NF-κB mediated inflammatory 
responses412. NF-κB is critical in the pathogenesis of MPM and the pathway is activated via 
asbestos-induced release of HMGB1 and TNF-α57. Thus dysfunctional SETD6 might 
represent another mechanism for the activation of NF-κB pathway in MPM. The oncogenic 
role of SMYD3 has been reported in several cancers and is implicated in MAPK signalling as 
described above413. In vitro study demonstrated the activity of SMYD3 could be reduced with 
BCI-121, a small molecule inhibitor, resulting in cell growth inhibition414. This may be of 
therapeutic importance especially in a small subset of MPM tumours harbouring SMYD3 
mutations. Overexpression of WHSC1L1 has been demonstrated in several cancer types and 
contributes to carcinogenesis by affecting the expression of cell cycle genes that promotes 
mitosis415. Its expression is low in normal tissues thus could be a potential therapeutic target 
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in various cancer types including MPM. The oncogenic role of ASH1L is not well understood 
but has been shown to be able to suppress IL-6 production by facilitating the ubiquitin-
enzyme A20 through histone modification at Tnfaip3 promoter416. IL-6 is a key mediator in 
MPM cell proliferation and confers resistant to chemotherapy thus deregulated ASH1L may 
have a role in MPM carcinogenesis. 
The importance of epigenetic alterations in MPM from our study was supported by previous 
studies that showed differential methylation profile in MPM compared to normal pleural and 
may be prognostic109,113. In addition, asbestos contributes to MPM carcinogenesis by altering 
the epigenome through hypermethylation of several cell cycle genes114. These have led to the 
use of histone deactylase inhibitors (HDACi) and methyltransferase inhibitors (DNMTi) in 
patients with MPM including vorinostat that was trialled in the largest phase III clinical trial 
in MPM117. However this did not translate into an overall survival benefit and it may be a 
combination of both HDACi and DNMTi that may provide therapeutic benefits as 
demonstrated by an in vivo study417. 
Comparing our study to the recent sequencing studies by Guo et al and Lo et al, one of the 
main differences is that the tumour tissues in both reported studies were obtained from 
patients who had been treated with chemotherapy (40% in Guo et al and 100% in Lo et 
al)144,146. Thus the chemotherapy effect on the genome may have contributed to the mutations 
detected and may not truly reflect the mutational landscape of MPM. On the contrary, the 
main limitations of our study include smaller sample size of tumour/normal pairs and lower 
tumour cellularity.  These may limit the power to detect SNV that may be pathogenic but 
occurring at a very low frequency. The International Cancer Genome Consortium has set out 
guidelines in collecting high quality tumour samples for next generation sequencing studies 
and one of the recommendations is a minimum of 80% tumour cellularity366. However, less 
stringent criteria may apply to certain tumour types whereby obtaining adequate tissues may 
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be challenging such as MPM due to its lower incidence compared to other solid cancers. In 
terms of data analysis, we utilised UnifiedGenotyper for variant calling and currently there is 
no gold standard algorithm or tool. This tool is comparable to the recently introduced Mutect 
but lacks sensitivity in detecting allele sites with low fraction. Another potential limitation of 
our study is using Sanger sequencing as the method of choice to validate variants. Sanger 
sequencing is considered the gold standard for mutation detection and is highly sensitive for 
the detection of point mutations, splice site mutations, and small insertions and deletions. 
However, one of its drawbacks is having a lower sensitivity in detecting variants with an 
allele frequency of less than 20%. Despite the identification of candidate variants and genes in 
our study, the lack of matched normal in the validation cohort meant the somatic status of 
some of these variants could not be verified.  
In conclusion, the findings of our study are in keeping with published reports including 
absence of known oncogenes, frequent mutations in BAP1, NF2 and alterations in MAPK and 
WNT pathways. However, we identified several genes encoding these two pathways that have 
not been previously reported in MPM and may potentially be targetable. Other findings that 
contribute further insights into MPM carcinogenesis include significantly altered focal 
adhesion signalling pathway that is clinically relevant given the positive results from clinical 
trials with FAK inhibitor in patients with MPM. In addition, we identified genes other than 
BAP1 that are involved in chromatin remodelling indicating the potential roles of epigenetic 
events in MPM carcinogenesis. 
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Chapter 5 - Summary and future work 
5.1 General conclusions 
The genetic landscape of malignant pleural mesothelioma (MPM) is still far from being fully 
characterised but increasing research efforts have been invested to provide better 
understanding and insights into this complex disease. To date, the recurrent findings from 
published works have been dominated mainly by the following: 
1.  Chromosomal alterations including deletions (1p, 3p, 4q, 6q, 9p, 13q, 14q, and 22q) 
and gains (1q, 5p, 7p, 8q, and 17q) of specific chromosomal regions364.  
2.  Frequent molecular aberrations involving CDKN2A, NF2 and BAP1106,157,163. 
This thesis work aimed to identify molecular alterations in MPM by studying the expression 
and mutational profiles. In Chapter 3, we studied the gene expression profile of 25 MPM 
tumours and 5 non-malignant pleural. We identified 643 differentially expressed genes with a 
Benjamin Hochberg corrected p-value of ≤0.01 and absolute fold change in the level of 
expression of ≥ 2. Next, we constructed MPM-associated co-expression network and identify 
modules of highly connected genes with weighted gene co-expression network analysis 
(WGCNA) tool203. The major findings from this chapter were: 
1. Significant deregulated expression of genes involved in cell migration, invasion, cell 
 cycle and the immune system that contribute to the malignant phenotype of MPM. 
2. Focal adhesion kinase (FAK) signalling appears to be a common denominator in many 
of the upregulated genes and pathways identified. 
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3. Genes involved in WNT and transforming growth factor beta (TGF-ß) signalling 
pathways that are linked with epithelial mesenchymal transition (EMT) process are 
associated with molecular subtype classification. 
4. Genes involved in cell cycle process are associated with poor survival prognosis. 
In Chapter 4, the exomes of seven tumour-normal pairs were successfully sequenced and 
revealed 1, 226 somatic mutations distributed in 1,074 genes. In addition, the exome data 
from 29 tumours were available. The major findings from this study were: 
1. Absence of mutations in known oncogenes  
2. Frequent mutations in BAP1 and NF2 consistent with published data. 
3. Significant alterations in FAK, mitogen-activated protein kinases (MAPK) and WNT 
signalling pathways of which many of the genes encoding these pathways are novel in 
MPM. 
4. Mutations in genes involved in chromatin remodelling other than BAP1 modulating 
epigenetic events that may contribute to disturbance in global gene expression in 
MPM. 
5. Low frequency of recurrent mutational events might suggest heterogeneity in mutation 
profile between tumours. 
6. Identification of potential targetable mutations and pathways that might have 
 therapeutic importance for patients with MPM. 
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This research has not only confirmed findings from previous works but also provided new 
information about the molecular landscape of MPM. From our study, the molecular alterations 
in MPM may be better defined by activation of common signalling pathways instead of a 
defined set of genes or mutations. These are evident from the identification of significant 
alterations in FAK and WNT signalling pathways at both deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA) levels. Aberrant activation of FAK promotes cancer through complex 
signalling networks involving cell survival, proliferation, migration, invasion, EMT, 
angiogenesis and cancer stem cell activities. Our findings highlighted the importance of this 
pathway in MPM carcinogenesis and in fact targeting FAK  in vitro and in tumour xenograft 
models demonstrated good cytotoxicity effect especially in MPM tumours with low 
expression of merlin418. In addition to FAK, we also identified significant alteration in WNT 
pathway with mutations and deregulated expression of novel components. This pathway 
regulates various processes involved in cancer progression, including tumour initiation, 
tumour growth, cell senescence, cell death, differentiation and metastasis. Targeting this 
pathway has been challenging mainly due to lack of specific targets, potential redundancy of 
pathway components and cross talks with other oncogenic pathways. Interestingly, recent 
studies have shown that FAK and WNT pathways are interconnected to promote 
tumorigenesis. This was demonstrated in an APC deleted model of colorectal cancer whereby 
the FAK/PYK2 axis is required for the activation of the WNT pathway and in breast cancer, 
the inhibition of FAK in vivo and in vitro led to decreased self-renewal capacity and reduced 
levels of WNT3A and CTNNB1419,420. Thus, our findings support the relevance of these two 
pathways that may have a dynamic and complex interactions in promoting MPM 
carcinogenesis that require further research. 
In light of the exciting era of cancer immunotherapy, it is worth noting the identification of 
significantly altered expression of genes associated with the immune system from our study. 
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The discovery of immune checkpoint receptors such as cytotoxic T lymphocyte antigen-4 
(CTLA-4) and programmed death-1 (PD-1) responsible for inactivating the immune system in 
cancers have gained immense interest. Blocking immune checkpoints have shown significant 
improvement in clinical outcomes in several cancer types including melanoma and non-small 
cell lung cancer421,422. In MPM, preclinical data and clinical studies with anti-CTLA4 and 
anti-PD-1 antibodies have already shown promising results346–348. Studies have also examined 
the expression of PD-L1 (ligand of PD-1) by immunohistochemistry in MPM and found 
overexpression of PD-L1 in tumours ranging between 20-90% especially in sarcomatoid 
subtype and is associated with poorer survival423,424.We identified downregulation of 78 genes 
involved in immune functions including T cell, B cell activation, cell adhesion and cytokine-
cytokine receptor interactions. Interestingly, CD28 is one of the underexpressed genes and 
CTLA-4 induces T-cell inactivation by competing with CD28 for B7 ligands CD80 and CD86 
expressed on antigen presenting cells. Taking all these together, defective antitumor immunity 
is evident in MPM and further research is needed to improve our understanding in the role of 
the immune system in MPM carcinogenesis that may unravel new therapeutic targets. 
Genomic intra- and intertumoral heterogeneity are recognised features in cancers. Previous 
transcriptomic study in MPM revealed distinctive genomic profiles in growth factors involved 
in differentiation, metabolism, and regulation of apoptosis that determined MPM 
differentiation425. Our study also revealed differences in gene expression between subtypes 
and heterogeneous mutational profiles between each tumour. However, the full molecular 
profile may be under-represented due to single sampling from each tumour being studied. 
Through multiregional sequencing of a tumour, other studies have revealed tumours evolve 
through different branches with subclones that harbour distinct genomic profiles that can lead 
to tumour recurrence, metastasis and present challenges to precision medicine426,427. This 
approach has not been explored in MPM and could potentially reveal a more comprehensive 
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genomic profile and identify dominant signalling pathways and biological processes with 
actionable mutated genes.  
The advent of next generation sequencing methods (NGS) including targeted, whole genome 
or whole transcriptome sequencing coupled with bioinformatics-based data analysis offer 
unparalleled high-throughput approach in studying cancer genomics. We utilised microarray-
based and whole exome sequencing approaches to examine the gene expression and 
mutational profiles in MPM respectively. These may have their limitations in comparison to 
other methods. 
Microarray-based technology allows a comprehensive simultaneous characterisation of the 
expression of thousands of genes in a given cell at a given time point. On the other hand, 
RNA sequencing allows a more comprehensive characterisation of tumour transcriptome and 
correlation with structural and copy number alterations, insertions, deletions and single 
nucleotide mutations. In comparison to microarray-based approach, RNA sequencing allows 
rapid and higher sensitivity in the detection of not only known but also discovering novel 
transcripts, global transcriptomic alterations with absolute instead of relative value and post-
transcriptional changes on a larger scale428. The data can also be mined to detect alternative 
splice variants, fusion transcripts and microRNAs as demonstrated in different cancer 
types429–431. Despite the unprecedented offers of RNA sequencing, microarray-based approach 
is still commonly preferred mainly due to its lower cost and is a less complex dataset to 
analyse. RNA sequencing is fairly new in MPM and to date there is only one published study 
on transcriptome sequencing involving four MPM tumours182. This study revealed a different 
mutational profile in each tumour and found novel mutations in thousands of expressed genes 
of which XRCC6, PDZK1IP1, ACTR1A, and AVEN could be associated with MPM 
carcinogenesis.  
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One of the limitations of exome sequencing is that it covers only the protein-coding regions 
(1% of the genome). Whole genome sequencing provides an unbiased interrogation of both 
the coding and non-coding regions of the genome. Although little is known about the 
pathogenic significance of the non-coding regions, emerging evidence have revealed their 
roles in diseases including cancer such as a single nucleotide polymorphism in the 5’ 
untranslated region of RAD51 as a modifier of breast cancer risk in BRCA1 and BRCA2 
mutation carriers432. In addition, whole genome allows detection of larger genomic alterations 
including structural variants, loss of heterozygosity and copy number that may be difficult to 
detect with exome data. This was demonstrated in a study that sequenced both the genome 
and exome of myeloma specimens and found half of the protein-coding mutations occurred in 
chromosomal translocations that were missed by exome sequencing433. Recently, the whole 
genome of 10 MPM tumours were sequenced and identified novel mutations in genes 
associated with integrin-linked kinase pathway and clinical correlation revealed molecular 
differences between gender and histology subtypes involving BAP1, TP53, MYH9 and RHOA 
that may be involved in MPM carcinogenesis434. However, no significant mutations in non-
protein coding regions or large structural variants such as translocations were reported.  
Aside from NGS methods, DNA methylation and proteomic profiling are two other 
approaches that can reveal important epigenetic and functional events respectively driving the 
disease process.  As such, a combined methodological approach comprising mutational, 
transcriptomic, methylation and proteomics data may eventually reveal the full molecular 
landscape of MPM. Recently, Bueno et al published a comprehensive genomic analysis of 
216 MPM tumours (the largest sample size to date) with RNA, whole exome and targeted 
exome sequencing435. Using RNA sequencing data, they identified four molecular subtypes 
(sarcomatoid, epithelioid, biphasic-epithelioid and biphasic-sarcomatoid) of MPM. As 
sarcomatoid MPM was not represented in our samples, we were able to stratify the tumours 
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into three molecular subtypes (biphasic in CL1, epithelioid in CL3 and biphasic-epithelioid in 
CL2 as described in Chapter 3) with WGCNA of our gene expression data. The study also 
identified 10 significantly mutated genes and pathway alterations in Hippo, mammalian target 
of rapamycin, histone methylation, RNA helicase and p53 signalling. Of these, mutations in 
NF2, BAP1 and SETD2 together with aberrations in chromatin remodelling were also 
identified in our exome findings (Chapter 4). 
 Nevertheless, unravelling the full molecular alterations in MPM remains a challenging 
research task and collaborative efforts are paramount to ensure this goal is achieved. Both the 
International Cancer Genome Consortium and The Cancer Genome Atlas are compiling omics 
data from all types of cancers including mesothelioma in order to improve our understanding 
of the molecular mechanisms driving cancer. As part of our continuous research effort in 
MPM, the section below describes our ongoing work and future directions in this project. 
5.2 Ongoing and future work 
As mentioned, one of the main limitations from our study was the small sample size that 
makes it difficult to allow identification of recurrent events occurring at low frequency or 
assessing significant correlation with clinical features. Hence, we aimed to obtain more 
samples to allow detection of significant mutations. In addition, sarcomatoid subtype was not 
represented in our study to allow expression or mutational characterisation. Therefore, in 
addition to the sequenced 7 matched tumour-normal pairs from our study, our group had 
extracted genomic DNA from a further 14 paired tumour tissues acquired from the MesobanK 
tissue repository and the exomes have been successfully sequenced. Both datasets will be 
merged in due course and reanalysed to define significantly mutated genes with the recently 
introduced MutSigCV algorithm436. This approach will remove a high number of artefactual 
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findings and allow identification of genes relevant to MPM. Along with this, copy number 
alterations that are indicative of chromosomal instability will also be analysed. There will also 
be plans to perform whole transcriptome shotgun sequencing contingent on the availability of 
adequate tumour samples. This will not only allow further evaluation of gene expression and 
single nucleotide variants (SNV) discovery but also post-transcriptional SNV and fusion gene 
detections. 
Candidate variants will then be confirmed with Sanger sequencing.  The frequency of 
candidate variants will be determined in an independent set of tumours with targeted capture 
sequencing that enables robust detection of clinically informative genes from formalin fixed, 
paraffin-embedded (FFPE) tumour DNA437. FFPE tissues remain the standard material for 
analysis in the clinical settings. The preservation of tissue morphology in FFPE enables the 
isolation and analysis of relatively enriched tumour material space. Furthermore, the ease and 
low cost involved in storage is an advantage compared to frozen tissues. The protein 
expression of candidate variants will also be examined by either immunohistochemistry or 
fluorescence in situ hybridisations methods.  
In preparation for this, we have acquired 307 MPM FFPE blocks as the follow up cohort. 
These were identified from the Royal Brompton and Harefield NHS Trust (RBHT) Diagnostic 
Tissue Bank and St George’s Hospital (SGH) under an ethically approved study, Molecular 
Epidemiology of Malignant Mesothelioma (MEMO) (see Chapter 2). These were sectioned, 
stained with routine haematoxylin and eosin, and reviewed by two certified pathologists to 
verify tumour histology and abundance as described in Chapter 2 section 2.2.2.2 and 2.2.2.3. 
FFPE sections were prepared on a total of 122 and 185 tumour FFPE tissues from RBHT and 
SGH respectively with 30% or more viable-appearing malignant cells. Genomic DNA had 
been successfully isolated as described in Chapter 2 section 2.2.5.3. Tumour tissue 
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microarrays will be prepared from the FFPE blocks to examine the protein expression of 
candidate variants.  
The baseline clinical characteristics of the follow up cases were summarised in Table 5.1. 
Majority of the cases were of male gender and epithelioid MPM was the predominant 
subtype. 
Table 5.1. Cases demographic and clinical characteristics. 
Characteristics Follow up cohort n= 307 
Age, years 
Median 
Range 
≤ 70 
> 70 
 
71 
45-91 
153 (49.8%) 
154 (50.2%) 
Sex 
Male 
Female 
 
242 (78.8%) 
65 (21.2%) 
Histological subtypes 
Epithelioid MPM 
Biphasic MPM 
Sarcomatoid MPM 
 
214 (69.7) 
60 (19.5) 
33 (10.7) 
 
Survival data was also available for 302 cases and patients who were alive at last follow up 
were censored. A total of 287 events were observed. The median overall survival (OS) for all 
cases was 10.2 months (95% CI 8.3- 12.1) (Figure 5.1). Univariate survival analysis by 
histological subtypes (Figure 5.2) showed OS was significantly longer in epithelioid MPM 
(median OS 13.1 months, 95% CI 11.3- 15.0) than biphasic MPM (median OS 7.2 months, 
95% CI 4.6-9.8) and sarcomatoid MPM (median OS 5.1 months, 95% CI 3.3-6.9) after a 
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median follow-up time of 12.9 months, 5.9 months and 5.1 months respectively (Figure 5.2). 
The hazard ratio was 1.73 (95% CI 1.3-2.3) for biphasic MPM and 2.99 (95% CI 2.0-4.4) for 
sarcomatoid MPM. Multivariate survival analyses showed age and gender was not significant 
in the final model. 
 
Figure 5.1. Kaplan-Meier curve for OS in all 302 cases. 
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Figure 5.2. Kaplan Meier curves for OS by histological subtypes. Log rank p value < 
0.0001. E= epithelioid, B= biphasic, S= sarcomatoid.  
The data generated will be analysed for the following: 
1. Identification of targetable variants and signalling pathways for subsequent functional 
assays.  
2. Correlation with clinical data to allow patient stratification and identification of 
diagnostic and prognostic biomarkers.  
Lastly, we hope the knowledge generated by this research project will have great potential in 
providing further insights into the molecular mechanisms involved in MPM carcinogenesis. 
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Future directions of our work are not limited to those described above and we hope this 
project will serve as a platform for further collaborative work with other investigators in an 
effort to improve the clinical outcomes of patients with this deadly disease. 
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Study title: MEMO- Molecular Epidemiology of Malignant MesOthelioma 
Protocol version: 2.0 
Version date:   03/06/2014 
 
Approved by Chief Investigator 
Dr Sanjay Popat BSc MBBS MRCP PhD 
Date: 
 
By signing the above, the investigator agrees to adhere to the protocol as outlined and that this study will be conducted in 
accordance with the principles outlined in the NHS Research Governance Framework for Health and Social Care. It will be 
conducted in compliance with the protocol, the Data Protection Act, and other regulatory requirements as appropriate.  
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Sponsor 
The Royal Marsden NHS Foundation Trust is the main research sponsor for this study. For 
further information regarding the sponsorship conditions, please contact the Research and 
Development Manager at: 
Clinical Research & Development Office 
DM20, Royal Marsden Hospital 
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Tel: 020 8661 3909  
Funder 
This study is funded by the Royal Marsden Hospital Lung Unit 
This protocol describes the “MEMO” study and provides information about study design and management. 
Every care was taken in its drafting, but corrections or amendments may be necessary. These will be circulated to 
investigators in the study. Problems relating to this study should be referred, in the first instance, to the Chief 
Investigator.  
This study will adhere to the principles outlined in the NHS Research Governance Framework for Health and 
Social Care. It will be conducted in compliance with the protocol, the Data Protection Act, the principles of Good 
Clinical Practice (GCP), and other regulatory requirements as appropriate.  
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Study Synopsis 
Title MEMO 
Short Title Molecular Epidemiology of Malignant Mesothelioma 
Study Design A retrospective study investigating the molecular 
epidemiology of patients with malignant mesothelioma 
Study Objectives 1. An exploratory retrospective study to document 
molecular abnormalities in tumour biopsies of 
patients with malignant mesothelioma seen at the 
Royal Marsden Hospital or St George’s Hospital and 
their associations with clinical outcomes 
2. To act as a validation dataset for molecular 
aberrations identified from whole genome analysis 
of mesothelioma 
Inclusion Criteria 1. Patients with a confirmed pathological diagnosis of 
malignant mesothelioma (any primary site) and 
availability of archival tissues 
2. Patients seen at the Royal Marsden Hospital or St 
George’s Hospital between 2000 to 2009 
3. Age ≥18 years; 
Exclusion Criteria 1. Patients for whom a tissue diagnosis of confirmed 
mesothelioma has not been made 
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1. Background and Rationale 
1.1 General background 
Outcomes from malignant mesothelioma (MM) are generally poor, with few long-term 
survivors and a 5-year survival of around 5%. Whilst this is in part due to presentation of 
patients with advanced/locally advanced disease, other significant factors include lack of 
effective therapies, and a poor understanding of the biology of these tumours, especially in the 
UK. 
This lack of research into thoracic tumours when compared to other tumour types was 
highlighted in an National Cancer Research Institute (NCRI) framework review (1). This 
identified a need for research into thoracic tumours including MM 
Our study into the underlying biological processes of MM aims to address these deficiencies, 
with a view to exploring molecular aberrations in patients with mesothelioma, and to generate 
a validation dataset for which findings of ongoing whole genome/transcriptome analyses at 
Imperial College London (ICL) can be validated. 
1.2 Malignant Mesothelioma 
MM is an uncommon but almost universally fatal malignant cancer of mesothelial cells, 
principally affecting the pleura and peritoneum. Exposure to asbestos is the primary causative 
environmental carcinogen, and a long latency is observed, with a median of 50 years (2). 
Although the disease is traditionally considered rare, due to this long latency incidence has 
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been rising rapidly, and has risen 12-fold from 1968-2001 in the UK. Deaths from MM have 
risen rapidly from 153 in 1968 to 1,848 in 2001, and the disease currently accounts for 
approximately 2,000 new cases in the UK per year, (3). However, incidence continues to rise 
rapidly, and epidemiological modelling predicts a peak between 2011-15.  
Prognosis from MM is usually poor and early diagnosis is unusual. Even in those fit for 
chemotherapy, median survival is approximately 1 year in unselected cases (4). Despite this, a 
number of active chemotherapy regimens have shown efficacy in improving survival (5;6), 
and importantly, in palliating symptoms (7-9). Moreover, radical and debulking surgery or 
multimodality therapy (10), has potential to play a role in improving survival and palliation 
(10;11), in selected patients.  
Given the poor understanding of carcinogenic pathways involved in MM development, there 
is a need to validate and identify new targets for therapy. In the case of systemic therapy, 
platinum-based pemetrexed doublet therapy has become an international standard (4), but 
despite this, clinical and radiological responses are only seen in the minority of cases. 
Discovery of markers with prognostic and predictive utility are therefore urgently required to 
better target the limited therapies available, and a number of such biomarkers have been 
proposed. 
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2.0 Biomarkers and Molecular Epidemiology 
Whilst MM is an increasingly common disease in many countries, the molecular 
epidemiology and biomarkers of outcome have been poorly investigated. However, the 
limited studies of MM biology have demonstrated a number of cytogenetic abnormalities, 
including losses at chromosome 1p, 3p, 9p, and 6q, 13q, and 15q. Loss of an entire copy of 
chromosome 4 or 22 is also often observed. Recurrent areas of deletion include chromosome 
9p21 (which includes the loci CDKN2A/ARF and CDKN2B) and 22q12 (including NF2), with 
functional studies showing that re-introduction of the encoded protein at these loci results in a 
regression of the malignant phenotype (12;13). Moreover a heterozygous (+/-) NF2 knockout 
mouse demonstrates an accelerated rate of MM development when exposed to asbestos (14). 
Studies have also suggested that NF2 somatic mutations are common and activate integrin-
dependent mammalian target of rapamycin complex 1 (mTORC1) signalling (15;16). NF2 
encodes a membrane-cytoskeleton-associated protein, merlin that regulates cell growth via the 
Hippo signalling pathway to inhibit the transcriptional and oncogenic function of yes-
associated protein 1 (Yap 1) (17;18). Everolimus, an mTOR inhibitor, is currently being 
trialled in MM patients and loss of NF2 is being investigated as a potential biomarker to 
predict drug sensitivity. mTOR inhibition results in compensatory activation of other 
signalling pathways such as MET, insulin growth factor receptor (IGFR) and epidermal 
growth factor receptor (EGFR) with activation of downstream AKT pathways, and so it is 
likely that combination therapy will be required. Recent data also suggest a role for NF2 loss 
and functional interaction between Hippo and tissue growth factor beta (TGF-B) pathways, 
and imply connective tissue growth factor (CTGF) over-expression as transforming (19). 
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A number of signalling pathways may be involved in mediating the malignancy phenotype, 
including phosphoinositide 3-kinase (PI3K) signalling through either aberrant AKT activity 
(20), or through MEK/Fra1 (21). However, clearly identified mechanisms of carcinogenesis in 
MM remain unclear, with significant heterogeneity in findings from tumours. 
The role of focal adhesion kinase (FAK) in promoting cell migration and invasion has been 
suggested in several cancer types including MM. NF2 loss induces FAK phosphorylation 
which enables it to interact with Src and the p85 subunit of PI3K (22). These data provide the 
rationale for testing FAK, Src kinase, and PI3K inhibitors.  
Finally, BRCA-1 associated protein 1 (BAP1) regulates cell proliferation through histone 
modifications and somatic mutations are common in MM (23). It occurs mainly in epithelioid 
sub-type MM and germline BAP1 mutation is associated with increased risk of MM. Histone 
deacetylase (HDAC) inhibitor, vorinostat has been tested in MM and demonstrated no 
survival advantages but molecular subset analysis of this trial has not been performed. 
Standard systemic therapy for MM is based on a combination of platinum and pemetrexed 
chemotherapy. Despite this, however, response rates remain low, with many patients not 
benefitting from such therapy. A number of molecular phenotypes have been investigated for 
patients with MM. The biological and clinical significance of many of these features, 
however, remains uncertain. Further investigation of MM, correlating molecular phenotype 
with clinical outcome remains key to understanding the biological processes underlying 
tumourigeneis and therapeutic sensitivity. 
Pemetrexed is a cytotoxic anti-folate and actions as a selective thymidylate synthase (TS) 
inhibitor. It has been hypothesised in the basis of cell line data to be most active in tumour 
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types with inherent low TS expression (adenocarcinoma) and poorly active in those with high 
TS expression (small cell lung cancer) (24). The role of TS expression in MM has been poorly 
characterized, as well as its inter-relationship with other prognostic or predictive markers e.g. 
proliferation index, with some studies suggesting that TS expression level correlates with 
outcome from pemetrexed-based chemotherapy, and others not (25;26). 
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3.0 Study Objectives/Endpoint 
3.1 Objectives 
1. To retrospectively explore and document molecular abnormalities in tumour biopsies 
of patients with MM seen at the Royal Marsden Hospital (RMH) or St George’s 
Hospital (SGH) and their associations with clinical outcomes 
 
2. To act as a validation dataset for molecular aberrations identified from whole genome 
analysis of MM 
 
3.2 Endpoints 
1. To document and estimate the frequencies of different molecular abnormalities 
identified in tumour specimens of MM 
2. To correlate the molecular abnormalities with clinical outcomes such as survival and 
response to chemotherapy to generate potential biomarkers for patients with MM  
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4.0 Eligibility 
4.1 Inclusion Criteria 
1. Patients with a confirmed pathological diagnosis of MM (any primary site) and 
availability of archival tissues 
2. Patients seen at the RMH or SGH between 2000 to 2009 
3. Age ≥18 years 
4.2 Exclusion Criteria 
1. Patients for whom a tissue diagnosis of confirmed MM has not been made 
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5.0 Study Design and Procedures 
5.1 Patient Identification 
Patients will be identified from those seen at the RMH or SGH with a pathological diagnosis 
of MM. Patient records will be cross-referenced with the inclusion/exclusion criteria to 
identify potentially eligible patients. In the first instance, patients will be identified if having 
undergone surgical thoracoscopy or other diagnostic procedures at the RMH or SGH. 
5.2 Consent  
No patients will be involved in this study. All specimens used from patients are formalin-fixed 
paraffin embedded (FFPE) material surplus to clinical requirements, and will be used in a 
linked-coded manner. There will be no study specific consent form.  
5.3 Sample and Clinical Data Collection 
Patients meeting the inclusion / exclusion criteria with FFPE material will be identified. 
Patient demographics and outcomes will be collected from the case notes at the RMH and 
SGH, using a common template. A common clinical data dataset without patient identifiers 
will be held at the RMH. 
Tumour and normal (reactive pleural fibrosis) FFPE materials will be collected from both 
institutions then transferred and stored at the pathology laboratory at RMH Biomedical 
Research Centre (BRC). Material transfer agreements (MTA) will be sought and put in place 
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between (a) tissue-providing centres and the RMH and (b) collaborators, if different from 
tissue-providing centres, and the RMH. 
Central pathological review will be performed on the FFPE tumour materials to confirm the 
diagnosis and tumour abundance. FFPE analyses including tissue microarray (TMA) 
formation will be performed with collaborators at ICL/Royal Brompton Hospital (RBH), 
where the chief investigator holds an academic position. The clinical dataset will be 
forwarded to ICL/RBH if required, to facilitate exploratory analyses. Immunohistochemistry 
(IHC) will be carried out at the laboratory at ICL/RBH/RMH. Surplus FFPE materials will 
otherwise be returned to the RMH and SGH upon completion of analyses.  
5.4 Planned Laboratory Analyses 
Samples will be used for investigation into MM carcinogenesis, and molecular variants 
influencing drug therapy.  
Laboratory analyses will involve primarily IHC or CISH and other techniques (including 
molecular methods e.g. sequencing) to meet the ends of this study. Contingent on numbers of 
blocks obtained, samples will be classified into epithelioid and non-epithelioid subtypes, and 
into patients treated with systemic therapy or not. FFPE material may be used for formation 
into TMA, or single section analyses. 
IHC or CISH, if appropriate, on tumours will be performed at a number of markers contingent 
on the literature. This may involve Ki67, TS, NF2, YAP, FAK and BAP1. Other potential 
biomarkers may be assessed contingent on the field.  Appropriate IHC scoring systems will be 
used contingent on type of marker analysed and will range from semi-quantitative 0-+++ or a 
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quantitative H-score. Clinical covariates including survival and response to chemotherapy 
will be assessed contingent on marker status.  
FFPE material will be primarily used as a validation dataset to estimate the frequencies and to 
examine the distribution of novel carcinogenic markers identified from whole genome 
sequencing/expression profiling analyses occurring with ICL and other external collaborators, 
and may also be used for exploratory analyses. 
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6.0 Regulatory Issues 
6.1 Ethics Approval 
The Chief Investigator will have been granted Ethics Committee approval for this study, and 
will take responsibility for the conduct of the study. The study will be conducted in 
accordance with the NHS Research Governance Framework for Health and Social Care, the 
Data Protection Act, and other regulatory requirements as appropriate.  
The tissue used in this research will be surplus archived samples obtained as part of diagnosis 
or treatment. Consent for use of tissue will not be required for patients diagnosed before 1st 
September 2006 according to the Human Tissue Act regulations and Medical Research 
Council guidelines.  For patients diagnosed after 1st September 2006 and alive, samples will 
be used only if patients provided written consent on the generic institution consent form. Due 
to the poor prognosis of mesothelioma, majority of patients enrolled in this study will have 
died and samples from deceased patients may be analysed without giving generic institution 
consent and we do not intend to seek consent from relatives of deceased patients. In addition, 
the results from the research will not affect patient's clinical outcomes/interests and we will 
not be looking for germline mutations that could affect patient's family.  
6.2 Confidentiality 
The Chief Investigator will preserve the confidentiality of participants taking part in the study 
as per the Data Protection Act. All molecular analyses will be performed on linked-coded 
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(anonymized) samples.  
6.3 Indemnity, Sponsorship, and Funding 
The RMH NHS Foundation Trust will act as the main sponsor for this study. This study is part 
funded by the RMH Lung Unit. Further grant support for this study will be applied for, as 
appropriate. 
6.4 Study Management, Audits and Inspections  
The overall monitoring of the study will be performed by the study management group. 
Investigators will also meet regularly to discuss study progress. 
The study may be subject to inspection and audit by the sponsor and other regulatory bodies 
to ensure adherence to appropriate guidelines and laws.  
6.5 Intellectual Property 
Biological specimens will be treated as “gift” from patients, and will not be used for 
commercial exploitation. It is recognised that intellectual property (IP) may arise from the 
results of laboratory analyses. This will be addressed by a contract-specified material-transfer-
agreement (MTA) for the protocol between the RMH, SGH and ICL/RBH as required. 
6.6 Study Management 
The day-to-day management of the study will be co-ordinated by the study management 
 241 
group and collaborators at the National Heart and Lung Institute, ICL.   
7.0 Statistical Considerations 
7.1 Study Power 
This is an exploratory study and the plan is to include all cases that meet the 
inclusion/exclusion criteria and this has been estimated to be around 300. The expected rates 
of abnormality in the ICL cohort are expected to be between 30-50%. 95% confidence limits 
have been calculated to determine the lower and upper confidence limits expected for our 
cohort with 300 patients. 
Alpha 
% Abnormal in 
ICL Cohort 
95% Confidence 
interval Width 
Lower Upper 
0.95 30 5.2 24.8 35.2 
0.95 35 5.4 29.6 40.4 
0.95 40 5.5 34.5 45.5 
0.95 45 5.6 39.4 50.6 
0.95 50 5.7 44.3 55.7 
 
7.2 Data Analysis 
Cases will be divided into groups according to their marker status and the proportion of cases 
with individual marker or a combination will be given with 95% confidence intervals. This 
grouping will be correlated with outcome measures using standard statistical methods. Time-
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to-endpoint analyses, overall survival defined as from time of diagnosis to time of death will 
be measured and examined by the Kaplan-Meier method for groups with and without the 
markers and groups compared by the logrank test for univariable tests, and using Cox’s 
proportional hazards for known clinical factors. For each different markers of interest, the 
response rates to chemotherapy will be compared between groups with and without the 
markers and examined using the Χ2 test. Other statistical analyses will be invoked as 
appropriate (e.g. K-means clustering for microarray data). 
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8.0 Results Dissemination and Publication Policy 
The results of this study will be disseminated by presentation at academic meetings and 
publication in peer-reviewed journals. Investigators will be asked to contribute to co-
authorship of any publications arising from this study. 
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Appendix 3.1 - List of Differentially Expressed Genes 
probesets Gene.symbols logFC AveExpr adj.P.Val 
16761012 A2M -0.79 9.95 0.005028618 
16908316 AAMP 0.52 6.08 0.029999525 
16823109 ABCA3 1.79 6.58 0.004665936 
16839294 ABR 0.52 7.78 0.01350639 
16843728 ACACA 0.83 7.31 0.004319194 
16876440 ACP1 0.47 7.23 0.008999768 
16716350 ACTA2 -1.25 6.01 0.032396736 
16881594 ACTG2 -0.64 2.38 0.024462218 
16886308 ACVR2A -0.85 6.05 0.016955195 
16751381 ACVRL1 -1.48 4.90 0.002719692 
17045806 ADCY1 -0.92 4.34 0.0177897 
16958201 ADCY5 -0.56 4.03 0.031777783 
17044905 ADCYAP1R1 -0.68 3.16 0.014441129 
16706238 ADK -0.60 8.19 0.029803028 
16709245 ADRA2A -1.75 5.73 0.011077896 
16727702 ADRBK1 -0.48 7.28 0.040390831 
16928428 ADRBK2 -0.75 7.06 0.000661477 
16917183 JAG1 -0.87 8.40 0.008138164 
16700385 AGT -0.93 4.93 0.001049806 
16738400 APLNR -1.55 6.78 0.014616204 
16918496 AHCY 1.04 7.68 0.001431864 
17030643 AIF1 -0.53 8.01 0.044388831 
17006683 AIF1 -0.52 7.66 0.038484879 
17027817 AIF1 -0.52 7.66 0.038484879 
17038140 AIF1 -0.52 7.66 0.038484879 
17040735 AIF1 -0.52 7.66 0.038484879 
17035441 AIF1 -0.55 8.01 0.030724616 
17011302 AIM1 -1.52 6.46 0.001094005 
16872352 AKT2 0.29 5.77 0.030939687 
16757160 ALDH2 1.01 8.85 0.015439261 
16727976 ALDH3B1 1.23 6.98 0.002550094 
16763182 ABCD2 -1.74 3.82 0.000739182 
16817790 ALDOA 0.56 7.11 0.001811295 
16704375 ALOX5 -0.73 7.11 0.032508512 
16830220 ALOX12P2 2.63 6.11 0.001690497 
17080082 ANGPT1 -1.56 4.65 0.000653427 
17074259 ANGPT2 -1.91 6.95 0.000510132 
16969911 ANK2 -1.63 5.79 0.000275103 
16972912 SLC25A4 0.89 6.41 0.038950581 
17106574 SLC25A5 0.73 8.19 0.006157436 
16968213 ANXA3 4.14 8.11 3.57E-05 
16881069 ANXA4 0.90 9.27 0.00326115 
17001800 ANXA6 -0.99 9.25 0.01202954 
17056701 AOAH -0.91 7.42 0.027275532 
16863124 APOC1 1.24 6.89 0.032242602 
17101368 SHROOM2 1.21 4.13 0.000716615 
16834621 ARL4D 1.45 7.03 0.011018364 
17109078 ARHGAP6 -1.03 4.74 0.000212944 
16761843 ARHGDIB -0.91 5.10 0.00130173 
16966214 RHOH -1.65 4.10 0.000530151 
16997519 ARSB -0.74 5.59 0.009767157 
16858687 ASNA1 0.61 9.08 0.02412805 
 248 
17090296 ASS1 1.02 9.13 0.011824105 
16890490 ATIC 0.65 8.69 0.007531991 
16673525 ATP1B1 0.84 8.19 0.009117949 
16830621 ATP1B2 -0.67 5.98 0.030146833 
16839887 ATP2A3 -1.51 6.02 0.00074238 
16854928 ATP5A1 0.62 8.73 0.030551116 
16999379 ALDH7A1 0.49 5.87 0.04676989 
16766260 ATP5B 0.54 10.68 0.005028198 
16924537 ATP5J 0.58 5.11 0.013898501 
16663792 ATP6V0B 0.52 5.73 0.005667457 
16925293 ATP5O 0.49 6.08 0.034913704 
16766946 AVPR1A -1.14 5.76 0.01384768 
16727462 BBS1 0.59 6.40 0.006821203 
16802771 BBS4 1.18 7.40 0.000154278 
16874082 BCAT2 0.86 5.93 0.001361864 
16855673 BCL2 -0.78 6.76 0.034910126 
16815918 TNFRSF17 -1.08 3.09 0.021821543 
16856216 HCN2 1.06 4.22 0.010861211 
16788036 BDKRB1 1.52 4.51 0.04496503 
16749759 BICD1 -0.81 6.11 0.021198014 
17011279 PRDM1 -1.20 6.27 0.00228695 
17065750 BLK -1.01 4.27 0.015558878 
16732037 CXCR5 -1.41 3.72 0.001690497 
16812746 BNC1 5.31 7.88 1.18E-07 
16793129 BMP4 1.76 7.32 0.000356926 
17101698 BMX -1.56 2.97 3.70E-06 
16856203 BSG 0.96 9.97 0.000227676 
16775364 KLF5 1.26 6.44 0.000563279 
17112735 BTK -0.99 5.75 0.008999768 
16901755 BUB1 1.35 5.47 0.041013206 
17008544 BYSL 0.73 5.57 0.0073213 
17070653 OSGIN2 0.90 5.94 0.031386654 
16726707 MRPL49 0.49 5.72 0.0338111 
16739117 TMEM258 0.51 5.32 0.008537511 
16725670 DAGLA 1.00 5.77 0.004631814 
16926445 PTTG1IP 0.52 9.83 0.023532536 
17084723 CA9 3.18 6.88 0.00150143 
16874012 CA11 1.29 6.66 0.038051871 
16746728 CACNA1C -0.92 6.06 0.046787896 
17059195 CACNA2D1 -1.47 7.00 0.006229481 
16903771 CACNB4 -1.62 4.91 0.000366196 
16878137 CAD 0.76 7.30 0.001978684 
16820849 CALB2 5.37 9.34 5.17E-05 
16987945 CAMK4 -0.89 4.63 0.015779003 
16993397 CANX 0.39 10.61 0.016439345 
16861380 CAPNS1 0.54 10.15 0.017597773 
17113362 CAPN6 3.04 7.55 0.007464485 
16743874 CASP5 -1.09 3.88 0.00412635 
16978959 CASP6 0.94 4.92 0.036283776 
16956983 CBLB -0.73 8.13 0.009225792 
16922477 CBR1 0.69 5.63 0.004470175 
16985599 CCNB1 2.00 5.67 0.001909284 
16991839 CCNG1 0.59 8.16 0.010317365 
16669169 CD2 -1.08 5.46 0.04086658 
16745016 CD3D -1.25 6.18 0.015439261 
16731806 CD3G -1.16 4.69 0.016955195 
16725468 CD5 -0.93 5.97 0.025936826 
16817489 CD19 -2.02 4.61 0.000799686 
 249 
16725252 MS4A1 -2.93 6.27 0.01631073 
16747261 CD27 -1.38 6.15 0.018376056 
16889807 CD28 -1.66 5.31 0.000235992 
17097653 TNFSF8 -1.09 6.59 0.013350291 
16864675 CD33 -0.60 6.29 0.040623853 
16874890 SIGLEC6 -0.69 3.58 0.040415958 
16698801 CD34 -1.16 8.86 0.007922723 
17047795 CD36 -1.96 4.23 0.002700734 
16772144 SCARB1 0.77 6.99 0.008444942 
16864059 CD37 -1.14 7.45 0.010039892 
16707791 ENTPD1 -1.29 4.56 6.16E-05 
17100304 ENTPD2 1.21 4.77 0.022818513 
16914449 CD40 -1.02 5.48 0.003837347 
17107329 CD40LG -1.38 3.46 0.001832257 
16723653 CD44 -1.61 6.43 0.001105987 
16695437 CD48 -1.04 7.02 0.015913143 
16668582 CD53 -0.81 9.50 0.015880796 
16761201 CD69 -1.53 6.49 0.027924641 
17093694 CD72 -0.75 5.24 0.01869106 
16862604 CD79A -2.36 7.01 0.01732704 
16847719 CD79B -1.50 4.83 0.002113366 
16720392 CD151 0.42 8.10 0.033546474 
16705159 CDK1 1.21 5.03 0.041773458 
16834056 CDC6 1.59 5.74 0.002569923 
16663514 CDC20 1.43 5.78 0.036215521 
16856187 CDC34 0.57 7.36 0.04212478 
16820486 CDH1 4.35 8.05 0.000864133 
16820463 CDH3 3.51 7.83 0.001349107 
16915541 CDH4 1.72 5.68 0.000873906 
16819794 CDH5 -1.58 7.68 0.005959278 
16821377 CDH13 -1.95 6.56 0.02292966 
16766683 CDK4 0.49 8.54 0.041307561 
17064360 CDK5 0.89 6.60 0.007909082 
16985637 CDK7 0.75 6.49 0.008127261 
16968468 CDS1 1.23 4.82 0.02004605 
16661149 CD52 -1.07 5.74 0.017875017 
16677425 CENPF 1.47 5.99 0.019355126 
17115077 CETN2 0.81 7.53 0.000181676 
16743111 CTSC -0.66 9.11 0.033266217 
16779024 RCBTB2 -0.60 6.44 0.01805536 
16795664 FOXN3 -0.65 6.65 0.006923742 
16905292 CHN1 -0.97 5.69 0.041734024 
16700806 LYST -1.14 7.04 0.000335481 
16796998 CKB 1.58 5.20 0.00955707 
16671503 CKS1B 1.15 6.06 0.000154278 
17086634 CKS2 1.62 8.28 0.0045247 
16948738 AP2M1 0.72 8.43 0.0003748 
17049692 AP1S1 0.68 6.06 0.015461148 
16872248 CLC -1.45 3.34 0.002961292 
16825333 CLN3 0.81 7.12 0.006532925 
16791419 CMA1 -1.77 3.58 5.17E-05 
16938707 CCR4 -0.90 4.28 0.009693681 
17014651 CCR6 -1.35 3.33 0.000380492 
16844381 CCR7 -1.83 6.22 0.005187186 
16769690 CMKLR1 -0.94 7.43 0.002795866 
16858496 CNN1 -2.29 6.88 0.010462986 
16683460 CNR2 -0.55 3.30 0.006380246 
17048473 COL1A2 -1.20 10.84 0.012224831 
 250 
16780929 COL4A1 -1.51 7.90 0.010144377 
16776431 COL4A2 -1.16 8.17 0.028313587 
17090957 COL5A1 -1.16 7.80 0.038095053 
16906352 COL5A2 -1.68 7.24 0.019713579 
16909828 COL6A3 -1.01 9.81 0.03424377 
17087430 COL15A1 -2.04 7.41 0.00712053 
16684461 COL16A1 -1.16 5.82 0.02390527 
17010042 COL19A1 -1.71 3.09 0.000197445 
16870453 COMP -2.60 7.65 0.020009556 
16821614 COX4I1 0.40 11.15 0.038094073 
16883205 COX5B 0.61 4.76 0.002597144 
17008088 COX6A1 0.57 11.45 0.005840512 
16861118 COX6B1 0.75 7.69 0.001175595 
17105010 COX7B 0.64 6.23 0.015739185 
16986983 COX7C 0.57 4.93 0.007628544 
16832768 CPD -0.64 8.08 0.030688059 
16664852 CPT2 0.57 6.33 0.02891434 
16676819 CR1 -1.74 6.05 0.029299821 
16676795 CR2 -2.46 3.70 0.003800106 
16789743 CRIP1 1.22 7.18 0.018572209 
16724194 CRY2 -0.48 5.79 0.030324898 
16766001 CS 0.44 7.30 0.040847974 
16914671 CSE1L 0.68 9.58 0.006205785 
16929677 CSF2RB -1.10 5.75 0.000883381 
16986913 VCAN -1.20 10.38 0.038867549 
16838887 SLC25A10 1.27 5.98 0.004528308 
16915015 CSTF1 0.56 6.66 0.006229481 
16889819 CTLA4 -1.24 3.59 0.019792018 
16989750 CTNNA1 0.44 7.77 0.005792415 
16676547 CTSE 5.02 8.05 0.000193974 
16791427 CTSG -1.61 3.52 0.000107648 
17096285 CTSV 1.33 3.76 0.007881553 
16920762 CTSZ -0.81 8.75 0.009569715 
17049729 CUX1 0.59 7.36 0.032981961 
17102538 CYBB -0.63 10.35 0.035280185 
17073565 CYC1 0.83 8.11 0.007017806 
16818842 CYLD -0.69 7.83 0.003851986 
16707541 CYP26A1 1.38 4.29 0.041638363 
16779701 DACH1 -1.02 4.26 0.001837551 
16940705 DAG1 0.77 6.67 0.010678171 
16752244 DGKA -0.77 6.36 0.038292709 
16962407 DGKG -0.65 3.74 0.003439455 
16874005 DBP 0.86 6.69 0.029093717 
16823087 ECI1 1.10 7.80 0.000999387 
16836896 ACE -0.96 5.23 0.004631814 
16738963 DDB1 0.41 8.32 0.00814217 
16701975 AKR1C1 -0.84 2.71 0.01373974 
16766578 DDIT3 0.73 4.16 0.0168028 
16682842 DDOST 0.61 7.83 0.002680938 
17055910 DFNA5 1.12 6.31 0.033104806 
16741501 DHCR7 1.77 6.99 3.69E-06 
16687618 DHCR24 2.68 8.98 4.22E-06 
16935669 CYB5R3 -0.61 7.71 0.014636766 
16827679 NQO1 2.25 8.40 0.000615713 
17105284 DIAPH2 -0.45 8.02 0.014903543 
16825779 37135 -1.05 6.04 0.011329237 
16731169 DLAT 0.54 6.95 0.017591588 
16742879 DLG2 -1.43 3.93 0.000869046 
 251 
16835656 DLX4 0.56 4.32 0.029564449 
16714998 DNA2 0.69 5.26 0.042727556 
17115571 DNASE1L1 0.45 7.29 0.044561067 
16712244 TRDMT1 -0.93 4.15 0.002719692 
16992122 DOCK2 -1.06 7.84 0.002388825 
16696120 DPT -2.50 8.07 0.004787552 
16925341 RCAN1 -0.88 4.45 0.007464485 
16851768 DSG2 1.65 7.68 0.014931101 
17004612 DSP 2.44 8.17 0.014728149 
16757391 DTX1 -0.85 4.52 0.008999768 
17095899 ECM2 -1.24 7.89 0.040983724 
16709128 DUSP5 -1.19 5.72 0.042518128 
16840550 DVL2 0.51 5.83 0.042544944 
16948712 DVL3 0.52 7.90 0.045255361 
16918445 E2F1 1.04 5.75 0.043738806 
16894539 E2F6 0.66 5.24 0.01480654 
17002278 EBF1 -1.80 6.25 0.001451103 
16682989 ECE1 -0.89 7.15 0.014739525 
16861887 ECH1 0.75 7.25 0.042992262 
16667760 S1PR1 -1.62 6.83 0.000520867 
16921258 EEF1A2 2.63 6.02 0.001958832 
16671642 EFNA1 1.60 5.75 0.003541398 
16856538 EFNA2 0.77 4.27 0.015547851 
16998682 EFNA5 2.25 7.71 0.000165075 
16830653 EFNB3 1.30 5.20 0.011077896 
16668170 CELSR2 1.30 5.90 0.001431864 
17046135 EGFR 1.63 8.52 0.002500349 
16682098 EPHA2 0.81 7.97 0.011018364 
17067963 EIF4EBP1 0.97 7.93 0.0421346 
16675924 ELF3 0.92 4.16 0.03234765 
17110481 ELK1 0.62 7.31 0.00879171 
16755339 ELK3 -0.88 7.30 0.006606747 
16709739 EMX2 -0.96 3.96 0.014607798 
17098594 ENG -1.13 8.78 0.001844689 
16969766 ENPEP -1.28 5.63 0.013889215 
16930534 EP300 -0.38 8.42 0.030396125 
16879721 EPAS1 -0.90 9.33 0.007097819 
17023551 EPB41L2 -0.57 8.35 0.036472257 
17066446 DMTN 0.73 5.14 0.025292216 
17098027 STOM -0.89 8.99 0.000459515 
17052690 EPHB6 2.00 6.12 0.013179829 
16687028 EPS15 -0.56 8.24 0.015558878 
16925602 ERG -0.97 6.45 0.035499302 
17013809 ESR1 -0.64 3.77 0.010876802 
16745997 ETS1 -1.11 8.04 0.003232985 
16748407 ETV6 -0.59 8.36 0.011724275 
16961331 MECOM -1.38 3.86 0.000246254 
16849047 EVPL 0.92 5.61 0.031794929 
16928761 EWSR1 -0.44 6.97 0.008101502 
17078134 EYA1 -0.79 3.11 0.010224618 
16986417 F2RL1 1.47 4.55 0.01051819 
17115729 F8 -0.89 6.11 0.015121652 
16776798 F10 -0.70 3.58 0.011294995 
17015331 F13A1 -1.65 9.42 0.000907558 
17078592 FABP4 -2.30 6.26 0.046135766 
16736722 FANCF 1.04 5.91 0.007335327 
16850107 FASN 0.90 7.37 0.033301454 
16808793 FBN1 -1.14 9.67 0.022734863 
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16897834 EFEMP1 0.62 11.77 0.008265301 
16725172 MS4A2 -1.01 3.21 0.002849275 
16867975 FCER2 -1.31 3.85 0.012588067 
17099707 FCN1 -1.58 5.31 0.005455767 
16855477 FECH 0.52 6.80 0.049019216 
16725735 FEN1 0.92 5.38 0.009933077 
16773086 FGF9 3.43 6.91 0.000146244 
16780754 FGF14 -1.11 3.34 0.021609667 
16746808 FKBP4 0.59 7.30 0.033279228 
17004198 FOXF2 1.49 5.05 0.009933077 
17091928 FOXD4 0.87 4.99 0.006244544 
16760048 FOXM1 1.22 5.80 0.040039322 
16778392 FOXO1 -1.01 6.49 0.001977587 
17011450 FOXO3 -0.98 6.36 0.010973189 
16733377 FLI1 -0.90 6.98 0.001343249 
17051286 FLNC 1.04 9.25 0.03559341 
16777715 FLT1 -0.89 6.49 0.015461148 
17003958 FLT4 -1.27 4.85 0.02412805 
16675638 NR5A2 -1.43 4.25 0.000897471 
16739208 FTH1 -1.03 7.76 0.013388643 
16785483 FUT8 -0.84 6.86 0.018958874 
16995601 FYB -0.88 8.92 0.006690857 
17016697 GABBR1 -0.86 6.78 0.011824105 
17028593 GABBR1 -0.87 7.21 0.010876802 
17026529 GABBR1 -0.90 7.04 0.010685173 
17031378 GABBR1 -0.92 7.42 0.00995933 
17033830 GABBR1 -0.90 6.89 0.009663603 
17036121 GABBR1 -0.91 7.19 0.009447187 
17038872 GABBR1 -0.91 7.19 0.009447187 
16795508 GALC -0.50 5.57 0.034910126 
16683397 GALE 1.27 4.95 0.002026515 
16925194 GART 0.60 6.43 0.028472331 
16958844 GATA2 -0.74 3.75 0.00326115 
16689354 GBP2 -0.74 7.52 0.047823906 
16689352 GBP2 -0.86 6.46 0.03238455 
16713877 GDF10 -0.51 3.42 0.027312731 
17079210 GEM -2.19 5.74 8.59E-05 
16814895 GFER 0.73 5.56 0.001977587 
17075248 GFRA2 -1.72 3.73 6.42E-06 
16662329 GJA4 -0.85 5.30 0.030464325 
16885153 GLI2 1.18 6.93 0.02522701 
16998293 GLRX -0.81 5.32 0.038329462 
16716239 GLUD1 -0.86 5.88 0.003512006 
17015033 GMDS -0.47 5.73 0.020787539 
17054614 GNA12 -0.51 6.12 0.025386404 
16856896 GNA15 -0.66 5.82 0.035788812 
16940988 GNAI2 -0.45 5.17 0.040611238 
16927874 GNAZ 0.60 5.50 0.041068624 
16717359 GOT1 0.73 7.87 0.023409439 
16661314 SFN 2.52 5.90 0.007880507 
16860709 GPI 0.68 9.89 0.0108719 
16845219 CCR10 -0.39 3.05 0.048764761 
16873352 GPR4 -1.25 4.69 0.003669752 
16943181 GPR15 -0.68 2.65 0.018616123 
16780585 GPR18 -1.05 4.86 0.012696086 
17105069 LPAR4 -1.11 4.16 0.031676711 
16930486 MCHR1 -0.82 3.89 0.001944711 
16942625 GPR27 0.90 4.34 0.025386404 
 253 
17062491 GPR37 3.13 6.01 0.000841666 
16991208 GPX3 -0.85 2.56 0.013961095 
16991192 GPX3 -1.07 5.72 0.012002805 
16833876 GRB7 2.03 5.20 0.001398413 
17106688 GRIA3 -0.96 3.21 0.000874966 
16937094 GRM7 -0.60 3.23 0.007472363 
17076063 GSR 0.60 9.14 0.03084029 
16727919 GSTP1 0.46 7.34 0.043440666 
16879923 MSH6 0.53 7.09 0.012795273 
16825210 GTF3C1 0.48 8.08 0.046769142 
16895772 GTF3C2 0.42 7.40 0.015630552 
16971712 GUCY1A3 -1.30 7.11 0.012588067 
16971737 GUCY1B3 -1.31 6.71 0.008753493 
16980245 GYPE -1.17 4.50 0.001052997 
16856195 GZMM -0.76 4.14 0.041307561 
16745236 H2AFX 0.85 7.65 0.038527446 
16978334 H2AFZ 0.43 5.92 0.046598957 
17005573 HIST1H2BD 1.64 4.30 0.004162135 
17111251 HSD17B10 0.64 6.81 0.020357132 
16874935 HAS1 2.63 6.70 0.012366834 
16734840 HBB -0.70 3.03 0.017773573 
16912472 HCK -0.76 7.43 0.023367556 
16957986 HCLS1 -0.84 7.27 0.017686424 
16809075 HDC -1.07 2.79 0.000181676 
16694742 HDGF 0.54 5.24 0.001837551 
16752061 NCKAP1L -0.74 7.84 0.017773573 
16811437 HEXA 0.46 8.03 0.040049302 
16707493 HHEX -0.95 4.51 0.000146108 
16785058 HIF1A -0.70 9.85 0.019587498 
16785083 HIF1A -1.71 5.20 0.000522176 
16999572 HINT1 0.64 6.31 0.009488344 
17024335 HIVEP2 -0.81 7.95 0.038051871 
17003124 HK3 -0.82 4.20 0.029647519 
17037290 HLA-DMB -0.50 6.90 0.046164473 
17007352 HLA-DPB1 -0.54 8.05 0.03949699 
17031219 HLA-DPB1 -0.54 8.05 0.03949699 
17041318 HLA-DPB1 -0.54 8.05 0.03949699 
16677723 HLX -0.52 4.85 0.048213306 
17107753 HMGB3 0.52 4.29 0.037187959 
16991859 HMMR 1.39 5.34 0.007934112 
16886105 HNMT -0.82 7.51 0.03559341 
16872052 HNRNPL 0.34 9.84 0.037233519 
17049366 AGFG2 1.11 6.83 0.035136085 
16821398 HSBP1 0.67 7.84 0.010366891 
17073759 HSF1 0.56 6.57 0.017667263 
16819994 HSF4 0.69 5.67 0.043397402 
16989146 HSPA4 0.49 7.96 0.019182147 
17000485 HSPA9 0.53 9.48 0.022323152 
16691414 IGSF3 1.42 5.54 0.004044647 
16968675 HSP90AB3P 0.63 5.73 0.040390831 
16906962 HSPD1 0.88 8.02 0.001689175 
16683105 HSPG2 -0.78 9.37 0.014343097 
16879958 FOXN2 -0.60 7.36 0.017854783 
16778938 HTR2A -2.54 4.67 0.001844689 
17097661 TNC -2.77 8.44 0.002244491 
16847760 ICAM2 -1.26 6.12 0.001240458 
16868679 ICAM3 -0.82 6.21 0.019633776 
16821621 IRF8 -0.73 7.70 0.04882767 
 254 
16837689 ICT1 0.58 8.35 0.035303656 
16769250 IGF1 -2.10 8.75 0.002639629 
16976211 IGFBP7 -0.84 10.40 0.024462218 
16797603 IGHG1 -2.08 4.51 0.032254679 
16797358 IGHG2 -0.89 6.30 0.033584759 
16976644 IGJ -2.07 7.53 0.043875221 
16900162 IGKC -1.91 7.64 0.038095053 
16965642 RBPJ -0.80 6.62 0.000836238 
16711501 IL2RA -1.49 5.98 0.004954729 
17111895 IL2RG -1.21 6.86 0.042411482 
17101111 IL3RA -1.21 5.52 0.00768316 
17115868 IL3RA -1.13 4.99 0.00712053 
16950216 IL5RA -0.50 2.73 0.013591094 
17044177 IL6 -2.46 5.11 0.003044902 
16984010 IL7R -1.58 6.42 0.019390771 
16731754 IL10RA -0.70 7.49 0.02889654 
17084523 IL11RA -0.70 5.66 0.010320732 
16665901 IL12RB2 -1.92 3.51 2.42E-06 
16744415 IL18 1.93 8.42 0.000197445 
16693515 ILF2 0.54 9.35 0.020594156 
17062679 IMPDH1 -0.79 6.51 0.029372633 
16883325 INPP4A -0.60 6.92 0.007785772 
16892446 INPP5D -0.59 7.40 0.031806444 
16870269 INSL3 -0.57 4.45 0.024509699 
16686538 IPP 0.54 6.46 0.014082538 
17115428 IRAK1 0.87 6.88 0.006465241 
17004167 IRF4 -1.65 5.47 0.004041282 
16835672 ITGA3 1.91 9.48 1.35E-05 
16888270 ITGA4 -1.00 7.35 0.015998855 
16765697 ITGA7 -1.49 5.36 0.004019872 
16938989 ITGA9 -0.99 7.03 0.021574616 
16817883 ITGAL -0.88 6.85 0.049019216 
16713144 ITGB1 -0.50 7.78 0.034573378 
16837938 ITGB4 2.76 9.13 0.001080715 
16918664 EIF6 0.72 7.78 0.001436653 
16991497 ITK -1.49 5.81 0.013521294 
16910974 ITPA 0.53 6.21 0.01555904 
16700058 ITPKB -0.65 6.66 0.021168723 
16936947 ITPR1 -0.83 6.22 0.033301454 
17007543 ITPR3 0.69 8.24 0.04628174 
16688164 JAK1 -0.47 9.80 0.015058806 
17083319 JAK2 -0.58 7.92 0.019097494 
16870274 JAK3 -1.47 6.08 0.000250224 
17005042 JARID2 -0.69 6.61 0.012773136 
16844872 JUP 0.91 7.60 0.02649727 
16828514 KARS 0.42 8.94 0.026308118 
16747121 KCNA1 -1.02 2.67 0.011077896 
16690739 KCNA2 -0.60 3.17 0.002202594 
16690754 KCNA3 -1.41 5.43 0.001909164 
16690735 KCNA10 0.44 3.33 0.019207889 
16920150 KCNB1 1.25 4.95 0.03519136 
16925328 KCNE1 -0.73 3.97 0.010525225 
16966855 KIT -1.37 4.57 0.013895473 
16707468 KIF11 1.31 6.55 0.033528421 
16817647 KIF22 0.98 6.61 0.004115128 
17011992 KPNA5 -0.49 6.56 0.028169656 
16764941 KRT5 4.21 6.92 1.55E-05 
16751491 KRT7 2.47 4.58 0.005118245 
 255 
16844752 KRT15 1.17 4.48 0.011712035 
16751554 KRT18 2.94 6.07 2.05E-07 
16844775 KRT19 3.73 8.88 1.95E-05 
16875478 LAIR1 -0.62 5.77 0.035992062 
17012447 LAMA2 -1.36 6.73 0.031938783 
16920939 LAMA5 1.30 7.99 0.003485 
16698883 LAMB3 1.73 5.84 0.042907557 
16674845 LAMC2 2.69 6.90 0.005232106 
16683723 STMN1 0.73 4.68 0.015136425 
16662052 LCK -0.87 4.89 0.016614321 
16778849 LCP1 -0.93 8.81 0.009309447 
17051152 LEP -1.64 3.19 0.001850621 
17042997 LFNG -0.83 5.24 0.004349187 
16849576 LGALS3BP 1.01 9.91 0.000463886 
16872029 LGALS4 -0.31 3.66 0.033703724 
16933760 LIF 1.05 5.15 0.04155983 
16929163 LIMK2 -1.02 6.29 0.003052261 
16837820 LLGL2 1.50 6.17 0.002331189 
16987565 LNPEP -0.40 8.62 0.035352582 
17066278 LPL -1.44 4.16 0.042550011 
16949467 LPP -0.65 7.10 0.007097178 
16904827 LRP2 4.93 7.24 0.001847311 
16720771 LSP1 -0.52 4.26 0.041605579 
17026762 LTB -0.85 4.63 0.033528421 
17029082 LTB -0.85 4.63 0.033528421 
17031867 LTB -0.85 4.63 0.033528421 
17034339 LTB -0.85 4.63 0.033528421 
17036587 LTB -0.85 4.63 0.033528421 
17039380 LTB -0.85 4.63 0.033528421 
17041863 LTB -0.85 4.63 0.033528421 
17017224 LTB -0.72 2.83 0.012161058 
16863074 BCAM 1.58 7.77 0.019247001 
17073259 LY6E 1.14 5.12 0.007017806 
16672669 LY9 -1.48 4.81 0.001587867 
16996813 CD180 -0.83 7.46 0.024493485 
16869391 LYL1 -0.69 5.93 0.001040497 
17069063 LYN -0.85 8.12 0.002826228 
17106795 SH2D1A -1.35 4.05 0.000995688 
16753914 LYZ -1.02 9.07 0.011077896 
16960355 TM4SF1 1.45 10.40 0.01108929 
16881138 MXD1 -0.95 6.68 0.003989474 
16979389 MAD2L1 1.23 4.65 0.009225792 
16971167 SMAD1 -0.70 4.63 0.014596176 
16882834 MAL -1.08 4.53 0.00165586 
17023150 MAN1A1 -0.85 8.70 0.017847035 
16978444 MANBA -0.62 7.21 0.046767865 
16677655 MARK1 -1.13 3.91 0.013871085 
16817666 MAZ 0.60 7.34 0.007197952 
16947061 MBNL1 -0.50 10.37 0.002409036 
16855617 MC4R -0.65 2.73 0.04209629 
16745281 MCAM -0.89 5.82 0.024427075 
16692775 MCL1 -0.60 9.65 0.020126598 
16945101 MCM2 1.17 6.15 0.004108398 
17020019 MCM3 0.64 7.92 0.033383735 
17068782 MCM4 1.18 7.51 0.009296335 
17060412 MCM7 0.90 7.23 0.008922121 
16880596 MDH1 0.66 6.75 0.00299001 
17047461 MDH2 0.77 7.21 0.000946504 
 256 
16676314 MDM4 -0.53 7.71 0.007978753 
16997953 MEF2C -0.94 5.92 0.000176441 
16880814 MEIS1 -1.10 5.51 0.009251812 
16807139 MEIS2 1.24 7.06 0.006202121 
16984945 MAP3K1 -0.59 8.48 0.047912995 
17014501 MAP3K4 -0.65 7.00 0.026407004 
16740074 MEN1 0.57 6.97 0.006495873 
16845427 MEOX1 -0.77 4.87 0.007619384 
17051626 MEST 1.30 6.32 0.015375785 
17050591 MET 2.37 9.41 0.003158441 
16963428 MFI2 1.30 7.77 0.021084877 
16934786 MFNG -0.89 5.87 0.001636024 
16783675 CTAGE5 -0.67 3.94 0.0311196 
16815828 CIITA -1.07 7.89 0.000848478 
17101193 CD99 -1.21 5.64 0.00330802 
16928098 MIF 0.65 9.66 0.037184243 
16942576 MITF -0.72 4.32 0.035352582 
17014714 MLLT4 0.79 8.28 0.026032596 
16819064 MMP2 -1.30 10.17 0.017996341 
16743751 MMP12 -2.24 3.26 0.00437143 
16819653 MMP15 1.46 7.11 0.017345479 
16765809 MMP19 -1.55 5.13 0.002145853 
16943944 CD200 1.07 9.21 0.042051728 
16803103 MPI 0.57 8.14 0.016435119 
17115692 MPP1 -0.74 7.69 0.017173716 
16702836 MRC1 -1.53 8.14 0.022837699 
16702881 MRC1 -1.54 8.20 0.020662433 
16888912 MYO1B -1.23 8.08 0.01256299 
16879883 MSH2 0.72 6.88 0.008543208 
16986748 MSH3 0.51 8.09 0.048021706 
16954295 MST1R 2.83 5.90 0.000239688 
17107697 MTM1 -0.46 6.23 0.02824918 
17019831 MUT 0.50 7.44 0.019276798 
16756804 MVK 0.77 4.91 0.04025301 
16934491 MYH9 -0.61 9.62 0.036154902 
16824258 MYH11 -2.89 6.25 0.001303698 
16809971 MYO1E -0.56 7.78 0.025836586 
16809457 MYO5A -0.83 7.87 0.011830864 
16855196 MYO5B 2.24 7.14 0.004950418 
16767932 PPP1R12A -0.36 8.64 0.04628174 
16996983 NAIP -0.91 8.73 0.001823563 
16929662 NCF4 -0.78 6.72 0.012753894 
17000800 NDUFA2 0.66 7.61 0.006187928 
16865175 NDUFA3 0.39 6.02 0.043458411 
16868138 NDUFA7 0.84 6.40 0.006823205 
17098071 NDUFA8 0.62 6.46 0.008452289 
16825097 NDUFAB1 0.54 6.88 0.028437442 
16889399 NDUFB3 0.58 5.53 0.036526044 
16944502 NDUFB4 0.58 5.83 0.002912399 
17093122 NDUFB6 0.65 6.50 0.047497843 
16869660 NDUFB7 0.72 6.56 0.03010687 
17072506 NDUFB9 0.58 5.97 0.031806444 
16814854 NDUFB10 0.58 5.19 0.007214542 
16724607 NDUFS3 0.58 6.38 0.018831684 
16727936 NDUFV1 0.69 6.76 0.002108584 
16662744 NDUFS5 0.48 8.19 0.035352582 
17007837 RPL10A 0.48 7.97 0.016052877 
16698984 NEK2 1.04 4.14 0.036461914 
 257 
16779369 NEK3 -0.57 6.32 0.041567289 
16802795 NEO1 1.40 8.78 0.023863252 
16920315 NFATC2 -0.81 7.01 0.000557252 
17092490 NFIB -0.85 8.94 0.00309707 
16856946 NFIC 0.49 9.15 0.040390831 
17006636 NFKBIL1 0.42 5.01 0.013225766 
17040689 NFKBIL1 0.44 5.15 0.01256299 
17027771 NFKBIL1 0.46 4.94 0.010685173 
17030597 NFKBIL1 0.46 4.94 0.010685173 
17033314 NFKBIL1 0.46 4.94 0.010685173 
17038094 NFKBIL1 0.46 4.94 0.010685173 
17035395 NFKBIL1 0.48 4.92 0.010007902 
16835592 NGFR -1.38 4.49 0.002818703 
16939668 NKTR -0.57 7.64 0.021492339 
17075536 NKX3-1 1.21 5.23 0.000108848 
16822801 NME3 0.59 6.63 0.038014865 
16814211 NME4 0.39 4.77 0.023863252 
16834883 NMT1 0.37 8.64 0.046718866 
16865214 CNOT3 0.36 7.35 0.043476839 
16869769 NOTCH3 -1.14 7.99 0.029828826 
17027038 NOTCH4 -0.78 4.93 0.009047056 
17042335 NOTCH4 -1.07 5.65 0.005096594 
17039839 NOTCH4 -1.03 5.40 0.004796972 
17029639 NOTCH4 -1.05 5.62 0.004665936 
17034630 NOTCH4 -1.09 5.60 0.004265429 
17037128 NOTCH4 -1.08 5.82 0.004109664 
16781536 PNP -0.67 6.48 0.015868743 
16671187 NPR1 1.81 7.25 0.010829092 
17048742 NPTX2 -1.40 4.55 0.013305094 
17086386 NTRK2 -2.18 4.22 0.000165075 
17109020 GPR143 1.67 6.41 0.010366891 
16894402 ODC1 0.68 9.22 0.048888147 
16761293 OLR1 1.95 7.09 0.003104576 
16687188 ORC1 0.80 4.53 0.038481195 
16903427 ORC4 0.52 6.59 0.027478999 
16839872 P2RX1 -0.97 4.64 0.004759764 
16757710 PEBP1 0.72 9.07 0.013196259 
16805776 PCSK6 0.59 4.50 0.015274977 
16872767 PAFAH1B3 1.43 6.61 0.000823584 
16686472 PRDX1 0.46 10.15 0.019678128 
16987673 PAM -0.88 7.85 0.011453436 
16767911 PAWR 0.98 6.76 0.0263308 
17093973 PAX5 -1.83 5.07 0.001726932 
16779667 PCDH9 -0.94 4.06 0.002498679 
16768857 CDK17 -0.49 7.99 0.042122558 
16676461 CDK18 0.65 5.14 0.029303762 
17056426 PDE1C -1.15 3.91 0.00913581 
16722321 PDE3B -1.43 4.00 0.003991338 
16665757 PDE4B -0.79 4.63 0.00236158 
17077774 PDE7A -0.98 6.60 0.007335327 
16804294 PDE8A -0.67 6.78 0.005959278 
16752103 PDE1B -0.49 5.11 0.04926514 
17001578 PDGFRB -1.27 8.92 0.007562595 
17102210 PDK3 -1.09 6.76 0.00521885 
17080516 ENPP2 -1.96 8.11 0.00174497 
17080554 ENPP2 -1.67 4.13 0.001737231 
17012598 ENPP3 -0.82 3.53 0.001080715 
17019260 PEX6 0.66 6.63 0.032246839 
 258 
16843462 PEX12 0.78 6.35 0.017592941 
17110463 CFP -0.59 3.66 0.042386257 
16914961 PFDN4 0.70 4.82 0.003669752 
16855510 ATP8B1 -1.15 6.95 0.007594687 
16750523 PFKM 0.63 5.45 0.037844332 
16960442 PFN2 1.06 7.62 0.000494327 
16665566 PGM1 1.05 8.60 0.03424377 
17085610 PGM5 -0.81 3.16 0.03160773 
17059451 ABCB4 -0.79 4.32 0.00102608 
16846416 PHB 0.72 5.15 0.000838223 
17102058 PHEX -0.80 2.96 0.005478009 
16818017 PHKG2 0.77 6.57 0.004796972 
16909021 SERPINE2 -1.40 5.87 0.032307131 
17050134 PIK3CG -0.96 7.76 0.012947456 
16712482 PIP4K2A -0.86 7.48 0.002553629 
17000104 PITX1 0.96 3.80 0.000563567 
16763032 PKP2 2.09 7.52 0.004486863 
16771279 PLA2G1B 1.03 4.76 0.025292216 
16660282 PLA2G5 -1.14 4.58 0.003271895 
17024394 PLAGL1 -1.11 7.58 0.03201727 
16821326 PLCG2 -0.53 2.77 0.027615981 
16821330 PLCG2 -1.17 7.34 0.000716011 
16961551 PLD1 -0.88 5.87 0.031303776 
16880942 PLEK -1.15 7.78 0.003104576 
16829557 SERPINF2 -1.02 4.55 0.014549322 
16817017 PLK1 1.25 6.59 0.035188462 
16946485 PLS1 1.35 4.37 0.017998952 
16919703 PLTP -0.86 9.77 0.022514505 
16953329 PLXNB1 1.58 6.74 0.000686385 
17067393 PNOC -0.59 3.32 0.04926514 
16841561 PMP22 -0.71 7.10 0.023388426 
17060545 PMS2P1 0.82 4.80 0.002746274 
17047247 PMS2P5 0.72 4.17 0.00495321 
16673636 PRRX1 -1.24 7.47 0.012778755 
16847137 38231 -0.93 5.09 0.001177318 
17057174 POLD2 0.67 5.87 0.031978027 
16819509 POLR2C 0.54 8.14 0.009933077 
16866565 POLR2E 0.67 8.28 0.011077896 
16871613 POLR2I 1.14 7.08 0.000443686 
16734154 POLR2L 0.52 7.02 0.037515824 
17059932 PON2 0.50 8.59 0.026095642 
16744247 POU2AF1 -0.56 2.83 0.008973363 
16872705 POU2F2 -0.81 4.80 0.003552569 
16931339 PPARA -0.45 6.09 0.019097494 
16937741 PPARG -1.61 5.03 0.000739652 
17045738 PPIA 0.51 6.34 0.024368191 
16823666 PPL 3.11 7.53 0.000197445 
16672779 PPOX 0.55 4.67 0.042115558 
16740977 PPP1CA 0.53 6.57 0.016925456 
16963099 PPP1R2 -0.71 5.20 0.003033218 
16974049 PPP2R2C 1.29 4.34 0.010414507 
16677228 PPP2R5A -0.48 7.03 0.004768442 
16788833 PPP2R5C -0.75 5.33 0.000292977 
16817811 PPP4C 0.50 8.54 0.020401607 
16715505 PPP3CB -0.44 7.70 0.03465356 
17066627 PPP3CC -0.55 6.53 0.036030551 
16704464 NPY4R 0.96 3.92 0.015074582 
16761549 PRB1 -0.60 5.04 0.016667474 
 259 
16742787 PRCP -0.83 5.15 0.002932545 
16705507 SRGN -0.64 10.80 0.032682761 
17009862 PRIM2 0.51 6.28 0.049019216 
16995685 PRKAA1 -0.58 7.25 0.00243619 
16666616 PRKACB -0.96 7.49 0.000942856 
17054254 PRKAR1B 0.60 4.92 0.039218109 
16817044 PRKCB -1.02 4.49 0.004762177 
16879679 PRKCE -0.69 4.45 0.005553029 
16785003 PRKCH -1.34 4.93 0.000804953 
16947875 PRKCI 1.07 8.99 0.001754644 
16711533 PRKCQ -1.18 4.86 0.012427259 
16858468 PRKCSH 0.47 10.41 0.030033578 
16704977 PRKG1 -1.59 5.45 0.007077087 
16704660 MAPK8 -0.49 5.34 0.014924133 
16677391 PROX1 -1.39 4.36 0.002378446 
17106031 PRPS1 0.86 7.42 0.002145853 
17061298 RELN -1.97 4.51 0.001448824 
16874731 KLK10 1.47 6.44 0.02259675 
17057035 PSMA2 0.54 9.52 0.008987831 
16803540 PSMA4 0.62 7.81 0.013715892 
16685144 PSMB2 0.59 9.17 0.002565523 
16833698 PSMB3 0.51 9.22 0.022819564 
17049965 PSMC2 0.48 8.67 0.005899177 
16862145 PSMC4 0.63 8.75 0.011345175 
16948871 PSMD2 0.55 8.63 0.001837551 
16861704 PSMD8 0.43 10.64 0.041059079 
16833139 PSMD11 0.44 7.87 0.031901828 
17057946 PSPH 0.81 5.96 0.00798639 
16856257 PTBP1 0.37 10.05 0.023563726 
16707030 PTEN -0.67 6.87 0.011744728 
16984287 PTGER4 -0.77 6.92 0.011924989 
16666471 PTGFR -1.69 4.42 0.001218332 
16873562 PTGIR -0.87 5.76 0.022276315 
16921268 PTK6 0.62 3.81 0.041591961 
17097000 PTPN3 1.66 6.02 0.013317113 
16747623 PTPN6 -0.71 7.21 0.02138633 
16811816 PTPN9 0.66 7.49 0.011077896 
16699174 PTPN14 0.90 8.85 0.031140551 
16767422 PTPRB -1.23 6.33 0.004935448 
16675578 PTPRC -1.19 8.48 0.003485 
17092331 PTPRD -1.43 5.29 0.020083682 
16740997 PTPRCAP -1.43 7.15 0.01631073 
16663621 PTPRF 2.41 8.96 1.58E-05 
16875656 PTPRH 1.45 4.29 0.034807093 
16850759 PTPRM -1.14 8.79 0.000769357 
16863091 PVRL2 0.82 6.94 0.005841687 
16759592 PXMP2 0.87 6.86 0.003437283 
16747770 PEX5 0.50 5.57 0.022002025 
16739979 PYGM 1.71 5.98 0.027473959 
16752322 RAB5B 0.43 5.98 0.018019088 
16852463 RAB27B 2.13 6.40 0.041307561 
16791244 RABGGTA 0.71 5.90 0.022575571 
16934749 RAC2 -0.57 5.15 0.040039322 
16838977 RAC3 1.56 6.15 0.002929216 
17087933 RAD23B 0.49 9.29 0.049029427 
16759202 RAN 0.64 7.66 0.01072311 
16668712 RAP1A -0.56 7.06 0.00643613 
16753779 RAP1B -0.86 6.46 0.012178643 
 260 
16683022 RAP1GAP 0.99 3.88 0.01223952 
16946393 RASA2 -0.89 6.93 0.003866024 
16784664 ARID4A -0.44 6.67 0.048093219 
16662134 RBBP4 0.47 9.60 0.003132044 
17109396 RBBP7 0.62 7.99 0.002360681 
16880414 REL -0.79 8.33 0.006367131 
16740495 RELA 0.41 6.92 0.004810414 
16726832 DPF2 0.36 6.59 0.039984612 
17022623 REV3L -0.77 7.64 0.000557252 
17058617 RFC2 0.78 6.52 0.004665936 
16773946 RFC3 0.59 6.96 0.047574394 
16962493 RFC4 0.91 6.01 0.002538591 
16757687 RFC5 0.86 6.49 0.004567792 
16869519 RFX1 0.41 5.48 0.034147773 
17088230 RGS3 -0.55 4.93 0.042473943 
16675312 RGS13 -1.05 3.38 0.015516112 
17064544 RHEB 0.50 5.63 0.047708696 
16790115 RNASE1 -0.59 6.41 0.047497843 
17041209 RNF5 0.46 7.01 0.033584759 
16733920 RNH1 0.48 6.62 0.035110005 
16675903 RNPEP 0.37 8.40 0.038464821 
16810133 RORA -0.82 5.79 0.039532232 
17085951 RORB -1.12 3.79 0.005048834 
17110086 RPGR -1.04 5.80 0.000239688 
17055191 RPA3 0.70 6.21 0.013011825 
16859648 RPL18A 0.42 11.10 0.032874172 
16956952 RPL24 0.40 6.19 0.035188462 
16865675 RPL28 0.62 4.85 0.010221593 
16950133 RPL35A 0.43 5.97 0.01541723 
16837482 RPL38 0.40 5.76 0.022549607 
16861907 MRPS12 0.81 4.86 0.016643305 
16729103 RPS3 0.42 6.58 0.033386639 
16866282 RPS5 0.58 11.53 0.016333651 
16856581 RPS15 0.45 10.87 0.010861211 
17036038 RPS18 0.35 6.84 0.04297597 
16862596 RPS19 0.39 10.97 0.03234765 
16915676 RPS21 0.69 6.09 0.041059079 
16706412 RPS24 0.47 5.77 0.040623853 
17004551 RREB1 -0.36 7.87 0.038014865 
16721126 RRM1 0.76 6.91 0.004019872 
17038750 VPS52 0.35 5.88 0.049019216 
17028466 VPS52 0.41 5.85 0.025491785 
17031280 VPS52 0.41 5.85 0.025491785 
17033765 VPS52 0.41 5.85 0.025491785 
17036029 VPS52 0.41 5.85 0.025491785 
17041336 VPS52 0.41 5.85 0.025491785 
17034947 VPS52 0.42 8.40 0.021336701 
16790413 SALL2 0.79 4.87 0.042489049 
16951409 SATB1 -0.95 6.15 0.000907558 
16972155 MSMO1 0.73 8.33 0.035188462 
17015862 ATXN1 -0.52 7.54 0.034233212 
16904514 SCN3A -1.14 3.02 0.010665065 
17117567 SCN8A 0.84 3.96 0.024635244 
16751319 SCN8A 1.38 5.20 0.019484538 
16760350 SCNN1A 2.98 5.84 0.011426997 
16833231 CCL13 -1.71 4.00 0.012161058 
16843541 CCL16 -0.63 3.00 0.02159481 
16833411 CCL18 -1.14 4.66 0.012398429 
 261 
17093543 CCL21 -3.02 8.62 0.010685173 
16843567 CCL23 -0.68 3.08 0.017054569 
17058870 CCL24 -1.23 3.12 0.040273669 
16819484 CX3CL1 -0.62 5.64 0.011077896 
16919567 SDC4 1.83 8.70 0.000546493 
16842766 SDF2 0.37 6.90 0.04926514 
16696251 SELE -2.33 4.85 0.002483481 
16696237 SELL -1.96 6.73 0.002963593 
16696217 SELP -1.50 5.33 0.044175368 
16866993 SGTA 0.57 8.54 0.008999768 
17094064 SHB 1.05 8.53 0.011819549 
16842103 SHMT1 0.98 5.49 0.005934022 
16827793 ST3GAL2 -0.54 6.94 0.027548904 
16762202 ST8SIA1 -1.10 3.61 0.000351234 
16686796 STIL 1.10 6.16 0.018889578 
16727017 SIPA1 -0.51 6.06 0.011077896 
16984032 SKP2 1.28 8.94 0.000443686 
16695422 SLAMF1 -1.58 4.74 0.001280256 
16725984 SLC3A2 0.68 8.04 0.001636024 
17053553 SLC4A2 0.88 6.00 0.009473381 
16934198 SLC5A4 -1.47 3.31 2.51E-05 
16937645 SLC6A1 -1.19 4.51 0.01634837 
16932706 SLC7A4 1.79 6.15 0.004432742 
16944588 SLC15A2 -0.81 5.71 0.033811243 
16691023 SLC16A1 1.52 6.48 0.000456269 
16709713 SLC18A2 -0.74 3.51 0.01068741 
17014442 SLC22A3 -2.26 4.80 0.011781352 
16989018 SLC22A5 1.97 7.68 0.000679899 
16919547 SLPI 4.42 10.21 0.000456269 
17077004 SNAI2 -1.22 9.57 0.033663804 
16926433 SUMO3 0.56 5.77 0.004872828 
16848755 SUMO2 0.65 8.24 0.013099441 
16862333 SNRPA 0.54 8.85 0.018803979 
16916546 SNRPB 0.73 8.56 0.007072458 
17007661 SNRPC 0.79 5.48 0.001521727 
16873391 SNRPD2 0.56 7.20 0.018958351 
16965519 SOD3 -1.72 6.22 0.001248774 
16896710 SOS1 -0.32 8.53 0.034250461 
17005276 SOX4 1.37 9.40 0.003485 
16840696 SOX15 1.17 4.23 0.049558299 
16864518 SPIB -0.98 4.65 0.006646723 
16799690 SPINT1 2.04 7.19 0.008738402 
16881434 SPR 1.68 7.26 0.000572613 
16740867 SPTBN2 1.41 4.79 0.012126133 
16738429 SSRP1 0.75 7.99 0.008537511 
16837426 SSTR2 -0.93 3.73 0.000217555 
16906571 STAT4 -1.10 5.45 0.040335382 
16845096 STAT5B -0.51 6.94 0.002567779 
16920100 STAU1 0.33 8.74 0.029810598 
16914147 STK4 -0.73 7.80 0.006495873 
16825377 SULT1A2 1.01 5.09 0.001325644 
16857703 STXBP2 0.60 7.26 0.034323795 
16847087 SUPT4H1 0.48 9.71 0.022309677 
16705531 SUPV3L1 0.42 7.49 0.029382558 
17086708 SYK -0.88 6.37 0.004665936 
17068093 TACC1 -0.64 7.70 0.016667474 
16899401 TACR1 -1.88 3.64 1.41E-05 
17000854 TAF7 0.76 7.51 0.016535009 
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16996917 TAF9 0.42 5.47 0.041012517 
16686784 TAL1 -0.58 3.10 0.021821543 
16751857 TARBP2 0.48 5.70 0.041117157 
16983800 TARS 0.67 7.92 0.021084877 
17078342 TCEB1 0.47 5.93 0.038221159 
16823193 TCEB2 0.39 8.78 0.023233376 
16855382 TCF4 -0.94 8.36 0.007594659 
16989202 TCF7 -1.18 4.76 0.003652987 
16928988 TCN2 -0.89 5.52 0.004937041 
16869324 PRDX2 0.69 7.13 0.01758657 
16722189 TEAD1 0.95 9.30 0.000224628 
16746906 TEAD4 0.92 6.69 0.002849275 
16789960 TEP1 -0.64 7.18 0.002929216 
16961372 TERC 2.11 9.55 6.47E-05 
17015540 TFAP2A 1.55 5.00 0.001049806 
16915091 TFAP2C 1.80 4.88 0.001407849 
16823512 TFAP4 0.72 5.56 0.014510297 
16805422 NR2F2 -1.02 4.59 0.00746182 
16906308 TFPI -1.67 6.37 0.007628544 
16677556 TGFB2 1.78 7.65 0.049797276 
16938562 TGFBR2 -0.75 9.79 0.033584759 
16689546 TGFBR3 -1.14 6.19 0.010039892 
16791219 TGM1 3.67 7.80 0.00046013 
16799315 THBS1 -1.67 10.09 0.031512587 
16951567 THRB -0.93 4.80 0.019713579 
16663457 TIE1 -1.42 4.88 0.003082722 
16849379 TK1 1.29 5.97 0.022323152 
16867018 TLE2 1.13 5.99 0.044453176 
17086208 TLE4 -1.05 5.89 0.002954329 
16972198 TLL1 -1.61 6.30 0.012675849 
16720416 TSPAN4 0.55 6.01 0.02138633 
16726680 TM7SF2 0.86 4.14 0.019028688 
16832438 TNFAIP1 0.62 9.03 0.019786978 
16875599 TNNT1 2.44 5.28 0.025292216 
16908251 TNS1 -1.07 6.86 0.002145853 
16844312 TOP2A 1.71 8.05 0.00955707 
16840732 TP53 0.55 8.39 0.047708696 
17012281 TPD52L1 1.74 5.54 0.009049385 
17097941 TRAF1 -0.73 5.38 0.011105871 
16789080 TRAF3 -0.51 6.68 0.026161652 
16694529 CCT3 0.71 8.82 0.017352007 
17049557 TRIP6 0.69 8.40 0.021751719 
16743593 TRPC6 -1.09 3.51 0.00122328 
17080342 TRPS1 -0.97 6.80 0.003898923 
16736508 TSG101 0.43 7.27 0.043034204 
16787068 TSHR -0.55 3.03 0.017198424 
16934671 TST 1.13 7.63 0.024951715 
17010552 TTK 1.17 5.01 0.044172882 
16670894 TUFT1 1.74 6.55 0.00019927 
16756163 TXNRD1 0.90 6.77 0.009975704 
16850477 TYMS 1.31 6.86 0.008236083 
16831434 UBB 1.01 5.32 0.004848101 
16944325 UPK1B 6.01 8.98 6.16E-05 
16976524 UGT2B17 -0.90 1.90 0.000462616 
16970001 UGT8 -1.29 3.81 0.005962736 
16756627 UNG 0.93 6.59 0.001531279 
16816739 UQCRC2 0.50 9.53 0.010366891 
16664048 UROD 0.73 6.91 0.005253203 
 263 
16665447 USP1 0.58 7.72 0.045269698 
17013283 UTRN -0.58 8.95 0.015983939 
16857490 VAV1 -0.98 6.99 0.006570848 
16667702 VCAM1 -1.36 7.89 0.04025301 
16706298 VDAC2 0.53 6.11 0.009910072 
17025191 EZR 1.52 10.68 0.000356926 
16939637 VIPR1 -0.52 3.75 0.038287583 
17083197 VLDLR 2.26 8.07 0.008599003 
16760257 VWF -1.66 8.14 0.002385386 
16905238 WIPF1 -1.06 7.28 0.000180119 
16846022 WNT3 1.57 5.03 0.002351716 
16936044 WNT7B 0.83 4.22 0.015700481 
16668785 WNT2B 1.90 7.37 0.004236839 
16700147 WNT9A 1.80 5.94 0.000241896 
16737105 WT1 0.98 8.30 0.043476839 
16933535 XBP1 -0.97 9.01 0.001507011 
17106852 XPNPEP2 -0.98 3.79 0.022708138 
16914103 YWHAB -0.31 8.39 0.044495749 
16839331 YWHAE 0.39 7.44 0.020583412 
16883232 ZAP70 -1.11 5.24 0.011383908 
17060394 ZNF3 0.47 5.88 0.049702356 
17073961 ZNF7 0.41 4.90 0.035302047 
16866031 ZNF17 0.60 5.54 0.007777057 
16713498 ZNF32 0.53 5.48 0.048137916 
17049090 ZSCAN21 0.52 6.04 0.015886272 
16933044 ZNF70 -0.48 6.72 0.047314746 
16868410 ZNF121 0.54 8.92 0.010681072 
16843987 PCGF2 0.51 7.57 0.03720646 
17033956 TRIM26 0.49 6.72 0.049788184 
17041583 TRIM26 0.51 6.74 0.038039243 
17016832 TRIM26 0.51 6.74 0.036557098 
17031500 TRIM26 0.51 6.74 0.036557098 
17036239 TRIM26 0.52 6.77 0.035669357 
17026623 TRIM26 0.53 6.72 0.031400664 
17107919 ZNF185 1.46 6.58 0.001657106 
16735231 ZNF214 0.55 4.07 0.045222289 
16721535 ZNF215 -1.64 3.50 0.001657106 
16873174 ZNF229 1.35 4.89 0.017796154 
16683250 LUZP1 -0.54 5.73 0.035352582 
16659478 PRDM2 -0.46 6.14 0.024870637 
16901624 MALL -0.74 4.03 0.01758657 
16903140 CXCR4 -1.20 9.35 0.039290159 
16941024 SEMA3B 2.05 7.47 0.011329237 
16998532 ST8SIA4 -1.11 6.98 0.003801595 
17017244 BAG6 0.42 7.16 0.016813999 
17031933 GPANK1 0.46 4.70 0.012217639 
17036651 GPANK1 0.44 4.65 0.008999768 
17017290 GPANK1 0.45 4.62 0.006249259 
17034403 GPANK1 0.45 4.62 0.006249259 
17029148 GPANK1 0.45 4.55 0.005270531 
17039446 GPANK1 0.45 4.07 0.004759764 
17041929 GPANK1 0.45 4.07 0.004759764 
17007393 HSD17B8 0.94 5.90 0.035352582 
17028442 HSD17B8 0.94 5.90 0.035352582 
17031254 HSD17B8 0.94 5.90 0.035352582 
17033739 HSD17B8 0.94 5.90 0.035352582 
17036003 HSD17B8 0.94 5.90 0.035352582 
17038722 HSD17B8 0.94 5.90 0.035352582 
 264 
17019728 PLA2G7 -1.65 6.05 0.025836586 
17043355 AIMP2 0.98 7.29 0.00041147 
17052939 ARHGEF5 1.04 5.26 0.024614831 
16712168 CUBN -1.36 4.15 1.58E-05 
16719417 ADAM12 -1.99 7.59 0.019402743 
16720219 RASSF7 0.87 4.69 0.009127161 
16747501 USP5 0.66 7.46 0.018780741 
16753923 YEATS4 0.69 7.48 0.049710075 
16796451 TCL1A -0.90 3.64 0.005113143 
16857429 CLPP 0.58 8.33 0.047832757 
16918722 GDF5 1.37 4.23 0.027490456 
16922584 CHAF1B 1.00 4.91 0.037915247 
17108943 PNPLA4 0.98 6.89 0.01555904 
17103104 USP11 0.47 7.78 0.030939687 
17115597 UBL4A 0.75 6.61 0.006011845 
17108264 TKTL1 -0.38 2.89 0.041841038 
16881353 DYSF -1.26 6.42 0.03312773 
16743017 PICALM -0.43 8.95 0.016606769 
16822408 AXIN1 0.58 6.05 0.049074575 
17071625 FZD6 0.73 8.03 0.029083363 
16840145 SLC25A11 0.56 8.51 0.020386669 
16977833 SPARCL1 -1.26 9.43 0.002145853 
17110071 SRPX -1.80 7.57 0.000494327 
16670681 ANXA9 2.64 5.78 0.024746435 
17023677 STX7 -0.68 8.37 0.002826228 
16825602 DOC2A 1.34 4.73 0.008085068 
16933378 TPST2 -1.04 4.00 0.00102608 
17046640 TPST1 -0.86 5.96 0.040623853 
16825592 HIRIP3 0.88 4.99 0.002521056 
16768014 PPFIA2 -0.78 3.10 0.014510297 
16686557 PIK3R3 -0.83 5.88 0.00461557 
16933667 NIPSNAP1 0.57 6.12 0.031697406 
16836315 DGKE -0.93 5.76 0.008787723 
16912130 CST7 -1.10 7.52 0.040366916 
16667662 CDC14A -0.96 6.04 0.000837802 
16679349 KMO -1.01 5.35 0.042809558 
16923365 PDXK 0.68 5.61 0.002105466 
16923397 RRP1 0.53 5.75 0.034311793 
16682691 AKR7A2 0.53 5.35 0.01387128 
16891208 STK16 0.56 5.13 0.005350587 
16905076 SLC25A12 -0.49 6.23 0.032309437 
16873826 PLA2G4C -0.80 4.62 0.010610622 
16958812 RUVBL1 0.72 6.31 0.010778949 
16866394 PPAP2C 2.03 7.14 0.002958086 
16925674 PSMG1 0.62 6.23 0.012981672 
16859952 RFXANK 0.58 6.18 0.049131964 
16752682 HSD17B6 1.99 5.11 0.047708696 
16846195 SKAP1 -1.48 5.15 0.005959278 
16834516 AOC3 -1.63 6.80 0.004097602 
17018841 KCNK5 1.61 5.47 0.011077896 
16904793 ABCB11 -0.73 2.70 0.005864399 
16780917 IRS2 1.02 7.26 0.047063771 
17042946 EIF3B 0.64 7.33 0.00864139 
16662031 EIF3I 0.51 8.41 0.035994321 
16967631 SLC4A4 2.30 8.26 0.034233212 
16856906 S1PR4 -0.93 4.42 0.030146833 
16957738 B4GALT4 1.19 6.19 0.001384232 
16681142 TNFRSF25 -0.48 4.81 0.027420464 
 265 
17002194 ADAM19 -1.57 6.94 0.01631073 
16794321 ADAM20 -0.88 4.37 0.01508554 
16728331 FADD 0.83 6.64 0.00077203 
17092421 MPDZ -1.06 7.09 0.0148032 
16899580 SUCLG1 0.43 6.90 0.017337887 
16727224 BANF1 0.77 7.07 0.002093973 
16794220 DCAF5 -0.46 7.46 0.035472697 
16992347 FGF18 2.17 7.24 0.007930215 
16980160 INPP4B -1.35 5.12 0.000210675 
16713187 NRP1 -1.05 8.77 0.000909279 
17041393 SYNGAP1 -0.46 6.62 0.015976368 
17007499 SYNGAP1 -0.51 6.65 0.010973189 
16695406 CD84 -0.69 6.04 0.024133658 
16947235 GMPS 0.58 8.20 0.003765835 
16755131 SOCS2 -0.57 4.03 0.040476987 
17077659 GGH 0.73 4.77 0.018006229 
17000900 HDAC3 0.48 6.32 0.025992935 
16809827 ALDH1A2 2.63 5.84 0.000456269 
16925057 SYNJ1 -0.41 5.95 0.034741738 
16776537 ARHGEF7 -0.44 6.40 0.036215521 
17023736 VNN2 -1.70 4.29 0.000605575 
16993458 SQSTM1 0.52 6.90 0.017941275 
16827170 NAE1 0.51 8.14 0.019028688 
16786548 EIF2B2 0.45 6.98 0.048211231 
16918485 EIF2S2 0.36 9.22 0.044982261 
17048908 BUD31 0.64 6.45 0.002651133 
17109342 AP1S2 -0.54 6.20 0.018616123 
16810376 HERC1 -0.60 8.09 0.001961033 
16886174 KYNU -1.16 5.65 0.00179239 
16958963 H1FX 0.58 7.39 0.036437576 
16726489 RPS6KA4 0.55 5.59 0.031509868 
16693082 SELENBP1 1.30 7.11 0.0421346 
16944798 KALRN -1.43 4.60 0.003324144 
17100201 CLIC3 2.19 5.72 0.000307563 
16758463 HIP1R -0.46 5.04 0.026161652 
16748529 GPRC5A 2.81 7.57 0.001585662 
17024053 MAP7 0.77 5.04 0.035188462 
16918832 NFS1 0.70 7.00 0.001977587 
16813342 PRC1 1.16 6.35 0.024418781 
16790493 SLC7A7 0.65 4.75 0.044982261 
16696811 ANGPTL1 -1.47 6.61 0.03759471 
17067970 ASH2L 0.83 8.60 0.033336533 
16974626 LDB2 -1.47 5.81 0.000520867 
16814310 PIGQ 0.56 5.58 0.012231536 
16815513 DNAJA3 0.99 6.71 0.000318147 
17021323 TBX18 0.89 8.16 0.004044647 
16745343 USP2 2.00 5.39 0.00279959 
16837709 SLC16A5 0.84 4.61 0.036030551 
17088185 PRPF4 0.57 7.22 0.032813136 
16801557 CCNB2 1.82 6.66 0.001303698 
16860531 PDCD5 0.46 7.70 0.02317122 
16838855 HGS 0.52 7.76 0.030724616 
16679411 EXO1 1.03 4.40 0.036908249 
17049120 AP4M1 0.87 6.37 0.001080715 
16753270 SLC16A7 -0.86 6.00 0.000968081 
16778067 DCLK1 -1.08 6.37 0.006148242 
17111918 ZMYM3 0.52 7.39 0.042473943 
16892918 LRRFIP1 -0.70 7.18 0.007197952 
 266 
16698697 FAIM3 -1.84 5.91 0.007273879 
16715849 DLG5 0.79 7.56 0.030804916 
16681827 DHRS3 0.86 8.53 0.043822882 
16795794 RPS6KA5 -0.71 5.33 0.009917418 
17074474 MFHAS1 -0.49 5.87 0.042255035 
16676643 MAPKAPK2 -0.50 8.05 0.033295891 
16906733 STK17B -1.23 7.98 0.000554518 
16849501 CYTH1 -0.73 6.24 0.004696863 
16674080 GPR52 -1.10 5.97 0.001029348 
17051336 ATP6V1F 0.61 8.50 0.009786926 
16982635 TRIP13 1.04 5.25 0.037132095 
16833441 ZNHIT3 0.73 7.71 0.002719692 
16760792 CD163 -1.20 8.16 0.016877145 
16920169 B4GALT5 0.76 9.37 0.003669752 
16773919 KL -1.08 4.31 0.000446262 
16811739 COX5A 0.71 8.41 0.01135105 
16848845 RECQL5 0.53 5.54 0.024413743 
16930348 GRAP2 -1.20 4.26 0.006193453 
17077723 CYP7B1 -0.95 6.91 0.020424774 
16695121 AIM2 -1.23 5.10 0.027222301 
16900053 EIF2AK3 -0.50 7.64 0.010722608 
16812685 HOMER2 1.11 5.39 0.007351206 
17011121 FHL5 -2.15 5.16 0.000352982 
17114520 ARHGEF6 -1.00 7.51 0.001217017 
16858941 IL27RA -0.89 4.86 0.033386639 
16951150 SH3BP5 -0.91 5.81 0.001431864 
16661497 THEMIS2 -0.82 7.35 0.025925514 
16910655 PSMF1 0.39 8.67 0.01065877 
16802519 KIF23 1.47 6.31 0.013388643 
16951756 SLC4A7 -0.78 7.43 0.013370922 
16751269 SLC4A8 -0.35 3.30 0.04846312 
16695627 ADAMTS4 -1.79 5.84 0.005999718 
16976706 ADAMTS3 2.04 6.97 0.03972789 
16924602 ADAMTS1 -1.58 6.51 0.030688059 
17049939 PMPCB 0.47 8.72 0.027924641 
16872194 GMFG -1.08 9.06 0.003426839 
16733045 EI24 0.47 7.72 0.031350721 
16878406 MRPL33 0.61 5.68 0.016545435 
16797103 C14orf2 0.73 4.77 0.001688896 
17047138 GTF2IRD1 1.62 6.72 1.60E-05 
17075529 ENTPD4 -1.71 5.34 0.009510468 
17014295 WTAP -0.37 8.13 0.04995222 
16903931 CYTIP -1.58 6.04 0.002492816 
16832588 TRAF4 0.65 5.68 0.026095642 
16995409 NUP155 0.69 8.09 0.003723708 
17065173 ARHGEF10 0.91 7.65 0.000114562 
16696614 KIAA0040 -0.72 6.98 0.004123709 
16929283 DEPDC5 -0.50 5.60 0.01286048 
16663665 KDM4A 0.72 8.05 0.02193634 
17020044 TRAM2 -0.95 9.45 0.02249075 
16842350 ULK2 1.39 7.50 0.00129038 
16673012 NOS1AP 1.32 4.74 0.008265301 
16699932 TMEM63A -0.58 7.16 0.008189262 
16814250 RAB11FIP3 0.65 5.82 0.027088074 
17043882 HDAC9 -0.73 4.49 0.033736362 
16818090 SETD1A 0.50 6.38 0.009510468 
16822762 IFT140 0.71 5.64 0.013827493 
16830374 ACAP1 -1.45 6.30 0.010038939 
 267 
17013223 PHACTR2 -0.75 6.99 0.033075537 
17104344 STARD8 -0.83 5.42 0.027490456 
17077502 TOX -1.01 5.88 0.049319963 
16757969 MLEC 0.44 9.21 0.017801063 
16986700 ZFYVE16 -0.62 7.50 0.015569485 
16810543 KIAA0101 1.15 5.22 0.010683734 
16916901 RASSF2 -1.23 8.43 0.001227082 
16849667 EIF4A3 0.58 8.12 0.018889578 
16912492 TM9SF4 0.34 9.16 0.037428899 
16784710 KIAA0586 -0.59 7.46 0.003465238 
17080897 MTSS1 -0.93 7.12 0.038484879 
16715269 SPOCK2 1.47 6.99 0.040623853 
16929222 SFI1 -0.66 5.52 0.007438592 
16868743 KEAP1 0.61 7.70 0.013925031 
17019287 CUL7 0.56 6.94 0.017793929 
16920180 SPATA2 0.68 4.65 0.00995933 
16665687 DNAJC6 1.69 5.78 0.01677511 
16789790 KIAA0125 -2.09 4.63 0.002692499 
16808094 LCMT2 0.77 6.43 0.009565363 
16912192 GINS1 1.41 5.97 0.004053283 
16903356 ZEB2 -1.15 7.24 0.000494327 
16765657 TESPA1 -1.18 4.90 0.001690497 
17104283 HEPH -1.07 5.61 0.047497843 
17056740 ELMO1 -1.22 6.89 0.000103096 
16707884 ZNF518A -0.62 5.93 0.031965487 
17091090 PPP1R26 0.76 5.47 0.016667474 
16956773 TOMM70A 0.46 7.46 0.039715058 
16979256 SEC24D -0.64 8.54 0.039929076 
16741864 FCHSD2 -0.83 7.83 0.001398413 
16779792 TBC1D4 -0.73 6.82 0.008267155 
16667516 LPPR4 -1.49 5.72 0.022312862 
17011593 FIG4 -0.56 6.67 0.003068299 
16805124 SV2B -1.08 4.57 0.020391125 
16693559 DENND4B -0.41 6.69 0.048211231 
16674025 RABGAP1L -0.70 5.70 0.006761023 
16831247 ARHGAP44 2.13 6.13 0.015855612 
16803710 ARNT2 1.32 5.81 0.007880507 
16674319 FAM20B 0.68 7.65 0.014342333 
16950912 IQSEC1 -0.66 7.85 0.00165586 
16659171 MFN2 0.64 7.38 0.026601496 
16697695 KIF14 1.39 5.27 0.036461914 
16880982 ARHGAP25 -1.08 5.49 0.003322562 
17003924 GFPT2 1.63 8.61 0.002631483 
17113320 AMMECR1 0.83 6.85 0.015855612 
16782710 REC8 2.30 6.98 0.000545429 
17047881 DMTF1 -0.46 8.41 0.047085512 
17001040 GNPDA1 0.55 4.78 0.033431058 
16757098 SH2B3 -0.59 6.46 0.049456502 
17093920 GNE -0.43 6.36 0.024664444 
16836214 TOM1L1 2.38 8.39 2.74E-06 
17098567 SH2D3C -0.97 5.67 0.007880507 
16947556 SMC4 0.70 7.85 0.009225792 
16762154 ABCC9 -1.77 7.85 0.000482426 
17064459 ABCF2 0.65 6.96 0.025590639 
16694117 SCAMP3 0.72 6.26 0.010631929 
16727427 DPP3 0.68 6.90 0.012778755 
16811832 SNUPN 0.67 6.75 0.038187727 
16920338 ATP9A 0.87 6.81 0.024862959 
 268 
17103509 PQBP1 0.68 6.41 0.01349409 
16811975 TSPAN3 1.32 9.14 0.001754644 
16691314 TSPAN2 -1.40 5.34 0.042865525 
16814837 NUBP2 0.70 6.54 0.012778755 
16753202 TSFM 0.54 5.62 0.002708088 
16706499 PPIF 0.65 7.09 0.036557098 
16989054 RAD50 0.48 8.93 0.045878888 
16989636 KIF20A 1.82 5.90 0.01541723 
16900783 ACTR1B 0.39 7.32 0.048675912 
16897056 LRPPRC 0.56 8.30 0.013069553 
16823413 TRAP1 1.18 8.12 0.000307563 
17115207 BCAP31 0.90 7.37 0.000996424 
16846734 TOB1 1.08 7.89 0.025292216 
16977925 FAM13A -0.59 6.39 0.024493485 
16889779 ABI2 0.78 7.52 0.001769304 
16866337 TRIM28 0.51 9.33 0.044495749 
16686774 PDZK1IP1 2.31 7.11 0.002643438 
17059974 SLC25A13 0.48 7.62 0.012947456 
16940839 RBM6 -0.56 6.74 0.002383003 
16778355 LHFP -1.30 7.70 0.000259924 
16765945 RNF41 0.53 7.24 0.046648229 
16853120 TSHZ1 -0.52 5.15 0.013070795 
16962185 ALG3 0.54 6.39 0.029648298 
16906285 CALCRL -1.64 7.45 0.008085068 
16745002 MPZL2 -1.10 5.25 0.002351716 
16665373 INADL 1.40 7.79 0.020271225 
16773650 USPL1 -0.48 6.37 0.020271225 
16748095 KLRG1 -1.43 4.05 0.000104373 
16816408 COQ7 0.68 6.70 0.004097602 
16814366 MSLN 2.86 8.83 0.002360681 
17049904 LRRC17 -0.90 4.00 0.048213306 
16739942 RASGRP2 -0.85 4.73 0.027983291 
16785540 GPHN -0.70 4.85 0.028312719 
17049461 POP7 0.52 5.90 0.034229659 
16970435 SPRY1 -0.79 7.02 0.041594608 
16810847 DENND4A -0.46 8.55 0.029403396 
16741075 CDK2AP2 0.74 5.53 0.02649727 
17045787 RAMP3 -0.92 5.11 0.037290637 
16663014 ZMPSTE24 0.40 9.22 0.038484879 
16856232 FSTL3 1.24 8.34 0.001052997 
16790823 EFS -0.93 5.06 0.038039243 
17005799 PRSS16 0.79 4.31 0.014924133 
16875414 LILRB2 -0.93 5.48 0.019213072 
16891273 SPEG 1.25 5.32 0.00234422 
16826218 DNAJA2 0.39 8.36 0.0196481 
16861930 PAK4 1.18 5.57 0.004665936 
16810945 SNAPC5 0.59 5.64 0.043440666 
16996194 CCNO 0.70 3.92 0.040827531 
16726096 RTN3 0.59 8.52 0.004787777 
17046041 IKZF1 -1.44 6.57 0.001448824 
16859643 B3GNT3 -0.40 3.06 0.030939687 
16735764 MRVI1 -1.15 5.77 0.003485 
17091695 TUBB4B 0.52 8.32 0.010535139 
17074848 DLC1 -1.24 5.51 0.005879129 
17071162 CPQ -0.68 6.31 0.004067726 
16763666 RAPGEF3 -0.68 5.01 0.047498576 
16730503 YAP1 0.42 8.16 0.026786124 
16722278 SPON1 -1.35 8.94 0.033104806 
 269 
16790556 PRMT5 0.79 6.85 0.013011825 
16861047 TMEM147 0.64 8.79 0.002687511 
16726825 CDC42EP2 0.51 4.81 0.040351348 
16690343 VAV3 -1.30 4.80 0.000107648 
16671381 HAX1 0.71 5.98 0.007431953 
16838750 BAIAP2 1.69 6.37 0.000255998 
16840473 CLEC10A -1.27 5.78 0.029648298 
16984730 FST -1.79 5.20 0.032915321 
16868038 TIMM44 0.72 6.99 0.010147804 
17007446 PFDN6 0.49 5.99 0.013305094 
17028495 PFDN6 0.51 6.01 0.009527594 
17031309 PFDN6 0.51 6.01 0.009527594 
17036058 PFDN6 0.51 6.01 0.009527594 
17038779 PFDN6 0.51 6.01 0.009527594 
16723294 EIF3M 0.60 9.49 0.015265839 
17005138 CAP2 0.92 7.50 0.035930768 
16867349 SEMA6B -0.98 5.26 0.021140737 
17059119 SEMA3C 1.83 10.20 0.005319332 
16840018 MYBBP1A 0.68 6.57 0.024987511 
16935042 DDX17 -0.53 9.20 0.00061078 
16712373 NEBL 1.44 5.40 0.035280185 
16726925 SSSCA1 0.53 7.21 0.037148447 
16858714 RNASEH2A 0.83 5.85 0.04995222 
16786616 BATF -0.73 4.12 0.007755504 
16913065 PROCR 2.25 9.10 0.002687511 
17048859 ARPC1A 0.72 8.49 0.004445565 
16965606 SLC34A2 2.68 5.36 0.037870862 
16881485 CCT7 0.41 8.03 0.022048344 
16898175 CCT4 0.67 8.28 0.006244544 
16753964 CCT2 0.71 7.87 0.006889201 
16716795 SORBS1 -1.62 4.74 0.001066574 
16720077 IFITM2 0.56 8.62 0.034913704 
16727168 DRAP1 0.50 5.01 0.033141686 
16839473 PRPF8 0.38 9.87 0.043268088 
16786941 AHSA1 0.52 5.54 0.017064738 
16995957 PAIP1 0.77 7.41 0.000460838 
16814872 TBL3 0.53 6.08 0.043292532 
16887993 MTX2 0.52 7.36 0.01223952 
16861630 SPINT2 1.27 7.99 0.046028879 
16855810 CD226 -0.92 5.48 0.03729073 
16847921 GNA13 -0.48 8.70 0.024291321 
17075650 PNMA2 0.83 5.74 0.010488802 
16694094 FAM189B 0.80 5.75 0.000776261 
16728994 POLD3 0.50 6.05 0.021563285 
16661323 NUDC 0.33 6.08 0.044561067 
16766283 PTGES3 0.63 9.10 0.006349684 
16831621 RAI1 0.61 6.58 0.015247659 
16869643 GIPC1 0.98 6.54 0.003283805 
16906184 NCKAP1 0.45 10.06 0.016666479 
17112349 CYSLTR1 -1.12 5.64 0.004102027 
16810686 CLPX 0.50 6.75 0.017337887 
16873296 PPP1R13L 0.95 7.48 0.000431202 
16863946 RUVBL2 0.84 7.75 0.017789967 
17066921 ADAM28 -1.23 6.90 0.014251566 
16882999 ARID5A -0.52 6.15 0.045963111 
16976117 NMU 3.47 6.76 0.001080715 
16845812 C1QL1 0.99 5.30 0.008568736 
16984542 MRPS30 0.69 7.21 0.005368851 
 270 
16669288 WDR3 0.69 6.59 0.030341415 
16877836 RAB10 0.27 9.67 0.039003889 
16913077 MMP24 4.22 7.87 5.68E-05 
16735751 LYVE1 -1.82 8.89 0.019097494 
17000358 BRD8 0.39 5.57 0.02134502 
17032175 EHMT2 0.42 6.85 0.0369283 
17042143 EHMT2 0.57 7.30 0.012566269 
16823097 RNPS1 0.38 8.64 0.018745508 
16853996 AFG3L2 0.79 7.68 0.003980048 
17101465 MSL3 -0.63 5.38 0.006381972 
16924305 BTG3 0.75 5.70 0.028840337 
16846181 CBX1 0.74 6.16 0.008099407 
16919508 TOMM34 0.80 6.35 0.011551228 
17010929 PNRC1 -0.53 9.16 0.044547833 
16726224 STIP1 0.58 6.51 0.041083214 
16686088 EBNA1BP2 0.61 6.78 0.0190991 
16875387 LILRB5 -0.98 3.63 0.017463229 
16865424 LILRB4 -0.79 4.61 0.010665065 
16754373 GLIPR1 -0.95 9.07 0.028949304 
16874740 KLK11 2.55 7.14 0.000218948 
16875432 LILRA3 -0.71 3.65 0.000716615 
16996956 SMA4 -0.82 7.36 0.02212934 
17110670 PIM2 -1.56 6.21 0.012043754 
16740770 B3GNT1 0.66 6.07 0.0217199 
16915656 ADRM1 0.70 6.96 0.010515102 
17070514 WWP1 -0.55 8.30 0.012333777 
17088589 CNTRL -0.82 6.09 0.001958832 
16914315 UBE2C 1.31 4.79 0.028201334 
16713562 C10orf10 -1.32 5.54 0.023369511 
17090827 CACFD1 0.53 4.31 0.049973013 
16719066 ATE1 -0.48 6.69 0.006889201 
16878069 EMILIN1 -1.46 6.99 0.029770839 
16756475 PWP1 0.44 8.45 0.028218895 
16817824 CORO1A -0.80 8.76 0.042473943 
17067902 ERLIN2 0.61 6.52 0.0190991 
16996684 ADAMTS6 -1.77 5.06 0.028963716 
16959187 MRPL3 0.43 8.58 0.026295083 
17098322 RPL35 0.46 5.93 0.024547543 
16886717 GALNT5 -1.94 5.91 0.017710657 
16956749 FILIP1L -0.88 4.30 0.020424774 
16891843 SP140 -1.18 4.70 0.015906168 
16918455 PXMP4 0.61 5.84 0.043561541 
16843795 SYNRG -0.36 8.19 0.028880252 
16779766 KLF12 -1.19 7.65 0.00514969 
17104159 KLF8 -0.89 4.66 0.022688153 
16952349 SCN11A -0.46 2.94 0.029219679 
17003748 MGAT4B 0.70 7.67 0.004620619 
16849355 TMC6 -0.67 5.96 0.021336701 
16760649 PHB2 0.60 8.80 0.003570315 
16807605 OIP5 1.11 4.35 0.010148425 
16981523 SCRG1 -0.68 2.76 0.006394524 
16792954 NID2 -1.12 7.88 0.043846677 
17062049 TFEC -0.71 5.61 0.043148562 
16735994 RRAS2 0.86 6.49 0.044547833 
16844207 IKZF3 -1.60 6.13 0.00565905 
16907912 IKZF2 -0.84 4.58 0.002145853 
16970536 HSPA4L 1.16 6.08 0.019439063 
17082309 PUF60 0.66 4.33 0.012774275 
 271 
16898617 AAK1 -0.50 6.88 0.026758922 
17048706 LMTK2 0.49 7.01 0.043890331 
16813871 CHSY1 -0.77 7.03 0.007562595 
16840321 NLRP1 -1.16 7.14 0.000370855 
16990862 ABLIM3 -0.90 5.56 0.043476839 
16830957 ARHGEF15 -0.86 5.30 0.017595598 
16873880 CARD8 -0.72 5.81 0.000566528 
16967563 RUFY3 -0.87 7.28 0.003485 
16939592 TRAK1 -0.52 6.57 0.010728175 
16940110 SACM1L -0.42 8.32 0.02604879 
16968878 MMRN1 -2.94 4.46 0.000107648 
16917859 CD93 -1.18 7.90 0.002746274 
16983172 CCT5 0.53 7.36 0.035352582 
16912379 TPX2 1.70 7.09 0.012000329 
16877795 EFR3B 0.88 5.66 0.022575571 
16918102 NINL 1.38 6.03 0.00129038 
16746348 IGSF9B 1.08 5.28 0.038093304 
16749398 STK38L -0.76 6.63 0.017801063 
16770828 FBXO21 0.54 7.27 0.011376867 
16900474 SNRNP200 0.33 8.82 0.036136556 
16956285 PDZRN3 -1.12 5.99 0.02298019 
16660624 KDM1A 0.46 7.91 0.040623853 
17010639 DOPEY1 -0.65 6.72 0.03559341 
16784333 SAMD4A -0.75 6.29 0.01541723 
16828046 PHLPP2 1.38 7.18 0.015058806 
17010789 ZNF292 -0.57 6.89 0.034807093 
16983692 PDZD2 2.73 6.63 0.001794995 
16961501 TNIK -1.20 5.64 0.004097602 
16815461 CLUAP1 0.60 6.46 0.024505304 
16825057 GGA2 -0.39 7.61 0.026095642 
17099263 SETX -0.45 9.04 0.027880792 
16682631 EMC1 0.53 7.21 0.032885701 
16721861 SWAP70 -0.63 7.47 0.014549322 
16779855 MYCBP2 -1.07 8.15 9.89E-06 
17083492 KDM4C -0.54 6.47 0.011809069 
16990483 ARHGAP26 -0.97 6.07 0.002903599 
16997068 MRPS27 0.61 6.27 0.020945503 
16829690 RAP1GAP2 1.06 5.44 0.035818627 
16930383 TNRC6B -0.54 7.80 0.005232106 
16952031 CLASP2 -0.61 6.66 0.002113366 
16959007 PLXND1 -0.84 8.23 0.011474569 
16740161 ATG2A 0.56 5.69 0.019713579 
16941184 RAD54L2 -0.41 6.18 0.049710075 
16853631 EPB41L3 -0.91 7.90 0.011819549 
16839913 ZZEF1 -0.29 7.65 0.042473943 
16772704 ANKLE2 0.44 6.58 0.029422391 
16774623 LRCH1 -0.85 7.05 0.0009769 
17082088 ZC3H3 0.57 5.77 0.015333828 
17113606 38961 -0.77 6.83 0.009212268 
16848761 GGA3 0.56 7.48 0.030029639 
16941560 STAB1 -0.87 8.85 0.026095642 
16877225 LPIN1 -0.36 5.83 0.042615055 
16739396 GANAB 0.42 9.46 0.018042933 
16725065 DTX4 1.44 6.87 0.005523101 
17111611 ARHGEF9 -0.47 6.38 0.022811696 
17057813 COBL 2.79 6.20 0.000882223 
16850865 ANKRD12 -0.69 8.74 0.002496637 
16776709 MCF2L -0.46 4.24 0.043890331 
 272 
16675673 CAMSAP2 0.60 8.86 0.012178643 
16839642 CLUH 0.96 6.82 0.002085347 
16991991 WWC1 3.54 7.48 7.26E-06 
17043015 IQCE 0.57 5.57 0.04572034 
16766403 TMEM194A 0.86 7.43 0.004767564 
16926302 ICOSLG 0.68 5.95 0.029462278 
16852573 NEDD4L 1.36 6.62 0.000942253 
17013520 SASH1 -0.90 6.93 0.048219895 
16852497 WDR7 -0.40 8.28 0.034568907 
16850541 SMCHD1 -0.46 8.84 0.034030944 
17084549 KIAA1045 -0.43 3.41 0.005350358 
16861068 HAUS5 0.57 5.09 0.041932468 
16687638 USP24 -0.40 7.71 0.027615981 
16908834 OBSL1 1.17 5.71 0.002826228 
17056680 KIAA0895 1.16 3.94 0.014549322 
16735121 RRP8 0.45 5.55 0.031904308 
16694472 SMG5 0.50 7.10 0.041567289 
17090357 EXOSC2 0.53 6.93 0.008967779 
16796325 DICER1 -0.60 8.47 0.006229481 
17004958 SIRT5 0.61 5.80 0.032819637 
16767170 GRIP1 1.70 5.43 0.001637265 
17098477 ANGPTL2 -1.15 7.60 0.014745112 
17078102 TRAM1 0.60 9.67 0.016714625 
16772486 RIMBP2 -0.99 3.00 0.024534533 
16666965 LRRC8B -0.89 5.24 0.007126085 
16912520 POFUT1 0.63 6.64 0.013631888 
16837699 KCTD2 0.82 7.85 0.035256746 
17082263 SCRIB 0.64 5.70 0.039718909 
16928127 CABIN1 -0.43 6.52 0.011781352 
16856421 HMHA1 -0.68 7.36 0.049487214 
16963055 ACAP2 -0.78 7.04 0.000676748 
16931788 MAPK8IP2 0.95 4.82 0.040942781 
17062230 TSPAN12 -0.48 3.37 0.012588067 
16671178 SNAPIN 0.62 7.52 0.022323152 
16819469 ARL2BP 0.64 9.64 0.029382558 
16848489 CDC42EP4 0.86 6.85 0.0492371 
16765491 SMUG1 0.46 5.05 0.012200196 
16823750 CARHSP1 1.32 8.51 0.000661477 
16818600 ORC6 0.94 4.72 0.009926585 
16875710 HSPBP1 0.70 5.68 0.019725297 
16745414 TRIM29 1.30 3.79 0.036347499 
17056461 LSM5 0.52 5.26 0.037077613 
17048967 ZKSCAN5 0.45 4.93 0.0263308 
16661459 STX12 -0.42 8.07 0.027615981 
16891603 KCNE4 -1.27 5.21 0.011031043 
16986552 BHMT2 -0.76 3.26 0.024360334 
16933445 PITPNB -0.48 6.62 0.025386404 
16917373 FLRT3 4.55 6.52 0.000103096 
16936230 BRD1 -0.40 5.77 0.042524459 
16738119 MTCH2 0.54 8.70 0.037428899 
17060894 CLDN15 2.26 8.07 0.004187214 
17019365 ZNF318 -0.40 7.21 0.041564991 
16878994 RASGRP3 -1.18 5.61 0.000429178 
16879174 QPCT -0.73 4.78 0.004432742 
16697971 LMOD1 -2.00 4.24 0.000882223 
16870387 LSM4 0.69 8.73 0.009833083 
16703563 BAMBI 1.41 6.71 0.019856998 
16726439 PRDX5 1.32 8.68 5.60E-05 
 273 
16737260 ABTB2 1.57 5.59 0.004759764 
16967875 PARM1 -1.73 7.11 0.001944711 
16857353 RPL36 0.62 9.52 0.000869046 
16823746 TMEM186 0.62 4.61 0.023880365 
16956792 ABI3BP -1.87 8.25 0.005048834 
16708489 DPCD 0.54 5.57 0.023959933 
16693762 C1orf43 0.49 10.29 0.035297293 
16937181 THUMPD3 0.59 6.50 0.007519822 
16724901 ZDHHC5 0.35 8.27 0.038009976 
16939439 MYRIP -0.78 4.28 0.01965373 
16854360 ZNF521 -1.11 6.27 0.01864703 
16837205 NOL11 0.54 8.67 0.035073833 
16898533 CNRIP1 -0.92 5.25 0.028346472 
17002078 GEMIN5 0.65 7.27 0.005048834 
16919022 SAMHD1 -0.67 9.27 0.008516971 
16916712 C20orf194 -0.57 7.36 0.029435864 
16890794 PNKD 0.40 6.10 0.04997158 
17021922 PNISR -0.57 8.39 0.018559034 
16687598 PARS2 0.84 5.27 0.01256299 
16664091 MMACHC 0.72 5.35 0.00931027 
16947287 TIPARP -0.82 7.16 0.032307131 
16913305 AAR2 0.44 6.77 0.013650974 
16941405 DNAH1 -0.80 6.44 0.006549575 
16893349 SNED1 -1.07 6.29 0.038156908 
16829972 RNF167 0.55 7.29 0.0232947 
16725556 DAK 0.64 5.69 0.017033223 
16859294 FAM32A 0.50 9.11 0.043034204 
16833171 TMEM98 1.48 8.64 0.003800106 
16785410 PLEKHG3 1.09 6.18 0.012947456 
16852132 SETBP1 -1.22 6.45 0.010414232 
16913666 PPP1R16B -1.50 5.68 0.00086785 
16842587 POLDIP2 0.72 9.65 0.001485978 
17001846 CCDC69 -1.35 5.74 5.29E-06 
16823991 RSL1D1 0.88 8.78 0.002932971 
16915609 MTG2 0.65 5.79 0.012428724 
16691090 PTPN22 -1.19 6.43 0.00329089 
16669389 PHGDH 1.90 6.05 0.001587867 
16967286 STAP1 -1.90 5.07 0.043148562 
16681735 FBXO2 1.46 6.10 0.030199753 
16679777 OR2L2 -0.64 2.90 0.023391738 
16679769 OR2L1P -0.65 6.07 0.020016721 
17000256 KLHL3 -1.51 5.20 0.000440433 
17094009 FBXO10 -0.45 5.76 0.043369986 
16682785 PLA2G2D -2.49 4.75 0.002261678 
16832610 ERAL1 0.63 6.44 0.012379122 
16935703 ARFGAP3 -0.79 7.47 0.001636024 
17098079 LHX6 -0.86 4.45 0.00173818 
16793999 PLEK2 1.24 6.40 0.018745508 
16708122 CNNM1 1.13 3.66 0.041840468 
16738536 TIMM10 0.52 6.12 0.042079131 
16793460 TIMM9 0.64 6.29 0.01631073 
16744408 TIMM8B 0.83 6.90 0.000997071 
17085975 OSTF1 -0.90 7.70 0.000838223 
17058499 TBL2 0.58 6.23 0.026107361 
16823046 SNORD60 1.39 6.93 0.044452617 
16869291 SNORD41 0.69 11.28 0.010677187 
17064054 TPK1 -0.65 4.72 0.005871795 
17105712 NGFRAP1 0.77 3.80 0.00150143 
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16969229 DAPP1 -1.26 5.37 0.001016216 
16842242 B9D1 0.73 4.75 0.002714294 
16837172 CACNG4 4.34 7.09 0.000310311 
16674089 CACYBP 0.43 5.60 0.045169965 
16822014 CPNE7 1.08 4.68 0.037223575 
17020942 FILIP1 -1.56 5.83 0.00077321 
16890998 STK36 0.65 6.44 0.011796115 
16976994 NAAA -0.74 7.58 0.035900295 
16993027 PRELID1 0.52 5.27 0.017591588 
16693626 SLC39A1 0.52 5.23 0.01432291 
17102801 GPR82 1.22 4.10 0.028625366 
16863593 C5AR2 -1.30 4.65 0.001525473 
16884050 SULT1C4 -1.08 4.33 0.011072258 
17093713 SIT1 -1.08 4.56 0.015439351 
16876182 CHMP2A 0.57 9.64 0.006957854 
16903461 MMADHC 0.57 7.57 0.003460416 
16775136 PCDH17 -1.23 6.40 0.031977413 
16937930 LSM3 0.75 6.84 0.012428734 
16661508 SMPDL3B 1.22 5.29 0.030880448 
16982161 PDLIM3 -1.88 6.97 0.008839991 
17066961 ADAMDEC1 -2.33 5.35 0.004022384 
16914888 MOCS3 0.95 5.08 0.014510297 
16742814 RAB30 -0.67 5.05 0.001398413 
16721055 PGAP2 0.59 5.34 0.029821026 
17105076 P2RY10 -1.70 5.71 0.001831526 
17107293 HTATSF1 0.44 6.41 0.033613941 
16875763 UBE2S 0.89 5.16 0.047497843 
16738869 PRPF19 0.67 8.15 0.012588067 
17090109 TOR1B 0.47 6.92 0.037129821 
16935767 MCAT 0.60 4.74 0.027628988 
16930446 SGSM3 -0.48 5.24 0.02490063 
16881786 HTRA2 0.47 6.81 0.048976319 
17059249 PCLO 1.48 4.08 0.02389242 
16782026 TRAV20 -1.62 5.23 0.005554394 
16782090 TRAJ17 -2.28 3.66 0.000318238 
16782116 TRAC -1.06 2.84 0.013925031 
16912309 REM1 -1.18 3.96 0.000519244 
16671889 LAMTOR2 0.63 5.11 0.016643305 
16845259 COA3 0.80 6.96 0.001080715 
16842999 GIT1 0.74 7.65 0.029648298 
16988539 SNX24 0.53 6.03 0.019555184 
16729444 AAMDC 0.92 5.19 0.025040481 
17006324 MRPS18B 0.75 7.03 0.006495873 
17027506 MRPS18B 0.75 7.03 0.006495873 
17030351 MRPS18B 0.75 7.03 0.006495873 
17033056 MRPS18B 0.75 7.03 0.006495873 
17035176 MRPS18B 0.75 7.03 0.006495873 
17037835 MRPS18B 0.75 7.03 0.006495873 
17040549 MRPS18B 0.75 7.03 0.006495873 
16827687 NOB1 0.61 8.77 0.033319597 
17080614 MRPL13 0.65 5.54 0.013658915 
17080749 ATAD2 0.93 7.33 0.00821564 
16904956 METTL5 0.45 6.04 0.024505304 
17068956 MRPL15 0.97 8.05 0.002108584 
16698023 UBE2T 1.27 6.29 0.003879445 
16853042 TIMM21 0.67 6.93 0.011353392 
16991447 MRPL22 0.52 4.33 0.047497843 
16752223 ORMDL2 0.53 7.99 0.032946177 
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16677933 CNIH4 0.89 6.87 0.000739652 
16826871 C16orf80 0.52 7.70 0.043289987 
16748205 CLEC2D -1.15 6.97 0.035404894 
16716918 BLNK -0.77 6.08 0.03949699 
16801122 TMOD2 -0.72 6.86 0.038484879 
16905175 OLA1 0.51 8.10 0.033104806 
16933049 VPREB3 -0.70 2.86 0.004830661 
16889829 ICOS -1.19 4.26 0.033839976 
17054540 SNX8 0.48 6.07 0.034147773 
16865730 CCDC106 0.57 5.25 0.007315962 
16960554 GPR171 -0.97 4.26 0.04496503 
16829508 TIMM22 0.56 7.27 0.04926514 
16937152 LINC00312 -2.18 4.50 0.001977587 
16797224 GPR132 -0.83 4.86 0.00982264 
17105315 RPA4 -0.65 3.48 0.002942907 
16692892 CERS2 0.63 6.47 0.02028869 
17054532 FTSJ2 0.53 5.48 0.030777154 
16727650 RHOD 1.18 8.06 0.018177667 
16937137 LMCD1 -1.32 7.57 0.024427075 
17098642 ST6GALNAC6 -0.70 8.07 0.001501303 
16993335 ZNF354C 0.58 5.54 0.04212478 
16848731 NT5C 0.80 6.87 0.007767765 
16868000 CD209 -1.89 4.98 0.000244467 
16833616 SOCS7 0.61 5.92 0.007097819 
16807763 EHD4 -0.82 7.22 0.023557189 
16878731 EHD3 -1.31 6.01 0.01993518 
16756212 CHST11 -0.62 6.45 0.036136556 
16772588 GALNT9 2.24 6.08 0.001847311 
16817271 IL21R -1.05 5.37 0.009363653 
16895208 ITSN2 -0.39 7.76 0.043645591 
17007795 DEF6 -0.92 5.72 0.010039892 
16839254 GEMIN4 0.80 6.28 0.011691773 
16885638 ARHGEF4 0.94 4.54 0.022966771 
17107907 NSDHL 0.85 7.15 0.00287891 
16761502 TAS2R14 -0.94 6.15 0.007580112 
16695490 F11R 1.15 8.52 0.001518036 
16943719 TRAT1 -1.96 5.45 0.002963593 
16820249 PARD6A 0.68 5.30 0.007464485 
16921331 STMN3 0.79 7.30 0.012502456 
16745870 CDON 1.57 8.24 0.009837228 
16899050 TPRKB 0.50 5.26 0.03697616 
16791044 EMC9 0.60 5.04 0.018309158 
17023308 HDDC2 0.67 8.83 0.003033218 
16715426 MRPS16 0.52 7.76 0.02649727 
17060909 FIS1 0.64 5.86 0.042007207 
16670391 BOLA1 0.63 5.41 0.015247659 
16779444 VPS36 -0.46 7.43 0.048968767 
16661063 ZNF593 0.65 5.90 0.020059911 
17005396 GMNN 1.23 5.72 0.002454214 
16718047 CALHM2 -0.53 6.53 0.036944981 
17019319 MRPL2 0.51 7.16 0.02743648 
16858122 MRPL4 0.83 7.24 0.003888986 
16786475 FCF1 0.43 7.55 0.047708696 
16910485 THAP4 0.62 6.64 0.005086295 
16837754 MRPS7 0.72 9.09 0.006214756 
16826760 PLLP 5.13 8.88 2.45E-05 
16731605 SIDT2 -0.59 6.34 0.016574588 
16679650 SCCPDH 1.25 8.56 0.000440433 
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16913936 IFT52 0.61 6.10 0.01270852 
16684241 MECR 0.49 5.13 0.032399453 
16692741 APH1A 0.61 6.87 0.001070637 
17078121 LACTB2 1.44 7.14 0.006465241 
17091097 MRPS2 0.44 4.38 0.042011774 
16992446 RPL26L1 0.67 4.62 0.000995688 
16774808 PHF11 -0.77 5.91 0.003485 
16750277 IRAK4 -0.58 6.59 0.001978684 
17057983 CHCHD2 0.88 6.56 0.000496545 
16760546 ING4 0.41 6.57 0.0303931 
16660199 MRTO4 0.78 6.36 0.008922121 
16848739 HN1 0.85 6.01 0.042914577 
17091281 EGFL7 -1.21 5.47 0.001263485 
16978834 LEF1 -0.99 5.56 0.040845786 
16834015 RAPGEFL1 0.64 4.42 0.019555184 
16792810 NIN -0.68 7.82 0.008112069 
17051553 CPA4 3.80 7.50 0.000182085 
17066018 ZDHHC2 1.00 7.52 0.020424774 
16799793 NUSAP1 1.62 7.64 0.002287834 
16836977 TACO1 0.68 6.26 0.024631948 
16787951 GLRX5 0.64 3.94 0.012193296 
16790202 ZNF219 0.84 4.85 0.006678351 
16846163 COPZ2 -1.06 7.34 0.040783602 
16925495 PIGP 0.63 5.53 0.004872828 
16874467 VRK3 0.62 6.31 0.005187186 
16879067 CRIM1 1.31 10.29 0.000799328 
16989867 PAIP2 0.30 7.14 0.034568907 
17111808 PDZD11 0.83 7.34 0.002226908 
16664150 TMEM69 0.65 7.25 0.022323152 
17056515 NT5C3A 0.79 5.55 0.030622512 
16664947 MRPL37 0.61 8.57 0.019439063 
16760406 MRPL51 0.51 5.33 0.011383858 
16725608 TMEM216 0.43 4.71 0.047447463 
16761259 CLEC1A -1.00 4.85 0.010414507 
16868130 CD320 0.92 6.90 0.010228669 
17001024 PCDH12 -0.92 3.60 0.01303921 
17015324 NRN1 -1.68 6.02 0.009527594 
17101537 TLR8 -1.03 5.93 0.002849275 
16980974 FAM198B -1.33 5.24 0.000588116 
16882416 MRPL35 0.70 7.96 0.003521128 
16837298 AMZ2 0.56 9.03 0.018889578 
16804778 NGRN 0.70 7.11 0.022031904 
16725184 MS4A4A -0.95 6.25 0.033731714 
16784760 DACT1 -1.52 5.29 0.015132334 
16770961 TAOK3 -0.49 6.96 0.035352582 
16723283 WT1-AS 0.97 5.29 0.019614135 
17102017 MBTPS2 0.55 7.96 0.003883275 
16665302 HOOK1 1.39 5.27 0.048263673 
17046249 MRPS17 0.59 6.17 0.032925202 
16820584 NIP7 0.50 8.09 0.030242791 
16831442 TRPV2 -0.82 5.53 0.022026034 
16869221 WDR83OS 0.45 7.05 0.04750453 
16728949 PPME1 0.52 7.53 0.020617927 
16764732 BIN2 -0.79 6.60 0.023247247 
16959441 AMOTL2 0.85 6.79 0.004969977 
17014091 SNX9 -0.58 9.20 0.039065942 
17067314 SCARA3 1.69 8.64 0.021334442 
16661663 YTHDF2 0.37 6.42 0.046598957 
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16788339 EVL -0.83 6.11 0.005286964 
16870401 ISYNA1 2.06 8.37 0.000416005 
16739887 TRMT112 0.39 5.65 0.015003145 
16677201 DTL 1.06 6.45 0.038949092 
16953679 NCKIPSD 0.50 5.57 0.042473943 
17004760 TMEM14C 0.57 9.00 0.002202594 
16919408 OSER1 0.56 6.76 0.012502456 
16865726 ZNF581 0.90 6.27 0.008922121 
17018256 CUTA 0.54 5.69 0.009991301 
17042650 CUTA 0.55 5.80 0.007983133 
16860946 LSR 1.92 6.77 0.000239688 
16673822 METTL13 0.44 6.99 0.04882767 
16895172 SF3B14 0.43 8.35 0.010414232 
17018685 PPIL1 0.77 7.42 0.007759919 
16878662 YPEL5 -0.62 5.65 0.016561255 
16827234 FAM96B 0.43 7.68 0.049276937 
16846954 MRPS23 1.21 6.65 0.000300887 
17063656 MRPS33 0.72 4.96 0.028551639 
16847260 PTRH2 0.69 5.67 0.00995933 
17058891 STYXL1 0.85 6.66 0.00608227 
16828886 GINS2 1.53 4.95 0.005871795 
16876881 CPSF3 0.36 7.75 0.040273669 
16821882 TRAPPC2L 0.87 7.76 0.013750102 
17013072 HECA -0.65 6.73 0.013011825 
16978354 EMCN -1.43 6.01 0.006296201 
16816424 SYT17 2.32 6.90 0.000279195 
16762597 TM7SF3 0.80 9.14 0.029999113 
17021911 COQ3 0.56 3.92 0.048490926 
16897946 BCL11A -1.76 4.26 0.001512304 
16923179 UBASH3A -0.90 4.92 0.045521155 
16703340 MYO3A 1.55 4.00 0.020126598 
16749010 SLCO1C1 -1.03 3.12 3.06E-05 
16924966 MIS18A 0.68 5.65 0.011455321 
17117918 LRRC3DN 0.59 3.50 0.037187959 
16925911 RIPK4 2.49 5.55 0.00457055 
17019029 TREM2 1.32 7.14 0.006826972 
16784157 GNG2 -1.36 5.11 1.58E-05 
17070082 GDAP1 0.75 5.07 0.032508512 
16921428 SOX18 -1.06 5.27 0.006473873 
16973934 CYTL1 -1.06 6.66 0.024291321 
16683221 WNT4 1.65 4.74 0.047708696 
17106877 SASH3 -0.85 6.41 0.021751719 
17045198 ANLN 1.66 7.26 0.024133658 
16895118 ATAD2B -0.51 6.66 0.010665065 
16706779 CCSER2 -0.59 7.79 0.012656127 
16820414 PRMT7 0.59 6.27 0.032878371 
16695907 TMCO1 0.50 9.33 0.017455477 
16979875 PCDH18 -1.35 7.32 0.005406762 
17073527 EXOSC4 0.64 6.09 0.032843247 
16888708 ASNSD1 0.46 7.04 0.03626571 
16707503 EXOC6 -0.71 6.65 0.006109041 
16994969 MTMR12 0.44 7.80 0.04146164 
16958096 WDR5B 0.84 5.61 0.013786789 
16996771 SGTB -0.73 7.23 0.033386639 
16680258 MXRA8 -0.96 8.15 0.032622497 
16775643 NDFIP2 1.21 8.51 0.007435833 
17057329 DDX56 0.52 7.53 0.012367099 
16996119 ARL15 -0.72 6.10 0.008103354 
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16872203 PAF1 0.46 6.96 0.031799831 
16691078 RSBN1 -0.51 7.01 0.002026515 
16911238 CRLS1 0.63 8.02 0.01444663 
16940593 P4HTM 0.59 6.14 0.03500606 
16683875 GPN2 0.51 6.61 0.011077896 
16815670 RBFOX1 1.48 4.45 0.007077087 
16866667 PCSK4 0.52 4.63 0.037230334 
16827874 HYDIN 0.79 4.17 0.02083209 
16969414 TET2 -0.61 7.06 0.004464778 
16666448 GIPC2 -1.37 4.27 0.017996341 
16810177 VPS13C -0.43 8.72 0.041992918 
16742963 SYTL2 -1.51 5.43 0.002498679 
16944055 SIDT1 -1.25 4.53 0.005028618 
16669278 FAM46C -1.52 7.27 0.003955122 
16939796 SNRK -0.75 6.71 0.000996424 
16865590 EPS8L1 1.55 4.74 0.02957219 
16667530 PALMD -1.47 6.89 0.033848844 
17007673 UHRF1BP1 0.88 7.11 0.010853229 
16907526 INO80D -0.41 7.85 0.030199753 
16806564 MTMR10 -0.40 8.14 0.036621116 
16660212 PQLC2 0.73 5.68 0.009786926 
16676217 LAX1 -1.42 5.36 0.013094763 
16847007 MKS1 0.45 5.74 0.046389438 
17042735 HEATR2 0.87 6.65 0.002185771 
16874047 RASIP1 -1.44 4.98 0.009309447 
16870543 TMEM161A 0.85 6.83 0.036337183 
16943404 TRMT10C 0.52 6.55 0.048683111 
16662525 ADPRHL2 0.94 6.41 0.001238619 
16685427 C1orf109 0.54 4.47 0.014304573 
16810725 PARP16 0.49 7.18 0.04025301 
16873654 TMEM160 0.86 8.22 0.028755503 
16727770 SSH3 1.27 6.08 0.000821889 
16725405 TMEM132A 1.15 5.90 0.011735645 
16991604 THG1L 0.67 6.35 0.010563409 
16823255 HCFC1R1 0.64 6.30 0.023703726 
16915804 GID8 0.44 7.70 0.034720834 
16938429 OXSM 0.73 5.41 0.003040233 
16680274 AURKAIP1 0.57 6.10 0.044926034 
16929056 TUG1 -0.51 9.55 0.00760586 
16741643 LAMTOR1 0.38 6.46 0.028880252 
16931197 FAM118A -1.12 4.79 0.007595006 
16874313 PIH1D1 0.54 6.13 0.013925031 
16909303 PID1 -0.87 3.96 0.021086941 
16969267 BANK1 -2.06 4.25 0.001263485 
17113710 TMEM255A 2.15 6.63 0.015592393 
16852008 MOCOS 0.81 5.86 0.041059079 
16848079 WIPI1 -0.91 8.56 0.040273669 
16820676 PDPR 0.70 7.35 0.040039322 
17011378 SOBP -1.06 5.11 0.014335286 
17105914 CXorf57 -0.63 3.09 0.019306979 
16861969 SAMD4B 0.49 7.85 0.04545095 
16872594 ATP5SL -1.60 4.80 0.000661483 
16674292 RALGPS2 -1.24 7.10 0.018180207 
16986450 AGGF1 0.39 8.19 0.046240214 
16866912 PLEKHJ1 0.80 7.49 0.021222619 
16734779 TRIM68 0.71 6.13 0.001833969 
16662648 CDCA8 1.45 5.27 0.017160609 
17076821 THAP1 0.41 6.57 0.020357132 
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17043418 ZDHHC4 0.65 5.88 0.003082046 
17077760 ARMC1 0.55 7.15 0.042182779 
16673983 DARS2 0.53 6.55 0.026999666 
16835346 PNPO 0.86 7.56 0.007813504 
17009482 CENPQ 0.94 5.43 0.012156683 
17019208 MRPS10 0.44 7.47 0.02650514 
16836504 SMG8 0.57 5.22 0.01647169 
16749747 KIAA1551 -0.61 7.26 0.00671532 
16769514 APPL2 -0.42 6.95 0.029435864 
16974925 LGI2 -1.12 6.28 0.044058872 
16692805 GOLPH3L 0.72 7.88 0.036610869 
16804559 FANCI 1.37 6.90 0.000644597 
16715155 LRRC20 1.00 4.89 0.001374972 
17009676 LRRC1 2.70 8.34 0.001049806 
16873541 PNMAL1 1.53 4.97 0.004588824 
16884956 STEAP3 1.37 7.29 0.030609357 
16972616 NEIL3 1.36 4.56 0.01976673 
16774669 NUDT15 0.53 5.03 0.044982261 
16717498 CWF19L1 0.69 6.69 0.04028811 
17051943 TMEM140 -0.69 6.28 0.014395131 
16689020 MCOLN3 1.37 4.53 0.011077896 
16980693 FBXW7 -0.75 6.28 0.001978684 
16749537 CCDC91 -0.51 5.44 0.018661333 
16983907 BRIX1 0.67 6.38 0.006254419 
17053384 GIMAP4 -0.66 7.34 0.044173415 
16820737 DDX19A 0.54 7.04 0.00982264 
17095043 RFK 0.76 5.07 0.04997158 
16911070 AP5S1 0.52 5.35 0.034540826 
16916396 TMEM74B -0.54 3.62 0.013096869 
16843179 COPRS 0.55 5.96 0.014173779 
17071208 LAPTM4B 0.90 9.58 0.043723507 
17009132 TMEM63B 0.64 6.66 0.010973189 
16920699 PPP4R1L -0.84 3.88 0.048943191 
16889503 STRADB 0.87 5.46 0.006294787 
16704182 CSGALNACT2 -0.69 7.87 0.009910072 
16827606 SMPD3 2.50 6.60 0.008999768 
17079005 TMEM55A -0.60 6.38 0.038633276 
16736120 SOX6 2.52 5.32 0.014818595 
16883552 CNOT11 0.32 7.13 0.029999113 
16755988 STAB2 -2.03 3.97 0.004041282 
16693789 UBE2Q1 0.60 7.13 0.007777057 
16861987 MED29 0.72 8.08 0.004621635 
16695463 ITLN1 6.45 8.13 0.000466702 
17048576 PPP1R9A 1.55 4.96 0.006504942 
16917061 FERMT1 1.01 5.66 0.041564991 
16917400 KIF16B -0.79 6.24 0.014395164 
16909081 DOCK10 -1.02 8.34 0.002003568 
16867278 STAP2 1.63 4.90 0.001363353 
16688386 DEPDC1 1.37 4.39 0.01805536 
17069272 CHD7 -0.61 6.11 0.012310204 
17003479 NHP2 0.82 7.08 0.006826972 
16875979 ZNF416 0.88 5.18 0.01631073 
16786780 GPATCH2L -0.55 6.32 0.019655181 
16730296 KDM4D 0.61 4.63 0.019555184 
16677616 IARS2 0.54 7.79 0.033810453 
16897719 CCDC88A -0.64 7.56 0.035825301 
16687418 NDC1 1.09 7.50 0.000466755 
16919864 ZNF334 1.29 5.57 0.001212101 
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16826779 DOK4 0.69 7.44 0.024493485 
16839582 TSR1 0.75 6.96 0.008799118 
16662009 IQCC 0.85 4.53 0.006109041 
16869588 ASF1B 0.95 6.03 0.02412805 
16762573 ASUN 0.73 7.77 0.004960091 
16918633 EDEM2 0.53 6.61 0.028094589 
16968051 40787 -1.03 7.47 0.046212555 
16907458 WDR12 0.43 5.57 0.029382558 
16768675 FGD6 1.47 8.66 0.000587344 
17075168 CSGALNACT1 -0.71 3.98 0.045963111 
16827566 DDX28 0.56 5.08 0.026981053 
16941885 CACNA2D3 1.40 4.92 0.04962496 
17078558 PAG1 -0.87 6.89 0.03559341 
16798652 DCAF6 1.07 5.12 0.006244544 
16950632 EMC3 0.59 8.07 0.009225792 
16944574 EAF2 -1.23 7.47 0.001175595 
16886200 ARHGAP15 -1.51 5.24 0.000141059 
16886232 ARHGAP15 -1.76 4.37 6.22E-06 
17075776 PBK 1.77 5.64 0.002567779 
16947796 MYNN 0.49 6.62 0.00760586 
16749162 CMAS 0.52 7.60 0.023657938 
17046181 LANCL2 0.87 5.87 0.000858371 
16930811 37865 0.97 5.44 0.04086658 
16768628 NDUFA12 0.27 3.92 0.047315765 
17060143 BAIAP2L1 1.30 6.93 0.006294787 
16671653 SLC50A1 0.88 8.11 0.002316293 
16816996 UBFD1 0.50 8.49 0.024950681 
16990312 PCDHB13 1.22 6.85 0.015965317 
16990304 PCDHB12 1.55 7.01 0.020046072 
16990292 PCDHB9 1.37 5.04 0.041965303 
17081106 GSDMC -1.14 2.91 0.000149647 
16660992 MTFR1L 0.46 5.74 0.04249774 
16917004 GPCPD1 -0.85 8.21 0.004665936 
16903863 RPRM 1.43 5.07 0.010665065 
16771632 DIABLO 0.42 6.12 0.014793498 
16708370 C10orf2 0.66 5.18 0.047832543 
16721746 AKIP1 0.55 6.81 0.038485765 
17078355 JPH1 1.97 5.43 0.002177593 
16916104 SLC2A4RG 0.59 6.62 0.042217762 
16726372 GPR137 0.52 5.28 0.006272434 
16880924 PNO1 0.61 6.24 0.037830553 
16811299 THAP10 0.88 4.97 0.024678151 
16854016 SPIRE1 0.57 7.67 0.040039322 
16872567 EXOSC5 1.02 6.67 0.041591961 
16867541 DUS3L 0.68 6.45 0.019678128 
16743285 SMCO4 -0.61 4.99 0.024277737 
16945357 C3orf37 1.02 8.62 0.007017806 
16946228 MRPS22 0.43 6.14 0.029648298 
16999974 C5orf15 0.48 9.36 0.017345479 
16831598 NT5M 0.66 3.65 0.03424377 
16943313 NIT2 0.98 7.70 0.000696933 
16988931 CDC42SE2 -0.66 5.39 0.005934022 
16955822 ADAMTS9 -1.78 7.33 0.000639199 
17045354 YAE1D1 0.77 8.45 0.004294068 
16847605 CCDC47 0.43 9.25 0.027945513 
16727891 CABP4 -0.46 4.63 0.039731905 
16819497 COQ9 1.13 7.98 0.001049806 
16826767 CIAPIN1 0.90 7.87 0.003264143 
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17024414 HYMAI -0.99 4.47 0.002975858 
16659054 AGTRAP 0.57 5.91 0.035847469 
16760116 PARP11 -0.58 5.34 0.011913718 
16760216 ANO2 -0.87 4.76 0.000808862 
16865693 NAT14 0.53 4.78 0.017757647 
16753800 NUP107 0.59 6.87 0.035847469 
16740725 CD248 -1.25 6.77 0.045815477 
16898326 PELI1 -0.94 7.08 0.011910205 
16920370 SALL4 1.08 4.39 0.023388426 
16928533 ASPHD2 -0.68 4.53 0.026524724 
17003034 KIAA1191 0.64 7.61 0.001591953 
16875952 VN1R1 0.91 3.48 0.002957169 
17081829 SLC45A4 1.17 6.63 0.013350291 
17013126 GPR126 2.83 8.61 0.000127126 
16672635 VANGL2 1.09 5.97 0.04926514 
17012963 KIAA1244 2.28 5.94 0.010320732 
17024198 NHSL1 0.67 5.75 0.046224516 
16831338 ZNF286A 0.72 6.55 0.049767345 
16956897 SENP7 -0.63 6.77 0.009447187 
17005348 MRS2 0.73 7.35 0.009830557 
16785127 RHOJ -2.03 5.85 0.000514187 
16823561 NMRAL1 0.60 6.96 0.011734289 
16848784 MIF4GD 0.83 6.28 0.007211899 
16878800 BIRC6 -0.40 8.80 0.014432391 
16681159 PLEKHG5 -0.48 4.77 0.047359928 
16766923 PPM1H 1.23 5.07 0.018617743 
16903919 ERMN -0.90 3.30 0.023829296 
16921402 ZNF512B 0.59 7.00 0.037218869 
17110977 SHROOM4 -1.29 5.08 0.0009769 
17013694 PLEKHG1 -1.09 6.36 0.010005726 
16815985 MKL2 -0.95 8.64 0.000912967 
16879441 MTA3 0.58 5.22 0.01629462 
16911077 MAVS 0.59 6.64 0.009758006 
16999321 ZNF608 -0.94 5.43 0.019678128 
16774188 COG6 -0.69 7.02 0.027431694 
16944344 ARHGAP31 -1.02 6.79 0.002383003 
16800117 STARD9 -1.33 6.33 0.000134884 
16906749 HECW2 -1.38 5.11 0.007595006 
16782862 NYNRIN -0.99 6.32 0.017880257 
16670866 CGN 2.35 6.14 0.00376529 
16964764 TBC1D14 -0.47 7.49 0.006275479 
16965190 CC2D2A -0.69 5.40 0.016061466 
16695216 IGSF9 2.15 6.02 0.001196221 
16730471 KIAA1377 -0.90 5.50 0.012778755 
16854602 KLHL14 -1.11 3.40 0.000127126 
16793632 TRMT5 0.43 6.56 0.042050127 
16727843 CARNS1 2.33 6.77 0.002105113 
16920047 PREX1 -0.75 7.47 0.015698334 
16712944 KIAA1462 -1.71 6.45 0.007110118 
16860266 ZNF492 1.12 3.42 0.033528421 
16884827 DPP10 1.88 5.10 0.019721473 
16833629 ARHGAP23 0.81 7.40 0.005966995 
16772197 DHX37 0.59 5.65 0.016484012 
16662159 KIAA1522 1.80 6.18 3.57E-05 
16671723 HCN3 1.04 3.97 0.001844689 
16857676 CAMSAP3 1.22 4.71 0.006570848 
16885080 EPB41L5 1.10 6.87 0.003837347 
17063394 KIAA1549 0.91 5.62 0.024368191 
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17018654 CPNE5 -0.67 4.98 0.046240214 
16704690 WDFY4 -1.14 5.96 0.002351716 
16711562 SFMBT2 -0.67 8.26 0.048517249 
16708340 SEMA4G 0.73 4.75 0.041013206 
16990288 PCDHB16 1.66 5.81 0.020483503 
16870174 ANO8 0.68 6.51 0.049710075 
16919769 NCOA5 0.42 7.36 0.030339395 
16973753 ZFYVE28 -0.49 3.70 0.049824339 
16667456 PTBP2 -0.64 7.32 0.011913718 
16821467 WFDC1 -1.95 5.06 0.017942017 
16921832 JAM2 -1.21 5.59 0.014326211 
17082935 ZNF250 -0.70 6.33 0.012401471 
16864220 SCAF1 0.58 6.62 0.035352582 
16683541 IL22RA1 0.73 3.79 0.031230388 
16961806 GNB4 -0.56 7.24 0.041965303 
16751769 C12orf10 0.66 6.51 0.006229481 
17115617 FAM3A 0.47 5.43 0.018617743 
16848793 SLC25A19 0.89 6.14 0.029372633 
16749511 MRPS35 0.67 7.29 0.016367995 
16889375 NIF3L1 0.68 7.52 0.005937876 
16730742 AASDHPPT 0.74 6.71 0.004796972 
16878036 AGBL5 0.59 4.59 0.022937911 
16696504 GAS5 0.58 7.45 0.04025301 
16972773 TRAPPC11 -0.34 7.65 0.036619298 
16735205 MRPL17 0.44 6.44 0.040366916 
16847321 HEATR6 0.47 8.18 0.046598957 
17066224 SH2D4A 1.22 6.33 0.001992479 
16913403 MANBAL 0.82 7.29 0.006011845 
17002396 C5orf54 1.02 5.10 0.033848844 
16911394 ANKEF1 0.83 5.16 0.031386654 
16915448 FAM217B 0.62 6.72 0.009296335 
17017805 GPSM3 -0.70 5.14 0.015377204 
17057381 MYO1G -1.12 6.73 0.025298818 
16861641 C19orf33 4.09 8.79 1.41E-05 
17095345 SLC28A3 2.69 6.55 0.039993467 
16985911 MCCC2 0.83 6.39 0.006570848 
16893634 GAL3ST2 3.24 7.14 0.000393759 
16931068 PARVG -0.56 5.73 0.049710075 
17108694 CRLF2 -0.53 2.63 0.01133074 
16839116 FN3K 0.92 5.00 0.00078335 
16688799 ELTD1 -1.79 8.72 0.002958086 
16843221 C17orf75 0.65 5.95 0.036591224 
16965346 NCAPG 1.38 6.19 0.0274033 
16906440 OSGEPL1 0.58 4.51 0.028581919 
16701407 TFB2M 0.70 8.57 0.038712086 
16815023 MLST8 0.52 7.37 0.030724616 
16909891 RAB17 0.95 4.39 0.032354151 
16822296 RHBDF1 0.80 5.76 0.002974203 
16908433 RNF25 0.46 7.15 0.038494747 
17068972 SOX17 -0.98 4.85 0.006181299 
16766539 ARHGAP9 -0.81 4.90 0.013923264 
16785606 MPP5 0.87 7.40 0.00597007 
17000928 ARAP3 -0.82 4.77 0.019555184 
17084990 POLR1E 0.58 6.93 0.049710075 
16822548 NARFL 0.51 5.53 0.008464073 
17049426 MOSPD3 0.58 6.07 0.014155577 
17075628 EBF2 -2.28 5.40 0.000255998 
16882544 ANAPC1 0.65 6.56 0.024961361 
 283 
16925508 TMPRSS3 3.10 5.64 0.000456269 
16663033 SMAP2 -1.14 7.83 0.003033218 
16862646 ZNF574 0.53 5.80 0.01758657 
16731105 C11orf1 0.76 5.26 0.031989369 
16819678 GINS3 0.65 5.24 0.021641874 
16720268 EPS8L2 1.01 5.79 0.001637265 
17060923 RABL5 0.93 5.72 0.000873526 
17099309 DDX31 0.49 5.56 0.039993467 
16895941 FNDC4 -1.26 5.02 0.015377204 
16771397 C12orf43 0.35 5.79 0.042642625 
16913811 LPIN3 0.95 6.33 0.000941995 
16796590 BCL11B -1.00 5.23 0.046767865 
16869891 RASAL3 -0.93 6.43 0.03351212 
17019549 MRPL14 0.59 5.47 0.010414232 
17046740 STAG3L4 0.68 6.46 0.009758006 
16985614 CENPH 0.76 3.76 0.026323983 
16685281 MRPS15 0.46 8.79 0.015998855 
16804458 MRPS11 0.47 8.03 0.038253759 
16900245 MRPS5 0.51 7.16 0.014049167 
16994045 MRPL36 0.47 4.54 0.003485 
16740797 MRPL11 0.79 7.19 0.004320025 
16827394 ACD 0.54 5.39 0.013222891 
16884200 SOWAHC 0.76 4.77 0.011986686 
16995339 C5orf42 0.79 7.30 0.015503452 
16687264 SELRC1 0.66 4.81 0.0108719 
17082192 PYCRL 0.74 5.80 0.023113528 
16835497 UBE2Z 0.54 7.97 0.013011825 
17073994 C8orf33 0.82 7.46 0.00995933 
16758885 AACS 0.69 6.72 0.013973413 
16825819 ZNF747 0.39 5.48 0.041638363 
16916667 DDRGK1 0.49 7.51 0.026785346 
16822809 MRPS34 0.89 7.47 0.001997816 
17053316 LRRC61 1.13 5.93 0.005316307 
16834711 C17orf53 0.96 4.87 0.00935104 
17082081 RHPN1-AS1 0.73 3.50 0.032673404 
16683712 AUNIP 0.72 3.44 0.02649727 
16829426 DBNDD1 0.78 4.69 0.036145279 
16859486 DDA1 0.56 8.43 0.030724616 
17056358 GGCT 0.74 5.35 0.005096594 
16750488 TMEM106C 0.91 4.77 0.006778957 
17043437 C7orf26 0.40 6.05 0.030676619 
16752586 NABP2 0.64 7.54 0.007705785 
16742610 ALG8 0.47 7.95 0.047708696 
16994244 FASTKD3 0.56 5.24 0.018394064 
16825794 DCTPP1 0.75 7.79 0.010862113 
16739435 C11orf48 0.60 5.55 0.012429258 
16867715 SLC25A23 1.16 6.41 0.011744728 
16875323 MBOAT7 0.85 5.59 0.004670637 
16833476 DHRS11 0.88 5.68 0.031938783 
16755902 GNPTAB -0.75 2.13 0.032925202 
17059427 TMEM243 -0.52 6.59 0.026751385 
16846157 PRR15L 3.00 5.87 0.010973066 
16937909 TMEM43 0.56 9.68 0.017064738 
16826586 IRX3 1.30 5.67 0.011910205 
16815316 THOC6 0.59 8.17 0.006257496 
16694960 FCRL2 -2.27 3.54 0.001727434 
16758321 B3GNT4 0.71 3.53 0.017982198 
16850246 C17orf62 -0.46 8.34 0.032246839 
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16889209 C2orf47 0.69 6.19 0.010039892 
16694728 MRPL24 0.73 6.86 0.009385376 
16682835 MUL1 0.74 5.87 0.013408734 
16774917 RNASEH2B -0.65 6.68 0.004282625 
16970465 FAT4 -1.13 7.66 0.027873442 
16823636 ROGDI 0.94 6.57 0.031596331 
17114489 MAP7D3 -0.89 7.04 0.002221865 
16814738 TMEM204 -1.01 7.60 0.044926034 
16971308 ARHGAP10 -0.72 5.56 0.017172103 
16836538 DHX40 0.64 7.54 0.01890385 
17071086 PLEKHF2 -0.68 6.84 0.013989156 
16839106 FN3KRP 0.60 6.77 0.029647339 
16982024 MLF1IP 1.06 5.26 0.022208653 
16796412 LINC00341 -1.60 5.30 0.000628104 
17118421 ZNF322 0.57 6.62 0.040623853 
17113079 MORC4 0.62 7.35 0.016877145 
16791086 IPO4 0.69 6.65 0.031509868 
16903327 GTDC1 -0.78 6.03 0.009837228 
16663231 PPCS 0.48 6.56 0.02250299 
16702685 SUV39H2 0.79 5.44 0.020770795 
16825813 ZNF768 0.51 6.43 0.022377746 
16736638 E2F8 1.34 5.79 0.022514505 
16767788 BBS10 0.62 6.53 0.035226588 
16688864 TTLL7 -1.12 5.73 0.025836586 
17110352 CXorf36 -1.57 5.56 0.001263485 
16875776 ISOC2 1.23 7.82 0.000297388 
16820053 ELMO3 1.19 4.84 0.032160898 
16998162 MCTP1 -1.66 6.38 0.000393343 
17093038 MOB3B -0.68 3.19 0.004785635 
16688235 WDR78 0.73 5.29 0.028176721 
16795908 CATSPERB -0.63 2.85 0.023938113 
16945289 EFCC1 -0.40 4.20 0.033386639 
16852966 CCDC102B -1.65 6.55 0.001934668 
16738137 AGBL2 1.35 4.24 0.035604525 
16909042 FAM124B -0.80 4.29 0.008505961 
16732716 C11orf63 -0.89 5.33 0.016484012 
17019040 TREML2 -0.58 3.09 0.020009556 
16758671 TCTN2 0.99 7.52 0.005287219 
17106246 ALG13 -0.53 7.22 0.032715823 
16869506 PODNL1 -1.63 6.28 0.045169965 
16887589 CYBRD1 0.60 10.17 0.030557939 
16816386 TMC7 -0.76 4.14 0.030724616 
16833488 MRM1 0.83 5.49 0.011460725 
16661058 FAM110D -0.78 3.75 0.002689483 
16792688 L2HGDH 0.58 4.15 0.046164473 
17092208 ERMP1 0.98 6.84 0.015182653 
16867733 DENND1C -1.03 5.96 0.016550099 
16854046 CEP76 0.55 5.57 0.044373565 
16750792 DNAJC22 1.98 5.29 0.001035194 
17027518 ATAT1 0.42 5.61 0.049710075 
17006336 ATAT1 0.45 5.58 0.043107468 
17030363 ATAT1 0.45 5.58 0.043107468 
17033068 ATAT1 0.45 5.58 0.043107468 
17035188 ATAT1 0.45 5.58 0.043107468 
17037847 ATAT1 0.45 5.58 0.043107468 
17040561 ATAT1 0.45 5.58 0.043107468 
16978310 DNAJB14 -0.51 6.13 0.019201137 
16851309 GREB1L 1.25 4.86 0.02522701 
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16827574 ESRP2 2.43 5.65 0.002116254 
17067031 DOCK5 0.75 8.06 0.022446726 
16975234 TMEM156 -1.28 4.36 0.003329614 
16837849 MYO15B -0.65 6.02 0.00879171 
16910601 NRSN2 0.74 5.64 0.008632924 
16887097 CSRNP3 -0.85 4.48 0.032254679 
16857794 LRRC8E 0.82 5.02 0.014748667 
17098745 PTGES2 0.48 5.89 0.031350721 
16968122 FRAS1 2.30 7.70 0.00108891 
16720049 ATHL1 -0.89 5.60 0.00234422 
17013851 MYCT1 -2.11 6.23 0.00234422 
16815108 C16orf59 0.71 4.95 0.034233212 
16843680 MYO19 0.61 6.70 0.002652296 
16778887 KIAA0226L -1.16 5.85 0.001545581 
16925398 RUNX1-IT1 -1.79 6.25 0.002390586 
16670547 TARS2 0.56 5.80 0.033541237 
17076285 RAB11FIP1 0.94 6.25 0.02716733 
17109893 CXorf21 -0.79 5.60 0.012588067 
17069728 PREX2 -1.81 5.92 0.004002822 
16818114 HSD3B7 0.90 7.55 0.00431596 
16671516 FLAD1 0.58 5.11 0.029921031 
16713113 EPC1 -0.40 7.22 0.043423949 
16992557 CPEB4 -0.98 6.66 0.008999768 
16891107 WNT10A 1.29 4.14 0.013450106 
16676999 TRAF3IP3 -1.31 5.97 0.002633541 
16834351 COASY 0.56 6.74 0.02522701 
17097560 AKNA -1.05 6.40 0.002885546 
17006276 PRR3 0.41 5.71 0.043846966 
17033009 PRR3 0.41 5.71 0.043846966 
17035129 PRR3 0.41 5.71 0.043846966 
17027459 PRR3 0.42 5.70 0.040076207 
17030304 PRR3 0.42 5.70 0.040076207 
17037788 PRR3 0.42 5.70 0.040076207 
17040502 PRR3 0.42 5.70 0.040076207 
16711598 ITIH5 -1.43 4.36 0.010822287 
17047560 UPK3B 5.57 8.48 1.39E-05 
16657730 GLTPD1 0.60 5.68 0.025812227 
16885028 TMEM177 0.72 6.23 0.008787723 
16793096 DDHD1 -0.74 7.26 0.006123056 
17105655 BHLHB9 0.57 4.29 0.035788812 
16934434 APOL3 -0.75 4.98 0.02939432 
17063507 JHDM1D -0.84 6.65 0.000929601 
16980005 SETD7 -0.83 5.72 0.003537095 
16674742 NPL -0.80 7.13 0.020512308 
16920651 ZBP1 -0.78 3.88 0.024368191 
16720165 PTDSS2 0.50 6.12 0.049233283 
16923625 LRRC3 1.02 4.73 0.03137603 
16742244 GDPD5 1.04 5.98 0.010655184 
17057897 VOPP1 -0.61 4.46 0.003177931 
16894710 FAM49A -1.08 6.91 0.004191867 
16810828 VWA9 0.52 7.61 0.031794929 
16900591 LMAN2L 0.85 6.30 0.000837761 
16674973 C1orf21 -0.80 5.35 0.014793498 
16830988 NDEL1 -0.68 8.08 0.014626078 
16918280 PDRG1 0.70 5.53 0.01065877 
16748490 APOLD1 -0.61 6.16 0.024260471 
17020268 COL21A1 -1.01 4.18 0.010156453 
16978969 PLA2G12A 1.45 7.70 0.017591588 
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16821869 CDT1 0.83 5.12 0.019390771 
16779546 DIAPH3 1.30 6.15 0.021931658 
17060599 TSC22D4 0.53 4.99 0.020571399 
16816627 LOC81691 0.61 4.56 0.0263308 
16812009 LINC00597 -0.98 5.36 0.031509868 
17082982 DOCK8 -0.83 7.64 0.027569071 
16975203 TLR10 -1.47 4.62 0.004162135 
17004769 TMEM14B 0.64 6.08 0.018036573 
16864331 MED25 0.70 5.13 0.006589098 
16686158 HYI 1.39 7.06 0.001049806 
16814847 FAHD1 0.97 5.26 0.000138799 
16736891 KIF18A 1.83 6.25 0.000519244 
16860103 ZNF93 0.76 6.06 0.034834596 
16840362 PITPNM3 0.89 4.79 0.041873851 
16694886 FCRL5 -2.07 4.38 0.004665936 
17058582 ABHD11 0.75 5.69 0.017686424 
16760621 CDCA3 0.79 4.49 0.022781737 
16968497 ARHGAP24 -1.24 6.24 0.000393499 
17082362 EPPK1 3.05 5.77 0.000494242 
16870193 PLVAP -1.14 8.02 0.016484012 
17074567 SOX7 -0.95 4.61 0.013898337 
16940208 LRRC2-AS1 -0.38 2.91 0.031413638 
17110040 TMEM47 -1.21 8.50 0.030029639 
17045761 CCM2 -0.52 5.33 0.017854783 
16902611 AMMECR1L 0.32 7.07 0.027628988 
16804051 FAM103A1 0.59 8.27 0.013604132 
16711826 CCDC3 -0.84 3.79 0.003130407 
17074641 FAM167A 0.81 4.26 0.019499404 
16912941 DYNLRB1 0.39 5.38 0.013533716 
16746867 RHNO1 0.60 5.11 0.043499696 
16726255 FERMT3 -0.67 6.88 0.032418879 
16760031 NRIP2 -0.66 4.58 0.001958832 
16863783 GRWD1 0.60 6.19 0.043458411 
17095948 ZNF484 -0.55 6.13 0.03312773 
16657737 TAS1R3 -0.33 4.18 0.0338111 
17049924 ARMC10 0.51 6.99 0.024771781 
16946173 ESYT3 1.26 3.86 0.014670645 
16774789 SETDB2 -0.49 5.40 0.042489049 
16702330 TAF3 -0.48 6.34 0.016136191 
17058878 TMEM120A 0.53 7.34 0.005937876 
16731225 BCO2 2.89 7.03 0.00234422 
16870150 USHBP1 -0.62 3.17 0.010037299 
16829764 GSG2 1.03 4.34 0.042485814 
16730467 TMEM133 -1.21 5.85 0.035604525 
16916682 SLC4A11 1.09 5.32 0.046063999 
16796229 IFI27L2 -0.59 4.08 0.009539495 
16814143 ITFG3 0.46 6.28 0.043995971 
17079774 NCALD -1.06 3.12 0.000864133 
16847432 BRIP1 1.23 5.80 0.014510297 
16928716 KREMEN1 -0.84 5.91 0.005312114 
16980405 SLC10A7 -0.66 6.11 0.002543286 
16903028 ZRANB3 0.48 5.25 0.012588067 
16928699 ZNRF3 0.91 6.17 0.040039322 
16689042 SYDE2 1.49 4.69 0.002844935 
16705199 ARID5B -1.02 7.66 0.020099003 
16859319 C19orf44 0.74 4.93 0.04926514 
17084936 ZCCHC7 -0.46 7.13 0.024677029 
16750300 TMEM117 -0.80 4.65 0.016606769 
 287 
16666982 LRRC8C -1.02 3.38 6.65E-05 
16729684 TMEM126A 0.54 6.20 0.037835537 
16891637 RHBDD1 -0.44 5.12 0.018112692 
16743779 DCUN1D5 0.40 6.24 0.041691579 
16869242 FBXW9 0.57 4.27 0.041064833 
17054460 PSMG3 0.97 7.25 0.000351234 
16857438 ALKBH7 0.82 7.30 0.038931085 
17095307 C9orf64 0.59 5.52 0.035073833 
16884505 CHCHD5 0.40 4.67 0.040623853 
17058551 DNAJC30 0.55 5.25 0.0421346 
16678838 NTPCR 0.55 4.58 0.020126598 
16740645 EIF1AD 0.47 7.13 0.016435119 
16858668 WDR83 0.50 4.85 0.027983291 
16833605 MRPL45 0.68 9.29 0.016667474 
16834441 VPS25 0.59 9.06 0.026919424 
16822466 C16orf13 0.62 6.85 0.020046072 
16845518 TMEM101 0.58 5.40 0.035547006 
16869017 ELOF1 0.55 7.36 0.043034204 
16902357 MKI67IP 0.63 9.22 0.018347115 
16989977 CYSTM1 0.83 6.98 0.04086658 
16678851 KIAA1804 1.01 4.45 0.004665936 
16822109 SPIRE2 1.01 5.06 0.006340971 
16937405 JAGN1 0.63 6.56 0.003264143 
16912954 MAP1LC3A 0.60 5.07 0.013011825 
16978896 COL25A1 -0.66 4.43 0.02004605 
16914867 PARD6B 3.11 7.25 0.002498679 
17105082 GPR174 -1.78 7.04 0.015203053 
16896279 DPY30 0.62 9.20 0.002870355 
16815498 GLIS2 0.87 7.34 0.011924989 
17055804 FAM126A -1.25 7.40 0.005048834 
16984294 CARD6 -0.71 5.21 0.038523268 
16899298 PCGF1 0.34 5.89 0.044678725 
16865647 SUV420H2 0.44 4.85 0.041488155 
16874633 C19orf48 1.49 6.47 0.000246254 
16831313 MGC12916 -1.04 4.48 0.012524658 
17022216 RTN4IP1 -0.53 5.02 0.020794253 
16830182 TXNDC17 0.77 6.02 0.010610622 
16937440 IL17RC 0.45 6.34 0.016295421 
16672946 FCRLA -1.01 3.25 0.007716466 
16885421 SFT2D3 0.44 5.04 0.019678128 
17117934 MGC15705 -0.74 3.01 0.035378999 
17012392 RSPO3 -1.22 4.56 0.042921768 
16662945 MFSD2A 1.71 5.67 0.00461557 
16715088 AIFM2 1.03 5.26 0.001431864 
17098900 ZDHHC12 0.58 6.86 0.040801922 
16871180 CEP89 0.53 6.61 0.006597901 
17093724 ARHGEF39 0.72 4.46 0.015375785 
16884403 TMEM87B 0.35 7.68 0.02889654 
16820537 CIRH1A 0.68 7.73 0.005001538 
17024653 LRP11 0.98 6.61 0.037172643 
16875799 FIZ1 0.93 4.97 0.003723708 
16944724 DIRC2 0.44 8.99 0.027628988 
17062853 TMEM209 0.65 7.22 0.027490456 
16812803 WDR73 0.56 6.13 0.024493485 
17073405 TIGD5 0.68 5.75 0.022531696 
17080171 NUDCD1 0.75 7.48 0.007852844 
16661398 SYTL1 -0.50 4.16 0.019390771 
16790614 AJUBA 1.28 5.63 1.86E-05 
 288 
17072351 FAM83A 0.97 3.11 0.048093219 
17073865 PPP1R16A 0.57 5.66 0.022531696 
16811656 UBL7 0.49 7.87 0.038093304 
17091312 TMEM141 0.60 6.59 0.036764716 
17021946 USP45 -0.58 5.96 0.039276829 
17016457 HIST1H2BK 1.14 7.72 0.015377204 
16931815 SHANK3 -1.60 5.82 0.001448824 
16936325 TUBGCP6 -0.53 6.32 0.009155343 
16982672 NKD2 0.80 4.87 0.027924641 
16871202 RHPN2 3.39 7.14 1.62E-06 
16710852 KNDC1 1.13 4.54 0.007938986 
16738409 TNKS1BP1 0.87 7.46 0.006504942 
16897797 PNPT1 0.48 7.54 0.017303401 
16756865 ANKRD13A -0.56 8.43 0.021398717 
16933314 HPS4 -0.41 6.11 0.025466682 
16675794 NAV1 -1.09 8.02 0.033023532 
17086818 FGD3 -0.69 5.35 0.048938728 
16728731 ATG16L2 -0.54 5.18 0.030939687 
16962085 KLHL6 -1.21 6.03 0.002202594 
17063922 OR6W1P -0.43 2.78 0.047394383 
17098880 WDR34 0.70 4.90 0.034118755 
16816186 C16orf45 -0.66 5.46 0.048147783 
16733719 GLB1L2 1.45 5.13 0.013621346 
16819450 RSPRY1 0.79 8.18 0.017303401 
17021167 UBE3D -0.71 3.80 0.048996153 
17103525 CCDC120 1.22 5.38 0.003200808 
16914345 ZSWIM1 0.39 5.42 0.04146164 
16862529 CEACAM21 -0.76 4.46 0.002757052 
16875026 ZNF616 0.74 4.33 0.013827493 
16804631 TICRR 1.53 5.31 0.027862114 
16869387 GADD45GIP1 0.58 6.23 0.027171438 
16683574 STPG1 0.60 5.20 0.037184243 
16834523 AOC4P -0.98 3.26 0.000191736 
16778005 STARD13 -0.97 5.37 0.00236158 
16860123 ZNF486 1.26 5.19 0.011105871 
16936253 LOC90834 -0.76 5.27 0.005021773 
16822939 ZNF598 0.48 5.78 0.026455239 
16814779 HN1L 1.32 7.69 0.000146244 
17083433 IL33 -1.90 5.59 0.004486863 
16691621 ZNF697 0.83 5.55 0.031378105 
16745693 ESAM -1.20 6.40 0.009486909 
17052306 ADCK2 0.46 5.31 0.047540957 
16974900 CCDC149 -0.62 5.60 0.004487209 
16853674 L3MBTL4 1.35 6.20 0.0108719 
17002912 BOD1 0.64 5.19 0.009571117 
16933030 GUSBP11 -0.54 6.38 0.008300012 
16933062 DERL3 -1.01 5.45 0.044787174 
16928411 IGLL3P -0.82 4.22 0.012287873 
17000066 CDKN2AIPNL 0.75 5.42 0.023845531 
16906000 SESTD1 -1.01 7.02 0.01225416 
16860580 C19orf40 0.87 4.82 0.026981053 
16750416 PCED1B -0.77 4.98 0.014793498 
16906872 ANKRD44 -0.89 7.73 0.003650135 
16758569 C12orf65 0.56 5.50 0.027959341 
16982426 YTHDC1 -0.37 8.29 0.045774129 
16976502 YTHDC1 -0.67 5.18 0.040039322 
16794555 ELMSAN1 -0.44 5.22 0.049487214 
16788973 WDR20 -0.38 5.09 0.036591224 
 289 
16811061 CALML4 0.96 6.21 0.020083682 
17002115 TIMD4 -2.26 3.52 0.000936814 
16815925 SNX29 -0.71 7.90 0.001231555 
16905521 TTC30A 1.02 5.15 0.024264728 
16673393 RCSD1 -0.88 5.60 0.003394282 
16985629 MRPS36 0.83 5.28 0.001266727 
16757831 CCDC64 2.23 7.12 0.013362278 
16834700 G6PC3 0.70 8.57 0.004796972 
16862066 TIMM50 0.64 7.76 0.017060413 
16838931 MAFG-AS1 0.76 4.33 0.013222891 
16911675 MGME1 0.53 6.95 0.021212202 
16829422 CENPBD1 0.71 5.28 0.013869973 
16885526 IMP4 0.44 6.07 0.047590624 
16889154 MARS2 0.56 5.55 0.038935768 
16892122 B3GNT7 1.36 5.74 0.01202954 
17071871 PKHD1L1 3.62 6.78 0.012552128 
16871359 DMKN 2.51 6.20 0.000242765 
16868418 ZNF561 0.49 5.43 0.017198424 
16988565 PRDM6 1.21 5.01 0.047359928 
16870131 HAUS8 0.71 5.05 0.024260471 
16659021 FBXO44 0.75 5.11 0.0168028 
16868265 MUC16 4.12 7.58 0.001016216 
16860087 ZNF101 -0.73 5.51 0.029656021 
17112623 SYTL4 -0.89 4.56 0.020277577 
16824690 ERI2 0.81 5.70 0.007832502 
16875559 RDH13 0.90 5.52 0.013989156 
16817337 CCDC101 0.56 7.62 0.004663101 
16845826 PLCD3 1.33 8.03 0.005220318 
16747612 C12orf57 0.54 6.32 0.031596331 
17043588 GLCCI1 -1.01 4.72 0.005927861 
16781235 ADPRHL1 0.67 4.82 0.029882468 
16934045 PIK3IP1 -0.78 5.33 0.042302863 
16990083 SLC35A4 0.51 8.26 0.037800534 
16923929 MCM3AP-AS1 0.65 4.49 0.009627203 
16763195 SLC2A13 -0.73 5.47 0.010678024 
17072125 MAL2 3.96 6.80 0.000295474 
16684902 CSMD2 -1.23 4.75 0.018958874 
16695392 SLAMF6 -1.82 6.59 0.006448951 
16767794 OSBPL8 -0.65 8.34 0.015983939 
16951883 OSBPL10 -1.14 5.35 0.001637265 
16987986 EPB41L4A-AS1 0.76 4.81 0.012008193 
17068560 SMIM19 0.75 5.98 0.006571101 
16999421 37681 -1.16 5.61 0.025832762 
16779839 KCTD12 -0.62 9.13 0.005086295 
17042844 GPR146 -0.67 5.04 0.004796972 
16694980 FCRL1 -2.64 4.04 0.000588116 
16694928 FCRL3 -1.99 5.28 0.003119909 
16664912 LRRC42 1.06 6.84 0.000456269 
17044285 MALSU1 0.77 5.78 0.00071212 
17083452 UHRF2 -0.66 7.41 0.001755664 
16935512 TNFRSF13C -1.50 4.13 0.013895473 
16887194 NOSTRIN -1.74 4.31 7.10E-05 
16855545 ALPK2 -1.43 4.72 0.033104806 
16774976 WDFY2 -1.13 6.38 0.000318147 
16985043 RAB3C -0.45 2.83 0.007460396 
16924592 CYYR1 -1.39 5.49 0.0011262 
16960344 TM4SF18 -1.06 4.43 0.016637188 
17115777 RAB39B -0.52 3.41 0.037048064 
 290 
16697196 FAM129A -1.29 6.98 0.000446262 
16744708 APOA5 -0.35 4.55 0.042473943 
16911026 HSPA12B -0.81 5.28 0.030880448 
16766658 AGAP2 -0.89 5.20 0.022837699 
16688961 SSX2IP 1.06 5.16 0.007813504 
16847621 FTSJ3 0.56 6.88 0.01135105 
16938133 GALNT15 -1.38 4.80 0.006396074 
17025230 TAGAP -1.01 6.80 0.017847035 
17085868 TMC1 -0.37 2.84 0.02004605 
16748453 LOH12CR1 -0.54 5.90 0.013305094 
16977251 ANTXR2 -1.15 7.93 0.001017272 
16715494 MSS51 -0.64 5.17 0.006706077 
16717005 PIK3AP1 -0.98 7.76 0.001049806 
16719171 CPXM2 -1.91 6.16 0.001841098 
16743262 SLC36A4 0.51 6.81 0.012044671 
16731515 NXPE2 -0.51 2.58 0.0196481 
16744967 AMICA1 -0.91 5.68 0.033528421 
16735223 OR2D2 -0.83 2.80 0.002351716 
16749939 LRRK2 -0.89 5.78 0.006495873 
16763911 ZNF641 0.90 6.03 0.010610622 
16761830 ERP27 -1.37 5.23 0.002351716 
16769868 ALKBH2 0.61 4.13 0.025292216 
16796919 ANKRD9 0.92 5.50 0.016208242 
16789589 C14orf79 0.86 5.54 0.002745485 
16795943 TC2N -1.23 7.34 0.01864703 
16796667 SLC25A29 0.77 6.20 0.028063824 
16824301 FOPNL 0.65 8.84 0.007880507 
16822050 SPATA33 0.96 5.04 0.01287137 
16816542 IQCK 0.75 7.01 0.03238455 
16828608 CDYL2 -0.97 6.15 0.012566269 
16823588 ANKS3 0.33 5.44 0.047825453 
16823579 UBALD1 0.59 6.63 0.023307375 
16825081 EARS2 0.47 5.97 0.034451766 
16836375 MSI2 1.08 8.50 0.013772958 
16830782 CYB5D1 0.80 6.46 0.018678568 
16831046 USP43 1.51 4.33 0.005368851 
16845727 CCDC43 0.50 6.63 0.0238318 
16832695 ANKRD13B 1.32 6.31 0.004767564 
16830041 ZFP3 0.59 6.47 0.033584759 
16840054 GGT6 0.35 3.44 0.048761811 
16829801 SPNS2 -1.27 6.28 0.00955707 
16846121 MRPL10 0.53 5.39 0.014793498 
16854088 FAM210A 0.75 6.54 0.027767488 
16854954 LOXHD1 -0.53 3.19 0.009049385 
16874568 JOSD2 0.59 5.77 0.025906647 
16872239 EID2B 0.47 3.23 0.024885713 
16856998 GIPC3 -1.10 5.07 0.022575571 
16856249 MISP 2.55 5.64 0.000310311 
16860766 WTIP 0.74 7.19 0.000700211 
16871305 ZNF792 -0.48 5.37 0.045510264 
16870581 NR2C2AP 1.05 5.75 0.014312739 
16664828 PODN -1.05 9.06 0.02770472 
16685255 OSCP1 0.64 5.10 0.038527446 
16673043 UHMK1 0.51 7.99 0.01303921 
16694617 IQGAP3 1.37 5.38 0.023440167 
16672097 APOA1BP 1.21 9.03 0.000505614 
16678496 HIST3H2BB 1.67 5.52 0.000393343 
16914925 TSHZ2 -1.71 6.75 0.003366453 
 291 
16915405 ZNF831 -1.12 4.54 0.007419057 
16928339 SGSM1 -0.57 4.00 0.015592393 
16928735 EMID1 -0.68 4.71 0.017461527 
16884426 FBLN7 -0.75 5.08 0.024155995 
16902865 FAM168B 0.57 7.91 0.001312698 
16906991 RFTN2 -1.45 4.87 0.00073594 
16891555 SGPP2 2.80 6.86 0.009861007 
16886448 LYPD6 0.95 3.92 0.007922723 
16891392 TMEM198 0.62 4.25 0.019818196 
16891820 FBXO36 0.81 5.63 0.032046985 
16938228 KCNH8 -0.46 2.63 0.024885512 
16961919 DNAJC19 0.60 6.57 0.030724616 
16957433 CD200R1 -1.18 5.07 0.007148503 
16950999 CHCHD4 0.63 5.08 0.016439345 
16943107 CRYBG3 -0.56 7.48 0.014549322 
16949792 FAM43A -1.07 6.26 0.006259841 
16979719 SCLT1 -0.80 5.62 0.002226908 
16969817 C4orf32 -0.97 6.05 0.012588067 
16976110 PDCL2 1.30 3.77 0.048620662 
16978525 SLC9B2 -0.68 6.01 0.034072327 
16984189 EGFLAM -0.94 4.53 0.001561317 
16988471 ZNF474 -0.59 2.63 0.022417587 
16990897 AFAP1L1 -1.01 4.95 0.010039892 
17002510 NUDCD2 0.72 5.41 0.01135105 
17024362 ADAT2 -1.01 5.57 0.00131925 
17013468 STXBP5 -0.86 7.46 0.032819637 
17024669 RAET1E 1.98 4.92 0.038476061 
17081347 TMEM71 -0.68 4.65 0.047027139 
17069194 UBXN2B 0.80 5.93 0.002579982 
17068064 LETM2 1.10 5.48 0.017160609 
17099731 C9orf116 1.15 4.81 0.011228185 
17110342 FUNDC1 0.53 6.11 0.017527748 
17115677 GAB3 -0.98 5.92 0.000819564 
17107983 ZFP92 0.83 4.04 0.029372633 
16930173 APOBEC3D -0.73 7.41 0.047497843 
16934012 SELM -0.82 5.04 0.030015351 
16921064 GATA5 1.34 5.12 0.033075537 
16916289 C20orf96 0.69 5.92 0.02942075 
16912455 CCM2L -1.19 5.19 0.003946412 
16884980 TMEM37 0.80 5.58 0.02389048 
16705754 ADAMTS14 -1.46 5.13 0.03047644 
17094946 TRPM6 -0.99 3.59 0.005048834 
16916352 SRXN1 0.95 5.58 0.000675056 
16913198 ROMO1 1.05 6.23 0.000180119 
16918132 NANP 0.54 5.43 0.029372633 
16912317 LINC00028 -0.46 2.97 0.026095642 
16695478 ITLN2 2.55 5.57 0.004651327 
16709537 TRUB1 0.48 6.13 0.04628174 
16707343 HECTD2 -0.76 6.08 0.025305516 
16730429 ARHGAP42 -1.16 6.75 0.020919614 
16743994 CWF19L2 -0.34 5.60 0.044495749 
16758135 TMEM120B 0.54 5.44 0.017919538 
16748111 A2M-AS1 -1.39 5.64 0.000159962 
16789429 C14orf144 -0.39 4.12 0.043774545 
16788829 LINC00239 -0.39 3.20 0.045035006 
16786060 LOC145474 -0.89 4.32 0.040783602 
16786304 PTGR2 0.72 5.03 0.033386639 
16783739 LRFN5 -0.61 3.70 0.033104806 
 292 
16805397 LINC00924 -1.13 3.52 0.000204333 
16802316 C15orf61 0.58 4.63 0.030187411 
16813029 HAPLN3 -0.95 6.51 0.041229531 
16811886 NRG4 2.87 5.76 0.004665417 
16820208 RLTPR -0.75 5.40 0.01875379 
16827324 KCTD19 0.90 3.51 0.018575482 
16819816 BEAN1 1.43 4.74 0.032508512 
16823704 C16orf89 -0.85 4.02 0.03411456 
16845794 KIF18B 1.18 5.88 0.044112912 
16835797 EME1 0.79 4.42 0.048923179 
16842850 DHRS13 0.96 5.13 0.016295421 
16838300 TMC8 -1.02 6.39 0.024904242 
16831908 TRIM16L 0.64 4.26 0.042260099 
16868838 SPC24 1.09 5.43 0.043290212 
16866750 ATP8B3 0.53 3.96 0.012366834 
16671305 CREB3L4 0.72 5.04 0.013273644 
16696548 RC3H1 -0.42 7.62 0.007595006 
16663413 WDR65 0.56 2.93 0.048490926 
16663828 CCDC24 0.88 4.83 0.000907211 
16678501 RNF187 0.68 7.06 0.005197521 
16672373 PYHIN1 -1.62 5.99 0.003782007 
16932988 ZDHHC8P1 1.19 4.00 0.019555184 
16901957 CKAP2L 1.53 5.45 0.013096869 
16876742 LOC150622 3.13 5.09 0.000679804 
16905516 TTC30B 1.10 4.83 0.004995947 
16886602 ARL6IP6 0.59 5.72 0.013031472 
16879205 RMDN2 -0.51 4.88 0.027216605 
16909528 LINC00471 1.08 4.55 0.005638276 
16881770 LBX2-AS1 0.58 4.20 0.037446768 
16905216 GPR155 -0.76 6.69 0.017033223 
16951485 SGOL1 1.58 5.72 0.020787539 
16947613 PPM1L -0.49 3.78 0.01133074 
16961250 WDR49 -0.45 3.19 0.031341948 
16957363 BTLA -1.76 4.99 0.012178643 
17084866 GLIPR2 -0.91 7.07 0.019503195 
16938654 CMTM8 2.25 8.50 4.13E-06 
16945659 NUDT16P1 0.95 5.96 0.027487868 
16950056 NCBP2-AS2 0.67 5.81 0.013482206 
16938007 FGD5 -1.37 5.92 0.000929601 
16950655 CIDECP 1.02 4.44 0.00214664 
16966127 KLB -0.48 2.49 0.045576132 
16973561 FAM53A 0.72 3.43 0.02785898 
16977892 PPM1K -1.24 5.22 0.003420039 
16977309 RASGEF1B -0.96 5.37 0.018146777 
16985688 MARVELD2 1.73 5.02 0.001850621 
16994081 IRX2 0.81 4.58 0.037964557 
16990572 SH3RF2 2.17 6.83 0.021987733 
17013264 ZC2HC1B -0.73 2.85 0.001769304 
17053371 GIMAP8 -1.01 6.40 0.001403221 
17064160 ZNF425 0.68 3.36 0.01373974 
17070013 RDH10 2.48 9.59 0.00061078 
17081002 FAM84B 1.86 7.42 0.01091826 
17074029 TDRP 1.07 6.69 0.015175122 
17078254 SBSPON 3.61 7.31 0.014880251 
17098048 TTLL11 -0.45 5.18 0.037022715 
17092579 TTC39B -0.72 5.15 0.010875341 
17092531 FREM1 -1.23 4.24 0.009461259 
17092233 KIAA2026 -0.60 7.49 0.002309584 
 293 
17088139 KIAA1958 0.87 5.45 0.012588067 
17095056 PRUNE2 -1.55 5.38 0.005023525 
17111883 CXorf65 -0.78 4.03 0.030609357 
16761193 CLECL1 -0.65 3.10 0.047659102 
16769481 ALDH1L2 -2.30 6.31 0.001070637 
16762941 DENND5B -0.64 6.35 0.036742278 
16751420 GRASP -1.44 5.29 0.0009769 
16796414 SYNE3 -1.43 5.59 1.07E-05 
16792211 CLEC14A -1.06 6.01 0.013211011 
16793644 TMEM30B -0.81 4.41 0.036610869 
16800191 ADAL 0.82 6.00 0.033546474 
16854102 ZNF519 0.60 4.11 0.049952116 
16864829 ZNF610 1.26 5.37 0.02377921 
16872243 EID2 0.50 5.29 0.013450106 
16871321 LGI4 -0.51 4.30 0.026095642 
16674446 TOR1AIP2 0.69 3.26 0.011244089 
16696870 TOR1AIP2 0.93 8.31 0.000796119 
16685868 CITED4 0.63 4.04 0.024686756 
16689490 HFM1 -0.53 2.62 0.013317113 
16917054 LRRN4 5.33 9.24 4.83E-05 
16901109 LONRF2 1.31 5.25 0.020617927 
16884162 CCDC138 1.39 5.84 2.39E-05 
16877637 UBXN2A 0.64 6.42 0.022417587 
16944673 PARP15 -2.09 5.39 0.000739182 
16971382 DCLK2 -1.09 4.84 0.017956375 
16974779 GPR125 0.57 6.77 0.041125604 
16997097 ZNF366 -0.72 4.29 0.015830468 
17057599 PKD1L1 -0.58 3.48 0.006811348 
17053379 GIMAP7 -1.12 6.05 0.0023633 
17045078 BMPER -1.11 4.01 0.002145853 
16714104 C10orf128 -0.73 4.70 0.021693616 
16982870 ADAMTS16 -1.88 5.25 0.01563567 
16828550 ADAMTS18 -0.96 3.54 0.011077896 
17026687 PPP1R18 -0.57 7.63 0.04926514 
17031616 PPP1R18 -0.57 7.63 0.04926514 
17016946 PPP1R18 -0.60 7.99 0.047180396 
17034070 PPP1R18 -0.60 7.99 0.047180396 
17036337 PPP1R18 -0.60 7.99 0.047180396 
17028837 PPP1R18 -0.62 8.03 0.031794929 
16970118 SYNPO2 -1.78 7.38 0.001145514 
16776100 CLYBL 0.43 3.71 0.044661767 
16662430 AGO4 -0.64 6.89 0.002908654 
17096205 ZNF367 1.03 5.28 0.041965303 
16718779 EMX2OS -0.62 3.21 0.006811348 
16714086 VSTM4 -0.82 5.70 0.021123453 
16791319 ADCY4 -1.56 5.64 0.001070637 
16792644 C14orf183 -0.65 4.60 0.025491785 
16821581 LINC00311 -0.63 2.84 0.011131142 
16828344 MLKL -0.87 6.27 0.003322562 
16814389 WDR90 0.44 5.13 0.025694063 
16815394 CASP16 0.40 4.14 0.040366916 
16825196 NSMCE1 0.53 7.61 0.046324881 
16939315 TTC21A -0.51 4.72 0.032748845 
16873049 CADM4 1.67 6.10 0.001303698 
16859562 FAM129C -1.58 4.94 0.004872828 
16880955 APLF -0.61 4.35 0.025210832 
16890126 PIKFYVE -0.46 7.65 0.00690961 
16878284 KRTCAP3 1.25 4.98 0.029372633 
 294 
16949942 SLC51A 0.75 4.01 0.002244491 
16841768 CENPV 1.57 6.16 0.003040233 
16841852 PLD6 0.61 5.81 0.03559341 
16850063 STRA13 1.06 7.51 0.012217639 
16866292 ZNF584 1.11 5.54 0.004762177 
16944199 TIGIT -0.78 3.28 0.01384768 
16974588 TAPT1 -0.61 5.88 0.007550063 
17020499 KHDRBS2 -0.91 3.16 0.009776407 
17027559 TUBB 0.65 11.23 0.000230412 
17026211 TUBB 0.65 11.39 0.000146108 
17030404 TUBB 0.65 11.39 0.000146108 
17033109 TUBB 0.65 11.39 0.000146108 
17035229 TUBB 0.65 11.39 0.000146108 
17037888 TUBB 0.65 11.39 0.000146108 
17040602 TUBB 0.65 11.39 0.000146108 
17006378 TUBB 0.66 11.50 0.000141059 
17088408 C9orf91 -0.52 5.85 0.034225578 
17093042 C9orf72 -0.64 6.11 0.012143042 
17107773 VMA21 0.66 5.23 0.00320039 
16722890 ANO5 1.75 4.98 0.00279959 
16732520 TBCEL -0.48 6.92 0.0148032 
16732419 TMEM136 1.33 5.76 0.001063044 
16741314 MRPL21 0.56 6.13 0.01256299 
16738628 OR5B21 -0.59 2.94 0.021492339 
16738694 MPEG1 -1.16 8.99 0.008189262 
16738736 PATL1 0.44 9.35 0.009632832 
16732394 OAF -0.85 4.04 0.004347375 
16714547 FAM13C -1.34 4.81 0.002760845 
16714798 JMJD1C -0.50 8.54 0.045262457 
16711839 UCMA 0.43 3.24 0.026873849 
16739479 LRRN4CL -0.77 5.12 0.034568907 
16777278 SKA3 1.30 5.77 0.046605563 
16773191 SPATA13 -0.74 4.82 0.048241036 
16773197 SPATA13 -0.66 5.26 0.012043754 
17022980 FAM162B -1.30 6.08 0.002351716 
17019749 GPR116 -1.60 7.56 0.001021274 
17019389 LRRC73 0.75 4.47 0.019664797 
17008428 ADCY10P1 -0.77 4.35 0.015779003 
17041421 ZBTB9 0.57 5.40 0.027033615 
17007529 ZBTB9 0.57 5.97 0.018745508 
17039661 ZBTB12 0.43 3.87 0.02389048 
17006361 C6orf136 0.63 6.07 0.005689827 
17027543 C6orf136 0.69 5.94 0.002826228 
17030388 C6orf136 0.69 5.94 0.002826228 
17033093 C6orf136 0.69 5.94 0.002826228 
17035213 C6orf136 0.69 5.94 0.002826228 
17037872 C6orf136 0.69 5.94 0.002826228 
17040586 C6orf136 0.69 5.94 0.002826228 
17005169 KDM1B 0.55 6.70 0.025491785 
17004836 SMIM13 0.69 6.66 0.031932637 
17055263 THSD7A -1.43 4.43 0.000170382 
17057354 TMED4 0.43 8.16 0.033104806 
17044692 PRR15 3.61 5.90 0.000197445 
17061504 ATXN7L1 -0.43 5.95 0.049710075 
16878541 SPDYA -1.04 4.73 0.008944992 
16918235 DEFB124 -0.65 3.37 0.002117934 
16977196 CNOT6L -0.71 7.81 0.001219947 
16697843 TMEM9 0.74 5.42 0.002360681 
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16714536 IPMK -0.70 7.27 0.010635655 
16946366 ZBTB38 -0.73 5.82 0.035930768 
16719562 EBF3 -1.32 5.05 0.019506711 
16817721 ASPHD1 2.03 6.78 0.000679869 
17112376 BRWD3 -0.80 7.38 0.002958463 
16885191 LOC254128 0.57 5.54 0.008916461 
16729025 RNF169 0.37 7.45 0.047708696 
16974722 LCORL -0.46 5.90 0.029372633 
16727363 CNIH2 0.60 4.13 0.03267614 
16709760 CASC2 0.67 4.39 0.04997158 
16982936 LINC01018 1.59 5.02 0.024933926 
16969495 NPNT 1.92 8.14 0.020277577 
16830284 BCL6B -1.70 5.45 0.010857434 
16773556 PAN3 -0.43 8.05 0.016370602 
17090216 HMCN2 -1.35 4.07 0.000933017 
16733963 C11orf35 0.65 4.99 0.040242253 
16739346 EML3 -0.41 7.52 0.030289959 
17022276 SCML4 -1.11 3.79 0.003859461 
16979675 MFSD8 -0.37 7.00 0.047315765 
16727377 TMEM151A 2.33 5.73 0.002740044 
16754348 GLIPR1L1 -0.45 3.05 0.033496003 
16868145 KANK3 -0.77 5.05 0.013658915 
17095217 FRMD3 -0.84 4.84 0.001690497 
16695535 ARHGAP30 -0.82 6.23 0.009926585 
16731670 RNF214 0.43 6.25 0.009571117 
16688506 NEGR1 -1.06 5.12 0.024677029 
16697544 ASPM 2.85 7.17 1.15E-05 
16761526 TAS2R30 -0.89 5.68 0.01223952 
16761511 TAS2R20 -0.76 5.81 0.044561067 
16673466 TIPRL 0.60 7.80 0.00565905 
16927985 RGL4 -0.61 3.92 0.010563409 
16935686 ATP5L2 -0.67 4.23 0.047708696 
17041450 ZNF311 0.91 4.06 0.003922556 
17038835 ZNF311 0.84 3.91 0.003283805 
17016642 ZNF311 0.95 4.02 0.001657106 
17026490 ZNF311 0.95 4.02 0.001657106 
17028549 ZNF311 0.95 4.02 0.001657106 
17031330 ZNF311 0.95 4.02 0.001657106 
17033786 ZNF311 0.95 4.02 0.001657106 
16740378 SLC25A45 -0.40 5.18 0.034175166 
16744648 LINC00900 0.38 3.30 0.038095053 
16742086 PGM2L1 -0.68 5.61 0.036717693 
16726448 CCDC88B -0.61 4.20 0.026768373 
16725921 TTC9C 0.45 5.97 0.048241036 
16760760 CD163L1 -1.99 5.01 0.000143661 
17117636 LOC283588 -0.54 3.09 0.018745508 
16790229 LINC00641 -0.83 5.53 0.012719084 
16789536 CEP170B 0.64 5.93 0.031846554 
16801376 LINC00926 -1.75 5.43 0.000784502 
16806624 LOC283710 -0.85 3.02 0.008922121 
16825539 C16orf54 -0.86 4.86 0.006458814 
16840769 LOC284023 0.64 4.75 0.030109851 
16845671 FAM171A2 1.23 5.32 0.007077087 
16846539 LOC284080 0.48 3.31 0.037628129 
16838663 ENDOV 0.37 4.76 0.048934623 
16838787 C17orf89 0.52 5.98 0.049338055 
16841842 LOC284191 -0.41 4.18 0.028472331 
16872496 C19orf54 1.25 5.96 0.001207195 
 296 
16874032 MAMSTR 0.66 4.32 0.043107468 
16868251 ACTL9 -0.52 3.09 0.03805209 
16694178 RUSC1-AS1 0.51 4.99 0.021212202 
16685413 RSPO1 2.51 7.89 0.01325826 
16663223 RIMKLA 1.13 3.28 0.013225766 
16914595 LINC00494 -0.75 2.76 0.010583835 
16916462 SIRPB2 -0.66 5.21 0.024893542 
16905963 CCDC141 -1.51 3.94 7.26E-06 
17117853 FLJ38379 -0.73 3.04 0.002492816 
16879232 CYP1B1-AS1 -0.92 3.08 0.007909082 
16960084 SLC9A9 -1.18 6.83 0.000568641 
16956002 EOGT -0.76 8.03 0.03234765 
16968834 FAM13A-AS1 -0.69 4.86 0.031596331 
16977970 GPRIN3 -0.98 6.52 0.024635244 
17008676 RPL7L1 0.42 5.36 0.019402743 
17066811 LOC286059 -0.45 2.77 0.020424774 
17082250 FAM83H 2.16 7.00 3.66E-05 
17074075 LOC286083 -0.31 3.10 0.025496024 
17073297 ZFP41 0.50 5.05 0.033530783 
17088886 CRB2 2.65 6.64 0.000275103 
17098364 SCAI 0.88 6.65 0.047261273 
17100382 TPRN 1.12 4.01 0.003394282 
17087779 LOC286367 -0.76 4.30 0.012656127 
17116745 P2RY8 -0.92 5.41 0.03949699 
17108740 P2RY8 -0.81 5.68 0.00795511 
17117114 BCORP1 -1.07 3.46 0.000626937 
16700034 LIN9 0.82 5.28 0.00989778 
16796626 CCDC85C 1.01 4.42 0.007072458 
16837609 RAB37 -0.72 4.38 0.012455266 
16769924 MMAB 0.88 6.39 0.001961033 
16988906 CHSY3 -1.19 5.59 0.010016784 
17073290 GPIHBP1 -0.85 4.75 0.010320732 
16720115 B4GALNT4 1.94 5.64 0.000211324 
16769761 TMEM119 -1.27 4.70 0.003652987 
16836788 METTL2A 0.79 7.37 0.014510297 
16849913 ARL16 0.53 6.88 0.013011761 
16871680 ZNF260 0.65 8.04 0.008632924 
16867989 CLEC4G -1.15 4.01 0.001727434 
16680342 TMEM240 0.65 3.94 0.039715058 
16684674 MTMR9LP -1.32 4.87 0.002226908 
16897998 LOC339803 0.93 6.15 0.000836238 
16964107 NAT8L 1.11 4.55 0.021198014 
17024559 ZC3H12D -0.89 4.58 0.014108262 
17044315 FAM221A 1.39 6.04 0.01135105 
17082336 NRBP2 0.73 7.06 0.01384768 
17092512 ZDHHC21 -0.63 7.14 0.006567598 
17111994 RGAG4 -0.60 3.88 0.019330881 
17104832 NHSL2 -0.92 5.55 0.038335962 
17106067 VSIG1 -0.94 4.21 0.02957219 
16709795 NANOS1 0.79 5.66 0.017847035 
16829815 SMTNL2 2.08 5.72 0.003837347 
16900910 KIAA1211L 1.62 5.57 0.002889117 
16902945 NCKAP5 -1.03 4.71 0.01390577 
16938620 ZNF860 -0.80 3.83 0.013986609 
16995802 PLCXD3 -0.92 3.64 0.030086333 
17011980 RSPH4A -0.55 3.23 0.007281523 
17093397 KIF24 1.16 4.33 0.004236839 
16776936 TMEM255B -1.10 5.31 0.001233922 
 297 
16847238 SKA2 0.71 6.16 0.024547429 
16664754 FAM159A -1.02 3.81 0.00597007 
16936191 C22orf34 -0.85 3.41 0.004491121 
16963375 WDR53 0.40 5.69 0.022514505 
17045258 GPR141 -0.51 4.53 0.042473943 
16697580 ZBTB41 0.77 7.84 0.012000329 
16725041 FAM111B 1.44 6.05 0.015787574 
16725969 TMEM179B 0.51 5.80 0.006294787 
16727820 TBC1D10C -0.96 5.62 0.021693616 
16748196 LOC374443 -0.79 6.77 0.036793593 
16754646 PTPRQ 3.28 6.18 0.000275103 
16769315 C12orf42 -0.76 3.08 0.015935542 
16672214 PEAR1 -1.04 4.72 0.014210405 
16895193 PFN4 0.50 3.91 0.028472331 
16903529 RBM43 0.67 5.69 0.045048058 
16949991 NRROS -0.54 4.45 0.006258072 
17020480 GUSBP4 -0.89 5.81 0.013211011 
16657598 AGRN 1.79 8.37 0.000628104 
17062955 MKLN1-AS1 -0.79 6.94 0.035930768 
17015972 NHLRC1 0.68 3.45 0.03720646 
16996246 RNF138P1 -1.00 4.48 0.005046944 
16975560 KCTD8 2.45 5.27 0.005638276 
16923653 KRTAP10-7 -0.45 2.76 0.036136556 
17023066 CEP85L -1.06 3.82 0.000738173 
17023405 THEMIS -1.40 4.44 0.004067726 
16707836 CC2D2B -0.63 3.51 0.012704815 
16721304 OR56B1 -0.84 2.43 0.035352582 
16735214 GVINP1 -1.50 5.49 0.007187466 
16742115 LIPT2 1.00 5.61 0.000623709 
16810270 C2CD4B -0.79 3.66 0.035930768 
16817320 SBK1 0.74 4.26 0.040504046 
16826212 C16orf87 0.65 7.05 0.042961325 
16828228 C16orf47 -0.44 2.86 0.038878172 
16859034 CLEC17A -1.86 3.92 0.001618285 
16875760 TMEM238 1.38 7.17 0.012000329 
16658350 RNF207 0.66 5.84 0.03972536 
16661342 TRNP1 1.19 5.66 0.005187186 
16675533 C1orf53 0.68 5.56 0.047528766 
16678907 COA6 0.94 5.03 0.00234422 
16921627 LINC00478 -1.42 5.00 0.01384768 
16721307 OR52N4 -1.09 3.17 0.002085347 
16860545 NUDT19 0.79 6.99 0.010172466 
16679816 OR2G6 -0.62 2.94 0.026981053 
16895268 PTRHD1 0.61 4.52 0.002177593 
17042925 ELFN1 2.00 7.08 0.002202594 
16866702 MEX3D 0.86 6.33 0.012065993 
16813537 LOC400456 -1.71 3.86 2.42E-06 
16824566 KNOP1 0.72 6.60 0.002890948 
16829476 C17orf97 1.05 5.74 0.048934623 
16831857 FLJ35934 0.84 4.93 0.034084034 
16832024 GRAPL -2.12 4.92 0.000224628 
16875955 ZNF772 0.66 4.80 0.014525825 
16674273 C1orf220 -1.38 4.73 0.001049806 
16677808 FAM177B -1.54 3.60 0.000837761 
16935020 LOC400927 -0.47 5.62 0.034899663 
16876753 LOC400940 1.21 4.03 0.029372633 
16877530 LINC00954 -0.82 3.11 0.006577006 
16898375 LOC400958 -0.62 2.29 0.012022748 
 298 
16886257 TEX41 -0.62 2.79 0.03773156 
16949780 LINC00884 1.09 5.09 0.042473943 
16949933 LINC00885 1.14 4.07 0.047153863 
16965880 DTHD1 -1.40 4.15 0.004759764 
16968895 CCSER1 -0.85 3.63 0.009778355 
16979317 C4orf3 -0.35 4.91 0.044982261 
16985229 RGS7BP -1.21 3.94 0.00241872 
17026469 LOC401242 0.30 3.10 0.048925884 
17031327 LOC401242 0.30 3.10 0.048925884 
17033777 LOC401242 0.30 3.10 0.048925884 
17038814 LOC401242 0.30 3.10 0.048925884 
17016621 LOC401242 0.34 3.09 0.023657938 
17028916 LINC00243 -1.13 4.05 0.033997626 
17019348 CRIP3 -0.41 3.82 0.03485236 
17020214 KLHL31 2.42 5.65 0.002498679 
17055777 LOC401312 -0.77 2.90 0.002633541 
17092486 FLJ41200 -1.11 5.00 0.024771781 
17088148 SNX30 -0.54 7.86 0.026912903 
17101183 CD99P1 -0.76 5.26 0.015377204 
17115913 CD99P1 -1.39 3.55 0.005113143 
17110372 FLJ25917 1.20 4.91 0.041567289 
17051194 LINC01000 -0.54 7.13 0.006811348 
16734303 IFITM10 -1.13 4.75 0.019402743 
16868035 CTXN1 1.75 6.11 0.002719692 
16788534 MIR127 -0.75 3.97 0.017337887 
16847083 MIR142 -1.86 4.76 0.011744728 
16833017 MIR193A 0.71 3.94 0.043618386 
17104279 MIR223 -0.97 4.56 0.011735645 
17060442 MIR25 0.74 3.57 0.011024744 
17002176 FNDC9 -0.39 3.00 0.024746435 
17007417 HCG25 0.41 5.85 0.025491785 
17082817 C8orf82 0.62 5.00 0.022323152 
16702229 PRKCQ-AS1 -1.66 3.85 0.000363245 
16706610 LINC00857 1.36 4.61 0.005959278 
16755056 PLEKHG7 -0.47 2.55 0.043397402 
16795826 CCDC88C -0.97 5.80 0.002145853 
16798570 HERC2P9 -0.76 7.19 0.001587867 
16817583 SNX29P2 -1.06 5.52 0.000310311 
16851230 ANKRD20A5P -1.61 5.18 0.049767345 
16853325 HSBP1L1 1.18 7.14 0.001080715 
16870925 ZNF724P 1.56 5.08 0.000378504 
16896170 CAPN14 -0.47 2.50 0.020770795 
16884280 LOC440894 1.33 7.71 0.002529855 
16977378 TMEM150C -0.86 6.29 0.048213306 
16989038 C5orf56 -0.52 6.59 0.047315765 
17047597 DTX2P1-UPK3BP1-PMS2P11 0.91 7.23 0.018538243 
17072052 AARD 2.94 5.27 0.008607343 
16914733 ZFAS1 0.68 8.66 0.00995933 
17056845 TARP -0.57 3.47 0.048620662 
17056813 TARP -1.81 5.62 0.005410697 
17056823 TARP -1.81 5.62 0.005410697 
16940687 STGC3 -0.74 3.42 0.049287931 
17064269 GIMAP6 -0.64 6.31 0.047015132 
16756202 EID3 0.89 6.12 0.041638363 
16664235 LURAP1 -0.46 4.19 0.030029639 
17055786 LOC541472 -1.61 4.54 0.004187214 
16754324 ATXN7L3B 0.55 7.06 0.019818196 
16999754 LOC553103 1.46 4.87 0.013650974 
 299 
17094667 PGM5-AS1 -0.64 2.90 0.049004829 
16755035 CLLU1 -0.57 2.62 0.004796703 
16692772 ADAMTSL4-AS1 -1.37 5.52 0.004462291 
16702870 MIR511-1 -0.69 2.60 0.015878225 
16702914 MIR511-1 -0.69 2.60 0.015878225 
17000641 ECSCR -1.02 3.32 0.015592393 
17000644 ECSCR -1.55 6.18 0.0023633 
16893704 FAM110C 1.93 6.14 0.004796972 
16706562 LOC642361 0.57 4.78 0.047709521 
16719498 FAM196A 0.96 4.15 0.038720439 
16982083 SLED1 -1.52 4.06 0.011453436 
16996605 SMIM15 0.49 7.35 0.016535009 
17091815 EHMT1-IT1 -0.79 5.49 0.010685173 
16713754 LINC00842 3.86 7.20 0.000268728 
17011735 TRAF3IP2-AS1 -0.61 4.58 0.014314937 
16826606 CRNDE 1.37 5.23 0.024591035 
16995866 FLJ32255 -1.16 5.61 0.008607343 
16680362 C1orf233 1.08 6.30 0.013854361 
16861314 SDHAF1 0.62 3.92 0.022989941 
16691879 PPIAL4G -0.64 2.89 0.012533126 
16735656 LOC644656 0.47 3.98 0.046856391 
16842196 FAM83G 0.87 4.16 0.010876802 
16901558 FLJ38668 0.63 4.32 0.026842368 
16867427 ARRDC5 -0.97 4.82 0.004469784 
16703431 LINC00264 -0.58 2.69 0.034373373 
16882671 ANKRD36BP2 -1.15 3.17 0.002929216 
16666730 LOC646626 -0.54 3.82 0.038867549 
17056285 LOC646762 0.98 5.60 0.034240458 
16775234 LOC647264 0.45 4.43 0.04086658 
16854792 LINC00669 0.72 3.06 0.032512111 
16776953 GAS6-AS1 -0.75 5.30 0.001837551 
16996969 GUSBP3 -0.97 6.67 0.036886537 
16827255 KIAA0895L -0.47 5.92 0.031341948 
16817562 RRN3P2 -0.84 4.83 0.011603633 
16987992 SNORA13 0.93 4.73 0.013450106 
16847393 SCARNA20 0.90 4.77 0.014739525 
16677254 SNORA16B -1.41 4.08 0.000380459 
16874641 SNORD88B 0.88 5.83 0.010861211 
16811884 FBXO22-AS1 2.27 5.21 0.010973189 
16720213 LOC692247 1.15 4.97 0.030086333 
16670918 MIR554 1.91 4.97 0.000907211 
16878888 MIR558 -0.56 2.79 0.038481195 
16963685 MIR571 -0.80 5.35 0.008275304 
16996133 MIR581 -1.42 4.98 0.000293147 
16705006 MIR605 -1.47 2.23 0.000107648 
16769838 MIR619 -1.17 5.18 0.00546344 
16775763 MIR622 1.72 4.44 0.001587867 
16776050 MIR623 -0.94 4.75 0.01135105 
16809645 MIR628 -0.67 2.95 0.013211011 
16912939 MIR644A -0.79 7.79 0.019306979 
17076273 LOC728024 0.78 2.99 0.005089028 
16893697 LOC728323 -0.53 8.31 0.033319597 
16685359 LOC728431 0.77 5.73 0.029382558 
16932735 GGT2 -0.37 4.00 0.03238455 
16769403 C12orf73 0.69 6.00 0.014510297 
16663291 CCDC30 0.96 3.68 0.040628159 
16663282 CCDC30 0.81 4.29 0.036610869 
16713760 HNRNPA1P33 4.00 6.88 0.000152715 
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16867326 PLIN4 -1.59 4.58 0.016925456 
17014421 LOC729603 -0.50 4.33 0.040776405 
16682044 FLJ37453 0.59 4.05 0.017198424 
16971443 FAM160A1 2.05 5.10 0.001044656 
16879276 MORN2 0.60 6.71 0.037022715 
16824915 RRN3P1 -0.90 2.65 0.000259924 
17009615 LOC730101 -0.82 3.95 0.009537272 
16696785 LOC730102 -0.68 6.69 0.045389123 
16725901 METTL12 0.66 5.13 0.043230543 
16975157 RELL1 -0.67 6.64 0.019390771 
16970068 SNHG8 0.65 6.97 0.043323912 
16858120 SNORD105B 0.65 11.98 0.021656568 
16914743 SNORD12B 0.82 5.39 0.025662544 
16916156 MIR941-1 -0.81 7.99 0.007917033 
16833019 MIR365B 0.96 3.92 0.004969977 
16707824 C10orf131 -0.77 2.72 0.002328909 
16673652 LOC100127910 -1.86 6.61 0.003044902 
17117631 LOC100128075 -1.25 4.97 0.000180119 
17073477 FAM83H-AS1 0.65 5.33 0.022294811 
17107323 LINC00892 -0.80 3.04 0.018616123 
17118074 LOC100128482 -0.98 4.44 0.009842076 
16703062 NEBL-AS1 0.56 3.72 0.04997158 
17113038 LOC100128594 -0.42 3.22 0.024904242 
17117414 LOC100128751 -0.96 4.93 0.004347375 
17096145 LINC00476 -0.42 3.09 0.040335382 
17053769 LINC01003 0.66 5.49 0.042105503 
17072931 LOC100129104 0.43 3.95 0.033731714 
17118138 LOC100129233 2.28 5.75 0.00150143 
16943976 LOC100129297 -0.69 3.04 0.008738402 
16680634 LOC100129534 0.79 4.63 0.035879312 
16821324 LOC100129617 -1.06 4.72 0.000300887 
16821889 LOC100129697 -0.60 4.38 0.007777057 
17117811 LOC100129831 -0.94 4.25 0.010854508 
16933406 LOC100129936 -0.56 3.51 0.024368191 
16682726 LOC100130193 -0.96 5.24 0.002597144 
17080991 LINC00861 -1.71 3.63 0.001997066 
17004710 TFAP2A-AS1 0.68 3.22 0.031525772 
17077583 LOC100130298 -0.64 3.17 0.025023521 
17117547 LOC100130428 -0.93 5.50 0.038303393 
17118376 LOC100130458 -0.66 2.73 0.006803129 
17024176 LOC100130476 -0.56 3.04 0.025025521 
16853355 PARD6G-AS1 0.62 3.83 0.025023521 
17011185 TSTD3 -0.76 5.27 0.011702473 
17014235 C6orf99 0.51 3.08 0.033279228 
16813590 LOC100130976 -1.44 3.41 2.74E-06 
16727795 LOC100130987 0.54 4.08 0.038481195 
16697654 MIR181A1HG -0.80 5.06 0.038039179 
17005847 LOC100131289 -0.35 3.25 0.0421346 
17117545 LOC100131541 -1.01 6.57 0.048514946 
16776048 FKSG29 -1.10 6.29 0.002089143 
17117973 LOC100131802 -0.98 4.67 0.014395164 
17118030 LOC100131826 -1.90 4.87 0.010957166 
17069937 LOC100132891 -0.90 5.52 0.042432839 
16953237 LOC100133032 -0.75 4.12 0.049767345 
16777832 LINC00426 -1.07 3.86 0.006821203 
16824865 LOC100190986 -0.70 9.54 0.022002025 
16712071 PPIAP30 -1.09 5.67 0.001285787 
16763608 PCED1B-AS1 -1.09 5.60 0.003296619 
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17118102 LOC100272216 -0.76 6.28 0.029083363 
17118111 LOC100272216 -0.76 6.28 0.029083363 
17118115 LOC100272216 -0.76 6.28 0.029083363 
17118062 LOC100272216 -0.76 6.49 0.026095642 
17118070 LOC100272216 -0.76 6.49 0.026095642 
17118125 LOC100272216 -0.76 6.49 0.026095642 
17118132 LOC100272216 -0.76 6.49 0.026095642 
17118136 LOC100272216 -0.76 6.49 0.026095642 
17118121 LOC100272216 -0.78 5.85 0.018572209 
16996941 LOC100272216 -1.01 7.43 0.015058806 
16814353 LOC100287175 0.64 3.87 0.025903868 
16700507 LINC00582 -1.03 3.42 0.00461557 
16714269 TIMM23 0.49 9.19 0.035365838 
16750398 LOC100288798 -0.63 4.40 0.032095172 
17101387 LOC100288814 0.62 3.62 0.042051728 
16896343 LOC100288911 1.82 6.29 0.006006236 
16692764 LOC100289061 -0.75 5.14 0.016954776 
17117829 LOC100293044 0.87 6.03 0.012000329 
17056785 MIR1200 -1.63 3.85 0.000282222 
16831427 MIR1288 -0.48 3.45 0.024677029 
17011165 MIR2113 -0.51 3.34 0.038367592 
16888669 MIR1245A -1.53 3.16 0.045223684 
16705437 MIR1254-1 -0.68 6.15 0.029770839 
16823889 MIR548H2 -0.85 6.54 0.031759503 
16709237 MIR548E -0.53 2.37 0.037383347 
16828072 SNORA70D 0.60 4.05 0.033104806 
16981500 MIR548T -0.58 3.81 0.0162893 
17075060 MIR548V -1.84 4.81 0.002360681 
16956053 MIR3136 -0.68 2.61 0.020357132 
16980714 MIR3140 -1.17 3.41 0.027676678 
16709317 MIR4295 -1.00 6.25 0.009910072 
17095638 MIR4290 -0.63 3.33 0.020221958 
16971046 MIR3139 -0.92 4.26 0.038064633 
16907639 MIR2355 -0.86 3.85 0.049077824 
16920610 MTRNR2L3 -0.43 2.76 0.014739525 
16748119 LINC00987 -0.99 4.57 0.002736976 
16999767 MIR3936 2.21 5.32 0.002719692 
16989241 MIR3661 0.94 5.02 0.032953656 
16852564 LOC100505549 -0.69 4.94 0.009663603 
17008189 LOC100505550 -0.32 3.18 0.044342925 
16815852 LOC100505564 -0.76 4.35 0.00052561 
16833917 LRRC3C -0.79 3.69 0.014748667 
16862651 LOC100505622 -0.52 3.85 0.00507933 
16672489 LOC100505633 2.53 5.91 0.000443686 
16948555 LINC00888 -0.65 3.69 0.031117432 
16983152 SNHG18 1.11 6.57 0.00467563 
16968293 LINC00989 -0.81 3.53 0.003130957 
17044166 LOC100506178 -0.82 3.43 0.005903384 
16748539 LOC100506314 1.39 5.02 0.002226908 
16700070 ITPKB-IT1 -0.88 4.37 0.000366196 
16762642 LOC100506578 -0.58 3.36 0.048490926 
16757863 PXN-AS1 0.57 4.94 0.021838852 
16771319 DYNLL1-AS1 0.65 5.92 0.004314048 
16843446 SLFN12L -0.95 5.55 0.025898916 
17045320 TRG-AS1 -0.74 3.57 0.04803565 
16660392 LOC100506801 -0.83 3.83 0.001108949 
16766794 LOC100506844 0.49 3.33 0.016782224 
16888183 TTN-AS1 -0.57 5.72 0.048943191 
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17105719 LOC100506901 2.01 4.92 0.000244467 
16942419 PSMD6-AS2 -0.80 5.78 0.035784036 
17118039 LOC100507209 -1.30 5.30 0.002318907 
16838094 SNHG16 0.71 8.80 0.012241205 
17012676 LINC01013 -0.64 2.69 0.001384232 
16865718 ZNF865 0.61 4.27 0.0338111 
16949785 TMEM44-AS1 0.62 4.17 0.04997158 
16823043 LOC100507303 1.12 6.44 0.010660757 
17082032 LOC100507316 0.87 4.21 0.004636978 
16754118 LOC100507330 -0.59 3.05 0.005892147 
17010273 KCNQ5-IT1 -1.30 4.23 0.015886272 
16797326 LOC100507437 0.91 4.41 0.004002822 
17077191 LOC100507516 -1.26 5.21 0.012455266 
17077376 LINC00968 -0.60 2.46 0.002459618 
17117480 LOC100507663 -0.75 5.87 0.017767118 
16955935 LOC100508226 -1.17 4.29 0.007777057 
17088116 MIR4668 -1.06 2.87 0.031440911 
16872227 MIR4530 0.69 3.69 0.03805209 
16957673 MIR4796 -0.97 2.96 0.005979006 
16909154 MIR4439 -0.86 2.25 0.003033218 
16935510 MIR378I -1.24 4.85 0.023743259 
17093990 MIR4540 -0.93 2.45 0.006037426 
16777209 MIR4499 -0.88 2.34 0.004020055 
17082258 MIR4664 1.35 3.83 0.0009769 
16968521 MIR4451 -1.17 5.81 0.029382558 
16817918 MIR4518 -1.17 3.68 0.000976305 
16855161 MIR4744 -0.66 3.22 0.019306979 
17069359 MIR4470 0.52 3.00 0.024885713 
16750429 MIR4698 -0.47 3.16 0.045327886 
16992195 MIR378E -1.14 4.48 0.003270512 
16816680 SNX29P1 -0.62 3.18 0.048028746 
17118432 RBSG2 -0.45 4.25 0.027628988 
16756222 IGANRP -1.38 6.16 0.002498679 
16797535 LOC100653084 -1.98 3.44 0.016193023 
16904775 CERS6-AS1 0.51 2.72 0.040827531 
16773581 RNU6-82P -1.10 3.38 0.00251945 
16667948 VAV3-AS1 -0.87 3.08 0.001238051 
17056734 AOAH-IT1 -1.09 4.60 0.007097819 
17054885 RNF216-IT1 -0.42 5.49 0.01689906 
16753767 IFNG-AS1 -1.75 4.03 0.005962736 
16849391 LOC100996291 -0.40 3.46 0.04275753 
16989423 LOC100996485 0.72 4.31 0.025496024 
16987087 MEF2C-AS1 -0.80 3.06 0.000514472 
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Appendix 4.2 - Functional Prediction of Nonsynonymous SNV with SIFT, Polyphen2 
and MutationTaster  
Gene Exon Codon protein SIFT Polyphen2 
Mutation 
Taster 
GOLGA6L4 exon3 c.G253C p.E85Q T . P 
HS3ST6 exon1 c.G77T p.R26L T . D 
MAB21L1 exon1 c.C280G p.L94V T B D 
MPPED1 exon2 c.A20C p.D7A T B D 
PLXDC1 exon13 c.C1303G p.L435V T B D 
KLHL6 exon3 c.C733T p.H245Y T B D 
ASH1L exon3 c.G2233A p.V745I T B D 
ANO3 exon2 c.G121A p.A41T T B D 
NOP9 exon4 c.G869A p.R290H,NOP9 T B D 
TFAP2D exon2 c.C200A p.T67N T B D 
XRN2 exon21 c.G1967A p.R656Q T B D 
HNRNPU exon7 c.G1420A p.E474K,HNRNPU T B D 
DNAJB12 exon1 c.G153C p.K51N,DNAJB12 T B D 
KCNB1 exon2 c.G1882A p.G628R T B D 
TCEA3 exon8 c.C782T p.A261V T B D 
ROR1 exon6 c.G910A p.A304T,ROR1 T B D 
SP6 exon2 c.G250A p.D84N,SP6 T B D 
KRTAP5-1 exon1 c.T70C p.C24R T B D 
ADCY3 exon8 c.G1653T p.Q551H T B D 
PHF21A exon18 c.A1805G p.N602S,PHF21A T B D 
PLXNA3 exon6 c.C1477A p.Q493K T B D 
RTKN exon3 c.G359T p.R120L,RTKN T B D 
GIGYF1 exon11 c.G1223T p.G408V T B D 
 308 
HOXC5 exon1 c.A209C p.H70P T B D 
TTC7A exon4 c.C556A p.R186S,TTC7A T B D 
SNRPD2 exon3 c.G268A p.V90I,SNRPD2 T B D 
AMMECR1L exon5 c.G554T p.R185L,AMMECR1L T B D 
MAP3K10 exon3 c.C1000A p.R334S T B D 
TIMM44 exon9 c.G914T p.R305L T B D 
PIK3CB exon3 c.G426T p.M142I,PIK3CB T B D 
LRRC2 exon3 c.G162T p.R54S T B D 
SOCS5 exon2 c.G1040A p.S347N,SOCS5 T B D 
DOCK5 exon2 c.C67A p.Q23K T B D 
RUNX3 exon4 c.G650T p.G217V,RUNX3 T B D 
ACTN1 exon19 c.G2334T p.M778I,ACTN1 T B D 
TXN exon2 c.G40T p.A14S,TXN T B D 
INF2 exon18 c.C2704A p.Q902K,INF2 T B D 
ACSM4 exon3 c.C460A p.L154I T B D 
TPM4 exon1 c.C17A p.S6Y T B D 
ACOT1 exon1 c.A439G p.T147A T B D 
CYP3A5 exon10 c.G889T p.A297S,CYP3A5 T B D 
RBPJL exon6 c.C553A p.H185N,RBPJL T B D 
KRTAP2-1 exon1 c.C335A p.P112H T B D 
EIF4G1 exon2 c.C31A p.P11T,EIF4G1 T B D 
MPLKIP exon1 c.G83T p.R28L T B D 
PRRX2 exon4 c.C637A p.P213T T B D 
TPD52L1 exon1 c.C14A p.A5E,TPD52L1 T B D 
LPIN1 exon4 c.G389A p.G130D,LPIN1 T B D 
PRKAR2B exon1 c.G197T p.G66V T B D 
SLC9A5 exon5 c.C856A p.L286I T B D 
TRAK2 exon14 c.G1802T p.G601V T B D 
CARM1 exon1 c.C211A p.L71I T B D 
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CENPI exon6 c.C607A p.H203N T B D 
TVP23C exon3 c.G152A 
p.C51Y,TVP23C-
CDRT4 
T B D 
AGAP7P exon7 c.C1718A p.A573D T B D 
ANP32A exon4 c.G333C p.K111N T B D 
COL8A1 exon4 c.G1560T p.E520D,COL8A1 T B D 
NSUN7 exon9 c.C1207A p.Q403K T B D 
TTC28 exon15 c.G4278T p.E1426D T B D 
RPL17 exon4 c.G119T 
p.W40L,RPL17-
C18orf32 
T B D 
NBEAL2 exon6 c.G534T p.Q178H T B D 
INTS4 exon14 c.G1756T p.A586S T B D 
CCDC74A exon1 c.G68T p.R23L,CCDC74A T B D 
PRKDC    T B D 
SHANK3 exon21 c.G3376A p.G1126R T D N 
WNT6 exon4 c.C824T p.T275M T D N 
KIAA1462 exon3 c.C1391T p.A464V T D N 
SREBF1 exon3 c.G535T p.G179W,SREBF1 T D N 
SIGLEC11 exon3 c.C671T p.T224I,SIGLEC11 T D N 
HMBS exon2 c.C47A p.P16Q,HMBS T D N 
ARID3A exon3 c.C605A p.P202H T D N 
LRFN3 exon2 c.T676C p.S226P T D N 
CASP10 exon5 c.C598A p.P200T,CASP10 T D N 
C1orf167 exon15 c.C3275A p.P1092Q T D N 
RGPD3 exon17 c.A2468C p.K823T T D N 
ACAN exon11 c.C2258A p.P753Q,ACAN T D N 
NOTCH1 exon34 c.G6733T p.G2245W T D N 
SPATA31D1 exon4 c.C1634A p.P545Q T D N 
FAM9A exon4 c.C259A p.P87T,FAM9A T D N 
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EFCAB12 exon5 c.G1001A p.G334D T D N 
AMH exon5 c.G1183T p.G395C T D N 
FOXE3 exon1 c.G112T p.G38W T D N 
OBSCN exon47 c.C12614T p.T4205I,OBSCN T D N 
PKD1 exon10 c.C2027T p.P676L,PKD1 T D N 
IVL exon2 c.G846C p.Q282H T D N 
ANKRD2 exon3 c.C352A p.L118M,ANKRD2 T D N 
FAM214B exon3 c.G39T p.E13D T D N 
PLEKHA5 exon8 c.C557A p.P186H,PLEKHA5 T D N 
TOR2A exon1 c.G112T p.G38C,TOR2A T D N 
TCTN1 exon12 c.C1349A p.P450Q,TCTN1 T D N 
OTUD6A exon1 c.C854A p.P285Q T D N 
WISP3 exon1 c.C94A p.L32M,WISP3 T D N 
CCDC9 exon12 c.C1426A p.P476T T D N 
RGPD3 exon17 c.T2435G p.L812R T D N 
KIF20B exon13 c.C1445A p.P482Q,KIF20B T D N 
MCF2L exon1 c.C52A p.L18M T D N 
KLF2 exon2 c.C581A p.P194Q T D N 
FRG2C exon4 c.C605A p.P202Q T D N 
COL12A1 exon16 c.G3305A p.S1102N T D D 
DMAP1 exon3 c.G202A p.A68T,DMAP1 T D D 
SEC23IP exon16 c.G2605A p.D869N T D D 
GLTSCR1 exon7 c.C2248T p.P750S T D D 
GPHN exon7 c.A468C p.Q156H,GPHN T D D 
URGCP-
MRPS24 
exon4 c.G157A p.D53N,URGCP T D D 
GAB2 exon4 c.G947C p.R316P,GAB2 T D D 
POM121L2 exon1 c.G2677A p.G893R T D D 
SPAG9 exon5 c.A662G p.N221S,SPAG9 T D D 
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ALDH16A1 exon15 c.G2042A p.C681Y,ALDH16A1 T D D 
LRP12 exon4 c.C841G p.R281G,LRP12 T D D 
TBX22 exon5 c.A772G p.T258A,TBX22 T D D 
KLHL6 exon7 c.C1696T p.R566W T D D 
PTPN1 exon5 c.G415T p.V139L,PTPN1 T D D 
GLTSCR1L exon5 c.A460G p.N154D T D D 
SLC43A2 exon5 c.C554G p.P185R,SLC43A2 T D D 
ITPR1 exon20 c.A2353C p.T785P,ITPR1 T D D 
FES exon14 c.A1778G p.E593G,FES T D D 
FLT3 exon7 c.C772T p.P258S T D D 
GRID2 exon6 c.G745A p.D249N,GRID2 T D D 
KLHL2 exon13 c.G1387A p.D463N,KLHL2 T D D 
FAM118B exon7 c.C932A p.P311Q T D D 
SETD6 exon7 c.T1043C p.V348A,SETD6 T D D 
GRIA4 exon15 c.G2314A p.V772I T D D 
LRIT1 exon2 c.G346T p.G116W T D D 
ZNF680 exon4 c.G736A p.A246T T D D 
STAB1 exon15 c.C1598A p.S533Y T D D 
SOBP exon6 c.A1412C p.N471T T D D 
BANP exon2 c.C59A p.P20H,BANP T D D 
BRSK1 exon14 c.C1514A p.P505H T D D 
DNAAF3 exon6 c.G725T p.W242L,DNAAF3 T D D 
MED25 exon7 c.T716C p.L239P T D D 
MYOG exon2 c.C512A p.P171Q T D D 
FDFT1 exon3 c.C311A p.P104Q,FDFT1 T D D 
PLLP exon3 c.G352A p.A118T T D D 
STYK1 exon4 c.C88T p.P30S T D D 
WDR59 exon24 c.G2453T p.W818L T D D 
PKHD1 exon5 c.G308C p.G103A,PKHD1 T D D 
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TMEM25 exon5 c.C745A p.L249I,TMEM25 T D D 
UBTF exon7 c.C607A p.Q203K,UBTF T D D 
P2RX4 exon1 c.G133T p.G45W,P2RX4 T D D 
LRSAM1 exon2 c.C61A p.Q21K,LRSAM1 T D D 
CLEC2L exon1 c.G174T p.W58C T D D 
FAM43B exon1 c.C467A p.P156Q T D D 
MMRN2 exon6 c.T2263G p.F755V T D D 
SMPD4 exon14 c.G1591T p.D531Y,SMPD4 T D D 
TTC7A exon17 c.C1001A p.A334D,TTC7A T D D 
LAMA5 exon44 c.G5773T p.A1925S T D D 
DDHD2 exon8 c.C868A p.L290M,DDHD2 T D D 
CSDE1 exon17 c.G2238T p.R746S,CSDE1 T D D 
FOXRED1 exon8 c.C838A p.Q280K T D D 
NCL exon8 c.G1218T p.Q406H T D D 
CCDC108 exon16 c.G2615T p.R872L T D D 
PDCL3 exon5 c.C376A p.L126I T D D 
PBX4 exon1 c.C100A p.L34M T D D 
COL16A1 exon63 c.G3903T p.Q1301H T D D 
ZNF511 exon1 c.G134T p.R45L T D D 
AIDA exon6 c.G387T p.L129F T D D 
ARHGEF10L exon8 c.G794T 
p.G265V,ARHGEF10
L 
T D D 
COL12A1 exon33 c.G4047T p.L1349F,COL12A1 T D D 
PIGS exon8 c.G840T p.L280F T D D 
CFAP43 exon29 c.G3663T p.E1221D T D D 
CCDC33 exon4 c.C407A p.P136H T D D 
FBN3 exon55 c.C7073A p.T2358N T D D 
ARPP21 exon2 c.C71A p.P24Q,ARPP21 T D D 
NEB exon94 c.G13954T p.A4652S,NEB T D D 
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KIAA1549 exon9 c.G3832T p.G1278C,KIAA1549 T D D 
IGF2BP2 exon14 c.G1437T p.Q479H,IGF2BP2 T D D 
SOX18 exon2 c.C592A p.R198S T D D 
GADL1 exon3 c.G221T p.W74L T D D 
CEP250 exon10 c.C880A p.Q294K T D D 
BCAM exon14 c.C1769A p.P590Q T D D 
PRKDC    T D D 
NBPF9    T D D 
C10orf82 exon4 c.C412G p.L138V T P N 
RASGRP4 exon5 c.C409A p.H137N,RASGRP4 T P N 
BEND2 exon4 c.C391G p.Q131E,BEND2 T P N 
SPACA3 exon2 c.G37A p.V13M T P N 
COL22A1 exon37 c.A2824G p.R942G T P N 
SCG2 exon2 c.C1024A p.P342T T P N 
DPCR1 exon2 c.C2204T p.P735L T P N 
ZNF486 exon4 c.C917G p.P306R T P N 
CRB2 exon10 c.G2791T p.G931W T P N 
CABIN1 exon31 c.C5294A p.P1765Q,CABIN1 T P N 
CUX2 exon6 c.C490A p.L164I T P N 
RSPH10B2 exon14 c.C1589A p.P530Q,RSPH10B T P N 
SEMA3G exon1 c.C31A p.L11M T P N 
ZNF471 exon4 c.C227T p.T76M T P N 
FRG2 exon4 c.G450T p.R150S,FRG2 T P N 
MRPL11 exon1 c.G13T p.G5C,MRPL11 T P N 
AVIL exon16 c.G2011T p.A671S T P N 
MMP11 exon1 c.C92A p.A31D T P N 
ALG1 exon7 c.C758A p.P253Q T P N 
OR5H1 exon1 c.G149T p.W50L T P N 
ELF4 exon9 c.C1213A p.H405N,ELF4 T P N 
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RAET1G exon2 c.C134A p.P45H T P N 
C19orf52 exon2 c.C212A p.A71E T P N 
P2RX4 exon1 c.C26A p.A9E,P2RX4 T P N 
CNTRL exon17 c.C2803A p.L935I T P N 
SPATA31E1 exon4 c.G3386A p.C1129Y T P N 
TCEB3CL exon1 c.C905G p.A302G,TCEB3C T P N 
BCAR1 exon2 c.C386A p.P129Q,BCAR1 T P N 
ZNF552 exon3 c.C248A p.A83E T P N 
SHANK3 exon21 c.C2375A p.P792Q T P N 
TBX10 exon2 c.G80T p.W27L T P N 
ANKRD20A3 exon3 c.C382T 
p.L128F,ANKRD20A
2 
T P N 
MAPKBP1 exon23 c.G2675T p.R892M,MAPKBP1 T P N 
CGN exon12 c.C2146A p.Q716K T P N 
CCDC159 exon5 c.C406A p.Q136K T P N 
MUC20 exon2 c.G1087T p.A363S,MUC20 T P N 
TARBP1 exon1 c.C305T p.A102V T P N 
C9orf3 exon10 c.C1703A p.A568D,C9orf3 T P N 
MUC20 exon2 c.G1114T p.G372C,MUC20 T P N 
TJP3 exon5 c.C311A p.P104H,TJP3 T P N 
ADAMTS16 exon1 c.C40A p.L14M T P N 
FBRSL1 exon17 c.C2612A p.A871E T P N 
SMYD3 exon8 c.G732A p.M244I,SMYD3 T P D 
KCNN1 exon3 c.C339A p.F113L T P D 
FOXK1 exon2 c.C631A p.P211T T P D 
MN1 exon1 c.C1802T p.P601L T P D 
FAM73B exon9 c.A942C p.R314S T P D 
SEMA5A exon4 c.C193A p.P65T T P D 
WBSCR17 exon10 c.C1573A p.R525S T P D 
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NBEAL1 exon38 c.C5953A p.P1985T T P D 
FAM20C exon1 c.C581A p.P194H T P D 
FANCD2 exon34 c.G3457A p.E1153K,FANCD2 T P D 
HIVEP2 exon6 c.G5197T p.D1733Y T P D 
CELSR2 exon17 c.C6271A p.Q2091K T P D 
PIEZO1 exon24 c.C3436G p.P1146A T P D 
SYN1 exon12 c.G1505T p.S502I,SYN1 T P D 
POU3F1 exon1 c.G344T p.R115L T P D 
EPB41 exon13 c.C2044A p.Q682K,EPB41 T P D 
CDKAL1 exon6 c.C427A p.Q143K T P D 
KIAA1244 exon25 c.C4133A p.P1378Q T P D 
CDH22 exon7 c.C1234A p.L412M T P D 
ITGA9 exon16 c.G1695T p.R565S T P D 
SLC24A5 exon8 c.C1114A p.L372I T P D 
SEZ6L exon12 c.C2572A p.H858N,SEZ6L T P D 
USH2A exon46 c.G9063T p.Q3021H T P D 
RGMA exon1 c.G3T p.M1I,RGMA T P D 
C10orf54 exon6 c.G880C p.V294L T P D 
NAB2 exon2 c.T622C p.F208L T P D 
SMOC1 exon1 c.C22A p.R8S,SMOC1 T P D 
MRPS6 exon1 c.C7A p.R3S T P D 
C1orf106 exon9 c.C1570A p.Q524K,C1orf106 T P D 
DNAH17 exon70 c.G11282T p.G3761V T P D 
SPEG exon4 c.C2036A p.P679H T P D 
ADCY10 exon14 c.G1526T p.R509L,ADCY10 T P D 
ADARB2 exon8 c.G1812T p.E604D T P D 
ADAMTS6 exon20 c.G2460T p.L820F T P D 
DGKQ exon4 c.G506T p.R169L T P D 
SLC6A7 exon14 c.C1734A p.D578E T P D 
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SLC52A2 exon3 c.C199A p.L67I,SLC52A2 T P D 
TUBGCP5 exon22 c.C2971A p.H991N,TUBGCP5 T P D 
HK2 exon18 c.A2627T p.H876L T P D 
MUC16 exon66 c.T41639G p.L13880W T P . 
NOS1AP exon6 c.C578A p.P193Q,NOS1AP T P . 
MUC16 exon55 
c.A40562
G 
p.N13521S T P . 
MUC16 exon55 
c.G40547
A 
p.R13516K T P . 
C1orf167 exon2 c.C44A p.P15Q D . N 
POTEJ exon13 c.C1547A p.P516Q D . N 
CFAP46 exon29 c.G3968T p.C1323F D . N 
TTC34 exon4 c.G628T p.G210W D . N 
SEC14L6 exon9 c.C743A p.P248H D . D 
MUC3A exon2 c.C956T p.T319I D . . 
IL19 exon1 c.G10A p.E4K D B N 
MAPK13 exon3 c.G293A p.R98H D B N 
PLEKHA4 exon20 c.G2263A p.G755R D B N 
PRR29 exon5 c.G604A p.V202I D B N 
OR4C12 exon1 c.T806C p.V269A D B N 
RASIP1 exon5 c.C1493T p.A498V D B N 
PRR25 exon1 c.T235G p.W79G D B N 
TMEM173 exon5 c.C694T p.H232Y,TMEM173 D B N 
COL27A1 exon2 c.C77A p.S26Y D B N 
MUC5B exon31 c.A5779T p.T1927S D B N 
PHKB exon25 c.G2353A p.G785R D B N 
PODN exon1 c.C19A p.R7S,PODN D B N 
DUSP13 exon2 c.G3T p.M1I D B N 
ATP13A2 exon27 c.G3389T p.W1130L D B N 
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MAMLD1 exon5 c.C2977A p.Q993K D B N 
OLFML2A exon1 c.C71A p.P24H D B N 
NOC2L exon16 c.G1826T p.R609L D B N 
KRTAP4-8 exon1 c.G470T p.R157L D B N 
S1PR5 exon2 c.G775T p.A259S,S1PR5 D B N 
ZNF140 exon4 c.C1000A p.L334I,ZNF140 D B N 
NTN3 exon6 c.C1562A p.P521H D B N 
PNCK exon10 c.G1115T p.R372L,PNCK D B N 
ZNF75D exon3 c.C533A p.S178Y,ZNF75D D B N 
FOXD4L1 exon1 c.C1132A p.Q378K D B N 
PRSS58 exon4 c.G330T p.E110D D B N 
ATAD3A exon3 c.G363T p.Q121H D B N 
IGSF9B exon18 c.G3821T p.G1274V D B D 
RPL10 exon2 c.C19T p.R7C,RPL10 D B D 
ATG2B exon2 c.G264T p.Q88H D B D 
TRIB1 exon1 c.C49A p.R17S D B D 
SNRPD2 exon3 c.C273G p.N91K,SNRPD2 D B D 
CLK1 exon9 c.A1124G p.D375G,CLK1 D B D 
PRPH exon1 c.C433A p.Q145K D B D 
GNA11 exon1 c.G21T p.M7I D B D 
RPL4 exon7 c.G773T p.R258L D B D 
CNN2 exon1 c.G37T p.G13W,CNN2 D B D 
AIDA exon1 c.G32T p.R11L D B D 
CYP4F3 exon13 c.C1495T p.R499C,CYP4F3 D B D 
USP17L2 exon1 c.C337A p.H113N D B D 
MUC16 exon14 c.G36759T p.R12253S D B . 
FAM179B exon1 c.C1807T p.H603Y D D N 
ARHGEF11 exon26 c.T2374A p.W792R,ARHGEF11 D D N 
ZNF646 exon2 c.C2615A p.P872H D D N 
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PCDHGA5 exon1 c.G2086A p.A696T,PCDHGA5 D D N 
KIR3DL1 exon3 c.C90G p.F30L D D N 
PITPNM1 exon4 c.C382G p.L128V,PITPNM1 D D N 
PPP1R1A exon1 c.C38G p.T13R D D N 
ZNF845 exon4 c.C1276A p.L426I D D N 
COQ9 exon1 c.C5A p.A2E D D N 
SLC38A9 exon8 c.G586T p.G196W,SLC38A9 D D N 
GNB1L exon3 c.G106T p.G36W D D N 
PCDHA6 exon1 c.C1406A p.P469Q,PCDHA6 D D N 
SATL1 exon3 c.C1726A p.L576I D D N 
SPIDR exon4 c.A190T p.R64W,SPIDR D D N 
ENSA exon2 c.G189T p.W63C D D N 
MUC1 exon2 c.G282T p.W94C,MUC1 D D N 
ACAD10 exon12 c.C1628A p.P543H,ACAD10 D D N 
ARHGEF35 exon2 c.C1352A p.P451H D D N 
AKNA exon22 c.G4213T p.A1405S D D N 
CTC1 exon10 c.C1733A p.A578D D D N 
CR1 exon34 c.C5552A p.P1851Q,CR1 D D N 
RHBDF2 exon2 c.G25T p.G9W,RHBDF2 D D N 
LCE1D exon2 c.C131A p.S44Y D D N 
LAT2 exon12 c.C671A p.P224Q,LAT2 D D N 
PPP1R3F exon4 c.G261T p.Q87H,PPP1R3F D D N 
MIER2 exon8 c.G731T p.R244M D D N 
LILRB1 exon14 c.A1789T p.T597S,LILRB1 D D N 
ZNF624 exon2 c.G34T p.G12W D D N 
CNTNAP3 exon22 c.G3616T p.G1206W D D N 
IFNA10 exon1 c.G202T p.G68C D D N 
GZMH exon1 c.G49T p.G17W,GZMH D D N 
AKR7A2 exon1 c.G274T p.G92W D D N 
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CCL8 exon3 c.C233A p.P78H D D N 
CDC25A exon1 c.C14A p.P5Q,CDC25A D D N 
SHANK3 exon11 c.G1375T p.G459C D D N 
TNXB exon23 c.G8038T p.G2680W D D N 
KIR3DL2 exon2 c.C62A p.P21Q,KIR3DL2 D D N 
DNAH12    D D N 
PPM1F exon8 c.G1076T p.C359F D D D 
GPX8 exon1 c.G3A p.M1I D D D 
DENND5A exon12 c.G2312A p.G771D,DENND5A D D D 
FCN2 exon7 c.T710A p.L237Q,FCN2 D D D 
PPRC1 exon8 c.C3754T p.R1252W,PPRC1 D D D 
MAP1A exon4 c.A2714C p.K905T D D D 
STK4 exon6 c.G659A p.G220E D D D 
CACNA1B exon28 c.A4196G p.Y1399C,CACNA1B D D D 
INADL exon33 c.C4334T p.S1445L D D D 
MORN3 exon4 c.G541A p.G181S D D D 
ARHGAP44 exon16 c.A1490G p.D497G D D D 
LIG4 exon2 c.C2241G p.C747W,LIG4 D D D 
MYH11 exon8 c.C817T p.R273C,MYH11 D D D 
FZD2 exon1 c.G1399A p.V467M D D D 
KSR1 exon15 c.G1462A p.G488S D D D 
RAPGEF3 exon23 c.G2248A p.D750N,RAPGEF3 D D D 
MYH7B exon34 c.C4054T p.R1352C D D D 
KCNH6 exon5 c.A998C p.H333P,KCNH6 D D D 
GGT7 exon2 c.G308A p.R103H D D D 
PRDM16 exon7 c.C919T p.R307C,PRDM16 D D D 
COPS4 exon6 c.G574T p.A192S,COPS4 D D D 
WDR13 exon7 c.G980A p.R327H,WDR13 D D D 
SALL4 exon2 c.G194A p.R65Q D D D 
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PCDH8 exon1 c.C1456T p.R486C,PCDH8 D D D 
AICDA exon3 c.G374T p.G125V D D D 
NPTXR exon1 c.C460T p.L154F D D D 
MPPE1 exon8 c.G873C p.E291D,MPPE1 D D D 
KMT2A exon3 c.G1259A p.R420Q,KMT2A D D D 
ADD3 exon10 c.T1315C p.W439R,ADD3 D D D 
KIF26B exon12 c.G4535A p.G1512E D D D 
SLC25A23 exon6 c.G679T p.G227W D D D 
MBOAT7 exon4 c.G362A p.R121H,MBOAT7 D D D 
KCTD11 exon1 c.T569G p.V190G D D D 
AK2 exon6 c.T644C p.I215T,AK2 D D D 
CNBD2 exon11 c.T1274G p.F425C D D D 
MYO18A exon22 c.G3518T p.R1173L,MYO18A D D D 
PYGB exon12 c.A1462C p.T488P D D D 
IL17RE exon14 c.C1597T p.R533C,IL17RE D D D 
HK3 exon12 c.G1675A p.V559M D D D 
DNAJC11 exon8 c.C778T p.R260W D D D 
YME1L1 exon14 c.G1601T p.R534L,YME1L1 D D D 
PKN1 exon8 c.G1244T p.W415L,PKN1 D D D 
ADCY2 exon25 c.C3218T p.T1073M D D D 
RUNX1 exon6 c.C1330A p.R444S,RUNX1 D D D 
KBTBD11 exon2 c.C1012T p.R338C D D D 
LAMA5 exon16 c.G2080T p.G694W D D D 
SNPH exon6 c.T793C p.S265P D D D 
NFKBIB exon3 c.C190A p.R64S,NFKBIB D D D 
ZCCHC2 exon1 c.C473A p.P158Q D D D 
SYNE1 
exon12
6 
c.G22811T p.W7604L,SYNE1 D D D 
MFRP exon8 c.G904T p.G302W D D D 
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COL18A1 exon7 c.G1735A p.G579S,COL18A1 D D D 
MLPH exon8 c.C1001T p.S334L,MLPH D D D 
AIFM1 exon4 c.G296T p.R99L,AIFM1 D D D 
NCF1 exon2 c.G95T p.W32L D D D 
SERPINB12 exon4 c.G482T p.W161L D D D 
TTC39B exon14 c.G1312T p.G438W,TTC39B D D D 
CMA1 exon5 c.G631T p.G211W D D D 
MYL6 exon3 c.C128A p.P43H,MYL6 D D D 
DNAH7 exon53 c.G10061T p.W3354L D D D 
SLC6A13 exon4 c.G450T p.W150C D D D 
JMJD1C exon5 c.A188T p.D63V,JMJD1C D D D 
SLC34A1 exon6 c.C557A p.P186H,SLC34A1 D D D 
POLR1A exon13 c.G1727T p.R576L D D D 
ETV4 exon8 c.G703T p.G235W,ETV4 D D D 
AR exon1 c.C110A p.P37Q D D D 
SENP8 exon2 c.C469A p.Q157K,SENP8 D D D 
TRIM39-RPP21 exon3 c.A647G p.E216G,TRIM39 D D D 
HERC2 exon77 c.C11716T p.R3906C D D D 
LRP8 exon5 c.G514T p.G172W,LRP8 D D D 
YAF2 exon2 c.G138T p.K46N,YAF2 D D D 
NDUFV1 exon5 c.C662A p.P221H,NDUFV1 D D D 
LACTB2 exon4 c.G503T p.G168V D D D 
MLXIPL exon16 c.G2350T p.G784W,MLXIPL D D D 
HSPA8 exon2 c.G99T p.Q33H,HSPA8 D D D 
USP6 exon6 c.C371A p.P124H D D D 
FYTTD1 exon7 c.C728A p.P243Q,FYTTD1 D D D 
EPB41 exon6 c.C965A p.P322Q,EPB41 D D D 
FAM205A exon4 c.G923T p.W308L D D D 
ARHGEF11 exon3 c.G187T p.G63W,ARHGEF11 D D D 
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CLASP1 exon20 c.G1942T p.G648W,CLASP1 D D D 
SRCAP exon19 c.C2842A p.L948I D D D 
DOCK1 exon49 c.C5068A p.L1690M,DOCK1 D D D 
MMP3 exon3 c.A364G p.T122A D D D 
SEMA4D exon13 c.G1079T p.G360V,SEMA4D D D D 
FAM129B exon10 c.G1274T p.R425L,FAM129B D D D 
TARBP2 exon2 c.C29A p.P10Q,TARBP2 D D D 
TECR exon13 c.C829A p.Q277K D D D 
NOS3 exon12 c.C1577A p.S526Y,NOS3 D D D 
KIF1A exon46 c.G5066T p.R1689L,KIF1A D D D 
ZNF600 exon3 c.G1061T p.G354V D D D 
TNKS1BP1 exon4 c.G757T p.G253W D D D 
FILIP1L exon2 c.G240T p.E80D,FILIP1L D D D 
KNDC1 exon10 c.C1688A p.A563D D D D 
TMLHE exon5 c.G757T p.G253C,TMLHE D D D 
SKP1 exon4 c.G264T p.W88C,SKP1 D D D 
SAFB2 exon15 c.G2169T p.Q723H D D D 
ETHE1 exon7 c.G743T p.G248V D D D 
EBI3 exon5 c.C604A p.Q202K D D D 
EP400 exon37 c.A6646C p.T2216P D D D 
NRK exon9 c.C725A p.S242Y D D D 
BZRAP1 exon12 c.G1319T p.R440L,BZRAP1 D D D 
SEC14L4 exon9 c.C701A p.P234H,SEC14L4 D D D 
ISG20 exon3 c.C406T p.R136C D D D 
CACNA1A exon44 c.G6328T p.G2110W,CACNA1A D D D 
SCFD2 exon2 c.G905T p.G302V D D D 
PCDH19 exon2 c.G2458T p.G820C,PCDH19 D D D 
DDX17 exon6 c.G873T p.L291F,DDX17 D D D 
HECTD4 exon57 c.G8442T p.Q2814H D D D 
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AGAP1 exon16 c.C2012A p.P671Q,AGAP1 D D D 
NKIRAS2 exon3 c.C113T p.T38M,NKIRAS2 D D D 
STRN4 exon13 c.G1651T p.G551W,STRN4 D D D 
CTDSP2 exon4 c.C322A p.L108I D D D 
PROS1 exon4 c.G283T p.G95W D D D 
HERC2 exon28 c.G4309T p.G1437C D D D 
CDC14A exon4 c.G298T p.G100C,CDC14A D D D 
ABHD5 exon5 c.C769A p.P257T D D D 
CAPN5 exon2 c.A86C p.D29A D D D 
YY1AP1 exon2 c.G263T p.R88M,YY1AP1 D D D 
HELZ2 exon2 c.G11T p.W4L D D D 
TBPL1 exon7 c.C527A p.P176Q,TBPL1 D D D 
TRIM72 exon7 c.C1007A p.A336E D D D 
TSSC1 exon9 c.C1078A p.P360T D D D 
HMGA1 exon2 c.G36T p.L12F,HMGA1 D D D 
WAS exon7 c.G641T p.G214V D D D 
TRPV1 exon6 c.C1222A p.P408T,TRPV1 D D D 
PALLD exon9 c.G1459T p.V487F,PALLD D D D 
DBF4 exon12 c.C1841A p.P614Q D D D 
PRDM4 exon11 c.G2009T p.G670V D D D 
SLC4A5 exon16 c.G2185T p.G729C,SLC4A5 D D D 
UTP20 exon49 c.C6532A p.H2178N D D D 
CHRNA1 exon6 c.G547T p.D183Y,CHRNA1 D D D 
OR2T8 exon1 c.C842A p.P281H D D D 
APBA2 exon13 c.C2175A p.F725L,APBA2 D D D 
UBB exon2 c.C337A p.P113T,UBB D D D 
KCNH6 exon7 c.G1525T p.G509W,KCNH6 D D D 
FDFT1 exon3 c.C374A p.P125Q,FDFT1 D D D 
PATL2 exon12 c.G1208T p.R403M D D D 
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CDC25A exon1 c.G166T p.G56C,CDC25A D D D 
FYCO1 exon5 c.G311T p.G104V D D D 
XPC exon8 c.G920T p.R307L D D D 
IL17RD exon11 c.G1147T p.D383Y D D D 
OTOG exon29 c.A3703C p.T1235P,OTOG D D D 
TXN exon2 c.G56T p.G19V,TXN D D D 
HUWE1 exon26 c.G2545T p.D849Y D D D 
CTDSP2 exon1 c.G35T p.R12M D D D 
SEC24A exon6 c.C1148A p.P383Q,SEC24A D D D 
TFR2 exon15 c.G1796T p.S599I,TFR2 D D D 
DHX40 exon13 c.G1525T p.A509S,DHX40 D D D 
CD6 exon12 c.G1877T p.G626V D D D 
GRIN2C exon13 c.C2645A p.P882Q D D D 
GABPA exon9 c.G1069A p.A357T,GABPA D D D 
GLE1 exon15 c.C2000A p.S667Y D D D 
UBE2S exon3 c.G200T p.G67V D D D 
COL13A1 exon21 c.G1134T p.K378N,COL13A1 D D D 
AIM1L exon14 c.G4166T p.C1389F D D D 
PROSER2 exon4 c.C1105T p.R369C D D D 
RPS3 exon4 c.C110A p.P37H,RPS3 D D D 
TUBGCP6 exon13 c.G2223T p.R741S D D D 
HS6ST2 exon4 c.G1004T p.W335L,HS6ST2 D D D 
WIPF3 exon3 c.C212A p.P71Q D D D 
SEC16A exon16 c.C5407G p.Q1803E,SEC16A D D D 
TCEB2 exon3 c.G181A p.G61S,TCEB2 D D D 
FLNB exon34 c.C5759A p.A1920D,FLNB D D D 
GOLGA3 exon4 c.G518T p.R173M,GOLGA3 D D D 
PCDH15 exon7 c.G652T p.V218F,PCDH15 D D D 
SEMA4C exon4 c.G266T p.W89L D D D 
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EXOC3L1 exon3 c.G71T p.R24L D D D 
GGT5 exon3 c.G422T p.G141V,GGT5 D D D 
MYRF exon3 c.G184T p.G62W,MYRF D D D 
PRELID1 exon5 c.C578A p.A193D,PRELID1 D D D 
NDST3 exon5 c.C1286A p.P429H D D D 
SYNE2 
exon10
5 
c.C19046
A 
p.S6349Y,SYNE2 D D D 
LTBP1 exon1 c.C220T p.R74C D D D 
NPHS1 exon19 c.G2635T p.G879W D D D 
RABEP2 exon5 c.G875T p.W292L D D D 
L3MBTL4 exon14 c.G1147T p.G383W D D D 
UNC80 exon23 c.C3641A p.P1214H,UNC80 D D D 
CDIPT exon4 c.G304T p.G102W,CDIPT D D D 
GABRA3 exon3 c.G253T p.G85W D D D 
COL2A1 exon29 c.G1762T p.G588C,COL2A1 D D D 
CALR3 exon1 c.G89T p.G30V D D D 
MMADHC exon4 c.G226T p.G76W D D D 
NPHP3 exon24 c.C3512A p.P1171H D D D 
ACTL6A exon1 c.G23T p.G8V D D D 
VWA5A exon14 c.C1636T p.H546Y,VWA5A D D D 
SYNM    D D D 
PRSS48 exon2 c.T86C p.V29A D P N 
CAMSAP1 exon11 c.C2702T p.A901V D P N 
ENDOV exon2 c.C79T p.H27Y,ENDOV D P N 
C12orf40 exon6 c.C530T p.T177I D P N 
GPR25 exon1 c.G424T p.V142L D P N 
KIR2DL4 exon3 c.C182G p.T61R,KIR2DL4 D P N 
WDR87 exon6 c.G3410A p.R1137Q,WDR87 D P N 
L1TD1 exon4 c.C1792G p.H598D,L1TD1 D P N 
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KIR2DL1 exon6 c.G801C p.W267C D P N 
MYO1A exon24 c.G2534T p.R845M,MYO1A D P N 
ZNF93 exon4 c.T556C p.S186P D P N 
OPN1MW exon5 c.C893A p.P298H,OPN1MW2 D P N 
NBPF12 exon9 c.G426T p.Q142H D P N 
VEGFB exon6 c.A458C p.D153A,VEGFB D P N 
SHC2 exon1 c.C113T p.A38V D P N 
MUC5B exon8 c.C884A p.P295H D P N 
SAFB2 exon21 c.A2848C p.T950P D P N 
SLC20A2 exon7 c.G910T p.G304C,SLC20A2 D P N 
GGT1 exon5 c.C43A p.L15M,GGT1 D P N 
FAM153A exon10 c.G365T p.G122V D P N 
CNTN5 exon14 c.C1856T p.P619L,CNTN5 D P D 
RYR2 exon37 c.T5186C p.M1729T D P D 
XIRP2 exon7 c.G8170C p.E2724Q,XIRP2 D P D 
SLC25A5 exon2 c.T244A p.F82I D P D 
ASH2L exon1 c.C143A p.S48Y D P D 
FAM86B1 exon6 c.C751T p.R251C D P D 
ATN1 exon5 c.C2227A p.P743T,ATN1 D P D 
ANTXR2 exon11 c.G896T p.G299V,ANTXR2 D P D 
XPC exon9 c.T1271G p.V424G D P D 
ARHGAP6 exon9 c.G1269T p.M423I,ARHGAP6 D P D 
BAI2 exon4 c.G124T p.A42S,BAI2 D P D 
RPL7A exon3 c.C157A p.R53S D P D 
AIFM1 exon4 c.G366T p.K122N,AIFM1 D P D 
PELP1 exon7 c.G929T p.W310L,PELP1 D P D 
SEMA6B exon17 c.G1883T p.R628L D P D 
PDLIM7 exon5 c.C352A p.P118T,PDLIM7 D P D 
TMEM129 exon3 c.G701T p.G234V D P D 
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ATP1A1 exon14 c.G1845T p.M615I,ATP1A1 D P D 
TLK2 exon17 c.G1732C p.E578Q,TLK2 D P D 
AGAP4 exon7 c.G1040T p.G347V,AGAP4 D P D 
MYH14 exon25 c.G3236T p.G1079V,MYH14 D P D 
RAB34 exon1 c.G32T p.R11M,RAB34 D P . 
DOCK9 exon1 c.C23A p.P8H . B D 
RFFL exon6 c.G910T p.G304W . B D 
RGAG1 exon3 c.G1057A p.A353T . D N 
TEX11 exon8 c.G538T p.G180W,TEX11 . D N 
WDR86 exon3 c.G487T p.G163W,WDR86 . D N 
MUC4 exon2 c.G11554T p.G3852C . D N 
DLG5 exon23 c.G4463T p.R1488M . D N 
OTUD7B exon4 c.A466C p.I156L . D D 
ANK2 exon30 c.C3443A p.P1148Q,ANK2 . D D 
KIAA0100 exon14 c.G1771T p.G591C . D D 
NAV2 exon17 c.G2711T p.S904I,NAV2 . D D 
ADARB2 exon8 c.G1864T p.G622C . D D 
MXD4 exon2 c.G164T p.R55M . D D 
UGT2B7 exon6 c.G1455T p.W485C . D D 
HSD3B2 exon3 c.G244T p.A82S,HSD3B2 . D D 
LRP2 exon8 c.C803A p.P268Q . D D 
NRXN3 exon3 c.G13T p.D5Y . D D 
GATA3 exon2 c.C182A p.P61Q,GATA3 . D D 
TENM4 exon13 c.G1735T p.G579W . D D 
SIK1 exon7 c.G748T p.D250Y . D D 
MUC4 exon2 
c.C10976
G 
p.T3659R . P N 
TELO2 exon13 c.C1562A p.A521D . P N 
C16orf62 exon22 c.C2077G p.L693V,C16orf62 . P D 
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PCBD1 exon2 c.G8A p.G3D . P D 
SPICE1 exon8 c.G751T p.A251S . P D 
MOCS1 exon1 c.G98T p.G33V . P D 
TAGLN2 exon3 c.C346A p.L116I,TAGLN2 . P D 
CTAGE5 exon20 c.C1639A p.L547I,CTAGE5 . P D 
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Appendix 4.3 - Variants Chosen for Sanger Sequencing and the Corresponding Primers 
Gene 
Chromoso
me 
Protein 
change 
Mutation 
type 
Forward primer Reverse primer Tumour ID 
INADL 
chr1:6255
0277 
p.1216_
1216del, 
nonframe
shift 
deletion 
GAACTGCTCCA
CCGCCAA 
GGAAATGACGCC
ACAAAAGC 
MESOD5 
INADL 
chr1:6239
3477 
p.S1445
L 
nonsyno
nymous 
TCCTGTCACAC
ACACACGTA 
AGCCTAGCAACT
CACCTTGA 
MESOEQ40 
JMJD1
C 
chr10:649
28295 
p.T2241
I 
nonsyno
nymous 
GAACAGGACCT
AGAACACCCA 
TGGCTTTTCTTT
GCTCCACC 
MESOD15 
JMJD1
C 
chr10:649
75401 
p.D63V 
nonsyno
nymous 
GCGTCGTGATG
TAATGCCAA 
GGATCCCAAGCT
GATTTCTAAAC 
MESOEQ36 
SETD2 
chr3:4716
1908 
p.1380_
1406del, 
frameshif
t deletion 
TGTCCTGAAGC
TCACCATCA 
AAGGGGTCAGT
GCAAGCA 
MESOD26 
SETD2 
chr3:4705
9172 
p.G2497
fs 
frameshif
t 
insertion 
AGGTACACAGT
TTGCCCAGA 
ACAACTCCTTGC
CCTCTCTG 
MESOEQ40 
CACN
A1B 
chr9:1409
52590 
p.Y613
C, 
nonsyno
nymous 
TTAGGGCTGTC
TCCTTTGGG 
TCCACTGCAAGA
CTCCACAG 
MESOEQ21 
CACN
A1B 
chr9:1409
38328 
p.M113
0T 
nonsyno
nymous 
CAAGCAGAGGG
GAAGAAGGA 
CTGGCTACTGAG
ATCCCACG 
MESOD15 
RASG
RP4 
chr19:389
10871 
p.H137
N, 
nonsyno
nymous 
CAGGGAAGAGG
GGAGCAC 
CCCCTAGCTCAG
CACCTAG 
MESOEQ21 
STK4 
chr20:436
23864 
p.G165
E 
nonsyno
nymous 
ATACCATGGCC
AAGCGGAAT 
GTGCTGGGATTA
CACGTGTG 
MESOEQ40 
FZD2 
chr17:426
36455 
p.V467
M 
nonsyno
nymous 
CACCATCATGA
AGCACGACG 
TGAGCGTCATGA
GGTATTTGA 
MESOEQ30 
ASH1L chr1:1554 p.V745I nonsyno GCAAGAGATGG GCCTAAGTACTA MESOEQ21 
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50428 nymous AGCTGTGGA GTTTGCAGTCC 
SETD6 
chr16:585
52374 
p.V348
A, 
nonsyno
nymous 
TTGTAGACTGG
GTGGCAGAC 
TCAGCTCCTCTT
CAGTCAGC 
MESOEQ36 
SMYD
3 
chr1:2460
78913 
p.M55I, 
nonsyno
nymous 
GGCAACGGAAA
CAGTCACAT 
ACGTGTGATCAT
TTGGGTAGAG 
MESOEQ30 
DMAP
1 
chr1:4468
0379 
p.A68T 
nonsyno
nymous 
ACCTGAAGTCT
TTTGCTCCAG 
GGAAGAACATTG
CTCCGTCC 
MESOEQ40 
PHF21
A 
chr11:459
55757 
p.N556S 
nonsyno
nymous 
ACAGGTTTGGA
GAGGTCGAT 
TGTTCCTTAGGT
GGTAGCCG 
MESOEQ30 
SETD1
B 
chr12:122
242657 
p.H5fs 
frameshif
t deletion 
TTTCGCGTGTGT
GTAGAAGC 
CGGTACAGTTTA
TGATGCCCC 
MESOEQ30 
CDH8 
chr14:218
73555 
p.N1040
fs 
frameshif
t deletion 
TTGCGCAACTC
CATCATTGT 
TGAGAATGTTCG
CCCTCATCT 
MESOEQ30 
TBL1X
R1 
chr3:1767
69332 
p.N129f
s 
frameshif
t deletion 
CTGCACATGTA
CCCCGAATT 
GATGCCGTAATG
CCTGATGT 
MESOEQ30 
NF2 
chr22:300
35190 
p.76_76
del, 
nonframe
shift 
deletion 
GTGTGTTTGTCT
TTTGCTCTGC 
ACTCCTGGGCAA
GTTCTCTC 
MESOEQ40 
NF2 
chr22:300
57302 
p.R221
X, 
stopgain 
SNV 
GCTGTTCTTATT
GGATCCACAGA 
AGGGAAAGATCT
GCTGGACC 
MESOD14 
BAP1 
chr3:5244
0373 
p.R227
C 
nonsyno
nymous 
GCAGAGGCCAG
GAAGAAAGG 
GGGGCCTATACC
TACAGCTG 
MESOEQ22 
BAP1 
chr3:5243
6624 
p.Q684
X, 
stopgain 
SNV 
CTCTCATGGCCC
TCCCTG 
GACCAGAGAAG
GACCCACAA 
MESOD13 
BAP1 
chr3:5244
1430 
p.H141P
, 
nonsyno
nymous 
AACAGAGTCAG
GGCCCAAAA 
CTGCTCTCTGAA
GCTTTGCC 
MESOD18 
FLT3 
chr13:286
23882 
p.P258S 
nonsyno
nymous 
ACCTCCTCGAG
TGCTTTGTT 
AGGATATCTTTTG
TGATGAGGCA 
MESOEQ30 
GPHN 
chr14:673
89394 
p.76_76
del 
nonsyno
nymous 
CGAAACAGTTT
GATTGCCACC 
CTGGTAGTAGGA
GGAGGGGA 
MESOEQ30 
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PRDM
16 
chr16_1:3
321337 
p.R307
C 
nonsyno
nymous 
AGCTGTATGGTT
GGGGTCC 
GCAGTTTTCACA
TTCGAAGCG 
MESOEQ30 
RPL10 
chrx:1536
26879 
p.R7C 
nonsyno
nymous 
GGTGAGTAAGC
GCAGTTGTC 
CGGGAGGTGTAA
AACATAGGG 
MESOEQ30 
MN1 
chr22:281
94730 
p.P601L 
nonsyno
nymous 
TACGGGGCAGC
AGGTCTC 
CGGCCCTCATGA
TTAAGCAG 
MESOEQ30 
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Appendix 4.4 - Genes Implicated in Cancer Identified in Discovery Cohort  
Gene Mutation types Protein Tumour ID (D) 
AR nonsynonymous SNV p.P37Q MESOEQ22 
ATP1A1 nonsynonymous SNV p.M615I,ATP1A1 MESOEQ22 
BAP1 stopgain p.E373X MESOEQ22 
CCDC6 stopgain p.L265X MESOEQ30 
CHD8 frameshift deletion p.N1040fs,CHD8 MESOEQ30 
CLASP1 nonsynonymous SNV p.G648W,CLASP1 MESOEQ22 
CNTRL nonsynonymous SNV p.L935I MESOEQ30 
COL2A1 nonsynonymous SNV p.G588C,COL2A1 MESOEQ22 
CSF3R stopgain p.E24X,CSF3R MESOEQ22 
ELF4 nonsynonymous SNV p.H405N,ELF4 MESOEQ22 
ETV4 nonsynonymous SNV p.G235W,ETV4 MESOEQ22 
FAM118B nonsynonymous SNV p.P311Q MESOEQ22 
FANCD2 nonsynonymous SNV p.E1153K,FANCD2 MESOEQ40 
FLT3 nonsynonymous SNV p.P258S MESOEQ30 
FOXK1 nonsynonymous SNV p.P211T MESOEQ30 
GATA3 nonsynonymous SNV p.P61Q,GATA3 MESOEQ22 
GNA11 nonsynonymous SNV p.M7I MESOEQ22 
GPHN nonsynonymous SNV p.Q156H,GPHN MESOEQ30 
HMGA1 nonsynonymous SNV p.L12F,HMGA1 MESOEQ22 
HSP90AA1 stopgain p.G168X,HSP90AA1 MESOEQ22 
KDR stopgain p.G794X MESOEQ22 
KIAA1549 nonsynonymous SNV p.G1278C,KIAA1549 MESOEQ22 
KMT2A nonsynonymous SNV p.R420Q,KMT2A MESOEQ30 
MN1 nonsynonymous SNV p.P601L MESOEQ30 
MUC1 nonsynonymous SNV p.W94C,MUC1 MESOEQ22 
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MYH11 nonsynonymous SNV p.R273C,MYH11 MESOEQ22 
NAB2 nonsynonymous SNV p.F208L MESOEQ36 
NF2 nonframeshift deletion p.76_76del,NF2 MESOEQ40 
NF2 splicing  MESOEQ13 
NOTCH1 nonsynonymous SNV p.G2245W MESOEQ22 
PRDM16 nonsynonymous SNV p.R307C,PRDM16 MESOEQ30 
RNF213 nonsynonymous SNV p.K1552T MESOEQ30 
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Appendix 4.5 - Genes Implicated in Cancer Identified in Both Discovery and Validation 
cohorts 
Gene Mutation type protein 
change
MESO
D10
MESO
D12
MESO
D13
MESO
D14
MESO
D15
MESO
D16
MESO
D17
MESO
D18
MESO
D19
MESO
D1
MESO
D21
MESO
D22
MESO
D24
MESO
D25
MESO
D26
MESO
D27
MESO
D28
MESO
D29
MESO
D2
MESO
D30
MESO
D31
MESO
D32
MESO
D33
MESO
D34
MESO
D35
MESO
D3
MESO
D5
MESO
D6
MESO
D8
AR frameshift deletion p.Q60fs, 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
AR frameshift deletion p.60_63del, 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
AR nonframeshift deletion p.57_65del, 0/0 0/5 0/4 0/0 2/3 0/4 0/6 0/5 0/0 0/0 0/0 4/5 0/0 3/3 3/3 6/6 6/6 0/0 4/5 2/3 0/0 2/4 1/6 0/3 0/0 0/0 2/3 2/2 2/2
AR nonframeshift deletion p.457_460del, 0/0 0/3 0/0 0/3 2/2 0/0 0/0 0/3 0/0 0/0 0/0 0/0 0/0 3/3 0/0 3/3 0/0 0/0 0/0 3/3 3/3 0/0 0/0 1/1 0/0 0/0 0/0 0/0 0/2
BAP1 frameshift deletion p.56_62del, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
BAP1 frameshift deletion p.R114fs, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
BAP1 frameshift deletion p.558_560del, 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
BAP1 frameshift deletion p.162_162del, 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
BAP1 frameshift deletion p.146_147del, 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
BAP1 frameshift insertion p.K658fs, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
BAP1 nonframeshift deletion p.659_659del, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
BAP1 nonsynonymous SNV p.H141P, 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
BAP1 stopgain SNV p.Q684X, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
FOXK1 nonsynonymous SNV p.T683P, 0/0 0/1 0/1 0/1 0/0 0/1 0/0 0/0 0/0 0/1 0/1 0/0 0/0 0/0 0/1 0/1 0/1 0/1 0/0 0/0 0/1 0/1 0/1 0/0 0/0 0/0 0/1 0/0 0/0
GATA3 nonsynonymous SNV p.S407L,GATA30/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0
GNA11 nonsynonymous SNV p.S50R, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1
NAB2 nonsynonymous SNV p.P504S, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
NF2 frameshift deletion p.A354fs,NF2 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
NF2 frameshift deletion p.F35fs,NF2 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
NF2 frameshift insertion p.P129fs,NF2 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
NF2 stopgain SNV p.R221X,NF2 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
NOTCH1 nonsynonymous SNV p.T349P, 0/1 0/1 0/0 0/0 0/0 0/0 0/1 0/1 0/0 0/0 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/0 0/1 0/1 0/1 0/1 0/0
NOTCH1 nonsynonymous SNV p.T194P, 0/1 0/1 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/1 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/1 0/0 0/1 0/0 0/0 0/1 0/0
RNF213 nonsynonymous SNV p.L4696P, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0
RNF213 nonsynonymous SNV p.D578N,RNF2130/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
SETD2 frameshift deletion p.1380_1406del, 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
USP6 nonsynonymous SNV p.I67M, 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/0 0/1 0/1 0/1 0/1 0/1 0/0 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
USP6 nonsynonymous SNV p.R68W, 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/0 0/1 0/1 0/1 0/1 0/1 0/0 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
 
